CA3109981A1 - Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides - Google Patents

Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides Download PDF

Info

Publication number
CA3109981A1
CA3109981A1 CA3109981A CA3109981A CA3109981A1 CA 3109981 A1 CA3109981 A1 CA 3109981A1 CA 3109981 A CA3109981 A CA 3109981A CA 3109981 A CA3109981 A CA 3109981A CA 3109981 A1 CA3109981 A1 CA 3109981A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
group
ulm
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3109981A
Other languages
French (fr)
Inventor
Andrew P. Crew
Keith R. Hornberger
Jing Wang
Craig M. Crews
Saul Jaime-Figueroa
Hanqing Dong
Yimin Qian
Kurt Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Arvinas Operations Inc
Original Assignee
Yale University
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Arvinas Operations Inc filed Critical Yale University
Publication of CA3109981A1 publication Critical patent/CA3109981A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Abstract

The present disclosure relates to bifunctional compounds, ULM LPTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY
ACCELERATED
FIBROSARCOMA POLYPEPTIDES
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present disclosure claims the benefit and priority to U.S.
Provisional Application No. 62/728,581, filed 7 September 2018, and is a continuation-in-part of U.S.
Patent Application No. 15/853,166, filed 22 December 2017, published as U.S. Patent Application Publication No.
2018/0179183A1 on 28 June 2018, which claims priority to U.S. Provisional Application No.
62/438,803, filed 23 December 2016 and U.S. Provisional Application No.
62/582,698, filed 7 November 2017, all of which are incorporated herein by reference in their entirety.
INCORPORATION BY REFERENCE
[0002] U.S. Patent Application Serial No. 15/230,354, filed on August 5, 2016; and U.S.
Patent Application 15/206,497 filed 11 July 2016; and U.S. Patent Application 15/209,648 filed 13 July 2016; and U.S. Patent Application Serial No. 62/406,888, filed on October 11, 2016; and U.S. Patent Application Serial No. 14/686,640, filed on April 14, 2015, published as U.S. Patent Application Publication No. 2015/0291562; and U.S. Patent Application Serial No. 14/792,414, filed on July 6, 2015, published as U.S. Patent Application Publication No.
2016/0058872; and U.S. Patent Application Serial No. 14/371,956, filed on July 11, 2014, published as U.S. Patent Application Publication No. 2014/0356322; and U.S. Patent Application Serial No. 15/074,820, filed on March 18, 2016, published as U.S. Patent Application Publication No.
2016/0272639, are incorporated herein by reference in their entirety. Furthermore, all references cited herein are incorporated by reference herein in their entirety.
STATEMENT REGARDING FEDERALLY FUNDED RESEARCH
[0003] This invention was made with government support under grant number NIH
R35CA197589, as issued by the National Institutes of Health. The government has certain rights in the invention.
FIELD OF THE INVENTION
4 PCT/US2019/050114 [0004] The description provides bifunctional compounds comprising a target protein binding moiety and an E3 ubiquitin ligase binding moiety, and associated methods of use. The bifunctional compounds are useful as modulators of targeted ubiquitination, especially with respect to Rapidly Accelerated Fibrosarcoma (RAF) proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure.
BACKGROUND
[0005] Most small molecule drugs bind enzymes or receptors in tight and well-defined pockets. On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved. E3 ubiquitin ligases (of which hundreds are known in humans) confer substrate specificity for ubiquitination, and therefore, are more attractive therapeutic targets than general proteasome inhibitors due to their specificity for certain protein substrates.
The development of ligands of E3 ligases has proven challenging, in part due to the fact that they must disrupt protein-protein interactions. However, recent developments have provided specific ligands which bind to these ligases. For example, since the discovery of nutlins, the first small molecule E3 ligase inhibitors, additional compounds have been reported that target E3 ligases but the field remains underdeveloped. For example, since the discovery of Nutlins, the first small molecule E3 ligase mouse double minute 2 homolog (MDM2) inhibitors, additional compounds have been reported that target MDM2 (i.e., human double minute 2 or HDM2) E3 ligases (J.
Di, et al.
Current Cancer Drug Targets (2011), 11(8), 987-994).
[0006] Tumor suppressor gene p53 plays an important role in cell growth arrest and apoptosis in response to DNA damage or stress (A. Vazquez, et al. Nat. Rev.
Drug. Dis. (2008),
7, 979-982), and inactivation of p53 has been suggested as one of the major pathway for tumor cell survival (A. J. Levine, et al. Nature (2000), 408, 307-310). In cancer patients, about 50%
were found with p53 mutation (M. Hollstein, et al. Science (1991), 233, 49-53), while patients with wild type p53 were often found p53 down regulation by MDM2 through the protein-protein interaction of p53 and MDM2 (P. Chene, et al. Nat. Rev. Cancer (2003), 3, 102-109). Under normal cell condition without oncogenic stress signal, MDM2 keeps p53 at low concentration. In response to DNA damage or cellular stress, p53 level increases, and that also causes increase in MDM2 due to the feedback loop from p53/MDM2 auto regulatory system. In other words, p53 regulates MDM2 at the transcription level, and MDM2 regulates p53 at its activity level (A. J.
Levine, et al. Genes Dev. (1993) 7, 1126-1132).
[0007] Several mechanisms can explain p53 down regulation by MDM2. First, MDM2 binds to N-terminal domain of p53 and blocks expression of p53-responsive genes (J.
Momand, et al.
Cell (1992), 69, 1237-1245). Second, MDM2 shuttles p53 from nucleus to cytoplasm to facilitate proteolytic degradation (J. Roth, et al. EMBO J. (1998), 17, 554-564). Lastly, MDM2 carries intrinsic E3 ligase activity of conjugating ubiquitin to p53 for degradation through ubiquitin-dependent 26s proteasome system (UPS) (Y. Haupt, et al. Nature (1997) 387, 296-299). As such, because MDM2 functions as E3 ligase, recruiting MDM2 to a disease causing protein and effectuating its ubiquitination and degradation is an approach of high interest for drug discovery.
[0008] One E3 ligase with exciting therapeutic potential is the von Hippel-Lindau (VHL) tumor suppressor, the substrate recognition subunit of the E3 ligase complex VCB, which also consists of elongins B and C, Cul2 and Rbx 1 . The primary substrate of VHL is Hypoxia Inducible Factor la (HIF-1a), a transcription factor that upregulates genes such as the pro-angiogenic growth factor VEGF and the red blood cell inducing cytokine erythropoietin in response to low oxygen levels. The first small molecule ligands of Von Hippel Lindau (VHL) to the substrate recognition subunit of the E3 ligase were generated, and crystal structures were obtained confirming that the compound mimics the binding mode of the transcription factor HIF-1 a, the major substrate of VHL.
[0009] Cereblon is a protein that in humans is encoded by the CRBN gene.
CRBN orthologs are highly conserved from plants to humans, which underscores its physiological importance.
Cereblon forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). This complex ubiquitinates a number of other proteins. Through a mechanism which has not been completely elucidated, cereblon ubquitination of target proteins results in increased levels of fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10). FGF8 in turn regulates a number of developmental processes, such as limb and auditory vesicle formation. The net result is that this ubiquitin ligase complex is important for limb outgrowth in embryos. In the absence of cereblon, DDB1 forms a complex with DDB2 that functions as a DNA damage-binding protein.
[0010] Inhibitors of Apotosis Proteins (IAPs) are a protein family involved in suppressing apoptosis, i.e. cell death. The human TAP family includes 8 members, and numerous other organisms contain TAP homologs. IAPs contain an E3 ligase specific domain and baculoviral TAP repeat (BIR) domains that recognize substrates, and promote their ubiquitination. IAPs promote ubiquitination and can directly bind and inhibit caspases. Caspases are proteases (e.g.
caspase-3, caspase-7 and caspace-9) that implement apoptosis. As such, through the binding of caspases, IAPs inhibit cell death. However, pro-apoptotic stimuli can result in the release of mitochondrial proteins DIABLO (also known as second mitrochondria-derived activator of caspases or SMAC) and HTRA2 (also known as Omi). Binding of DIABLO and HTRA2 appears to block TAP activity.
[0011] SMAC interacts with essentially all known IAPs including XIAP, c-IAP1. c-IAP2.
NIL-IAP, Bruce, and survivin. The first four amino acids (AVPI) of mature SMAC
bind to a portion of IAPs, which is believed to be essential for blocking the anti-apoptotic effects of I.APs.
[0012] Bifunctional compounds such as those that are described in U.S.
Patent Application Publications 2015-0291562 and 2014-0356322 (incorporated herein by reference), function to recruit endogenous proteins to an E3 ubiquiuin ligase for degradation. In particular, the publications describe bifunctional or proteolysis targeting chimeric (PROTAC) compounds, which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, which are then degraded and/or otherwise inhibited by the bifunctional compounds.
[0013] An ongoing need exists in the art for effective treatments for disease associated with overexpression or aggregation of Rapidly Accelerated Fibrosarcoma (RAF), or the overactivation of RAF (such as constitutively active RAF). For example, current BRaf inhibitors (such as, vemurafenib and dabrafenib) may target V600 mutant BRaf. Thus, a need exists for diseases or disorders (such as, melanoma, lung cancer, pancreatic cancer, and/or colorectal cancers) that have different BRaf mutations that are insensitive to currently marketed agents.
Furthermore, resistance mutations can emerge in response to BRaf/MEK inhibitor therapy. For example, the p61 splice variant can emerge in melanoma patients treated with BRaf/MEK
inhibitor therapy, which leaves these patients with no clinical options.
Currently marketed agents also bind to and cause paradoxical activation of wild-type BRaf, which results in clinical complications. In addition, the family of hypoactive Class III BRaf mutants that signal through heterodimerization with CRaf, constitute 40% of BRaf mutations in non-small cell lung cancer (NSCLC), and also appear sporadically across other cancers, cannot be targeted with any currently approved or clinical-stage BRaf inhibitors. Class I BRAF mutants (V600E, V600K, V600D) have high kinase activity, are Ras and dimerization independent, and are sensitive to vemuragenib. Class II BRAF mutants has high to intermediate kinase activity, are Ras-independent and dimerization dependent, and are insensitive to vemurafenib.
Class III BRAF
mutatns have lot to no kinase activity, are Ras and dimerization dependent, and are insensitive to vemurafenib.
[0014] Thus, non-specific effects and the inability to target and modulate RAF, remain an obstacle to the development of effective treatments. As such, small-molecule therapeutic agents that effectively targets RAF (e.g., effectively inhibiting and/or degrading mutant forms of BRaf, while sparing wild-type BRaf) and that leverage or potentiate VHL's, cereblon's, MDM2's, and IAPs' substrate specificity would be very useful.
SUMMARY
[0015] The present disclosure describes bifunctional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods of using the same.
In particular, the present disclosure provides bifunctional or proteolysis targeting chimeric (PROTAC) compounds, which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, which are then degraded and/or otherwise inhibited by the bifunctional compounds as described herein. An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with the degradation/inhibition of targeted polypeptides from virtually any protein class or family. In addition, the description provides methods of using an effective amount of the compounds as described herein for the treatment or amelioration of a disease condition, such as cancer (e.g., renal cell carcinoma, pancreatic cancer, colorectal cancer, lung cancer, ovarian cancer, thyroid cancer, pilocytic astrocytoma, prostate cancer, gastric cancer, hepatocellular carcinoma, and melanoma), cardiofaciocutaneous syndrome, neurofibromatosis type 1, Costello syndrome, Noonan Syndrome, LEOPARD (Lentigo, Electrocardiographic abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retarded growth, Deafness) syndrome.
[0016] As such, in one aspect the disclosure provides bifunctional or PROTAC compounds, which comprise an E3 ubiquitin ligase binding moiety (i.e., a ligand for an E3 ubquitin ligase or "ULM" group), and a moiety that binds a target protein (i.e., a protein/polypeptide targeting ligand or "PTM" group) such that the target protein/polypeptide is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. In a preferred embodiment, the ULM (ubiquitination ligase modulator) can be Von Hippel-Lindau E3 ubiquitin ligase (VHL) binding moiety (VLM), or a cereblon E3 ubiquitin ligase binding moiety (CLM), or a mouse double miniute 2 homolog (MDM2) E3 ubiquitin ligase binding moiety (MLM), or an TAP E3 ubiquitin ligase binding moiety (i.e., a "ILM"). For example, the structure of the bifunctional compound can be depicted as:
PTM _________________________ ULM
[0017] The respective positions of the PTM and ULM moieties (e.g., VLM, CLM, MLM or ILM) as well as their number as illustrated herein is provided by way of example only and is not intended to limit the compounds in any way. As would be understood by the skilled artisan, the bifunctional compounds as described herein can be synthesized such that the number and position of the respective functional moieties can be varied as desired.
[0018] In certain embodiments, the bifunctional compound further comprises a chemical linker ("L"). In this example, the structure of the bifunctional compound can be depicted as:
PTM L ULM
where PTM is a protein/polypeptide targeting moiety, L is a linker, e.g., a bond or a chemical group coupling PTM to ULM, and ULM is a TAP E3 ubiquitin ligase binding moiety, or a Von Hippel-Lindau E3 ubiquitin ligase (VHL) binding moiety (VLM), or a cereblon E3 ubiquitin ligase binding moiety (CLM), or a mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase binding moiety (MLM).
[0019] For example, the structure of the bifunctional compound can be depicted as:
PTM L VLM or CLM or MLM or ILM
wherein: PTM is a protein/polypeptide targeting moiety; "L" is a linker (e.g.
a bond or a chemical linker group) coupling the PTM and at least one of VLM, CLM, MLM, ILM, or a combination thereof; VLM is Von Hippel-Lindau E3 ubiquitin ligase binding moiety that binds to VHL E3 ligase; CLM is cereblon E3 ubiquitin ligase binding moiety that binds to cereblon;

MLM is an MDM2 E3 ubiquitin ligase binding moiety; and ILM is a TAP binding moiety which binds to TAP.
[0020] In certain preferred embodiments, the ILM is an AVPI tetrapeptide fragment. As such, in certain additional embodiments, the ILM of the bifunctional compound comprises the amino acids alanine (A), valine (V), proline (P), and isoleucine (I) or their unnatural mimetics, respectively. In additional embodiments, the amino acids of the AVPI
tetrapeptide fragment are connected to each other thorugh amide bonds (i.e., ¨C(0)NH¨ or ¨NHC(0)¨).
[0021] In certain embodiments, the compounds as described herein comprise multiple independently selected ULMs, multiple PTMs, multiple chemical linkers or a combination thereof.
[0022] In certain embodiments, ILM comprises chemical moieties such as those described herein.
[0023] In additional embodiments, VLM can be hydroxyproline or a derivative thereof.
Furthermore, other contemplated VLMs are included in U.S. Patent Application Publication No.
2014/03022523, which as discussed above, is incorporated herein in its entirety.
[0024] In an embodiment, the CLM comprises a chemical group derived from an imide, a thioimide, an amide, or a thioamide. In a particular embodiment, the chemical group is a phthalimido group, or an analog or derivative thereof. In a certain embodiment, the CLM is thalidomide, lenalidomide, pomalidomide, analogs thereof, isosteres thereof, or derivatives thereof. Other contemplated CLMs are described in U.S. Patent Application Publication No.
2015/0291562, which is incorporated herein in its entirety.
[0025] In certain embodiments, MLM can be nutlin or a derivative thereof.
Furthermore, other contemplated MLMs are included in U.S. Patent Application 15/206,497 filed 11 July 2016, which as discussed above, is incorporated herein in its entirety. In certain additional embodiments, the MLM of the bifunctional compound comprises chemical moieties such as substituted imidazolines, substituted spiro-indolinones , substituted pyrrolidines , substituted piperidinones , substituted morpholinones , substituted pyrrolopyrimidines, substituted imidazolopyridines, substituted thiazoloimidazoline, substituted pyrrolopyrrolidinones, and substituted isoquinolinones.
[0026] In additional embodiments, the MLM comprises the core structures mentioned above with adjacent bis-aryl substitutions positioned as cis- or trans-configurations.
[0027] In certain embodiments, "L" is a bond. In additional embodiments, the linker "L" is a connector with a linear non-hydrogen atom number in the range of 1 to 20. The connector "L"
can contain, but not limited to the functional groups such as ether, amide, alkane, alkene, alkyne, ketone, hydroxyl, carboxylic acid, thioether, sulfoxide, and sulfone. The linker can contain aromatic, heteroaromatic, cyclic, bicyclic and tricyclic moieties.
Substitution with halogen, such as Cl, F, Br and I can be included in the linker. In the case of fluorine substitution, single or multiple fluorines can be included.
[0028] In certain embodiments, VLM is a derivative of trans-3-hydroxyproline, where both nitrogen and carboxylic acid in trans-3-hydroxyproline are functionalized as amides.
[0029] In certain embodiments, CLM is a derivative of piperidine-2,6-dione, where piperidine-2,6-dione can be substituted at the 3-position, and the 3-substitution can be bicyclic hetero-aromatics with the linkage as C-N bond or C-C bond. Examples of CLM can be, but not limited to, pomalidomide, lenalidomide and thalidomide and their derivatives.
[0030] In an additional aspect, the description provides therapeutic compositions comprising an effective amount of a compound as described herein or salt form thereof, and a pharmaceutically acceptable carrier. The therapeutic compositions modulate protein degradation in a patient or subject, for example, an animal such as a human, and can be used for treating or ameliorating disease states or conditions which are modulated through the degraded protein. In certain embodiments, the therapeutic compositions as described herein may be used to effectuate the degradation of proteins of interest for the treatment or amelioration of a disease, e.g., cancer.
In yet another aspect, the present disclosure provides a method of ubiquitinating/degrading a target protein in a cell. In certain embodiments, the method comprises administering a bifunctional compound as described herein comprising an ILM and a PTM, a PTM
and a VLM, or a PTM and a CLM, or a PTM and a MLM, preferably linked through a linker moiety, as otherwise described herein, wherein the VLM/ILM/CLM/MLM is coupled to the PTM
through a linker to target protein that binds to PTM for degradation. Similarly, the PTM
can be coupled to VLM or CLM or MLM or ILM through a linker to target a protein or polypeptide for degradation. Degradation of the target protein will occur when the target protein is placed in proximity to the E3 ubiquitin ligase, thus resulting in degradation/inhibition of the effects of the target protein and the control of protein levels. The control of protein levels afforded by the present disclosure provides treatment of a disease state or condition, which is modulated through the target protein by lowering the level of that protein in the cells of a patient.
[0031] In still another aspect, the description provides methods for treating or ameliorating a disease, disorder or symptom thereof in a subject or a patient, e.g., an animal such as a human, comprising administering to a subject in need thereof a composition comprising an effective amount, e.g., a therapeutically effective amount, of a compound as described herein or salt form thereof, and a pharmaceutically acceptable carrier, wherein the composition is effective for treating or ameliorating the disease or disorder or symptom thereof in the subject.
[0032] In another aspect, the description provides methods for identifying the effects of the degradation of proteins of interest in a biological system using compounds according to the present disclosure.
[0033] The preceding general areas of utility are given by way of example only and are not intended to be limiting on the scope of the present disclosure and appended claims. Additional objects and advantages associated with the compositions, methods, and processes of the present disclosure will be appreciated by one of ordinary skill in the art in light of the instant claims, description, and examples. For example, the various aspects and embodiments of the disclosure may be utilized in numerous combinations, all of which are expressly contemplated by the present description. These additional aspects and embodiments are expressly included within the scope of the present disclosure. The publications and other materials used herein to illuminate the background of the disclosure, and in particular cases, to provide additional details respecting the practice, are incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] The accompanying drawings, which are incorporated into and form a part of the specification, illustrate several embodiments of the present disclosure and, together with the description, serve to explain the principles of the disclosure. The drawings are only for the purpose of illustrating an embodiment of the disclosure and are not to be construed as limiting the disclosure. Further objects, features and advantages of the disclosure will become apparent from the following detailed description taken in conjunction with the accompanying figures showing illustrative embodiments of the disclosure, in which:
[0035] Figures 1A and 1B. Illustration of general principle for bifunctional compounes of the present disclosure. (A) Exemplary bifunctional compound comprises a protein targeting moiety (PTM; darkly shaded rectangle), a ubiquitin ligase binding moiety (ULM;
lightly shaded triangle), and optionally a linker moiety (L; black line) coupling or tethering the PTM to the ULM. (B) Illustrates the functional use of the bifunctional compounds as described herein.
Briefly, the ULM recognizes and binds to a specific E3 ubiquitin ligase, and the PTM binds and recruits a target protein bringing it into close proximity to the E3 ubiquitin ligase. Typically, the E3 ubiquitin ligase is complexed with an E2 ubiquitin-conjugating protein, and either alone or via the E2 protein catalyzes attachment of ubiquitin (dark circles) to a lysine on the target protein via an isopeptide bond. The poly-ubiquitinated protein (far right) is then targeted for degradation by the proteosomal machinery of the cell.
[0036] Figure 2A. Table 1A. Examplary protein targeting moieties and compounds of the present disclosure.
[0037] Figure 2B. Table 1B. Exemplary protein targeting moieties and compounds of the present disclosure.
[0038] Figure 2C. Table 1C. Examplary protein targeting moieties and compounds of the present disclosure.
[0039] Figure 2D. Table 1D. Examplary protein targeting moieties and compounds of the present disclosure.
[0040] Figure 3A. Table 2A. Data of exemplary protein targeting moieties and compounds of the present disclosure.
[0041] Figure 3B. Table 2B. Data of exemplary protein targeting moieties and compounds of the present disclosure.
[0042] Figure 3C. Table 2C. Data of exemplary protein targeting moieties and compounds of the present disclosure.
[0043] Figure 3D. Table 2D. Data of exemplary protein targeting moieties and compounds of the present disclosure.
[0044] Figure 4. Illustration of general principle of bifunctional compounds of the present disclosure.
[0045] Figure 5. Exemplary bifunctional compound of the present disclosure induces mutant selective degradation of BRAF.
[0046] Figure 6A, 6B, and 6C. Exemplary bifunctional compound of the present disclosure induces mutant BRAF degradation, inhibit cell proliferation, and suppresses MAPK signaling, while sparing wild-type BRAF.
[0047] Figure 7. Exemplary bifunctional compound of the present disclosure induces degradation of vemurafenib resistant mutant p61.
[0048] Figure 8A and 8B. Exemplary bifunctional compound of the present disclosure induces degradation of mutant BRAF in vivo (a) and decreases tumor volume (B).
[0049] Figure 9A and 9B. What mechanism underlies the selectivity of the exemplary bifunctional compound.
[0050] Figure 10. Wild-type BRAF is unable to recruit Cullin 2 (active E3 ligase).
DETAILED DESCRIPTION
[0051] The following is a detailed description provided to aid those skilled in the art in practicing the present disclosure. Those of ordinary skill in the art may make modifications and variations in the embodiments described herein without departing from the spirit or scope of the present disclosure. All publications, patent applications, patents, figures and other references mentioned herein are expressly incorporated by reference in their entirety.
[0052] Presently described are compositions and methods that relate to the surprising and unexpected discovery that an E3 ubiquitin ligase protein (e.g., inhibitors of apoptosis proteins (TAP), a Von Hippel-Lindau E3 ubiquitin ligase (VHL), a cereblon E3 ubiquitin ligase, or a mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase) ubiquitinates a target protein once it and the target protein are placed in proximity by a bifunctional or chimeric construct that binds the E3 ubiquitin ligase protein and the target protein. Accordingly the present disclosure provides such compounds and compositions comprising an E3 ubiquintin ligase binding moiety ("ULM") coupled to a protein target binding moiety ("PTM"), which result in the ubiquitination of a chosen target protein, which leads to degradation of the target protein by the proteasome (see Figure 1). The present disclosure also provides a library of compositions and the use thereof.
[0053] In certain aspects, the present disclosure provides compounds which comprise a ligand, e.g., a small molecule ligand (i.e., having a molecular weight of below 2,000, 1,000, 500, or 200 Daltons), which is capable of binding to a ubiquitin ligase, such as TAP, VHL, MDM2, or cereblon. The compounds also comprise a moiety that is capable of binding to target protein, in such a way that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and/or inhibition) of that protein. Small molecule can mean, in addition to the above, that the molecule is non-peptidyl, that is, it is not generally considered a peptide, e.g., comprises fewer than 4, 3, or 2 amino acids. In accordance with the present description, the PTM, ULM or PROTAC molecule can be a small molecule.
[0054] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure.
[0055] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise (such as in the case of a group containing a number of carbon atoms in which case each carbon atom number falling within the range is provided), between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the disclosure.
[0056] The following terms are used to describe the present disclosure. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.
[0057] The articles "a" and "an" as used herein and in the appended claims are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example, "an element" means one element or more than one element.
[0058] The phrase "and/or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases.
Multiple elements listed with "and/or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and/or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and/or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A
only (optionally including elements other than B); in another embodiment, to B
only (optionally including elements other than A); in yet another embodiment, to both A and B
(optionally including other elements); etc.
[0059] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and/or" as defined above. For example, when separating items in a list, "or" or "and/or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of' or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of."
[0060] In the claims, as well as in the specification above, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving,"
"holding,"
"composed of," and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of and "consisting essentially of shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
[0061] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a nonlimiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A
and/or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A);
in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
[0062] It should also be understood that, in certain methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited unless the context indicates otherwise.
[0063] The terms "co-administration" and "co-administering" or "combination therapy" refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent, preferably at effective amounts, at the same time. In certain preferred aspects, one or more of the present compounds described herein, are coadministered in combination with at least one additional bioactive agent, especially including an anticancer agent. In particularly preferred aspects, the co-administration of compounds results in synergistic activity and/or therapy, including anticancer activity.
[0064] The term "compound", as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives, including prodrug and/or deuterated forms thereof where applicable, in context.
Deuterated small molecules contemplated are those in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by deuterium.
[0065] Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds. The term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder. When the bond is shown, both a double bond and single bond are represented or understood within the context of the compound shown and well-known rules for valence interactions.
[0066] The term "ubiquitin ligase" refers to a family of proteins that facilitate the transfer of ubiquitin to a specific substrate protein, targeting the substrate protein for degradation. For example, TAP an E3 ubiquitin ligase protein that alone or in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein, and subsequently targets the specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first; a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome.
However, there are some ubiquitination events that are limited to mono-ubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono-ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.
[0067] The term "patient" or "subject" is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present disclosure is provided. For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present disclosure, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.
[0068] The term "effective" is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result.

The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application.
[0069] Compounds and Compositions
[0070] In one aspect, the description provides compounds comprising an E3 ubiquitin ligase binding moiety ("ULM") that is an TAP E3 ubiquitin ligase binding moiety (an "ILM"), a cereblon E3 ubiquitin ligase binding moiety (a "CLM"), a Von Hippel-Lindae E3 ubiquitin ligase (VHL) binding moiety (VLM), and/or a mouse double minute 2 homologue (MDM2) E3 ubiquitin ligase binding moiety (MLM). In an exemplary embodiment, the ULM is coupled to a target protein binding moiety (PTM) via a chemical linker (L) according to the structure:
(A) PTM-L-ULM
wherein L is a bond or a chemical linker group, ULM is a E3 ubiquitin ligase binding moiety, and PTM is a target protein binding moiety. The number and/or relative positions of the moieties in the compounds illustrated herein is provided by way of example only. As would be understood by the skilled artisan, compounds described herein can be synthesized with any desired number and/or relative position of the respective functional moieties.
[0071] The terms ULM, ILM, VLM, MLM, and CLM are used in their inclusive sense unless the context indicates otherwise. For example, the term ULM is inclusive of all ULMs, including those that bind TAP (i.e., ILMs), MDM2 (i.e., MLM), cereblon (i.e., CLM), and VHL (i.e., VLM).
Further, the term ILM is inclusive of all possible TAP E3 ubiquitin ligase binding moieties, the term MLM is inclusive of all possible MDM2 E3 ubiquitin ligase binding moieties, the term VLM is inclusive of all possible VHL binding moieties, and the term CLM is inclusive of all cereblon binding moieties.
[0072] In another aspect, the present disclosure provides bifunctional or multifunctional compounds (e.g., PROTACs) useful for regulating protein activity by inducing the degradation of a target protein. In certain embodiments, the compound comprises an ILM or a VLM or a CLM or a MLM coupled, e.g., linked covalently, directly or indirectly, to a moiety that binds a target protein (i.e., a protein targeting moiety or a "PTM"). In certain embodiments, the ILM/VLM/CLM/MLM and PTM are joined or coupled via a chemical linker (L). The ILM
binds the TAP E3 ubiquitin ligase, the VLM binds VHL, CLM binds the cereblon E3 ubiquitin ligase, and MLM binds the MDM2 E3 ubiquitin ligase, and the PTM recognizes a target protein and the interaction of the respective moieties with their targets facilitates the degradation of the target protein by placing the target protein in proximity to the ubiquitin ligase protein. An exemplary bifunctional compound can be depicted as:
(B) PTM¨ILM
(C) PTM¨CLM
(D) PTM¨VLM
(E) PTM¨MLM
[0073] In certain embodiments, the bifunctional compound further comprises a chemical linker ("L"). For example, the bifunctional compound can be depicted as:
(F) PTM¨L¨ILM
(G) PTM¨L¨CLM
(H) PTM¨L¨VLM
(I) PTM¨L¨MLM
wherein the PTM is a protein/polypeptide targeting moiety, the L is a chemical linker, the ILM is a TAP E3 ubiquitin ligase binding moiety, the CLM is a cereblon E3 ubiquitin ligase binding moiety, the VLM is a VHL binding moiety, and the MLM is a MDM2 E3 ubiquitin ligase binding moiety.
[0074] In certain embodiments, the ULM (e.g., a ILM, a CLM, a VLM, or a MLM) shows activity or binds to the E3 ubiquitin ligase (e.g., TAP E3 ubiquitin ligase, cereblon E3 ubiquitin ligase, VHL, or MDM2 E3 ubiquitin ligase) with an IC50 of less than about 200 i.i.M. The IC50 can be determined according to any method known in the art, e.g., a fluorescent polarization assay.
[0075] In certain additional embodiments, the bifunctional compounds described herein demonstrate an activity with an IC50 of less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 mM, or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 iiM, or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 nM, or less than about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 pM.
[0076] In certain embodiments, the compounds as described herein comprise multiple PTMs (targeting the same or different protein targets), multiple ULMs, one or more ULMs (i.e., moieties that bind specifically to multiple/different E3 ubiquitin ligase, e.g., VHL, TAP, cereblon, and/or MDM2) or a combination thereof. In any of the aspects or embodiments described herein, the PTMs and ULMs (e.g., ILM, VLM, CLM, and/or MLM) can be coupled directly or via one or more chemical linkers or a combination thereof. In additional embodiments, where a compound has multiple ULMs, the ULMs can be for the same E3 ubiquintin ligase or each respective ULM can bind specifically to a different E3 ubiquitin ligase. In still further embodiments, where a compound has multiple PTMs, the PTMs can bind the same target protein or each respective PTM can bind specifically to a different target protein.
[0077] In certain embodiments, where the compound comprises multiple ULMs, the ULMs are identical. In additional embodiments, the compound comprising a plurality of ULMs (e.g., ULM, ULM', etc.), at least one PTM coupled to a ULM directly or via a chemical linker (L) or both. In certain additional embodiments, the compound comprising a plurality of ULMs further comprises multiple PTMs. In still additional embodiments, the PTMs are the same or, optionally, different. In still further embodiments, wherein the PTMs are different, the respective PTMs may bind the same protein target or bind specifically to a different protein target.
[0078] In certain embodiments, the compound may comprise a plurality of ULMs and/or a plurality of ULM' s. In further embodiments, the compound comprising at least two different ULMs, a plurality of ULMs, and/or a plurality of ULM' s further comprises at least one PTM
coupled to a ULM or a ULM' directly or via a chemical linker or both. In any of the embodiments described herein, a compound comprising at least two different ILMs can further comprise multiple PTMs. In still additional embodiments, the PTMs are the same or, optionally, different. In still further embodiments, wherein the PTMs are different the respective PTMs may bind the same protein target or bind specifically to a different protein target. In still further embodiments, the PTM itself is a ULM (or ULM'), such as an ILM, a VLM, a CLM, a MLM, an ILM', a VLM', a CLM', and/or a MLM'.
[0079] In additional embodiments, the description provides the compounds as described herein including their enantiomers, diastereomers, solvates and polymorphs, including pharmaceutically acceptable salt forms thereof, e.g., acid and base salt forms.
[0080] The term "independently" is used herein to indicate that the variable, which is independently applied, varies independently from application to application.
[0081] The term "alkyl" shall mean within its context a linear, branch-chained or cyclic fully saturated hydrocarbon radical or alkyl group, preferably a Ci-Cio, more preferably a Ci-C6, alternatively a Ci-C3 alkyl group, which may be optionally substituted.
Examples of alkyl groups are methyl, ethyl, n-butyl, sec-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopen-tylethyl, cyclohexylethyl and cyclohexyl, among others. In certain embodiments, the alkyl group is end-capped with a halogen group (At, Br, Cl, F, or I). In certain preferred embodiments, compounds according to the present disclosure which may be used to covalently bind to dehalogenase enzymes. These compounds generally contain a side chain (often linked through a polyethylene glycol group) which terminates in an alkyl group which has a halogen substituent (often chlorine or bromine) on its distal end which results in covalent binding of the compound containing such a moiety to the protein.
[0082] The term "Alkenyl" refers to linear, branch-chained or cyclic C2-C10 (preferably C2-C6) hydrocarbon radicals containing at least one C=C bond.
[0083] The term "Alkynyl" refers to linear, branch-chained or cyclic C2-C10 (preferably C2-C6) hydrocarbon radicals containing at least one CC bond.
[0084] The term "alkylene" when used, refers to a ¨(CH2).- group (n is an integer generally from 0-6), which may be optionally substituted. When substituted, the alkylene group preferably is substituted on one or more of the methylene groups with a C1-C6 alkyl group (including a cyclopropyl group or a t-butyl group), but may also be substituted with one or more halo groups, preferably from 1 to 3 halo groups or one or two hydroxyl groups, 0-(C1-C6 alkyl) groups or amino acid sidechains as otherwise disclosed herein. In certain embodiments, an alkylene group may be substituted with a urethane or alkoxy group (or other group) which is further substituted with a polyethylene glycol chain (of from 1 to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units) to which is substituted (preferably, but not exclusively on the distal end of the polyethylene glycol chain) an alkyl chain substituted with a single halogen group, preferably a chlorine group. In still other embodiments, the alkylene (often, a methylene) group, may be substituted with an amino acid sidechain group such as a sidechain group of a natural or unnatural amino acid, for example, alanine, 13-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine.
[0085] The term "unsubstituted" shall mean substituted only with hydrogen atoms. A range of carbon atoms which includes Co means that carbon is absent and is replaced with H. Thus, a range of carbon atoms which is Co-C6 includes carbons atoms of 1, 2, 3, 4, 5 and 6 and for Co, H
stands in place of carbon.
[0086] The term "substituted" or "optionally substituted" shall mean independently (i.e., where more than substituent occurs, each substituent is independent of another substituent) one or more substituents (independently up to five substitutents, preferably up to three substituents, often 1 or 2 substituents on a moiety in a compound according to the present disclosure and may include substituents which themselves may be further substituted) at a carbon (or nitrogen) position anywhere on a molecule within context, and includes as substituents hydroxyl, thiol, carboxyl, cyano (C1\1), nitro (NO2), halogen (preferably, 1, 2 or 3 halogens, especially on an alkyl, especially a methyl group such as a trifluoromethyl), an alkyl group (preferably, Ci-Cio , more preferably, Ci-C6), aryl (especially phenyl and substituted phenyl for example benzyl or benzoyl), alkoxy group (preferably, Ci-C6 alkyl or aryl, including phenyl and substituted phenyl), thioether (Ci-C6 alkyl or aryl), acyl (preferably, Ci-C6 acyl), ester or thioester (preferably, Ci-C6 alkyl or aryl) including alkylene ester (such that attachment is on the alkylene group, rather than at the ester function which is preferably substituted with a Ci-C6 alkyl or aryl group), preferably, Ci-C6 alkyl or aryl, halogen (preferably, F or Cl), amine (including a five- or six-membered cyclic alkylene amine, further including a Ci-C6 alkyl amine or a Ci-C6 dialkyl amine which alkyl groups may be substituted with one or two hydroxyl groups) or an optionally substituted ¨N(CO-C6 alkyl)C(0)(0-Ci-C6 alkyl) group (which may be optionally substituted with a polyethylene glycol chain to which is further bound an alkyl group containing a single halogen, preferably chlorine substituent), hydrazine, amido, which is preferably substituted with one or two Ci-C6 alkyl groups (including a carboxamide which is optionally substituted with one or two Ci-C6 alkyl groups), alkanol (preferably, Ci-C6 alkyl or aryl), or alkanoic acid (preferably, Ci-C6 alkyl or aryl). Substituents according to the present disclosure may include, for example ¨SiRiR2R3 groups where each of Ri and R2 is as otherwise described herein and R3 is H or a Ci-C6 alkyl group, preferably R1, R2, R3 in this context is a Ci-C3 alkyl group (including an isopropyl or t-butyl group). Each of the above-described groups may be linked directly to the substituted moiety or alternatively, the substituent may be linked to the substituted moiety (preferably in the case of an aryl or heteraryl moiety) through an optionally substituted -(CH2)õ,- or alternatively an optionally substituted -(OCH2).,-, -(OCH2CH2).,- or -(CH2CH20).,- group, which may be substituted with any one or more of the above-described substituents. Alkylene groups -(CH2),,,-or -(CH2).- groups or other chains such as ethylene glycol chains, as identified above, may be substituted anywhere on the chain. Preferred substitutents on alkylene groups include halogen or C1-C6 (preferably Ci-C3) alkyl groups, which may be optionally substituted with one or two hydroxyl groups, one or two ether groups (0-C1-C6 groups), up to three halo groups (preferably F), or a sideshain of an amino acid as otherwise described herein and optionally substituted amide (preferably carboxamide substituted as described above) or urethane groups (often with one or two Co-C6 alkyl substitutents, which group(s) may be further substituted). In certain embodiments, the alkylene group (often a single methylene group) is substituted with one or two optionally substituted C1-C6 alkyl groups, preferably C1-C4 alkyl group, most often methyl or 0-methyl groups or a sidechain of an amino acid as otherwise described herein.
In the present disclosure, a moiety in a molecule may be optionally substituted with up to five substituents, preferably up to three substituents. Most often, in the present disclosure moieties which are substituted are substituted with one or two substituents.
[0087] The term "substituted" (each substituent being independent of any other substituent) shall also mean within its context of use Ci-C6 alkyl, Ci-C6 alkoxy, halogen, amido, carboxamido, sulfone, including sulfonamide, keto, carboxy, Ci-C6ester (oxyester or carbonylester), Ci-C6keto, urethane -0-C(0)-NR1R2 or ¨N(R1)-C(0)-0-R1, nitro, cyano and amine (especially including a Ci-C6 alkylene-NR1122, a mono- or di- Ci-C6 alkyl substituted amines which may be optionally substituted with one or two hydroxyl groups). Each of these groups contain unless otherwise indicated, within context, between 1 and 6 carbon atoms. In certain embodiments, preferred substituents will include for example, -NH-, -NHC(0)-, -0-, =0, -(CH2)6,-(here, m and n are in context, 1, 2, 3, 4, 5 or 6), -S-, -S(0)-, SO2- or ¨NH-C(0)-NH-, -(CH2)60H, -(CH2)SH, -(CH2)C00H, Ci-C6 alkyl, -(CH2)60-(Ci-C6 alkyl), -(CH2)nC(0)-(Ci-C6 alkyl), -(CH2)60C(0)-(Ci-C6 alkyl), -(CH2)6C(0)0-(Ci-C6 alkyl), -(CH2),INHC(0)-R1, -(CH2)C(0)-NR1R2, -(0CH2)60H, -(CH20),C00H, Ci-C6 alkyl, -(0CH2)60-(Ci-C6 alkyl), -(CH20)C(0)-(Ci-alkyl), -(0CH2)NHC(0)-Ri, -(CH20),C(0)-NR,R2, -S(0)2-Rs, -S(0)-Rs (Rs is Ci-C6 alkyl or a ¨(CH2).-NR,R2 group), NO2, CN or halogen (F, Cl, Br, I, preferably F or Cl), depending on the context of the use of the substituent. R, and R2 are each, within context, H
or a Ci-C6 alkyl group (which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups, preferably fluorine). The term "substituted" shall also mean, within the chemical context of the compound defined and substituent used, an optionally substituted aryl or heteroaryl group or an optionally substituted heterocyclic group as otherwise described herein.
Alkylene groups may also be substituted as otherwise disclosed herein, preferably with optionally substituted C1-C6 alkyl groups (methyl, ethyl or hydroxymethyl or hydroxyethyl is preferred, thus providing a chiral center), a sidechain of an amino acid group as otherwise described herein, an amido group as described hereinabove, or a urethane group 0-C(0)-N121122 group where Ri and R2 are as otherwise described herein, although numerous other groups may also be used as substituents. Various optionally substituted moieties may be substituted with 3 or more substituents, preferably no more than 3 substituents and preferably with 1 or 2 substituents.
It is noted that in instances where, in a compound at a particular position of the molecule substitution is required (principally, because of valency), but no substitution is indicated, then that substituent is construed or understood to be H, unless the context of the substitution suggests otherwise.
[0088] The term "aryl" or "aromatic", in context, refers to a substituted (as otherwise described herein) or unsubstituted monovalent aromatic radical having a single ring (e.g., benzene, phenyl, benzyl) or condensed rings (e.g., naphthyl, anthracenyl, phenanthrenyl, etc.) and can be bound to the compound according to the present disclosure at any available stable position on the ring(s) or as otherwise indicated in the chemical structure presented. Other examples of aryl groups, in context, may include heterocyclic aromatic ring systems, "heteroaryl" groups having one or more nitrogen, oxygen, or sulfur atoms in the ring (moncyclic) such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole or fused ring systems such as indole, quinoline, indolizine, azaindolizine, benzofurazan, etc., among others, which may be optionally substituted as described above. Among the heteroaryl groups which may be mentioned include nitrogen-containing heteroaryl groups such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, triazine, tetrazole, indole, isoindole, indolizine, azaindolizine, purine, indazole, quinoline, dihydroquinoline, tetrahydroquinoline, isoquinoline, dihydroisoquinoline, tetrahydroisoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, pyrimidine, phenanthroline, phenacene, oxadiazole, benzimidazole, pyrrolopyridine, pyrrolopyrimidine and pyridopyrimidine; sulfur-containing aromatic heterocycles such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles such as furan, pyran, cyclopentapyran, benzofuran and isobenzofuran; and aromatic heterocycles comprising 2 or more hetero atoms selected from among nitrogen, sulfur and oxygen, such as thiazole, thiadizole, isothiazole, benzoxazole, benzothiazole, benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine, pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyridine, furopyrimidine, thienopyrimidine and oxazole, among others, all of which may be optionally substituted.
[0089] The term "substituted aryl" refers to an aromatic carbocyclic group comprised of at least one aromatic ring or of multiple condensed rings at least one of which being aromatic, wherein the ring(s) are substituted with one or more substituents. For example, an aryl group can comprise a substituent(s) selected from: -(CH2),OH, -(CH2),-0-(Ci-C6)alkyl, -(CH2)n-0-(CH2)n-(C1-C6)alkyl, -(CH2)n-C(0)(Co-C6) alkyl, -(CH2)n-C(0)0(Co-C6)alkyl, -(CH2)n-OC(0)(Co-C6)alkyl, amine, mono- or di-(Ci-C6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, Cl) groups, OH, COOH, Ci-C6 alkyl, preferably CH3, CF3, OMe, OCF3, NO2, or CN group (each of which may be substituted in ortho-, meta- and/or para- positions of the phenyl ring, preferably para-), an optionally substituted phenyl group (the phenyl group itself is preferably substituted with a linker group attached to a PTM group, including a ULM group), and/or at least one of F, Cl, OH, COOH, CH3, CF3, OMe, OCF3, NO2, or CN group (in ortho-, meta- and/or para-positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted, an optionally substituted heteroaryl, preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted isothiazole including a methyl substituted isothiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, an optionally substituted benzimidazole or methoxybenzylimidazole, an optionally substituted oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, an optionally substituted pyridine group, including a halo-(preferably, F) or methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen), an optionally substituted furan, an optionally substituted benzofuran, an optionally substituted dihydrobenzofuran, an optionally substituted indole, indolizine or azaindolizine (2, 3, or 4-azaindolizine), an optionally substituted quinoline, and combinations thereof.
[0090] "Carboxyl" denotes the group --C(0)0R, where R is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl , whereas these generic substituents have meanings which are identical with definitions of the corresponding groups defined herein.
[0091] The term "heteroaryror "hetaryl" can mean but is in no way limited to an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole (including dihydroindole), an optionally substituted indolizine, an optionally substituted azaindolizine (2, 3 or 4-azaindolizine) an optionally substituted benzimidazole, benzodiazole, benzoxofuran, an optionally substituted imidazole, an optionally substituted isoxazole, an optionally substituted oxazole (preferably methyl substituted), an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted benzofuran, an optionally substituted thiophene, an optionally substituted thiazole (preferably methyl and/or thiol substituted), an optionally substituted isothiazole, an optionally substituted triazole (preferably a 1,2,3-triazole substituted with a methyl group, a triisopropylsilyl group, an optionally substituted -(CH2).,-0-Ci-C6 alkyl group or an optionally substituted -(CH2).,-C(0)-0-C1-C6 alkyl group), an optionally substituted pyridine (2-, 3, or 4-pyridine) or a group according to the chemical structure:
r 0 ______________________________________________________________ RHET
i_RHET 0 LURE
RuRE

RHET N:32.1 RHET RHET
Jµir RHET -rjN1(321 yC
wherein:
SC is CHRss, NRuRE; or 0;
RHET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably C1-C3 alkyl);
Rss is H, CN, NO2, halo (preferably F or CO, optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RuRE is ri¨, a Ci-C6 alkyl (preferably H or Ci-C3 alkyl) or a ¨C(0)(Ci-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and Yc is N or C-R, where RYc is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl).
[0092] The terms "aralkyl" and "heteroarylalkyl" refer to groups that comprise both aryl or, respectively, heteroaryl as well as alkyl and/or heteroalkyl and/or carbocyclic and/or heterocycloalkyl ring systems according to the above definitions.
[0093] The term -arylalkyl" as used herein refers to an aryl group as defined above appended to an alkyl group defined above. The arylalkyl group is attached to the parent moiety through an alkyl group wherein the alkyl group is one to six carbon atoms. The aryl group in the arylalkyl group may be substituted as defined above.
[0094] The term "Heterocycle" refers to a cyclic group which contains at least one heteroatom, e.g., N, 0 or S, and may be aromatic (heteroaryl) or non-aromatic. Thus, the heteroaryl moieties are subsumed under the definition of heterocycle, depending on the context of its use. Exemplary heteroaryl groups are described hereinabove.
[0095] Exemplary heterocyclics include: azetidinyl, benzimidazolyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, benzoxazolyl, benzothiazolyl, benzothienyl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dioxanyl, dioxolanyl, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane, furyl, homopiperidinyl, i idaz olyi, imidazolinyl, imidazolidinyl, indolinyl, indoiyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, naphthyridinyl, oxazolidinyl, oxazolyl, pyridone, 2-pyrrolidone, pyridine, piperazinylõ N-methylpiperazinyl, piperidinyl, phthalimide, succinimide, pyrazinyl, pyrazolinyl, pyridyl, pyrimidinyl, pyrroli di ny I , pyn-o I i n yl, pyrrol y I , qu i no lin yl, tetrah ydrofuranyi tetrahydropyran yl , tetrahydroquinoline, thiazolidinyl, thiazolyl, thienyl, tetrahydrothiophene, oxane, oxetanyl, oxathiolanyl, thiane among others.
[0096] Heterocyclic groups can be optionally substituted with a member selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, ¨SO-alkyl, ¨SO-substituted alkyl, ¨S Oaryl, ¨SO-heteroaryl, ¨S02-alkyl, ¨S02-substituted alkyl, ¨S02-aryl, oxo (=0), and -S02-heteroaryl.
Such heterocyclic groups can have a single ring or multiple condensed rings.
Examples of nitrogen heterocycles and heteroaryls include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, morpholino, piperidinyl, tetrahydrofuranyl, and the like as well as N-alkoxy-nitrogen containing heterocycles. The term "heterocyclic"' also includes bicyclic groups in which any of the heterocyclic rings is fused to a benzene ring or a cyclohexane ring or another heterocyclic ring (for example, indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, and the like).
[0097] The term "cycloalkyl" can mean but is in no way limited to univalent groups derived from monocyclic or polycyclic alkyl groups or cycloalkanes, as defnied herein, e.g., saturated monocyclic hydrocarbon groups having from three to twenty carbon atoms in the ring, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
The term "substituted cycloalkyl" can mean but is in no way limited to a monocyclic or polycyclic alkyl group and being substituted by one or more substituents, for example, amino, halogen, alkyl, substituted alkyl, carbyloxy, carbylmercapto, aryl, nitro, mercapto or sulfo, whereas these generic substituent groups have meanings which are identical with definitions of the corresponding groups as defined in this legend.
[0098] "Heterocycloalkyl" refers to a monocyclic or polycyclic alkyl group in which at least one ring carbon atom of its cyclic structure being replaced with a heteroatom selected from the group consisting of N, 0, S or P. "Substituted heterocycloalkyl" refers to a monocyclic or polycyclic alkyl group in which at least one ring carbon atom of its cyclic structure being replaced with a heteroatom selected from the group consisting of N, 0, S or P and the group is containing one or more substituents selected from the group consisting of halogen, alkyl, substituted alkyl, carbyloxy, carbylmercapto, aryl, nitro, mercapto or sulfo, whereas these generic substituent group have meanings which are identical with definitions of the corresponding groups as defined in this legend.
[0099] The term "hydrocarbyl" shall mean a compound which contains carbon and hydrogen and which may be fully saturated, partially unsaturated or aromatic and includes aryl groups, alkyl groups, alkenyl groups and alkynyl groups.
[0100] The term "independently" is used herein to indicate that the variable, which is independently applied, varies independently from application to application.
[0101] The term "lower alkyl" refers to methyl, ethyl or propyl
[0102] The term "lower alkoxy" refers to methoxy, ethoxy or propoxy.
[0103] In any of the embodiments described herein, the W, X, Y, Z, G, G', R, R', R", Q1-Q4, and A, can independently be covalently coupled to a linker and/or a linker to which is attached one or more PTM, ULM, ILM or ILM' groups.
[0104] Exemplary CLMs
[0105] Neo-imide Compounds
[0106] In one aspect the description provides compounds useful for binding and/or inhibiting cereblon. In certain embodiments, the compound is selected from the group consisting of chemical structures:
X X G X X G
õoõ..0Q4,...,.zz..,........_.< avvi._ N/ /
N QC)4........,..k 11 / __________ Z 11 / \ )Z
IQ 2/,'..----'' W 7K) Q2 ./. ..,..;;%\..... w ____________________________________________________________ N

Rn Rn \G' Rn R' (al) (b) G

G N Z
\ _________________________ N
X X/ X x Q4....,.......,,k II / N ) __ Z Qe4N jjj.
I I Rn Q2k ..sM/ ________________ N
Rn Qi A/ A \G' 02 /6õ..7\.,1 y .....,....,..õ
Z
X Rn (c) (dl) G

N Z X X
X
Qr.4 Q
,......,....A
Qe4 N jsr.r 0/
.......... wl / )- Z
II
M Rn Rn Rn Rn (e) (f), G

X z X X G N
X
/

Q( WA _____________________ N
Qe4N sj.sr 11 N 11 Rn y A ,..w, 1) Z

Rn , Rn Rn , (a2) (d2) X G X X
\
Z
71() Z
vv 1-0 Rn Rn , or Rn Rn (a3) (a4) wherein:
W of Formulas (a) through (e) [e.g., (al), (b), (c), (dl), (e), (f), (a2), (d2), (a3), and (a4)] is independently selected from the group CH2, 0, CHR, C=0, S02, NH, optionally substituted cycloalkyl (e.g., optionally substituted 3-6 member cycloalkyl, optionally substituted cyclopropyl group or optionally substituted cyclobutyl group), optionally substituted heterocycloalkyl, and N-alkyl;
W3 is selected from C or N;
X of Formulas (a) through (e) is independently selected from the group absent, 0, S and CH2, Y of Formulas (a) through (e) is independently selected from the group CH2, -C=CR', NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, 0, and S;
Z of Formulas (a) through (e) is independently selected from the group absent, 0, S or CH2 except that both X and Z cannot be absent or CH2, G and G'of Formulas (a) through (e) are independently selected from the group H, optionally substituted linear or branched alkyl, OH, R'OCOOR, R'OCONRR", -(CH2),,-0-P(=0)(0-C1_6a1ky1)(OH), -(CH2),,-0-P(=0)(0-C1_6alky1)2,-(CH2),, -0-P(=0)(OH)2, -CH2OCOO(CH2CH20),,,CH3, CH2-heterocycly1 optionally substituted with R', and benzyl optionally substituted with R';
n" is an integer from 8 to 35 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17. 18.
19. 20. 21. 22. 23 24. 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35);
Q1 - Q4 of Formulas (a) through (e) each independently represent a carbon C
substituted with a group independently selected from H, R, N or N-oxide;
A of Formulas (a) through (e) is independently selected from the group H, optionally substituted linear or branched alkyl, cycloalkyl, Cl and F;
R of Formulas (a) through (e) comprises, but is not limited to: H, -CONR'R", -OR', -NR'R", -SR', -502R', -S 02NR' R", -CR' R"-, -CR' NR' R"-, (-CR' 0),,R", halogen, optionally substituted-aryl (e.g., an optionally substituted C5-C7 aryl), optionally substituted alkyl-aryl (e.g., an alkyl-aryl comprising at least one of an optionally substituted C1-C6 alkyl, an optionally substituted C5-C7 aryl, or combinations thereof), optionally substituted-heteroaryl (e.g., an optionally substituted C5-C7 heteroaryl), unsubstituted or substituted linear or branched alkyl (e.g., a C1-C6 linear or branched alkyl optionally substituted with one or more halogen, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted alkoxyl group (e.g., a methoxy, ethoxy, butoxy, propoxy, pentoxy, or hexoxy; wherein the alkoxyl may be substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 , , , /
aryl)), optionally substituted Y
(e.g., optionally substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 c yclo alkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted , ' 0 , 0 )1):
Y
(e.g., optionally substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted-cycloalkyl (e.g., optionally substituted C3-C7 cycloalkyl), optionally substituted-heterocyclyl (e.g., optionally substituted C3-C7 heterocyclyl), -P(0)(OR')R", -P(0)R'R", -0P(0)(OR')R", -0P(0)R'R", -Cl, -F, -Br, -I, -CF3, -CN, -NR' S 02NR' R", -NR' CONR' R", -CONR' COR", -NR'C(=N-CN)NR' R", -C(=N-CN)NR'R", -NR'C(=N-CN)R", -NR'C(=C-NO2)NR'R", -SO2NR'COR", -NO2, -CO2R', -C(C=N-OR')R", -CR'=CR'R", -CCR', -S(C=0)(C=N-R')R", -SF5 and -0CF3;
each of x, y, and z are independently 0, 1,2, 3,4, 5, or 6;
R' and R" of Formulas (a) through (e) are independently selected from a H, optionally substituted linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic, -C(=0)R, optionally substituted heterocyclyl;
n and n' of Formulas (a) through (e) are each individually an integer from 1-10 (e.g., 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10);
:zz"---":------- represents a single bond or a double bond; and . of Formulas (a) through (e) represents a bond that may be stereospecific ((R) or (S)) or non-stereo specific.
[0107] Exemplary CLMs
[0108] In any of the compounds described herein, the CLM comprises a chemical structure selected from the group:
X X G X X G
Q .,n) __ N/
N/
c)Q4........õ,,,K
cl.,.... 4......1( 111"........_vvr NI) Z 11 N ________ Z
/ \ __________________________________________________________ ) Q2/. ,...õ."=\ vv N
1 Qi Rn Rn \G' Rn/ R' (al) (b) G

X X N Z
471i X x _________________________ N /G
Q(.....Q4,.......

/ ) Z Q N j'Pr I I Rn VV/ A N
Q1/ \ Q 2/ cr.7%.,..1 y .......===== ..õ, Rn Z
x G' Rn (c) (dl) G

N Z X X
X x C)4 uµrt, __ or Qe4N jµrd I I Rn I I ,N )- Z
Qy. Q ====".(..0" '''========... \ Alf /
Q2/ar.......N''....'--A Rn R Rn R, (e) (f), G

X xNz X X G
03'WA2:)4 srvZ N/
Q()4N sjj.
II N 11 Rn / ) ____ Z
Rn Rn Rn (a2) (d2) X G X X
Qi C ______ R/'' Or Rn/ A
plavvi _______________________ Z Q2 VV/ -1\40 Qi Rn Rn , (a3) (a4) wherein:
W of Formulas (a) through (e) [e.g., (al), (b), (c), (dl), (e), (f), (a2), (d2), (a3), and (a4)] is independently selected from the group CH2, 0, CHR, C=0, SO2, NH, optionally substituted cycloalkyl (e.g., optionally substituted 3-6 member cycloalkyl, optionally substituted cyclopropyl group or optionally substituted cyclobutyl group), optionally substituted heterocycloalkyl (e.g., an optionally substituted 3-6 member heterocyloalkyl), and N-alkyl;
W3 is selected from C or N;
X of Formulas (a) through (e) is independently selected from the group absent, 0, S and CH2;
Y of Formulas (a) through (e) is independently selected from the group CH2, -C=CR', NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, 0, and S;
Z of Formulas (a) through (e) is independently selected from the group absent, 0, S, andCH2 except that both X and Z cannot be absent or CH2;
G and G' of Formulas (a) through (e) are independently selected from the group H, optionally substituted linear or branched alkyl, OH, R'OCOOR, R'OCONRR", -(CH2),,-0-P(=0)(0-C1_6a11y1)(OH), -(CH2),,-0-P(=0)(0-C 1_6a1ky1)2, -(CH2),,-0-P(=0)(OH)2, -CH2OCOO(CH2CH20),,,CH3, CH2-heterocycly1 optionally substituted with R', and benzyl optionally substituted with R'; -n" is an integer from 8 to 35 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17. 18.
19. 20. 21. 22. 23 24. 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35);
Q1 - Q4 of Formulas (a) through (e) each independently represent a carbon C
substituted with a group independently selected from H, R, N or N-oxide;
A of Formulas (a) through (e) is independently selected from the group H, optionally substituted linear or branched alkyl, cycloalkyl, Cl and F;

R of Formulas (a) through (e) comprises, but is not limited to: H, -CONR'R", -OR', -NR'R", -SR', -S 02R' , -S 02NR' R", -CR' R"-, -CR' NR' R"-, (-CR' 0),,R", halogen, optionally substituted heterocyclyl (e.g., optionally substituted C3-C7 heterocyclyl), optionally substituted ¨aryl (e.g., an optionally substituted C5-C7 aryl), optionally substituted alkyl-aryl (e.g., an alkyl-aryl comprising at least one of an optionally substituted C1-C6 alkyl, an optionally substituted C5-C7 aryl, or combinations thereof), optionally substituted-heteroaryl (e.g., an optionally substituted C5-C7 heteroaryl), optionally substituted linear or branched-alkyl (e.g., a C1-C6 linear or branched alkyl optionally substituted with one or more halogen, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted alkoxyl group (e.g., a methoxy, ethoxy, butoxy, propoxy, pentoxy, or hexoxy; wherein the alkoxyl may be substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), , , ,.......
, 0 optionally substituted Y
(e.g., optionally substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-c yclo alkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted , ' 0 )H:
/
, 0 Y
(e.g., optionally substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substitutedcycloalkyl (e.g., optionally substituted C3-C7 cycloalkyl), optionally substituted-cycloalkyl (e.g., optionally substituted C3-C7 cycloalkyl), optionally substituted-heterocyclyl (e.g., optionally substituted C3-C7 heterocyclyl), -P(0)(OR')R", -P(0)R'R", -0P(0)(OR')R", -0P(0)R'R", -Cl, -F, -Br, -I, -CF3, -CN, -NR' S 02NR' R", -NR' CONR' R", -CONR' COR", -NR'C(=N-CN)NR' R", -C(=N-CN)NR'R", -NR'C(=N-CN)R", -NR'C(=C-NO2)NR'R", -SO2NR'COR", -NO2, -CO2R', -C(C=N-OR')R", -CR'=CR'R", -CCR', -S(C=0)(C=N-R')R", -SF5 and -0CF3, wherein at least one R (e.g., at least one of 0, OH, N, NH, NH2, C1-C6 alkyl, C1-C6 alkoxy, optionally substituted-cycloalkyl (e.g., optionally substituted C3-C7 cycloalkyl), optionally substituted-heterocyclyl (e.g., optionally substituted C3-C7 heterocyclyl), -alkyl-aryl (e.g., an ¨alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), heteroaryl aryl (e.g., C5-C7 heteroaryl), amine, amide, or carboxy) is modified to be covalently joined to a PTM, a chemical linker group (L), a ULM, a CLM' (e.g., CLM' is an additional CLM that has the same or different structure as a first CLM), or a combination thereof each of x, y, and z are independently 0, 1,2, 3,4, 5, or 6;
R' and R" of Formulas (a) through (e) are independently selected from a bond, H, optionally substituted linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic, -C(=0)R, optionally substituted heterocyclyl;
n and n' of Formulas (a) through (e) are each individually an integer from 1-10 (e.g., 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10);
. of Formulas (a) through (e) represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific
[0109] In certain embodiments described herein, the CLM or ULM comprises a chemical structure selected from the group:

N H
jK1 0 Rn Formula (g) wherein:
W of Formula (g) is independently selected from the group CH2, C=0, NH, and N-alkyl;
A of Formula (g) is independently selected from a H, methyl, alkyl (e.g., a or C1-C6 alkyl (linear, branched, optionally substituted));
R of Formula (g) is independently selected from a Hõ OHõ NH2, halogen, methyl, optionally substituted linear or branched alkyl (e.g., optionally substituted linear or branched C1-C6 alkyl), optionally substituted C1-C6 alkoxy, optionally substituted-cycloalkyl (e.g., optionally substituted C3-C7 cycloalkyl), optionally substituted-heterocyclyl (e.g., optionally substituted C3-C7 heterocycly1),optionally substituted-alkyl-aryl (e.g., an ¨
alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), optionally substituted aryl (e.g., C5-C7 aryl), amine, amide, or carboxy);
n of Formulas (g) represent an integer from 1 to 4 (e.g., 1, 2, 3, or 4), wherein at least one R
(e.g., at least one of OH, NH2, halogen, C1-C6 alkyl, C1-C6 alkoxy, -alkyl-aryl (e.g., an ¨
alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, or carboxy) is modified to be covalently joined to a PTM, a chemical linker group (L), a ULM, CLM (or CLM') or combination thereof;
and . of Formula (g) represents a bond that may be stereospecific ((R) or (S)) or non-stereo specific.
[0110] In any of the embodiments described herein, the W, X, Y, Z, G, G', R, R', R", Ql-Q4, and Aof Formulas (a) through (g) [e.g., (al), (b), (c), (dl), (e), (f), (a2), (d2), (a3), (a4), and (g)] can independently be covalently coupled to a linker and/or a linker to which is attached one or more PTM, ULM, CLM or CLM' groups.
[0111] In any of the aspects or embodiments described herein, the CLM
comprises from 1 to 4 R groups on Qi, Q2, Q3, Q4, or a combination, wherein each R is an independently selected functional groups or atoms, for example, OH, halogen, C1-C6 alkyl, C1-C6 alkoxy, optionally substituted-cycloalkyl (e.g., optionally substituted C3-C7 cycloalkyl), optionally substituted-heterocyclyl (e.g., optionally substituted C3-C7 heterocyclyl), -alkyl-aryl (e.g., an ¨alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, cyano, or carboxy, and optionally, one of which is modified to be covalently joined to a PTM, a chemical linker group (L), a ULM, CLM (or CLM') or combination thereof.
[0112] In some embodiments, the CLM is represented by the following structures with the dashed lines indicating linker attachment points:

1.1 N-20 1.1 40) NH
NH
0 0 :5
[0113] More specifically, non-limiting examples of CLMs include those shown below as well as those "hybrid" molecules that arise from the combination of 1 or more of the different features shown in the molecules below.

o 0\ o 0\ 0 0 ,......./..,,,_....,<. ...._Z NH
......./.... ....JK. NH NH
1...õ, 0 1/ Nil" 1/ 0 .-=\\( Rn/ 0 Rn 0 Rn 0 0 0 0 0\
\ ________________________________________________________________ ,õ..."-:õ.,___,=<. __ ....... NH __ \ NH NH
N H N111..... __ 0 1../....," ______ 0 All Alk Rn 0 Rn 0 Rn 0 ,õ....."..,_. ..,/K. NH __________ =,......."...../< ______ NH
NH
1 N ______ 0 N yl ............\.(N
S
/."---...../
1\/
Rn Rn 0 Rn S

r,.., ..õ.. N __ NH N ...õ. ____ NH ,,...,N. ________ NH
o N _____________________________________________________________________ 0 Rn 0 7 N 0 A.( Rn 0 O Rn 0 O 0 0 C. 0 0 \ N
.,,...,N....1( NH NH ,..õN.., _______ NH
1/ N _____________ 11 N
N _____________________________________________________________________ 0 N,./..., Rn Rn Rn 0 \ /
,...........,...,,K ( __ NH ...õ---",.... ....iK.
NH
0 A(N
Rn 0 Rn 0 Rn 0 ____________________ 0 N

\\ 41 \\ /0 iN ( ) r/N ( NE _____________________________ 0 ly N ) __ 0 7--g2 Rn 0 Rn Rn O uH 0 µ HN \
______________________________________________________________ N
HN ____ HN ____ HN _______________________________________________ ).---*----/I /
O ( N HN __ \
\ '''.....4 \

O uH S uH
uH
HN µ HN __ \
).-----/i HN
0 _____________________________________________________ ( N/1 I ( N
HN
1 ______________________________ \
)r--1 O uH 0 uH 0 uH
HN ________________________ HN _______________________ HN
)./ Y'=-./N
0 __ ( 1 0 ___ ( N ) ( N /
)rN
HN 0 __ \ HN __ \ N HN __ \

0 uH 0 uH
O uH
HN _________________________________________________________ N _______________________________ 0 N ______ NVY ) N)/IN 0 ( ) )f, HN __ \ HN ___________ N
HN ____ \ N \ 11 O uH S LJH
uH
HN ____________________________________________________ HN __ HN __________________________________ ).-----/i ).---*----/ N 0 __ ( N/1 )r_,1 HN ____ \ HN \ HN __ \

tHOS0/6IOZSI1LIDcl t9SISO/OZOZ OM

o o\
O : 0 0 ________________________________________________________________________ NH
___________________________________________ NH
__________________ NH ....,..--/K .,õ----<
rNONN.\
) __ 0 NW...
) _______________________________________________ 0 1 7"------õ,<N _____________________________________________________ ) __ 0 /*----.A.,( .--=-=...A( ______________________ NH
__________________ NH ____________________ NH
/
Rn 0 S
Rn 0 0 Rn 0 0 O 0 0 0 =0 S \
\NH
__________________ NH ____________________ NH ,,...--1 ..õ..--=<
N ___________________ 0 5.
) ) /I .,......,\.(N
) __ 0 -f _______________________________________________________________ NH
AI NH NH
1./...,..,..NlIAillik... /\
Rn 0 0 Rn 0 0 Rn 0 0 O 0 0 0\ 0 0\
__________________ NH .õ--1( ---/K
1 N ) __ 0 1/ N ) __ 0 NH NH
____________________________________________________ 1/ N ) __ S
...... ,...,.
________________________________________________________________________ NH
__________________ NH _____________________ NH
Rn Rn Rn 0 0 0 0 0 0 0 0\
\
___________________________________________ NH
__________________ NH N
N,.........._....,,<
________________________________________________________________________ NH
./.....,N.,,.,..z....,...., j.K =-----j( ,.../1 ...,..,õ ) ______________________ NH
0 1/...,....7. ) _______________ 0 (....;1,..N
__ ) 0 __________________ NH
________________________________________________________________________ NH
Rn 0 0 Rn 0 0 Rn 0 0 N
NH ?
) ___________________________________________ NH
) ly N....... ,...JKN
NH

1/ ....--1(,.... N
) ____________________ 0 11 N
Nt....,..,.."- ) =.N.4---A( __________________________________ NH _______________________ NH
NH
Rn Rn Rn O 0\ 0 0 0 0 OH
NH
/
? _______________________________________________________________________ N/
.,...--IK
1 N ) __ 0 N
) 0 1/..... (N _____ ) __ .-----....
t/-*\\( NH NH
)NH
Rn Rn 0 0 Rn/ 0< 0 0 NH
N 4.,...
________________________________________________________________________ NH

..,...-1( /.",./....A( / ) 0 _____ 1 N 0 y 02 NH ) _________________________________________ NH

Rn Rn 0 Rn 0 0 H

N / NNNN'ss' r/ NNNN'sss.

Rn7 Rn' H Rn' H
S N, ,0 N N. N NNN'sss.
O
Alk YO
Al k 1 /
H H
RnY Rn 0,,N,...,,0 Rn 0 0N,,..,.S

0 NHC) N N
N.
, Rn 7.s Rn Rn I N NN (N,, Rn H
0 ONO Rn/ H Rn H
N 0...õ N

NN (NN
1/No YKI0 N..../0 Rn Rn Rn' o ONHO 0 ONH 0 ONHO
N NN NiN=
YNO yo 1 /

H
Rn 1 Rn Rn 01 H

Yo S0 VO
RI Rn Rn HI\ HI\
N
0 0 'NI
UH UH

0 0 0 uu u H __ uH
N
Z. ==.,..;,.,.,N.,....s.,.,;...,. ,, 0 __ ( N O - 1 .,.,.,..,...,,.,õ..N,,,,,,...................,, 0,...,..! .....,,N^..,0 0 H
UN

H
UN UN UN
Ow/ Ow/ Ow/

............-=,..,..._õ/õ,N.,....,...õ
,............s.,...,N,......,,,,,,,, .,,,,,,,,.,õ,..._..N...,,,......

H H

tHOS0/6IOZSI1LIDcl t9SISO/OZOZ OM

O 0\ 0 0\ 0 0 ......Z _________ N
___________________________________________ NH NH
H
N _________________________________ 0 Nliiii... 0 Rn Rn Rn \ > >
\ __ NH
________________ NH ______________________ NH

Nu ____________________________________________ 0 N ______ 0 A: ________________________________ lAil:A"
Rn Rn Rn O 0\ S 0\ 0 0\
________________ NH
____________________________________________ NH
_______________________________________________________________________ NH
N __________________ 0 N ________ 0 N ________ S
Rn Rn Rn 0 0\

JK:NI ) \ _______________ NH
I
\ __________________________________________ NH
1 N.......
...........KN
_______________________________________________________________________ NH
N _________________________________________________________________________ 0 Rn R Rnn 0 O 0\ OH
/ 0 0 0 0\
N
r.....,, ____________________________________________ NH
_______________________________________________________________________ NH
N ___________________ 0 .....,,.. N
Rn 0 Rn Rn O 0\ 0 0 0\
/NH
( __________________________________________ N, 0 N _________________________________ 0 _______________________ N __ N
Rn Rn Rn ______________________ 4. 0 0 N
\ ________________________________________________ /N ____ NH
________________________________________________________________ 0 N __________________ 0 S

Rn Rn Pr uH
uH 0 HN ______________________________________________________________ S
HN __ \ ________________________ N 0 __ ( N/
S HN HN __ \
\ 0 0 uH
uH HN
HN
.0 __ K N
S _______________ ( \ N
HN

uH uH uH
HN ________________________ HN ______________________ HN ____________ N
N74 0 _________________________________________________ K ) ___ N

__________ N
I K .....,.., ) )........---0 HN _____________ HN ____________________________________________________________________ N
\ o N HN __ \ ).------.......sN \

uH uH
uH
HN ___________________________________________________ HN __ HN
HN
y.....= ...........,,N 0 __ ( Nc.:-.......:....., ...lj .,....... 1 ).i.,---- HN __ \ HN __ \ N
\ N
\ 0 0 0 0 uH
uH uH
(RN _______________________________________________________ HN _____________________________ HN ___ \ __ N N 0 _______ N
N _________________________________________________________ HN __ S HN\
/ o \ HO 0 tHOS0/6IOZSI1LIDcl t9SISO/OZOZ OM

o o o ......o o o ___________________________________________ NH
__________________ NH ________________________________________________ NH
N ) __ 0 NIVII... ) 0 .. N
) _________________________________________________________________________ 0 __________________ NH ____________________ NH _______________________ NH
Rn S
Rn 0 Rn 0 0 0\ 0 0 0 S
__________________ NH \ __ NH NH
) Nilm=-= _____________ 0 Wno. ) i 0 _________ N

) ) -..
Alk ______________ NH Alk / _______________________ NH
NH
Rn 0 Rn 0 Rn 0 0 0 S 0 0 0\
__________________ NH _____________________ NH
N _______________ ) __ 0 N ) __ 0 N ______ ) S NH
_______________________________________________________________________ NH
__________________ NH _____________________ NH
Rn Rn 0 Rn 0 0/

0 0 0 0\
,................õ....K
___________________________________________ NH
N ________________ NH N
N.,....................K
_______________________________________________________________________ NH
.---...--( ) ______________________________________________ ...õ,.......
....IN ) 0 1 N ____ ) __ 0 N
_______________________________________________________________________ NH
__________________ NH ____________________ NH N
Rn 0 Rn 0 Rn 0 _________________ NH r.......õN
/õ....... .....JK NH
NN............,( NH
N ) __ 0 ilit.......... ....f 0 I
) __ 0 N
S _______________ NH N? /........../N

_______________________________________________________________________ NH

Rn 0 Rn 0 R
0 n 0 0\ 0 0\ 0 0 OH
__________________ NH
___________________________________________ N/ _______________________ NI/
N ________________ ) __ 0 N ) __ 0 N ) __ __________________ NH ____________________ NH _______________________ NH
Rn Rn 0 Rn 0 ____________________________________________________ =
NH N
) ____________________ 0 N ) __ 0 NH __________________ NH
Rn Rn 0 0 o H o 0 N 0 0 Rn Rn Rn 0 H 0 ow N.,,..,, PaJ

O o 0 0Alk s N 0 N =
Alk OH
Rn Rn Rn 1 o O s N N
N
Rn H Rn H H
O Rn N 0 0 N 0 o 0 ri N N N NN
N/47õ/,......1 ,..........., H
H
(D 0 Rn 0 N 0 0 Rn Rn 0 0 c) N N
N NN
,.,........:.,..,...., ......,...
1 ir NN .A..,.......", Rn Rn Rn NN NN
N
Rn Rn Rn H H
N
N 0 c) 0 ON

N= NJ N
Rn Rn Rn H

Rn 6 ________________________________________ ) < 0 0 \ ___________________ NH ________________________________ NH

Rn "...--\-N HN __________ 0 Rn (-N HN 0 N) < 0 0 ____________________ NH NH
XRn -N HN ________________ 0 Re......'\ _________________ -N HN 0 /
___________ 0 0 ) </
\ ___________________ NH
Rn NN HN _________ 0
[0114] In any of the compounds described herein, the CLM comprises a chemical structure selected from the group:

v Q4.õ,...-1 NH (1Q4 NH P4=Q5 -NH
13 N 0 V -----/ __ N Q-3 N tO
OR2. %-- \--- Q2. )/% 6 Q \---Qi W Qi W 0 2 1 (h) (i) (i) C)4. Ql.
Q3 -Q5 0 0 Q2=Q3 -NH

Qi\ / N tO
Di y NL/NH Q3 L
R1' 0 11.

(k) (I) (m) 1 Nt1\15 0 Cezi---Ic_t_l_LIF-1 ce4rAN Ntlx _R2 " (52. %-- i \ 62: /---v\i \ /7 W N Qi W 0 Qi -\R1 R1 (n) (o) (10) 0 N 0 \

R'\ 0 ,-NH
N
I
=
HN

(r) (a) \
NH o 00 o N
= HN_r¨N,i1-1 0 NH
, _________________________________________________ 00 W ______________________________________________ oi (s) (t) x=( ______________________________________________ NH
NH
N

(u) (v) _c() _,\¨NH Q Qi, A _c4r0R4 R3 \ N __ ¨o ? 1 A I N
sx3;
Q4 "
R-, 0 0 (w) (x) Qc(:)4_ , _______________________________________________ NH
b3(:).4 ,N 0 &
N t R4 ¨/¨NH NQW \_ O
0 HN) R1 (y) (z) 1C)1=,( '¨NH
QIC 1 N¨ 0 (aa) 0 (R5) n (R2)1 \ 0 0 QC)1_kl /
X = X
________________________________________________________ NH
\Al 112 ___________________________ R6 Q-jK

Q3 ______________________ ) .
L_ 7 R' ,C)2 (ab) (R3) 11 (ac) \ / 0 \
________________________________________________________ N H
_...-N
---/ \
I I N ___ (1, N __ Q --X
1 (R)1 \ R' _______________________ 0 R1 R2 (ae) (ad) kR4 NH
HN-.........<
N ______________________________ 0 R'/
(ag) (af) H 0 0.,IN.ft 0 0\
Q(:)4...............,../K
) __ NH N Z
113 N¨(CH2)--N _________ 0 Q2 \i" n \ HO

Qi (ah) HO
0 0 (al) ____________________________________ N H
C)' : N _________ 0 (qi) H

R' Q2=Qi \ ________ NH 0 0 \)'LN R31 1\1 2 ___ 1 1 0 QcQ4---"AN4\---NH
Xi (R ')n I : R5 0 01 (R2)n (ak) (al) (am) // .
Qi sQ4 0 ?-( 0 04:05 NH N4 _________ i ____________________ 03 to , ______ / pl -CD
O2-Qi R4 NH
R1 0 , wherein:
W is independently selected from CH2, 0, CHR, C=0, S02, NH, optionally substituted cycloalkyl, optionally substituted heterocyclalkyl, and N-alkyl;
Ql, Q2, Q3, Q4, Q5 are each independently represent a carbon C or N
substituted with a group independently selected from H, R', N or N-oxide;
R1 is selected from absent, H, OH, CN, C1-C3 alkyl, C=0;
R2 is selected from the group absent, H, OH, CN, C1-C3 alkyl, CHF2, CF3, CHO, C(=0)NH2;
R3 is selected from H, alkyl (e.g., C1-C6 or C1-C3 alkyl), substituted alkyl (e.g., substituted C1-C6 or C1-C3 alkyl), alkoxy (e.g., C1-C6 or C1-C3 alkoxyl), substituted alkoxy (e.g., substituted C1-C6 or C1-C3 alkoxyl);
R4 is selected from H, alkyl, substituted alkyl;
R5 and R6 are each independently H, halogen, C(=0)R', CN, OH, CF3;
X is C, CH, C=0, or N;
Xi is C=0, N, CH, or CH2;
R' is selected from H, OH, halogen, amine, cyano, alkyl (e.g., C1-C3 alkyl), substituted alkyl (e.g., substituted C1-C3 alkyl), alkoxy (e.g., C1-C3 alkoxyl), substituted alkoxy (e.g., substituted C1-C3 alkoxyl), NR2R3, C(=0)0R2, optionally substituted phenyl;
n is 0-4;
/ is a single or double bond; and the CLM is covalently joined to a PTM, a chemical linker group (L), a ULM, CLM
(or CLM') or combination thereof.
[0115] In any aspect or embodiment described herein, the CLM or CLM' is covalently joined to a PTM, a chemical linker group (L), a ULM, a CLM, a CLM', or a combination thereof via an R
group (such as, R, R1, R2, R3, R4 or R'), W, X, or a Q group (such as, Qi, Q2, Q3, Q4, or Q5) of Formulas (h) through (ab).
[0116] In any of the embodiments described herein, the CLM or CLM' is covalently joined to a PTM, a chemical linker group (L), a ULM, a CLM, a CLM', or a combination thereof via W, X, R, R1, R2, R3, R4, R5, R', Qi, Q2, Q3, Q4, and Q5 of Formulas (h) through (ab).
[0117] In any of the embodiments described herein, the W, X, R1, R2, R3, R4, R', Qi, Q2, Q3, Q4, and Q5 of Formulas (h) through (ab) can independently be covalently coupled to a linker and/or a linker to which is attached to one or more PTM, ULM, ULM', CLM or CLM' groups.
[0118] More specifically, non-limiting examples of CLMs include those shown below as well as "hybrid" molecules or compounds that arise from combining 1 or more featrues of the following compounds:

NH -NH

Rn----7-R' //S ---0 (an) (ao) eN 0 Rn----1 _....---.,õ __________________________________________ N
N NH H
____________/-Rn- / 0 (ap) (aq) o 0 H
NH

Rn----c 1 71 ____________ \ -CN

1 , R2 N' (ar) (as) N_ NH

NJ\
Rn----kc / R1 (at) H
0 0 N ,0 N NH
N R3 N ________ 0 Rn------7-1 \ ( N \

(au) (av) 0\

N NH
R3-(\N 0 Rn- \
\ 7 1 \ ji _ 1 0 (aw) (ax) FN, ?
Rn---c-NH

(ay) aid( NH
N
/1 ...........w/N = R6 : ________________________________________________________ 0 i, /
R'VQ2 Rn (az) (ba) NH
,N ____ NH
1 N __ / _____ 0 -:.------ \

yvv/
R' Rn R1 (bc) (bb) R4 o cy<R4 o 0 N
)1 N __ HN-......\( ,N 0 (be) (bd) H IN

O \
> __________________________________ NH
.....,...--K N 0 V
1 / N¨(CH2)--N ____ 0 ------...w \
HO __________________________________________ 5:
Rn (bf) R1 O (bg) H
, wherein:
W is independently selected from the group CH2, CHR, C=0, S02, NH, and N-alkyl;
R1 is selected from the group absent, H, CH, CN, C1-C3 alkyl;
R2 is H or a C1-C3 alkyl;
R3 is selected from H, alkyl, substituted alkyl, alkoxy, substituted alkoxy;
R4 is methyl or ethyl;
R5 is H or halo;
R6 is H or halo;
R of the CLM is H;

R' is H or an attachment point for a PTM, a PTM', a chemical linker group (L), a ULM, a CLM, a CLM', Qi and Q2 are each independently C or N substituted with a group independently selected from H or Cl-C3 alkyl;
/ is a single or double bond;
n is an integer from 1 to 4 (e.g., 1, 2, 3, or 4); and R comprises : H, -CONR'R", -OR', -NR'R", -SR', -SO2R', -SO2NR'R", -CR'R"-, -CR'NR'R"-, (-CR'0).,R", halogen, optionally substituted heterocyclyl, optionally substituted -aryl (e.g., an optionally substituted C5-C7 aryl), optionally substituted alkyl-aryl (e.g., an alkyl-aryl comprising at least one of an optionally substituted Cl-C6 alkyl, an optionally substituted C5-C7 aryl, or combinations thereof), optionallys ubstituted heteroaryl (e.g., an optionally substituted C5-C7 aryl), -optionally substituted linear or branched alkyl (e.g., a Cl-C6 linear or branched alkyl optionally substituted with one or more halogen, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted alkoxyl group (e.g., a methoxy, ethoxy, butoxy, propoxy, pentoxy, or hexoxy; wherein the alkoxyl may be substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), , , ,.......
ii 00)( optionally substituted Y
(e.g., optionally substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted , 0 )1):
Y
(e.g., optionally substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted cycloalkyl, optionally substituted heterocyclyl, -P(0)(OR')R", -P(0)R'R", -0P(0)(OR')R", -0P(0)R'R", -Cl, -F, -Br, -I, -CF3, -CN, -NR' S 02NR' R", -NR' CONR' R", -CONR' COR", -NR'C(=N-CN)NR' R", -C(=N-CN)NR'R", -NR'C(=N-CN)R", -NR'C(=C-NO2)NR'R", -SO2NR'COR", -NO2, -CO2R', -C(C=N-OR')R", -CR'=CR'R", -CCR', -S(C=0)(C=N-R')R", -SF5 and -0CF3.
[0119] In any aspect or embodiment described herein, at least one R of Ql, Q2, Q3, Q4, Q5, or a combination thereof (e.g., at least one of OH, NH2, C1-C6 alkyl, C1-C6 alkoxy, -alkyl-aryl (e.g., an ¨alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, or carboxy) is modified to be covalently joined to a PTM, a chemical linker group (L), a ULM, a CLM' (e.g., CLM' is an additional CLM
that has the same or different structure as a first CLM), or a combination thereof.
[0120] In any of the embodiments described herein, the W, R1, R2, Ql, Q2, Q3, Q4, and R of Formulas (ac) through (an) can independently be covalently coupled to a linker and/or a linker to which is attached one or more PTM, ULM, ULM', CLM or CLM' groups.
[0121] In any of the embodiments described herein, the R1, R2, Ql, Q2, Q3, Q4, and R of Formulas (ac) through (an) can independently be covalently coupled to a linker and/or a linker to which is attached one or more PTM, ULM, ULM', CLM or CLM' groups.
[0122] In any of the embodiments described herein, the Ql, Q2, Q3, Q4, and R
of Formulas (ac) through (an) can independently be covalently coupled to a linker and/or a linker to which is attached one or more PTM, ULM, ULM', CLM or CLM' groups.
[0123] In any aspect or embodiment described herein, R of Formulas (ac) through (an) is modified to be covalently joined to the linker group (L), a PTM, a ULM, a second CLM having the same chemical structure as the CLM, a CLM', a second linker, or any multiple or combination thereof.
[0124] In any aspect or embodiment described herein, the CLM is selected from:

N

Linker ________________ NH I
N 0 Linker N NH
W \ _ H
0 0 N ,0 H

(N Linker I , LinkerN N
N%\
/ __________________________________________ N 0 N _____________________ NH Linker ___ , ___ ,/
HN __________________________________________________________ 0 Linker ______ N 0 / _________________________________________________________ NH
Of 0 0\
N_ NH N NH
\
N _______________________ 0 Linker __ \/ \ _ N 0 ilk R1 0 Linker \ ________________________________ NH LinkerA \ _________________ NH
N ) ___________________________________ 0 [ 1 N 0 rN R' 7//S/-----*-'0 1\1) 0 0 Linker 0 0 0 0 NH Linker¨A
NH
1 N ) __ 0 N ) __ 0 rN e IC) Linker N

NN4 _NIF-1 Linker 0 _t N NH
Linker 0 yN--..N
--- 'NI 0 0 \K

\

Linker 0 N 0 . \

LinkerrN,N¨NH
N-NN,,,:tH
"1\14 lF1 7N-..\( 0 _1._, ,N 0 0 0 Linker'N
\N-.... 0 0 Linker 1\1 Linker N-1\41 F

Of LinkerN

¨(NI
'l Linker \
0 / HN ¨C) ¨ NH NH
o 0 , wherein R' is a halogen and R1 is as described in any aspect or embodiment described herein.
[0125]
In certain cases, the CLM can be imides that bind to cereblon E3 ligase. These imides and linker attachment point can be but not limited to the following structures:

NH
NH

I I
Linker Linker NH
NH

) HN
I
I Linker Linker NH N
N ) __ 0 I Linker 0 N 0 Linker H
R' N N
1 , y N N , . ., . . . , ====,. , , , õ = . . , . . . . , . / \ . , Linker Linker H H

NH
N ) __ 0 rN
N Linker 0 NH
N ) __ 0 N
r N
Linker , wherein R' is a halogen.
[0126] Exemplary VLMs
[0127] In certain embodiments of the compounds as described herein, the ULM
is a VLM
and comprises a chemical structure of ULM-a:
=

x20 ULM-wherein:
a dashed line indicates the attachment of at least one PTM, another ULM or VLM
or MLM
or ILM or CLM (i.e., ULM' or VLM' or CLM' or ILM' or MLM'), or a chemical linker moiety coupling at least one PTM, a ULM' or a VLM' or a CLM' or a ILM' or a MLM' to the other end of the linker;
X1, X2 of Formula ULM-a are each independently selected from the group of a bond, 0, NRY3, CRY3RY4, C=0, C=S, SO, and S02;
12)(3, RY4 of Formula ULM-a are each independently selected from the group of H, optionally substituted linear or branched C 1_6 alkyl (e.g., optionally substituted by 1 or more halo), optionally substituted C 1_6 alkoxyl (e.g., optionally substituted with 0-3 RP
groups);
RP of Formula ULM-a is 0, 1, 2, or 3 groups, each independently selected from H, halo, -OH, C1-3 alkyl, C=0;
W3 of Formula ULM-a is selected from the group of an optionally substituted T, an la 113 optionally substituted A optionally substituted ¨T-N(R., ) optionally substituted ¨T-Aryl, an optionally substituted ¨T-Heteroaryl, an optionally substituted T-biheteroaryl, an optionally substituted ¨T-Heterocycle, an optionally substituted ¨T-biheterocycle, an optionally substituted -NR1-T-Aryl, an optionally substituted -NR1-T-Heteroaryl or an optionally substituted -NR1-T-Heterocycle;
X3 of Formula ULM-a is C=0, Ri, Ria; Rib;
Ri; ia;
tc Rib are each independently selected from the group consisting of H, linear or branched Ci-C6 alkyl group optionally substituted by 1 or more halo or -OH
groups, RY3C=0, RY3C=S, RY3S0, RY3S02, N(RY3RY4)C=0, N(RY3RY4)C=S, N(RY3RY4)S0, and NRY3RY4)S 02;
T of Formula ULM-a is selected from the group of an optionally substituted alkyl, ¨(CH2).-group, wherein each one of the methylene groups is optionally substituted with one or two substituents selected from the group of halogen, methyl, optionally substituted alkoxy, -(CH2)m,C(=0)(CH2)m,C(=0)(OH), (CH2)m'OCOCH2(CH2)m,OCH2(CH2)m,CO(CH2)m,OH, (CH2)m'OCOCH2(CH2)m,CO(CH2)m,OH, a linear or branched C1-C6 alkyl group optionally substituted by 1 or more halogen or OH, C(0) NR1Rla , or NR1Rla or R1 and ,s la I( are joined to form an optionally substituted heterocycle, or -OH
groups or an amino acid side chain optionally substituted;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);
W4 of Formula ULM-a is an optionally substituted -NR1-T-Aryl, wherein the aryl group may be optionally substituted with an optionally substituted 5-6 membered heteroaryl, optionally substituted aryl, or optionally substituted alkoxy, an optionally substituted -NR1-T-Heteroaryl group or an optionally substituted -NR1-T-Heterocycle, wherein -NR1 is covalently bonded to X2 and R1 is H or CH3, preferably H; and n is 0 to 6, often 0, 1,2, or 3, preferably 0 or 1.
[0128] In any of the embodiments described herein, T is selected from the group of an optionally substituted alkyl, ¨(CH2).- group, wherein each one of the methylene groups is optionally substituted with one or two substituents selected from the group of halogen, methyl, optionally substituted alkoxy, -(CH2)m,C(=0)(CH2)m,C(=0)(OH), (CH2)m'OCOCH2(CH2)m,OCH2(CH2)m,CO(CH2)m,OH, (CH2)m'OCOCH2(CH2)m,CO(CH2)m,OH, a linear or branched C1-C6 alkyl group optionally substituted by 1 or more halogen, C(0) NR1,.I( la , or NR1Rla or R1 and Rla are joined to form an optionally substituted heterocycle, or -OH groups or an amino acid side chain optionally substituted; each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4), and n is 0 to 6, often 0, 1, 2, or 3, preferably 0 or 1.
[0129] In any aspect or embodiment described herein, W4 of Formula ULM-a is , 1 H
iR 4a ' R 4a N Ri4a ;
= ' uaN R .N R14a g;
R14b 1R14b Rub ""Rub N
R14b R15 R15 R15 , R15 R15 , H
R14a R1 =,, gi R14b 1 N
,K

,or R15 , wherein:
W5 is optionally substituted phenyl, an optionally substituted napthyl, or optionally substituted 5-10 membered heteroaryl (e.g., W5 is optionally substituted with one or more [such as 1, 2, 3, 4, or 5] halo, CN, optionally substituted linear or branched C1-C12 alkyl optionally having one or more (e.g., 1, 2, 3, 4 or more) carbon atoms replaced with an oxygen atom, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy, or optionally substituted haloalkoxy);
R14a, R14b, are each independently selected from the group of H, haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, -(CH2)m,C(=0)(CH2).X(=0)(OH), (CH2)m'OCOCH2(CH2)m,OCH2(CH2)m,CO(CH2)m,OH, (CH2)m'OCOCH2(CH2)m,CO(CH2)m,OH, or optionally substituted linear or branched alkyl optionally with one or more carbon atoms replaced with an oxygen;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);
R1 is H, linear or branched C1-C6 alkyl group optionally substituted by 1 or more halo or -OH
groups;

W6 is an optionally substituted 8-14 membered bicyclic heterocycle (e.g., 0 , , . , .
, .
, ' -----IIIIIIII 111111 or ---'- 0 ); and Ri5 is selected from the group of H, halogen, CN, OH, NO2, N R14aR14b, OR14a, CONR14aR14b, NR14aCOR14b, SO2NR14aR14b, NRi4a SO2R14b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted haloalkoxy optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl.
[0130] In any aspect or embodiment described herein, W5 of Formula ULM-a is selected from the group of an optionally substituted phenyl or an optionally substituted 5-10 membered heteroaryl (e.g., W5 is optionally substituted with one or more [such as 1, 2, 3, 4, or 5] halo, CN, optionally substituted linear or branched C1-C12 alkyl optionally having one or more (e.g., 1, 2, 3, 4 or more) carbon atoms replaced with an oxygen atom, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted haloalkoxy, or hydroxy), Ri5 of Formula ULM-a is selected from the group of H, halogen, CN, OH, NO2, N
R14aR14b, OR14a, CONR14aR14b, NR14aCOR14b, SO2NR14aRl4b, NR14a SO2R14b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl;
[0131] In aspect or embodiment described herein, W4 substituents for use in the present disclosure also include specifically (and without limitation to the specific compound disclosed) the W4 substituents which are found in the identified compounds disclosed herein. Each of these W4 substituents may be used in conjunction with any number of W3 substituents which are also disclosed herein.
[0132] In aspect or embodiment described herein, ULM-a, is optionally substituted by 0-3 RP
groups in the pyrrolidine moiety. Each RP is independently H, halo, -OH, C1-3a1ky1, C=0.
[0133] In aspect or embodiment described herein, the W3, W4 of Formula ULM-a can independently be covalently coupled to a linker which is attached one or more PTM groups.
and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM') or a chemical linker moiety coupling at least one PTM or a ULM' or both to ULM.
[0134] In certain embodiments, ULM is VHL and is represented by the structure:
¨
HQ. HO Rci -N).......1(El R14a N
' ' 'Rub N .,d0R14b &N"""11141µ
w3-o o, 0 41) w 3 'LO
(R16)0 R15 (R16)0 ¨ ¨ or¨ ¨ , ULM-b wherein:
W3 of Formula ULM-b is selected from the group of an optionally substituted aryl, optionally 1¨(¨R10 substituted heteroaryl, or R11 ;
R9 and Rio of Formula ULM-b are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl, or R9, Rio, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;

Ril of Formula ULM-b is selected from the group of an optionally substituted heterocyclic, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted aryl, s R12 1_N¨(1R18)r) or =
R12 of Formula ULM-b is selected from the group of H or optionally substituted alkyl;
R13 of Formula ULM-b is selected from the group of H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;
R14a, R14b of Formula ULM-b, are each independently selected from the group of H, haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, -(CH2)m,C(=0)(CH2).X(=0)(OH), (CH2)m'OCOCH2(CH2)m,OCH2(CH2)m,CO(CH2)m,OH, (CH2)m'OCOCH2(CH2)m,CO(CH2)m,OH, or optionally substituted linear or branched alkyl optionally with one or more carbons replaced with an oxygen;
R1 is H, linear or branched Cu-C6 alkyl group optionally substituted by 1 or more halo or -OH
groups;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);
W5 of Formula ULM-b is selected from the group of an optionally substituted phenyl or an optionally substituted 5-10 membered heteroaryl, R15 of Formula ULM-b is selected from the group of H, halogen, CN, OH, NO2, N
R14aR14b, OR14a, CONR14aR14b, NR14aCOR14b, SO2NR14aRl4b, NR14a SO2R14b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl;
each R16 of Formula ULM-b is independently selected from the group of H, CN, halo, optionally substituted alkyl optionally having one or more carbon atoms replaced with an oxygen atom (e.g., optionally substituted with CN or OH), optionally substituted haloalkyl, hydroxy, or optionally substituted haloalkoxy;
o of Formula ULM-b is 0, 1, 2, 3, or 4;

R18 of Formula ULM-b is independently selected from the group of H, halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker;
and p of Formula ULM-b is 0, 1, 2, 3, or 4, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM') or a chemical linker moiety coupling at least one PTM or a ULM' or both to ULM.
Ri7 yN
--..../
[0135] In certain embodiments, R15 of Formula ULM-b is Xa wherein R17 is H, halo, optionally substituted C3_6cycloalkyl, optionally substituted C1_6alkyl, optionally substituted Ci_ 6a1keny1, and C1_6haloalkyl; and Xa is S or 0.
[0136] In certain embodiments, R17 of Formula ULM-b is selected from the group methyl, ethyl, isopropyl, and cyclopropyl.
[0137] In certain additional embodiments, Ri5 of Formula ULM-b is selected from the group consisting of:
F cs CI Br csss-.%- (- CS--- N "s=-=------- /--"N
/ ,I1 N . S--,./ . S = S = S == S =
, , ,, , oi ___________________ )N 1 0' __ S
1 __ b 1 ____ l N-N N-N N-N 1 = S ; S ; H = / ; H
= -N
0 =
Nzõ.1 N Ni 1 h ________ Cs.:-- / __ N e--1\j 1 (1\i = / ;
N \WC'. ,(S.' 0 ; 0 ;
, , KI-----0 r, 0 rõs /
zt..... ; r!) / F ; r1) / F; s2)------N . ..,.....N
\-=------N OH 7 1 > ____ -rTrj 1 ________________ -\N
and \ /I .
[0138] In certain embodiments, R11 of Formula ULM-b is selected from the group consisting of:

F Br 1¨N 1¨N 1¨N 1¨N
, . . , .
,= , CN
F = = Br. ; Br ;
, , 1¨N 1¨N
1¨N 1¨N
F ; CN ; CN = =
, , 1¨N OMe 1¨N
OMe 1 ¨N
. CI ;
, , 1¨N 0 CI
)\---.....
1¨N 1¨N I
\..---OMe = ;and N.
,
[0139] In certain embodiments, ULM has a chemical structure selected from the group of:

HO HO
)õ..,,N,....\.........(H R14a HO
N H
R14a H 4 ) Ri Riaa N
N
1 illik N Ri 0 \x 0 Ri5 OyNH
R15 ' I s., ULM-c ULM-d ULM-e wherein:
Ri of Formulas ULM-c, ULM-d, and ULM-e is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl;
Ri4a of Formulas ULM-c, ULM-d, and ULM-e is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl, (CH2)m'OCOCH2(CH2)m,OCH2(CH2)m,CO(CH2)m,OH, (CH2)m'OCOCH2(CH2)m,CO(CH2)m,OH, or cyclopropyl;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);
R15 of Formulas ULM-c, ULM-d, and ULM-e is selected from the group consisting of H, halogen, CN, OH, NO2, optionally substituted heteroaryl, optionally substituted aryl;
optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, cycloalkyl, or cycloheteroalkyl;
X of Formulas ULM-c, ULM-d, and ULM-e is C, CH2, or C=0 R3 of Formulas ULM-c, ULM-d, and ULM-e is absent or a bond or an optionally substituted or 6 membered heteroaryl; and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM
(ULM') or a chemical linker moiety coupling at least one PTM or a ULM' or both to ULM.
[0140] In certain embodiments, ULM comprises a group according to the chemical structure:

HO, RF:90o 0, ¨ ¨ , ULM-f wherein:
Ri4a of Formula ULM-f is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl, (CH2),,,,OCOCH2(CH2).,OCH2(CH2).,CO(CH2).,OH, (CH2).'000CH2(CH2).,CO(CH2).,OH, or cyclopropyl;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);
R9 of Formula ULM-f is H;
Rio of Formula ULM-f is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;

s R12 5 )., )L.
¨1\1 ¨N I j--(R18)p ¨N 1 ¨(Ris)p . 1\
R \-------r Rii of Formula ULM-f is 13 , r (R18)p 0 / --N D(R18)=.<1\1%
1 \N 1 \N ..4N p(R18)-C?
, , =
or optionally substituted heteroaryl;
p of Formula ULM-f is 0, 1, 2, 3, or 4;
each Ri8 of Formula ULM-f is independently halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker;
Ri2 of Formula ULM-f is H, C=0;
Ri3 of Formula ULM-f is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl, R15 of Formula ULM-f is selected from the group consisting of H, halogen, Cl, CN, OH, NO2, optionally substituted heteroaryl, optionally substituted aryl; optionally substituted cycloheteroalkyl;
:.... rõ-o r_s /
rio N
/ ; / F ; II) / 1 = S
OH

-re F cs CI Br F3C
( cs-( N N __ s-,_ . S-, . S = S = S = S = S =
, , , , , , , 1 1 Cill 1 _____ 01 ----"N
N js H = / ; O'N = / = S ; / =
NI' = V =

0 ;and the dashed line of Formula ULM-f indicates the site of attachment of at least one PTM, another ULM (ULM') or a chemical linker moiety coupling at least one PTM or a ULM' or both to ULM.
[0141] In certain embodiments, the ULM is selected from the following structures:
OH

4-Yrji iNN N
H

0 NIA 0 1\11-1 0 -- - N
N S z N ULM-a3 a----' SN---' --.."
ULM-a2 OH OH OH
0 Ni.rq 0 0 OH , NicrN F
H H

OH
N S N SN.," N
ULM-a4 ULM-a5 ULM-a6 OH OH
OH

44ril .1' N'..ir N1 '''KlIt'N'tfrN/
H

0 i CiN/

N /\
N ULM-a9 0, ULM-a7 ULM-a8 N
F OH OH

fr.N/LNIc.rNr. ' NY)rNF IE1 H H
0 NH 0 NH H 0 ..

ULM-a12 ¨
ULM-a10 N ULM-al all s z N
S--,,---"

0 µ jrAN
=,' N N ','i,)A
H k ::)1 n N-).iN
H

ULM-a13 CI
ULM-a14 CN ULM-a15 N
s' wherein n is 0 or 1.
[0142] In certain embodiments, the ULM is selected from the following structures:

3...,..... tl , 0 ?.....N4.,-A- '..'"?1 '1 1.µ ,... 0-kv)--sfs ..
µ ,s, , ..t.. ....; , .N.
N \-- )---,,AN

H K < H \
OH OH bH
ULM-b1 ULM-b2 ULM-b3 '')....,<
0 al , õ...) ...,.. y --õ, K,:. 0- -)L--,--' .., o 1 i ,, 1 40) 0 ..,--,--- Le , tg,4 \
OH OH
ULM-b4 ULM-b5 ULM-b6 qN -z--- \
=,,,,, , '''',I1 ( .11 0 ,y 0 akyj'17/" 1) ,,õ-,s1 n ====''''L,1"
, A =1 0 -1" 1 , , ."¨=-_________________________________________________________________ ti \
\ OH bH
OH
ULM-b7 ULM-b8 ULM-b9 )N,..
-0?
c........) /4-7\
' -- ''N

ULM-b10 ULM-bll ULM-b12 ULM-b7 ULM-b8 ULM-b9 HO, HO,.. H
HO)___)--1. . :IN ---\
JO) ----, .
--",),,,--k- v \\ -.CN-,,,,,=-L. c/
=''''' ''Nr '...
sl. , 6 ' , - N s 1 , el------N $ , -'14 %-----N ',ps, t , \\,-- N ,P--ULM-el ULM-e2 ULM-e3 HO\_____ HOõ
HO HO
H
in---' = ri H , C
0 ,..µ......õ, N
k., ,,- -= cs ..---1,. -A k, )-1 b ..i. ' N
t=-, r., ULM-e4 ULM-e5 ULM-e6 HO\ Haõ HO., o 1 ,/ 1 O
õ. ,,L, s,./.....1 ,..0-µ p f,õ ,.., ir---1 ro S..1-1.
.y,..N ,_...
\.:--õN
',....-===
ULM-e7 ULM-e8 ULM-e9 HO ;='=:>=f--,A, H H
\).---k H ri --, 1.---\ .N
f 'µ,. .,N,-. l' 'IL .
t , ....õ.. 1 .\-14/ -1(--1,( .
= 'N. ,a. -), .-..õJõ,..\''t 0 /...õ7 % ) ..:L:. 0 b ,.µ
........ , iµs,õ...1.,, ,,, --,..,,.. 0 ...
--- y 0 --, r\o ,,--- v s õ,....õ4 N 14 N i s\,,..
ts, S\t,- N .i.'-ULM-c10 ULM-ell ULM-c12 i , I
--Ak µ
- CI
--- 1'0 .,.
.:, , '1-'94 , ,'-': =I \ ,1 )'=--N4 .....- , I. - :
1' ULM-c13 ULM-c14 ULM-c15 HON 1-10\ _ HO
S KII
ULM-dl ULM-d2 ULM-d3 HO
H

i , \:=:;;N
ULM-d4 ULM-d5 ULM-d6 HO, )¨"\ )7Lõ /
N
0 "--\\
µ6,N ,t4 /"--1 ey HO ULM-d7 ULM-d8 ULM-d9 HN
/
¨N
wherein, the phenyl ring in ULM-al through ULM -a15, ULM -111 through ULM-b12, ULM-cl through ULM-c15 and ULM-dl through ULM-d9 is optionally substituted with fluorine, lower alkyl and alkoxy groups, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM') or a chemical linker moiety coupling at least one PTM or a ULM' or both to ULM-a.
[0143] In one embodiment, the phenyl ring in ULM-al through ULM-a15, ULM-bl through ULM-b12, ULM-cl through ULM-c15 and ULM-dl through ULM-d9 can be functionalized as the ester to make it a part of the prodrug.
[0144] In certain embodiments, the hydroxyl group on the pyrrolidine ring of ULM-al through ULM-a15, ULM-bl through ULM-b12, ULM-cl through ULM-c15 and ULM-dl through ULM-d9, respectively, comprises an ester-linked prodrug moiety.
[0145] In any of the aspects or embodiments described herein, the ULM and where present, ULM', are each independently a group according to the chemical structure:

RI:
Rx/

x,,R2,, ULM-g wherein:
121' of ULM-g is an optionally substituted C1-C6 alkyl group, an optionally substituted -(CH2),OH, an optionally substituted -(CH2),SH, an optionally substituted (CH2)n-0-(Ci-C6)alkyl group, an optionally substituted (CH2)n-WCOCW-(Co-C6)a1ky1 group containing an epoxide moiety WCOCW where each W is independently H or a Ci-C3 alkyl group, an optionally substituted -(CH2)nCOOH, an optionally substituted -(CH2)nC(0)-(Ci-C6 alkyl), an optionally substituted -(CH2),NHC(0)-Ri, an optionally substituted -(CH2),C(0)-NR1R2, an optionally substituted -(CH2)n0C(0)-NR1122, -(CH20)ntl, an optionally substituted -(CH2),OC(0)-(Ci-C6 alkyl), an optionally substituted -(CH2)nC(0)-0-(Ci-C6 alkyl), an optionally substituted -(CH20),COOH, an optionally substituted -(OCH2),0-(Ci-C6 alkyl), an optionally substituted -(CH20)nC(0)-(Ci-C6 alkyl), an optionally substituted -(OCH2),NHC(0)-Ri, an optionally substituted -(CH20),C(0)-NR1R2, -(CH2CH20)ntl, an optionally substituted -(CH2CH20),COOH, an optionally substituted -(OCH2CH2)n0-(Ci-C6 alkyl), an optionally substituted -(CH2CH20)nC(0)-(Ci-C6 alkyl), an optionally substituted -(OCH2CH2).NHC(0)-Ri, an optionally substituted -(CH2CH20),C(0)-NR1R2,an optionally substituted -SO2Rs, an optionally substituted S(0)Rs, NO2, CN or halogen (F, Cl, Br, I, preferably F or Cl);
Ri and R2 of ULM-g are each independently H or a Ci-C6 alkyl group which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine);
Rs of ULM-g is a Ci-C6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a -(CH2),,NR1122 group,;
X and X' of ULM-g are each independently C=0, C=S, -S(0), S(0)2 , (preferably X and X' are both C=0);

R2' of ULM-g is an optionally substituted ¨(CH2)-(C=0)u(NRi)v(S02)a1ky1 group, an optionally substituted ¨(CH2)-(C=0)u(NRi)v(S02)wNR1NR2N group, an optionally substituted ¨(CH2)n-(C=0)u(NRi)v(S02)w-Ary1, an optionally substituted ¨(CH2)n-(C=0)u(NROv(S02)w-Heteroary1, an optionally substituted ¨(CH2)-(C=0)vNRi(S02)w-Heterocycle, an optionally substituted -NR1-(CH2),-C(0),i(NROv(S02)w-alky1, an optionally substituted -NR1-(CH2)n-C(0)u(NRi)v(S02)w- NR1NR2N, an optionally substituted -NR1-(CH2)n-C(0)u(NR1)v(S02)w-NR1C(0)R1N, an optionally substituted -NR1-(CH2)n-(C=0)u(NRi)v(S02)w-Aryl, an optionally substituted -NR1-(CH2)n-(C=0)u(NR1)v(S02)w-Heteroaryl or an optionally substituted -NR1-(CH2)n-(C=0)vNR1(S02)w-Heterocycle, an optionally substituted -X'2'-alkyl group; an optionally substituted -XR2'- Aryl group; an optionally substituted -XR2'- Heteroaryl group; an optionally substituted -XR2'- Heterocycle group; an optionally substituted;
R3' of ULM-g is an optionally substituted alkyl, an optionally substituted ¨(CH2).-(0)u(NROv(S02)w-alkyl, an optionally substituted ¨(CH2)n-C(0)u(NRi)v(S02)w-NR1NR2N, an optionally substituted ¨(CH2)n-C(0)u(NRi)v(S02)w-NR1C(0)R1N, an optionally substituted ¨(CH2)n-C(0)u(NRi)v(S02)w-C(0)NRiR2, an optionally substituted ¨(CH2)n-C(0)u(NRi)v(S02)w-Aryl, an optionally substituted ¨(CH2)n-C(0)u(NRi)v(S02)w-Heteroaryl, an optionally substituted ¨(CH2)n-C(0)u(NROv(S02)w-Heterocycle, an optionally substituted -NR1-(CH2)n-C(0)u(NROv(S02)w-alkyl, an optionally substituted -NR1-(CH2)n-C(0)u(NRi)v(S02)w- NR1NR2N, an optionally substituted -NR1-(CH2)n-C(0)u(NRi)v(S02)w-NR1C(0)R1N, an optionally substituted -NR1-(CH2)n-C(0)u(NRi)v(S02)w-Aryl, an optionally substituted -NR1-(CH2)n-C(0)u(NRi)v(S02)w-Heteroaryl, an optionally substituted -NR1-(CH2).-C(0)u(NROv(S02)w-Heterocycle, an optionally substituted -0-(CH2)n-(C=0)u(NROv(S02)w-alkyl, an optionally substituted -0-(CH2)n-(C=0)u(NRi)v(S02)w-NR1NR2N, an optionally substituted -0-(CH2)n-(C=0)u(NRi)v(S02)w-NR1C(0)R1N, an optionally substituted -0-(CH2)n-(C=0)u(NROv(S02)w-Aryl, an optionally substituted -0-(CH2)n-(C=0)u(NRi)v(S02)w-Heteroaryl or an optionally substituted -0-(CH2).-(C=0)u(NR1)v(S02)w-Heterocycle; ¨
(CH2),-(V)'(CH2)n-(V),¨alkyl group, an optionally substituted ¨(CH2)-(V)n¨(CH2)n-(V).,-Aryl group, an optionally substituted ¨(CH2).-(V).,-(CH2).-(V).,-Heteroaryl group, an optionally substituted ¨(CH2).-(V).,-(CH2).-(V).,-Heterocycle'group, an optionally substituted -(CH2)n-N(Rr)(C=0)m-(V),,-alkyl group, an optionally substituted -(CH2)n-N(Ri,)(C=0)m,-(V),,-Aryl group, an optionally substituted -(CH2)n-N(Rr)(C=0)m-(V)n-Heteroaryl group, an optionally substituted -(CH2).-N(Ri,)(C=0)m,-(V).,-Heterocycle group, an optionally substituted -XR3- alkyl group; an optionally substituted -XR3- Aryl group; an optionally substituted -XR3- Heteroaryl group; an optionally substituted -X'3'-Heterocycle group; an optionally substituted;
RiN and R2N of ULM-g are each independently H, Ci-C6 alkyl which is optionally substituted with one or two hydroxyl groups and up to three halogen groups or an optionally substituted -(CH2),-Aryl, -(CH2),-Heteroaryl or -(CH2),-Heterocycle group;
V of ULM-g is 0, S or NRi;
Ri of ULM-g is the same as above;
R1 and Ri, of ULM-g are each independently H or a Ci-C3 alkyl group;
XR2' and XR3' of ULM-g are each independently an optionally substituted -CH2),-, -CH2),-CH(Xv)=CH(Xv)- (cis or trans), -CH2),-CtICH- , -(CH2CH20),- or a C3-C6 cycloalkyl group, where Xv is H, a halo or a Ci-C3 alkyl group which is optionally substituted;
each m of ULM-g is independently 0, 1,2, 3,4, 5, 6;
each m' of ULM-g is independently 0 or 1;
each n of ULM-g is independently 0, 1,2, 3,4, 5, 6;
each n' of ULM-g is independently 0 or 1;
each u of ULM-g is independently 0 or 1;
each v of ULM-g is independently 0 or 1;
each w of ULM-g is independently 0 or 1; and any one or more of R1', R2', R3', X and X' of ULM-g is optionally modified to be covalently bonded to the PTM group through a linker group when PTM is not ULM', or when PTM
is ULM', any one or more of R1', R2', R3', X and X' of each of ULM and ULM' are optionally modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
[0146] In any of the aspects or embodiments described herein, the ULM and when present, ULM', are each independently a group according to the chemical structure:

R1' _ _ F
R3 xz (iii1\1 ' ____________________________________ RI
0 , ULM-h wherein:
each of R1', R2' and R3' of ULM-h are the same as above and X is C=0, C=S, -S(0) group or a S(0)2 group, more preferably a C=0 group, and any one or more of R1', R2'and R3' of ULM-h are optionally modified to bind a linker group to which is further covalently bonded to the PTM group when PTM is not ULM', or when PTM is ULM', any one or more of R1', R2', R3' of each of ULM and ULM' are optionally modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
[0147] In any of the aspects or embodiments described herein, the ULM, and when present, ULM', are each independently according to the chemical structure:
R1' =
_ R-3-'----A .. R2' 0 0 , ULM-i wherein:
any one or more of R1', R2'and R3' of ULM-I are optionally modified to bind a linker group to which is further covalently bonded to the PTM group when PTM is not ULM', or when PTM is ULM', any one or more of R1', R2', R3' of each of ULM and ULM' are optionally modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
[0148] In further aspects of the disclosure, R1' of ULM-g through ULM-i is preferably a hydroxyl group or a group which may be metabolized to a hydroxyl or carboxylic group, such that the compound represents a prodrug form of an active compound. Exemplary preferred R1' groups include, for example, -(CH2),OH, (CH2),-0-(C1-C6)alkyl group, -(CH2),COOH, -(CH20).H, an optionally substituted -(CH2),OC(0)-(Ci-C6 alkyl), or an optionally substituted -(CH2),C(0)-0-(Ci-C6 alkyl), wherein n is 0 or 1. Where R1' is or contains a carboxylic acid group, a hydroxyl group or an amine group, the hydroxyl group, carboxylic acid group or amine (each of which may be optionally substituted), may be further chemically modified to provide a covalent link to a linker group to which the PTM group (including a ULM' group) is bonded;
[0149] X and X', where present, of ULM-g and ULM-h are preferably a C=0, C=S, -S(0) group or a S(0)2 group, more preferably a C=0 group;
[0150] R2' of ULM-g through ULM-i is preferably an optionally substituted -NR1-T-Aryl, an optionally substituted -NR1-T-Heteroaryl group or an optionally substituted -NR1-T-Heterocycle, where R1 is H or CH3, preferably H and T is an optionally substituted ¨(CH2).-group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, an amino acid sidechain as otherwise described herein or a C1-C3 alkyl group, preferably one or two methyl groups, which may be optionally substituted; and n is 0 to 6 (e.g., 0, 1, 2 or 3, such as 0 or 1). Alternatively, T may also be a ¨(CH20).- group, a ¨
(OCH2),- group, a ¨(CH2CH20),- group, a ¨(OCH2CH2),- group, all of which groups are optionally substituted.
[0151] Preferred Aryl groups for R2' of ULM-g through ULM-i include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl or naphthyl group is optionally connected to a PTM group via a linker group to which is attached a PTM group (including a ULM' group), a halogen (preferably F or Cl), an amine, monoalkyl-or dialkyl amine (preferably, dimethylamine), F, Cl, OH, COOH, Ci-C6 alkyl, preferably CH3, CF3, OMe, OCF3, NO2, or CN group (each of which may be substituted in ortho-, meta-and/or para-positions of the phenyl ring, preferably para-), an optionally substituted phenyl group (the phenyl group itself is optionally connected to a PTM via a linker group, including a ULM' group), and/or at least one of F, Cl, OH, COOH, CH3, CF3, OMe, OCF3, NO2, or CN group (in ortho-, meta- and/or para- positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted, an optionally substituted heteroaryl, preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted isothiazole including a methyl substituted isothiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, an optionally substituted benzimidazole or methoxybenzylimidazole, an optionally substituted oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, an optionally substituted pyridine group, including a halo- (preferably, F) or methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen), an optionally substituted furan, an optionally substituted benzofuran, an optionally substituted dihydrobenzofuran, an optionally substituted indole, indolizine or azaindolizine (2, 3, or 4-azaindolizine), an optionally substituted quinoline, an optionally substituted group according to the chemical structure:
HET so0 r RHET
R
,- - = = = N
LURE
RuRE

RHET

RHET RHET
=isj.ss"

RPRO
Ir--kN -(CH2), wherein:
SC of ULM-g through ULM-i is CHRss, NRuRE, or 0;

RHET of ULM-g through ULM-i is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably C1-C3 alkyl);
Rss of ULM-g through ULM-i is H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RuRE of u= . --- Em g through ULM-i is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a ¨
C(0)(C1-C6 alkyl) each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted phenyl group, an optionally substituted heteroaryl, or an optionally substituted heterocycle, preferably for example piperidine, morpholine, pyrrolidine, tetrahydrofuran);
RPR of ULM-g through ULM-i is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
RpRol and RPRO2 of ULM-g through ULM-i are each independently H, an optionally subsituted C1-C3 alkyl group or together form a keto group; and each n of ULM-g through ULM-i is independently 0, 1,2, 3,4, 5, or 6 (preferably 0 or 1), or an optionally substituted heterocycle, preferably tetrahydrofuran, tetrahydrothiene, piperidine, piperazine or morpholine (each of which groups when substituted, are preferably substituted with a methyl or halo (F, Br, Cl), each of which groups may be optionally connected to a PTM group (including a ULM' group) via a linker group.

3(RPRO2 linN-(CH2R) Pn R
[0152] In certain preferred aspects, 0 of ULM-g through ULM-i is a RpRo RPRO
N-(CH2), II
/
N-(CH2), 0 or group, where RPR and n of ULM-g through ULM-i are the same as above.
[0153] Preferred heteroaryl groups for R2' of ULM-g through ULM-i include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole, an optionally substituted indolizine, an optionally substituted azaindolizine, an optionally substituted benzofuran, including an optionally substituted benzofuran, an optionally substituted isoxazole, an optionally substituted thiazole, an optionally substituted isothiazole, an optionally substituted thiophene, an optionally substituted pyridine (2-, 3, or 4-pyridine), an optionally substituted imidazole, an optionally substituted pyrrole, an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted oximidazole, or a group according to the chemical structure:
HET
r t.-4 0 _RHET
"ez N
RuRE
RuRE

RHET
RHET A I _ RHET
=Pr RHET
yC
wherein:
SC of ULM-g through ULM-i is CHRss, NRuRE, or 0;

RHET of ULM-g through ULM-i is H, CN, NO2, halo (preferably Cl or F), optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra of ULM-g through ULM-i is H or a Ci-C6 alkyl group (preferably Ci-C3 alkyl);
Rss of ULM-g through ULM-i is H, CN, NO2, halo (preferably F or CO, optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RuRE of ULM-g through ULM-i is H, a Ci-C6 alkyl (preferably H or Ci-C3 alkyl) or a ¨
C(0)(Ci-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and Yc of ULM-g through ULM-i is N or C-R, where RYc is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably Ci-C3 alkyl), each of which groups may be optionally connected to a PTM group (including a ULM' group) via a linker group.
[0154] Preferred heterocycle groups for R2' of ULM-g through ULM-i include tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline, piperidine, piperazine, pyrrollidine, morpholine, oxane or thiane, each of which groups may be optionally substituted, or a group according to the chemical structure:

RPRO \/ RPRO2 RPRO
/
¨11-3(N¨(CH2), RHET __ 1--:.-....\ /
L------0 or 0 RPRO
----\ / 0 II
/PRO
N¨(CH2)n 5,ss 172r---- N¨(CH2)n preferably, a 0 or group, wherein:
RPRO of ULM-g through ULM-i is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl, heteroaryl or heterocyclic group;
RPR01 and RPR 2 of ULM-g through ULM-i are each independently H, an optionally subsituted Ci-C3 alkyl group or together form a keto group and each n of ULM-g through ULM-i is independently 0, 1,2, 3,4, 5, or 6 (often 0 or 1), each of which groups may be optionally connected to a PTM group (including a ULM' group) via a linker group.
[0155] Preferred R2' substituents of ULM-g through ULM-i also include specifically (and without limitation to the specific compound disclosed) the R2' substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R2' substituents may be used in conjunction with any number of R3' substituents which are also disclosed herein.
[0156] R3' of ULM-g through ULM-i is preferably an optionally substituted ¨T-Aryl, an optionally substituted¨T-Heteroaryl, an optionally substituted ¨T-Heterocycle, an optionally substituted-NR1-T-Aryl, an optionally substituted -NR1-T-Heteroaryl or an optionally substituted-NR1-T-Heterocycle. In a preferred embodiment R1 is H or a Ci-C3 alkyl group, preferably H or CH3, T is an optionally substituted ¨(CH2).- group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, a Ci-C6 alkyl group (linear, branched, optionally substituted) or the sidechain of an amino acid as otherwise described herein, preferably methyl, which may be optionally substituted; and n is 0 to 6,e.g. 0, 1, 2, or 3 ( such as 0 or 1).
Alternatively, T may also be a ¨
(CH20),- group, a ¨(OCH2),- group, a ¨(CH2CH20),- group, a ¨(OCH2CH2),- group, each of which groups is optionally substituted.
[0157] Preferred aryl groups for R3' of ULM-g through ULM-i include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl or naphthyl group is optionally connected to a PTM group (including a ULM' group) via a linker group and/or a halogen (preferably F or Cl), an amine, monoalkyl- or dialkyl amine (preferably, dimethylamine), an amido group (preferably a ¨(CH2)õ,-NR1C(0)R2 group where m, Ri and R2 are the same as above), a halo (often F or Cl), OH, CH3, CF3, OMe, OCF3, NO2õCN or a S(0)2Rs group (Rs is a a Ci-C6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a -(CH2).NR1R2 group), each of which may be substituted in ortho-, meta- and/or para- positions of the phenyl ring, preferably para-), or an Aryl (preferably phenyl), Heteroaryl or Heterocycle.
Preferably said substituent phenyl group is an optionally substituted phenyl group (i.e., the substituent phenyl group itself is preferably substituted with at least one of F, Cl, OH, SH, COOH, CH3, CF3, OMe, OCF3, NO2, CN or a linker group to which is attached a PTM group (including a ULM' group), wherein the substitution occurs in ortho-, meta-and/or para- positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted including as described above, an optionally substituted heteroaryl (preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, a benzylimidazole or methoxybenzylimidazole, an oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, a pyridine group, including a halo- (preferably, F) or methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen) or an optionally substituted heterocycle (tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperidine, morpholine, piperazine, tetrahydroquinoline, oxane or thiane. Each of the aryl, heteroaryl or heterocyclic groups may be optionally connected to a PTM group (including a ULM' group) via a linker group.
[0158] Preferred Heteroaryl groups for R3' of ULM-g through ULM-i include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole (including dihydroindole), an optionally substituted indolizine, an optionally substituted azaindolizine (2, 3 or 4-azaindolizine) an optionally substituted benzimidazole, benzodiazole, benzoxofuran, an optionally substituted imidazole, an optionally substituted isoxazole, an optionally substituted oxazole (preferably methyl substituted), an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted benzofuran, an optionally substituted thiophene, an optionally substituted thiazole (preferably methyl and/or thiol substituted), an optionally substituted isothiazole, an optionally substituted triazole (preferably a 1,2,3-triazole substituted with a methyl group, a triisopropylsilyl group, an optionally substituted -(CH2)6,-0-Ci-C6 alkyl group or an optionally substituted -(CH2)6,-C(0)-0-C1-C6 alkyl group), an optionally substituted pyridine (2-, 3, or 4-pyridine) or a group according to the chemical structure:
r..------.õ- sc ET
ro 0 ¨ ¨1 1 _IRHET
HET t, ..ji' N \ N
LURE
RU RE

RHET ir...k..... ) RHET IIIIIIIjN4 RHET

N'32z' or RHET 1 , K ') yc , wherein:
SC of ULM-g through ULM-i is CHRss, NRuRE, or 0;
RHET of ULM-g through ULM-i is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably C1-C3 alkyl);
Rss of ULM-g through ULM-i is H, CN, NO2, halo (preferably F or CO, optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C 1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RuRE of ULM-g through ULM-i is H, a Ci-C6 alkyl (preferably H or Ci-C3 alkyl) or a ¨
C(0)(Ci-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and Yc of ULM-g through ULM-i is N or C-R, where RIrc is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably Ci-C3 alkyl). Each of said heteroaryl groups may be optionally connected to a PTM group (including a ULM' group) via a linker group.
[0159] Preferred heterocycle groups for R3' of ULM-g through ULM-i include tetrahydroquinoline, piperidine, piperazine, pyrrollidine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxane and thiane, each of which groups may be optionally substituted or a group according to the chemical structure:
RpRoi RPRO1 RPRO RPRO RPRO
/ A / ._....-, /
_lr-----\<N-(CH2),-, RHET ..
ft.....,e -(c H2) N-(CH2), 1."--- 177-r------0 or 0 , preferably, a 0 /RpRo .ssel N-(CH2),, or group, wherein:
RPR of ULM-g through ULM-i is H, optionally substituted C1-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a Ci-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
RPR01 and RPR 2 of ULM-g through ULM-i are each independently H, an optionally subsituted Ci-C3 alkyl group or together form a keto group, and each n of ULM-g through ULM-i is 0, 1,2, 3,4, 5, or 6 (preferably 0 or 1), wherein each of said Heteocycle groups may be optionally connected to a PTM group (including a ULM' group) via a linker group.
[0160] Preferred R3' substituents of ULM-g through ULM-i also include specifically (and without limitation to the specific compound disclosed) the R3' substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R3' substituents may be used in conjunction with any number of R2' substituents, which are also disclosed herein.
[0161] In certain alternative preferred embodiments, R2' of ULM-g through ULM-i is an optionally substituted -NRi-X'2'-alkyl group, -NRi-X'2'-Aryl group; an optionally substituted -NRi- X'2'-HET, an optionally substituted -NRi-X'2'-Aryl-HET or an optionally substituted -NRi- XR2'-HET-Aryl, wherein:
Ri of ULM-g through ULM-i is H or a C1-C3 alkyl group (preferably H);
XR2' of ULM-g through ULM-i is an optionally substituted ¨CH2)n- , ¨CH2)n-CH(Xv)=CH(Xv)- (cis or trans), ¨(CH2)n-CtICH- , -(CH2CH20).- or a C3-C6 cycloalkyl group; and Xv of ULM-g through ULM-i is H, a halo or a C1-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
Alkyl of ULM-g through ULM-i is an optionally substituted C 1-C io alkyl (preferably a Cl-C6 alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a Cl or Br);
Aryl of ULM-g through ULM-i is an optionally substituted phenyl or naphthyl group (preferably, a phenyl group); and HET of ULM-g through ULM-i is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a Ci-C3 alkyl group, preferably methyl or a halo group, preferably F or CO or a group according to the chemical structure:
Sc HET RHET
Ryjr ¨
42< ,===
LURE
RURE

RHETrn N':4227 RHET RHET
Jsr ,RPRO2 RPRO1 RPRO
ri<
RHET j iN¨(CH2), r RHET L NI¨

L' yd.
o 0 0 =
SC of ULM-g through ULM-i is CHRss, NRuRE, or 0;
RHET of ULM-g through ULM-i is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a C1-C6 alkyl group (preferably C1-C3 alkyl);
Rss of ULM-g through ULM-i is H, CN, NO2, halo (preferably F or CO, optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);

RuRE of u= . --- Em g through ULM-i is H, a Ci-C6 alkyl (preferably H or Ci-C3 alkyl) or a -C(0)(Ci-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;
Yc of ULM-g through ULM-i is N or C-R, where RYc is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably Ci-C3 alkyl);
RPR of ULM-g through ULM-i is H, optionally substituted Ci-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a Ci-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
RPR 1 and RPR 2 of ULM-g through ULM-i are each independently H, an optionally subsituted Ci-C3 alkyl group or together form a keto group, and each n of ULM-g through ULM-i is independently 0, 1,2, 3,4, 5, or 6 (preferably 0 or 1).
[0162] Each of said groups may be optionally connected to a PTM group (including a ULM' group) via a linker group.
[0163] In certain alternative embodiments of the present disclosure, R3' of ULM-g through ULM-i is an optionally substituted -(CH2).-(V).,-(CH2).-(V)a-Rs3'group, an optionally substituted-(CH2).-N(RF)(C=0)õ,,-(V)a-Rs3' group, an optionally substituted -X'3' -alkyl group, an optionally substituted -XR3'-Aryl group; an optionally substituted -XR3'-HET group, an optionally substituted -XR3'-Aryl-HET group or an optionally substituted -XR3'-HET-Aryl group, wherein:
Rs3' is an optionally substituted alkyl group (Ci-Cio, preferably Ci-C6 alkyl), an optionally substituted Aryl group or a HET group;

121' is H or a Ci-C3 alkyl group (preferably H);
V is 0, S or NR1';
XR3' is ¨(CH2).- , -(CH2CH20).-, ¨CH2).-CH(Xv)=CH(Xv)- (cis or trans), ¨CH2).-CHCH- , or a C3-C6 cycloalkyl group, all optionally substituted;
Xv is H, a halo or a Ci-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
Alkyl is an optionally substituted Ci-Cio alkyl (preferably a Ci-C6 alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a Cl or Br);
Aryl is an optionally substituted phenyl or napthyl group (preferably, a phenyl group); and HET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), or a group according to the chemical structure:
,ro RHET c? > >¨ --1 I I __ RHET
..------N \ N/\
% 1 RuRE
RuRE

RHET 11..................'n RHET ¨'N RHET ).LI
Ni:22.4-......l_ N_......../
N
=J''''' \ ,RPRO2 RPRO1 R

PRO r.----`c / RHET ¨<
') RHET 1 IL,__ /N¨(CH2), rx yc or 0 0 =
, SC of ULM-g through ULM-i is CHRss, NRuRE, or 0;
RHET of ULM-g through ULM-i is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably Ci-C3 alkyl);
Rss of ULM-g through ULM-i is H, CN, NO2, halo (preferably F or Cl), optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RuRE of u= . --- Em g through ULM-i is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a ¨
C(0)(Co-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;
Yc of ULM-g through ULM-i is N or C-R, where RYc is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a C1-C6 alkyl group (preferably Ci-C3 alkyl);
RPR of ULM-g through ULM-i is H, optionally substituted Ci-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a Ci-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
RPR 1 and RPR 2 of ULM-g through ULM-i are each independently H, an optionally subsituted Ci-C3 alkyl group or together form a keto group;
each n of ULM-g through ULM-i is independently 0, 1,2, 3,4, 5, or 6 (preferably 0 or 1);
each m' of ULM-g through ULM-i is 0 or 1; and each n' of ULM-g through ULM-i is 0 or 1;

wherein each of said compounds, preferably on the alkyl, Aryl or Het groups, is optionally connected to a PTM group (including a ULM' group) via a linker group.
[0164] In alternative embodiments, R3' of ULM-g through ULM-i is -(CH2)n-Aryl, -(CH2CH20).-Aryl, -(CH2)n-HET or -(CH2CH20).-HET, wherein:
said Aryl of ULM-g through ULM-i is phenyl which is optionally substituted with one or two substitutents, wherein said substituent(s) is preferably selected from -(CH2),OH, Ci-C6 alkyl which itself is further optionally substituted with CN, halo (up to three halo groups), OH, -(CH2)nO(C1-C6)alkyl, amine, mono- or di-(Ci-C6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, Cl) groups, or said Aryl group of ULM-g through ULM-i is substituted with -(CH2),OH, -(CH2)n-0-(Ci-C6)alkyl, -(CH2)n-0-(CH2)n-(Ci-C6)alkyl, -(CH2)n-C(0)(Co-C6) alkyl, -(CH2)n-C(0)0(Co-C6)alkyl, -(CH2)n-OC(0)(Co-C6)alkyl, amine, mono- or di-(Ci-C6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, Cl) groups, CN, NO2, an optionally substituted -(CH2).-(V).-CH2),-(V).-(Ci-C6)alkyl group, a -(V).,-(CH2CH20).-RPEG group where V is 0, S
or NRF, Ri, is H or a C1-C3 alkyl group (preferably H) and RP' is H or a C1-C6 alkyl group which is optionally substituted (including being optionally substituted with a carboxyl group), or said Aryl group of ULM-g through ULM-i is optionally substituted with a heterocycle, including a heteroaryl, selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, benzofuran, indole, indolizine, azaindolizine, (when substituted each preferably substituted with a Cl-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), or a group according to the chemical structure:

Sc RHET >¨ I I __ RHET
N
RuRE
RuRE

RHET NI(k RHET I to _ RHET
0 RPRoi ,RPRO2 RPRO1 RPRO

/ HET r"\
RHET 7¨(CH2)n R
,\(yc or SC of ULM-g through ULM-i is CHRss, NRuRE, or 0;
RHET of ULM-g through ULM-i is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably C1-C3 alkyl);
Rss of ULM-g through ULM-i is H, CN, NO2, halo (preferably F or CO, optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RuRE of ULM-g through ULM-i is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a ¨
C(0)(Co-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;
Yc of ULM-g through ULM-i is N or C-R, where RIrc is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably Ci-C3 alkyl);
RPR of ULM-g through ULM-i is H, optionally substituted Ci-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a Ci-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine;
RPR 1 and RPRO2 of ULM-g through ULM-i are each independently H, an optionally subsituted Ci-C3 alkyl group or together form a keto group;
HET of ULM-g through ULM-i is preferably oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a Ci-C3 alkyl group, preferably methyl or a halo group, preferably F or Cl), benzofuran, indole, indolizine, azaindolizine, or a group according to the chemical structure:

HET 2¨ 0 Dj¨RHET
,===
LURE
RuRE

RHET N':4227 RHET RHET
Jsr RPRO
rIA
RHET 7¨(CH2), o "=-yc r RHET

SC of ULM-g through ULM-i is CHRss, NRuRE, or 0;

RHET of ULM-g through ULM-i is H, CN, NO2, halo (preferably Cl or F), optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C i-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a Ci-C6 alkyl group (preferably Ci-C3 alkyl);
Rss of ULM-g through ULM-i is H, CN, NO2, halo (preferably F or CO, optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RuRE of u= . --- Em g through ULM-i is H, a C1-C6 alkyl (preferably H or C1-C3 alkyl) or a ¨
C(0)(Co-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted;
Yc of ULM-g through ULM-i is N or C-R, where RYc is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group ¨CC-Ra where Ra is H or a C1-C6 alkyl group (preferably Ci-C3 alkyl);
RPR of ULM-g through ULM-i is H, optionally substituted Ci-C6 alkyl or an optionally substituted aryl, heteroaryl or heterocyclic group;
RPR01 and RPR 2 of ULM-g through ULM-i are each independently H, an optionally subsituted Ci-C3 alkyl group or together form a keto group;
each m' of ULM-g through ULM-i is independently 0 or 1; and each n of ULM-g through ULM-i is independently 0, 1,2, 3,4, 5, or 6 (preferably 0 or 1), wherein each of said compounds, preferably on said Aryl or HET groups, is optionally connected to a PTM group (including a ULM' group) via a linker group.
[0165] In still additional embodiments, preferred compounds include those according to the chemical structure:
R1' =
:7 _______________________________________________ RI
0 0 , ULM-i wherein:
R1' of ULM-i is OH or a group which is metabolized in a patient or subject to OH;
R2' of ULM-i is a ¨NH-CH2-Aryl-HET (preferably, a phenyl linked directly to a methyl substituted thiazole);
R3' of ULM-i is a ¨CHRcR3'-NH-C(0)-R3'1 group or a ¨CHRcR3'-R3'2 group;
12cR3' of ULM-i is a Ci-C4 alkyl group, preferably methyl, isopropyl or tert-butyl;
R3P1 of ULM-i is Ci-C3 alkyl (preferably methyl), an optionally substituted oxetane group (preferably methyl substituted, a ¨(CH2).00H3 group where n is 1 or 2 (preferably 2), or CH3 CH20 ____________ 1.1 ......\_.
____________________ ...--Irrs' a \
group (the ethyl ether group is preferably meta-substituted on the phenyl moiety), a morpholino grop (linked to the carbonyl at the 2- or 3-position;

RHET ..----1N _ 1 _ ''-=.----i R3P2 of ULM-i is a group;
Aryl of ULM-i is phenyl;
HET of ULM-i is an optionally substituted thiazole or isothiazole; and RHET of ULM-i is H or a halo group (preferably H);
or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, wherein each of said compounds is optionally connected to a PTM group (including a ULM' group) via a linker group.
[0166] In certain aspects, bifunctional compounds comprising a ubiquitin E3 ligase binding moiety (ULM), wherein ULM is a group according to the chemical structure:
,Z2....( R15 Ri5 G ' - -1C R25 4(R16)o SR7 kJ' _z,,,zi (R16)o , E R25 Y G/ R1 :1R 14 M , E
M
, ULM-j1 ULM-j2 wherein:
each RS and R6 of ULM-j is independently OH, SH, or optionally substituted alkyl or RS, R6, and the carbon atom to which they are attached form a carbonyl;
R7 of ULM-j is H or optionally substituted alkyl;
E of ULM-j is a bond, C=0, or C=S;
G of ULM-j is a bond, optionally substituted alkyl, -COOH or C=J;
J of ULM-j is 0 or N-R8;
R8 of ULM-j is H, CN, optionally substituted alkyl or optionally substituted alkoxy;
M of ULM-j is optionally substituted aryl, optionally substituted heteroaryl, optionally 1¨R10 substituted heterocyclic or R11 ;
each R9 and Rio of ULM-j is independently H; optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted thioalkyl, a disulphide linked ULM, optionally substituted heteroaryl, or haloalkyl; or R9, R10, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;
Ri 1 of ULM-j is optionally substituted heterocyclic, optionally substituted alkoxy, optionally Ri2 substituted heteroaryl, optionally substituted aryl, or R13;
R12 of ULM-j is H or optionally substituted alkyl;

R13 of ULM-j is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl; optionally substituted (oxoalkyl)carbamate, each R14 of ULM-j is independently H, haloalkyl, optionally substituted cycloalkyl, optionally substituted alkyl or optionally substituted heterocycloalkyl;
R15 of ULM-j is H, optionally substituted heteroaryl, haloalkyl, optionally substituted aryl, optionally substituted alkoxy, or optionally substituted heterocyclyl;
each R16 of ULM-j is independently halo, optionally substituted alkyl, optionally substituted haloalkyl, CN, or optionally substituted haloalkoxy;
each R25 of ULM-j is independently H or optionally substituted alkyl; or both R25 groups can be taken together to form an oxo or optionally substituted cycloalkyl group;
R23 of ULM-j is H or OH;
Zi, Z2, Z3, and Z4 of ULM-j are independently C or N; and o of ULM-j is 0, 1, 2, 3, or 4, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
[0167] In certain embodiments, wherein G of ULM-j is C=J, J is 0, R7 is H, each R14 is H, and o is 0.
[0168] In certain embodiments, wherein G of ULM-j is C=J, J is 0, R7 is H, each R14 is H, R15 is optionally substituted heteroaryl, and o is 0. In other instances, E is C=0 and M is 1¨R10 R11 .
[0169] In certain embodiments, wherein E of ULM-j is C=0, Rii is optionally substituted ¨NI, 1¨Rio heterocyclic or R13 , and M is R11 .

1¨eR10
[0170] In certain embodiments, wherein E of ULM-j is C=0, M is R11 , and Ril is )\--.....
1¨N 1 p ¨(R ) 1-11)\---;r(Rit3) \__ 18 p \-----\N-or , each R18 is independently halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, or haloalkoxy; and p is 0, 1, 2, 3, or 4.
[0171] In certain embodiments, ULM and where present, ULM', are each independently a group according to the chemical structure:

......./õf Se:23 R14 G' ,E
M , ULM-k wherein:
G of ULM-k is C=J, J is 0;
R7 of ULM-k is H;
each R14 of ULM-k is H;
o of ULM-k is 0;

1 ......-N
jj R15 of ULM-k is S ; and R17 of ULM-k is H, halo, optionally substituted cycloalkyl, optionally substituted alkyl, optionally substituted alkenyl, and haloalkyl.
[0172] In other instances, R17 of ULM-k is alkyl (e.g., methyl) or cycloalkyl (e.g., cyclopropyl).
[0173] In other embodiments, ULM and where present, ULM', are each independently a group according to the chemical structure:

R6 R /.....R15 R541 __ 23 R14 Rn25 p cc -, (R16)0 NI - R1'4R14 E
nr , wherein:
G of ULM-k is C=J, J is 0;
R7 of ULM-k is H;
each Ri4 of ULM-k is H;
o of ULM-k is 0; and R15 of ULM-k is selected from the group consisting of:
Br F3 /
, C
N; 1 1_1-3 1 1 1 __ ifii 1 __ c[ 1 __ hi s ; s ; ________ s h , . __ s b . s- \ ; s- ii ; s ;
,,N ____________________________________________________ ......_N
1 1 __ CIN ____________________________________ H
N-- __ __ N-N N N-N / ________ 0 N
H =, / = H =, 0N , - = / = , / = N =
, , , cN,... H ______________________________________________________ cl....\1H
1_ -1 _____ f---=.--y _____ h 1 __ 01 _rilH
\--0. 0 = =0 ? ......-----1. = 0 ; NC
, , , ,=

N S SU-N 1 __ S-N
\ II
N ; N-N ; N-N =
, 1 CIF1 /431 l_cO N 1 3 _\
N ; NJ' ; N ; and wherein R30 of ULM-k is H or an optionally substituted alkyl.
[0174] In other embodiments, ULM and where present, ULM', are each independently a group according to the chemical structure:

R
Z i R5/1 5(23 1:114 R 6 R5inõ,. 23 I
7N ---- \ R7 H
R25 (-4' ', (R16)o R25 ,N \riic 1 ki `16/o R25 Nil - R14R14 R25 N G

, ME
ME , ULM-kl ULM-k2 wherein:
E of ULM-k is C=0;

1 ( R10 M of ULM-k is R11 ;and Rii of ULM-k is selected from the group consisting of:

F Br 1¨N

CN s 1¨N
i¨N 1¨N ¨N
F = Br ; Br ;
, ,=

1¨N 1¨N
1¨N 1¨N
F ; N; ON;
,=

¨N OMe 1¨N
1¨N
\ OMe CI ;
,= , i¨N 0 )--1¨N 1¨N 1 \-----N OMe = ;and .
,
[0175] In still other embodiments, a compound of the chemical structure, R6 R _pR15 Z
R5;. _________ c,,23 1:114 R5niõ,. 1 µ23 \
rx7 N ---- \ R7 H

G' (R16)0 R25 ,N \pp 1 N G ..w/R ki `16/o R25 Fil R14R14 R25 1 14 M , ULM-kl ULM-k2 wherein E of ULM-k is C=0;

, Nci Rii of ULM-k is ¨NH R20 , and 1¨R10 M of ULM-k is R11 ;
q of ULM-k is 1 or 2;
R20 of ULM-k is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally HN¨IK
substituted aryl, or R22.
R21 of ULM-k is H or optionally substituted alkyl; and R22 of ULM-k is H, optionally substituted alkyl, optionally substituted alkoxy, or haloalkyl.
[0176] In any embodiment described herein, Rii of ULM-j or ULM-k is selected from the group consisting of:
0\\
0\\ 0\\ 0 ( 0 Ok\
\ ,\
/
__________________ s ) ( ¨NH . ¨NH . 1¨NH ) ¨NH . . z¨NH ____ . ¨NH .
, , , , , , 0 Ok ¨Ntb ¨NH
4* 1NH 0 \ __________________________________________ / '11 ¨ .
\ ,¨NH

1¨NH . ON
1¨NH . . 1 , ,¨NH ,¨NH
11.
0 0 OMe 0 Me0 1¨NH OMe 1¨NH 1¨NH
, 1::_c) ) 0, \
N 0\ N=, -N 0 ( \\ C) \ / 1 \ / 5 7 _____ \
1-NH _______ 1¨NH ____ / . 1 NH ___________ NH ________ ¨NH NH2, o 0, 0 0 /
, _________ \ 0 ( , __ ( 0 ( ,¨NH HN¨µ 1¨NH HN¨µ li ¨N , ¨NH NH2, -\ 1¨NH
0 ; 0 =
, =
. 0 0 F
1 ______________________________ OV 1¨N 1¨N
1¨NH = . 1¨NH = 0-N = = =

F Br , s CN
1¨N , 1¨N ¨N 1¨N
= = F = =

1¨N ¨N 1¨N
1¨N 1¨N
Br; Br ; F ; CN ; ON;

_N; _N

OMe ¨N
\ OMe = . .
, , , ¨N 1¨N 0 CI 0 CI 0 OMe 1¨N i¨N 1¨N
CI ; OMe = = = =

0 Br 0 0 0 )\---- 0 1¨N 1¨N 1¨N 1¨N I
\---N
1¨N)L-= OMe; CI.
OMe= \---.
, , N,V
(17 141r 141r 1¨ II N N-N
N-N 1¨ 11 1¨ 1 S-N = S-N = 0-N = H = 0---\= SjN=
, H
0 S S 0 N N-NH . - = N- = N- = N-= N--- ;
, N-..... N-..., N--7 N-...."
N
I 1¨ I 1¨ 1 1 ___________________________________ er\jr _____ ON; SN= C) ; S = %Co = ` S =
, , , N=N
N/ . =
..-NH . __________________________ CP N= N\
1 = 1 _______________________________ ?= 1 /) 1¨K\; N j N=> ;
/, ).\
1¨N I
\----.
and N.
[0177] In certain embodiments, Ril of ULM-j or ULM-k is selected from the group consisting of:

0 F , ¨N , 1-N ¨N
;
= =
, F ;

1¨N 1¨N
1¨N ¨N
F ; CN; CN = =

CN 1¨N Br 1¨N , ¨N 1¨N
= Br; Br = =

1¨N 1¨N 0 1¨N
\,-e.
OMe; CI = =
, 0 R\
1¨N OMe, OMe 1¨N ¨NH ) \ .

* li ¨NH ON;
0 0 0 OMe ¨NH 1¨NH OMe 1¨NH
. .

0 Me0 1¨NH lit; 0 ( 1¨NH\----N 1¨NH HN¨µ
=OMe = 0 ;
, , ( o( 1¨NH HN¨ 1 __ er7 0 ; 0-N

¨c---N
:1 z., 1 S / 1 1.1 ,.....õ1, c ; c,õ \\\....."- ---õ,.. ---4\\=\ ...õ, ..,õ,- , c; \\.,.......;,.. ,..... ,...õ---1,4,e/
...V
U i , S
11 d mi 0.-
[0178] In certain embodiments, ULM (or when present ULM') is a group according to the chemical structure:

\ ) X
HO, N
Y

, wherein:
X of ULM-1 is 0 or S;
Y of ULM-1 is H, methyl or ethyl;
R17 of ULM-1 is H, methyl, ethyl, hydoxymethyl or cyclopropyl;

/-eRi0 M of ULM-1 is is optionally substituted aryl, optionally substituted heteroaryl, or R11 ;

R9 of ULM-1 is H;
Rio of ULM-1 is H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted hydroxyalkyl, optionally substituted thioalkyl or cycloalkyl;
R11 of ULM-1 is optionally substituted heteroaromatic, optionally substituted heterocyclic, ¨1\1 optionally substituted aryl or Ri3;
R12 of ULM-1 is H or optionally substituted alkyl; and R13 of ULM-1 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl; optionally substituted (oxoalkyl)carbamate.
[0179] In some embodiments, ULM and where present, ULM', are each independently a group according to the chemical structure:

\ ) S
HO, , ___________________________________ H .
N
R 9>ro Y

, ULM-m wherein:
Y of ULM-m is H, methyol or ethyl R9 of ULM-m is H;
Rio is isopropyl, tert-butyl, sec-butyl, cyclopentyl, or cyclohexyl;
Rii of ULM-m is optionally substituted amide, optionally substituted isoindolinone, optionally substituted isooxazole, optionally substituted heterocycles.
[0180] In other embodiments of the disclosure, ULM and where present, ULM', are each independently a group according to the chemical structure:

S
HO, N.......1(FNII
R9.> 0 Rlo R11 , ULM-n Wherein:
Ri7 of ULM-n is methyl, ethyl, or cyclopropyl; and R9, Rio, and Ri 1 of ULM-n are as defined above. In other instances, R9 is H;
and Rio of ULM-n is H, alkyl, or or cycloalkyl (preferably, isopropyl, tert-butyl, sec-butyl, cyclopentyl, or cyclohexyl).
[0181] In any of the aspects or embodiments described herein, the ULM (or when present, ULM') as described herein may be a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof. In addition, in any of the aspects or embodiments described herein, the ULM (or when present, ULM') as described herein may be coupled to a PTM
directly via a bond or by a chemical linker.
[0182] In certain aspects of the disclosure, the ULM moiety is selected from the group consisting of:

HO, HO, HO, H
c N
N N N

7L(LO 7L(LO )"'.(LO
N N N
0 Br 0 0 S S S
. \--=--N
. \--=-N \;--N
HO, HO, F
i=
c N &)N HR
. H

N
7L(LO 7L(L 0 N 0 N 7L(LO
---. --- N

4 1 \:----N
CI \-----N S --,...
\;---N
HOõ 1-10, . ____ H 1 - H Br N HO, ).....c(N
>LrLO 70 N
O,NH N 0 S ---.. (LO
\--=-*N \-----N c),NH
F
HOõ
C S ---.
. ____ H \----N
)....,c(N 1-10, & ).....1cH 1-10, N N
0 . H
7L(0 N & ......c(N

--..
S N >LrLO
0 ---, S\,_N c),NH
CZ S ---.
\--=-N
1-10,. __ H
)....,c(N F 1-10, O N
7L(0 0 O N >Lr0 --... c),NH
S
S
Vh' \---N

HQ, FIR HQ, . H
N
N N N

>Lr0 7L(0 4104 7L(LO
N S\---H N N
0 0 Br --.. ---S
(:) \---=N

/ -'sU II
FIR HO, HQ, . H , . __ H . H
__________ .....c(NI
N N N
O >LrLO 0 7L(0 . 7L(LO
N N
0 (:),INH 0 Br ---.. --..
S S
\----;N =
a \---=-N
FIR
F
H
HQ, , __ \ ,H HO __ . H

N
--... 0 NH
S \--:--N
S
\----:- S ---..
NC 110 \---=N
FIR Br FIR FIR H
__________ H H
ON
......c(N --1\-7,..Ic. N N

N

0 7L(LO
>Lr0 SvYC) olr ,NH (:)NH --...
I S ---\;.---N
S N Br S
\--:--N

FIR HQ, FIR
i= ___ H , __ \ H /- H
c ......ccN
...... J.L1 O OyL ii 0 0 >Lr0 0 OH HN OH
S\ ---:N '1,17 S ..) S --, FIR
i= ___ H FIR
>Lr _____________________________________ H FIR
1( ,....I(N
N /- H
O N c NN
),.....0 0 7L,r0 (:) NH

)'`-- S ---\--r-N 0 N
\
F S ''---:"---N 0 N
S
FIR -'-4. \--=-N
i= ___ H FIR
c ),...7(N H HQ, ......µ(N
N H
O )...1vLN 0 >LrLO 0 Q--"ICN

0 NH OyL 0 ---.. 0 N
S --, = N S\--=--N 0 ---...
S\--=N
4.
HO,, CN
i= __ \ .H
N FIR HO, , __ H
_____________________________________ ).....1cH .
,.....ccN
7L(Lo O 714..17% 0 .
N
N

----.

4.
S\----zN N 0 N
S
--:--- S____, CN = CN \ N
FIR \ N
, )yiLH\ .1-I
N
O
HN,S,,, ----, S \____,N

HO ________________________ ,, HO ________________ HO, N N N

7L(LO 11104 >LrIC) HSO

= I. , Si 4. S -,..
\:.-----N
HO,, _______________________________________________ HO __ . H . H
......IcN ......e HO,, N H _____________ N
AVLO
HO N

H0 -,..
HN S
4. 1\1-- 0 N
--...
S\....,__N . \--=-N
HO,, 4. HQ, i= _______ H . H
c ..,7(N
HO,, N H N
0 ,....\.(N _________ 0 7L(0 0170 N

-.... __...7L0 -....
S S
\---=
44, \--:--N
Br N 0 N ---..
S
HR
= \---."-N
HQ, . H H
__________ ,...N N
HO,, N i= H HO
>LrLO o'''YLO
N

H
--, S\N S

S ---.. \:------N
\---:"-N
ON NC

HO,. HOõ. H ,OH HO, H
c \ 0 HN 0 0 NH
ClyL

N --,-/S 7 'Ts"),., Sv_.N
NH

0,NH
0)\
----. -----S I S IH
V.--N
N

7L(LO
HO,. HR. N
&

S

N 7L(Lo --T:-.
0 0 1 \N
7L(0 0 H0a.: H
S I S
411 \-.---N
. \--=-N N

LrLO
\\ 0 N
---,.
OMe S
\--:---N
Me0 HO,.

H
HR.
H
N .....I(N HR.

arLO n y 0 N
N \S2Y0 0 ---. N
S\,....... 0 Me0 0 . N
II , s N \_-=- S -\;.----N
HR.
H HR.
....e HO,, .....7(1-H N
N ).....\.(N
N

OrLO0 0 N HeYLC) S -,..
. \----N
)''= S --'' =.---- S
\ N
-\--=-N

HO HQ, HOõ
H i= __ H i= __ H
N >L17LN 0 N

>LrLO >LrLO

----. --... --..
S\----N S
L) S\--7=N
* NC 001 \...N .-=-N
HO, HQ, I
cz.....\c= H
HOõ
i= H
0 Me0 0 71..., IrL1 0 c .....c(N

---. 0 N >LrLO0 S .... 0 NH
S\___,.N ----.
S
HO,v r_\ OMe HO,, H
........e =
/-N
Me0 0 0 OMe 7L(LN 0 0 HO, ---. H
N 0 N ),...e N
S
HOõ. -...

&\ ,1-1 14`17L0 le-""c(N 0 NH
---..
)k"=-(LO CI S
\--=-N
HQ, N
0 c ....,c(H
i=
--, N

CI 0 Me0 HQ, HOõ 0 N i= ___ H
. _______ H
........el S\ __r_ N
N
N O0 >LrLO0 7L(L

(:),NH ---.
1 ---..
S\ ,.....N N\5 S
V.--N
--.

HON/ HO HQ, OH
.N--I(N
1\17-.7(N

>Lr0 0 0 S ' Me0 ---.
* Me0 \:.--N S\_N
FIR
FIR, FIR i= H
H . H
F N
7L..(N 0 o, N FF>yLo 0 >Lr0 NH2 --...
0 N 0 NH S\---=N
/\ ---.
S\,...._N
. N

FIR
. H
( ).....el HO, . _____ H FIR F N
( )...1(N i= H F 0 c ,..1(N F>H7L0 714... JLI 0 o, N (N,NH

1 --...
0 S\
,___N
0 N OMe (:),NH

__\,--z.-N c ,..1(H
i N
FIR 714....(LN 0 0 HO,, i H
c ,..1(N
. H
& ).....1(N N N

0 (C) 7L(LO (N.,NH
. 0 N ---.

---. \--N HO
Sx,_____N
II FIR
H
N
N N
7LrL , N

0,0 ¨N
\:.--N

SIT

=
r µN
N/

N
N)L-cN
H

N%\s * .
N-%-\ *
-.. N=N, * N¨

NH , NH N 0 N
# 0 CYNIV
N(1) 0 o Y7 )L-c_ NI) )\.....c_N31 N' H H
''OH N'OH
H
'OH
N---%\
WO
S
N.%\s . -,...
NH S
NR
N--"\

---,.

N 4.....,N
0)LO.
N OV

".....O 'OH
H
''OH N
H
N-%\ * N.-%\ ()H
N"--\
N¨I S
===.. --,.. ---N N N
0y7 OyNIV 0 ".....O
N N"16'-cN NI' H H H
'OH ''OH 'OH
N%---"\s * N--%\ * N"--\s S *
-,.. .... --,..

N N N
0y7 d 0y7 # 0 CYNIV 0 0 )1...._O
N N N
H ' H H
'OH ''OH ''OH
t1100/610ZSI1/13.1 t9SISO/OZOZ OM

HO,, HO, ____________________ FIR, H i= H H
.,.,c(1\1 N N N

7L(LO . 7L(LO 7L(LO
N N

--.. --..
N .1__-_-Z S = al N OMe \.-:----N
Ho s---HO, "4---)....INj N i HO, H --... , H
& ________ .......e N & ,....e N HN 714.....(LN 0 0 .

VrLO 0 N

=\----zN
*
HO
HO.
'N .....\,(H
H N
),....e HO, 7 0 1 ic_..t H
>L(NIL 0 N
7 .
0.,N 0 N
I --, S\.,...._N
4. 0 N
HO.
H HO, 4. 0 ),.....e c ....1(H i=
N N
HS, .N
N -.
7L(LO 0 ---1411 0 141 --.. N HN

\_.----N 0 HO,.
4. N
H
_..,..e 7L...(NLO HO
N Ho IP
Os .& .,,,(H
714.,(LN 0 0 . /--_\ Mec) S'eN
N -----....
S
4.

a HN

4.
IIP

HR
---HQ
S'N HR.
.,.... N 1 ,e11-1 --... N
NH
I ICN3'.) N

* Ill 4. S ---..
\--=-N
HR. HO,.
H H
N(N ( ,....\(N HO,, 1 ylcH

>Lr0 7L(13 o NH 0 \s--N N
, 1 HI ' 0 0 ---.
2'0 0 S
HR
\---.:-'N
. 4.
___________ H HR.
_...(N1 1 ylcH
N HO, - 0--"N
N

>LrLO 700 NH
). N 0 N
--... 0 \--=----N S
H2N '''' \--r-"N
F10. ft =
(N711 HR.
H HO
>LrL
''. __ ,...iccH
N
(D.,NH 0 N
, 1 HN) S ----VO
N

---, (D'O S
1 --...
HR. . \--%N S
\:------N
H R
,..e ..
HR. H c.....c(' H
N H N
>LrL0 & ____ .......µN

NH

\.--r--N 7L(L-S
(:),,,NH
1 S =.. -N S -'-\.:-.---N1 \.--r--N

HQ.. o-N HO Ha . )õ...c(H H
I ic-""le N N

--,... ---.
S S
= -1\I
\--=-N -1\1 \---=-N
Ho, N HOt, ___ ),..."ccH HO PH
' H
b N
--...
I lc N N

HN 7L,r0 7L(0 0 --, S I s -....
. . \---::-'N
.
HO,, HQ, HO,, . H H H
...."c(N1 ......e /-N N N
0 c0 - S
\.----N 1\i \.:-.---N \:--N
HO.. OH HO
i= __ H 1, OH _ c----c(' H
H N
N
N
1"'= 0 0 -IV
\--=-VLIVLO

7Tc0 0 -1\1 S
"N --,.
\----;"-N
HO,, = \--=.1\1 HQ, H
c ...".\(N .......e HQ, N i= __ H N
0 c ......(N N 0 ----. --..
-IV --ni s \--=-*N / 0 \s-----N
--,.
S
V.--N

HO,, HO,, HO,, N N N

It ---, --....
¨N 0 ¨ S ¨N S
\--:--N Ni \:-.--; N \--=--N
HO,, HO, HR
......ccN ( .......c(N ......ccN
N N N

0 0 7TcL, 0 ---, --- ---, ¨IV 0\----N ¨Ni S ¨IV S\---- \-..--N N
HO,, HR HO, H , i _______________________ . ______________________________ H
N N N

0 filt 0 410 7TcLo 0 \ \ \
¨NI 0 ¨Ni S -Thi S
HR HR HR
. H . ____ H H
N N N
O 0 = 0 .
7TcL) 0 VT:L) 0 0 --...

\--=-N \----=N \:---N
HO,, HR HO,, . H H . H
).....(N
N N N
O 0 = 0 --, \--:--N \:-.---1\1 \--=--N

HO,õ HO,õ HO,õ
H H H
( N c( N N

VILO 7Tc0 0 . 0 ---. N'S --- NN
\ i --.
¨N 0 7--Ni S 0 S
\---=N \--=--N \---;N
HQ, HO,õ HR.
H H H
)......c(N ,...,c(1\1 ).....c(N
N HLN N

--.. Nc / 0 T
\ / ---, ¨N 0 /)¨NSx..____N S S\----N
\:---N
HR. HO,õ HR.
H H H
).......e ).....c(N _.,...e N N N
0 = 0 0 O VLJCO HCLO

--- ---.--, ¨Ni 0 )=INI S )\---g S
\::---N \--5--N \---r---N
HQ, HR. HQ, H H H
.....1(1\1 N...1(N1 N N

O 7L)L0 VHCO

--- --- ---.
----N 0 )=-- s )\--O s \--=-N \:---N \:---N
HO,, HR. HO,õ
H H H
.......c(N1 N N N

Z S S N
N NN
---. --- \ , --.
-----N S S NH S
\--szN )=-- \--=--N \---;N

HO,õ HO,õ HO,õ
H H H
( N c( N c( N

HNN
7L/1(0 71 S 1(cLO 0 N ---. --- V N ---, )---i \---=N1 )\---0 S
\--=--N 1%
N S
\:.---N
HO, HO,õ HO,õ
H H H
, .....sc(N
......ccN ,...,c(1\1 N N N

VL)0 0 0 V
0 N NI ---, 71**12(cL --.. I --, S
)-----j S\ -_--N ;\--S S\,___N N
\:.---N
HO,õ
HO,õ HO,õ H
),....el ).....c(N1 N

7L)L0 0 )kNI:1 ---.
S NN ---, HN S
)-----1 S
\:.--N )------N
\--5--N \----;1\1 HO,õ
HQ, HQ,. H
Q,....c(N
H H
,..,1(1\1 & .....1(N

NO 0 ---. --- I\I S

\----;1\1 S
\--=--N \---=N
HO HQ,.
H H
N N
.......c(N1 ),...,c(N

/ N
le S ---. I S --...
)---j S
\--szN
\..---N

SN HO, HO,,.

jNI)fC) HN
HN
>rLC) OyNH r ¨N1 FIR HR HO
c )......e & ),....c(N ,..7(N
N N HO N
0 . S
yL0 0 410 ,,,,.yL0 0 110 OF \N
N
S S S
\ * ..--N 0 0 \---=N \--.--zN
HO,, HO
õ.
HR.
H ,....1(N
HO N
N 0 0 /s \ 0 o, 0 * õ0=(:) HeYLO
N C)NH ONH

S \.-----N \_----N
* \--:=---N
)----- )-----HR, HO,, H .....\,(H
-N-7....7(N N
\ (1\1(Fil N
HSvY0 0 4110 7L,r0 ilt N c)NH N

S S S
* \--=-N
\:-----N
* \----N

.spH HR. =
H H H0 ..7: H
e N N
N)7....4 N
. 0 OAy 7HN 0 (:)i-1 N

N....VS S\---:--N S ---...
41 \--=-N
HO,,a1( HR. HR.r_i H
OH
H
ci......e N N

1\1)41 0 tilt 0 Me0 * 0 Me0 0 0 0 N
S S
*
\---N \-----N
Ho,.
s--1 c-31 :ICI N
R H. HR
F
H H
& N....1 )(N & c(N
F N

HN
F>0 . 0 *
F>YLO 0 N

S
-... /' s ---..
\---N \----N
HS.
S*---N Ho, s , 0:41:- 9 ---% Ho, o , . s ,N ---%
HN
0 HN i ICN3-.44\

HR Ho, HQ, H S H
)......el --N
(1\--Xl. N
C3rNH
N
>Lt70 =

7L(0 =
OrNH 0 N N
HN) s \:.---N 0 S
?COrLO 411 \---N
HQ, HQ, HO,, H H H
c/...IN QAN fy_IN
vLro 0 . vLro 0 * 7L(Lo 0 411, S S S
lit \---;--N
41 \--.-=-N \--=-N
HR. HQ, HO,.
H H
N N H
& ),.7(N ),....el N
0 ilt 0 Alp 0 0 .

-N1 s --NI s ¨NI s N
HR. H0i,L \ ,H HR.
H N H
)......e N(-.1( )......e 0 . 7L,r0 lot 0 0 N 0 .

/ 0 S /o \-..--- N
-1\1 S -1\1 S
\---:--N 4. \--=--N

OH
r_1µ H
Ho, HO, )...."c(N )....".c(N
0 0 * N N

0 . ),,,. 0 0 .
S z o z o * \:---N
-N s \--1--*N -1\1 s \:.----N
HO,õ .91-1 H
HO,,. HO,,.
1 ic)-.47(N H H
c....7(N
0 *
VT(30 0 S z o * \---::-N
-1\1 s \.--N -IV S
\---N
HO,õ HO,õ HR.
H H H
N ,...7(N

0 * 0 . 0 4110 0 7c3L, 0 \_---=N \--=-N
HO,, HO HO,, õ.
H H H
),....7(N
N N

N 1110 0 *
0 oN T 7c3, 0 0 VT3L, / 0 -N ¨Ni s -.- s \:.-- 11 \:---N

HO,, HO,, HO,, H H H
),..7N
N N N( 0 . 0 . 0 .
. 0o .0 s s 7 _N, s \_--:---N \_--:---N \_--:---N
HR HO,, HR
H H H
N N N
0 * 0 * 0 illp O 0 7TcL1 0 ¨IV S N
¨1\1 S ¨1\1 S
HO,, HO,, HO
H H H
N N N
0 . 0 = 0 410, ¨1\1 S ¨1\1 0 ¨1\1 0 FIR FIR HR
_________ H H H
O . ....,\,(1\1 .....\,(N
N N N
0 1110i 0 *

VTI VT/
0 ¨1\1 0 HO,õ HO,õ NO,,.
H H H
N N N
0 * 0 = vHco 0 =

/ 0 / N z S
-NI 0 -N S )=--I S
V---:-- N \-----N \---N
HO,õ HO, HO, H H H
).......c(N & ),..,c(N .......c(N
N N N
7L/LO o, 7L/LO

o, 7L0 o, N z 0 õ HN N N 0 N N
ti\I S
\r----N -1\S
\--=-N
HO,, Ng,. HO,, H HH
)......e & ),...7(N
N N N
0 * = *
VLb 0 00 S N N N N N N
\ / \ i ?1\1 S
\---=-N 0 S
\--.-;--N S S
\--.-=-N
HO,õ HO,õ HO, H H H
N N N
0 = 7Ljo 0 . HcLo 0 .

N N N N N N N
)\----g s )\--O s \ , s NH
\---N \;---N \--:--N

HO,, HO,, HO,, H H H
).......el & 0 ),..i(N )....7(N
N N N
0 * 7Ljco 0 = 7Ljc() 0 =
VLX

)---1 S
\-----N )---1 S
\-----N
\---N
HR HR HO
H H H
N N
0 = c( N 7L,/cLo 0 410 0 .
le VLJLO VN5cLO

)----j S
\r----N )-----1 S
\--:=N )\--O S
\--=-N
HO,, HO,, HO
H H
)......e & ),...7(NI \ .H

0 lit N
= 0 00 .
HN
)\--S S S
\:::---N 7-- \:.--N S

FIR HO,, HO
H H H
N N N
,,o 0 tipt 00 = 0 410 I S It 1 N S N S
\:---N \----N \---=-N

HO, HO, , H , -, _______________________ N......c( H HO, <-, )........\,(N c N .
N
NtN
7L7cL0 0 *

------4"*---------0 N ' N
....õ
It -.......
--, OH
N S N S
'.1 r'''? s \
N --'----- N
\:..---- N \------N \
Ho, HQ, :.
... N
CLN-....., . N =%
e=-,k ,/:= ---.......
.>µ....., . L-=2=,,,,,.:. ,7 0 -.,õ, =,.., ,>=-.
/". .

/NH
I , $ ,..) HO, HO
..; ....................................................
, ________ H ., ; H
>14......(LN 0 0 = .1 .. ,s H N : \ ), ,.
--.-"4.---.J.=.0 V isµ =,== .N :
....õ,. µ;, . / sss, ,, = ...
.. - ¨ .. .....
-......../ / -.....-...,-'i HN)''''' \:::---N ==,µ.. N %
0 0 : ',....v., N \:.........,=:7 HQ. HQ
. .
'--., H ................. ; H
=i \ N -..", i 'N . : .L.,., N. =,, '1 t \ H 4, \ ...7 s% i b ? = .N ,,,,, ' ,... 11 '..1 ..- r '0 µ ,' i ,."......,,, .....) N' ', N =,::
.
/ =
.s. N )., ,. 1 -.-4`,, -- '=' 1 ksl, .... ft µ'. 'N .,. .-.
S i .)' .. = S. 1 \44 N 'f / \==::;==.-N = i ...,..... ¨
%
t l'.% ................................................ 8 : \ .? 4:s= \ S 1 ,,, ....., HQ
HC).
;.' ....... H
HQ,.
1 = N¨..,., -- --Y-s t) , ,s, As.s.,-.<? `b 6 i N- \' =
% =
1 $ = ,,--.:\ ..,-.A....õ,....--";:;. % , ,N $ $= -= 3 0 % ) %
/ ' S,. ;
,,,,, ....-.:2=N s P s. /

.:''.----. S 1 N ---- ' r K .s.>"- 6 õ,;(/ t'N
OH HQ
I 1 ) ., \
. - ' i ._1( \, H
P...õ..." -,r. __ k .__ Ki--- N..
N i 13 's-----,, i:' .
=-s.õ..) 0 ...:/ ¨NH
6.= , õ.. ,--=,; 00 i / ¨ /.."'s , .
ON
'N. ..Y
S---('--"' and wherein the VLM may be connected to a PTM via a linker, as described herein, at any appropriate location, including, e.g., an aryl, heteroary, phenyl, or phenyl of an indole group, optionally via any appropriate functional group, such as an amine, ester, ether, alkyl, or alkoxy.
Exemplary ILMs
[0183] AVPI tetrapeptide fragments
[0184] In any of the compounds described herein, the ILM can comprise an alanine-valine-proline-isoleucine (AVPI) tetrapeptide fragment or an unnatural mimetic thereof. In certain embodiments, the ILM is selected from the group consisting of chemical structures represented by Formulas (I), (II), (III), (IV), and (V):

iNN//N\/ R6 (I) (II) ..:N.

H W- ['Lk 1.4 R tr "
(m) (w) H Q shµ
roN =.=-=AN"..-'\. = -14 z ---;&\
0' N.
(V) wherein:
R1 for Formulas (I), (II), (III), (IV), and (V) is selected from H or alkyl;
R2 for Formulas (I), (II), (III), (IV), and (V) is selected from H or alkyl;
R3 for Formulas (I), (II), (III), (IV), and (V) is selected from H, alkyl, cycloalkyl and heterocycloalkyl;

R5 and R6 for Formulas (I), (II), (III), (IV), and (V) are independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, or more preferably, R5 and R6 taken together for Formulas (I), (II), (III), (IV), and (V) form a pyrrolidine or a piperidine ring further optionally fused to 1-2 cycloalkyl, heterocycloalkyl, aryl or heteroaryl rings, each of which can then be further fused to another cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring;
R3 and R5 for Formulas (I), (II), (III), (IV), and (V) taken together can form a 5-8-membered ring further optionally fused to 1-2 cycloalkyl, heterocycloalkyl, aryl or heteroaryl rings;
R7 for Formulas (I), (II), (III), (IV), and (V) is selected from cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aryl-C(0)-R4, arylalkyl, heteroaryl, heteroaryl-C(0)-R4, heteroaryl-R4, heteroaryl-naphthalene, heteroarylalkyl, or -C(0)NH¨
R4, each one further optionally substituted with 1-3 substituents selected from halogen, alkyl, haloalkyl, hydroxyl, alkoxy, cyano, (hetero)cycloalkyl, (hetero)aryl, ¨C(0)NH¨R4, or -C(0)¨R4; and R4 is selected from alkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, further optionally substituted with 1-3 substituents as described above.
[0185] As shown above, P1, P2, P3, and P4 of Formular (II) correlate with A, V, P, and I, respectively, of the AVPI tetrapeptide fragment or an unnatural mimetic thereof. Similarly, each of Formulas (I) and (III) through (V) have portions correlating with A, V, P, and I of the AVPI
tetrapeptide fragment or an unnatural mimetic thereof.
[0186] In any of the compounds described herein, the ILM can have the structure of Formula (VI), which is a derivative of IAP antagonists described in WO Pub.
No. 2008/014236, or an unnatural mimetic thereof:

R N
R.3 (VI), wherein:
RI of Formula (VI) is, independently selected from H, C1-C4ralky, Ci-alkynyl or C3-Cio- cycloalkyl which are unsubstituted or substituted;

R2 of Formula (VI) is, independently selected from H, C1-C4-alkynyI or C3-Cio- cycloalkyl which are unsubstituted or substituted;
R3 of Formula (VI) is, independently selected from H, -CF3, -C2H5, - CH2-Z or any R2 and R3 together form a heterocyclic ring;
each Z of Formula (VI) is, independently selected from H, -OH, F, Cl, -CH3, -CF3. -CH2C1, -CH2F or -CH,OH;
R4 of Formula (VI) is, independently selected from Ci-C 16 straight or branched alkyl, CI-C16-alkenyl, CI-C16- alkynyl, C3-Cio-cycloalkyl, -(CH2)o-6-Zi, -(CH2)o-6-aryl, and -(CH2)0_ 6-het, wherein alkyl, cycloalkyl, and phenyl are unsubstituted or substituted;
R5 of Formula (VI) is, independently selected from H, Ci-Jo-alkyl, aryl, phenyl, C3-7-cycloalkyl, -(CH2)1-6-C3_7- cycloalkyl, -(CH2)0-6-C3_7-cycloa1kyl-(CH2)o-6-phenyl, -(CH2)04-CHE(CH2)14- phenyl.12, indanyl, -C(0)-C1-10-alkyl, -C(0)-(CH2)1.6-C3.
7-cycloalkyl, -C(0)-(CH2)11.6-phenyl, - (CH2)a.6-C(0)-phenyl, -(CH2)G.6-het, -C(0)-(CH2)1_6-het, or R5 is selected from a residue of an amino acid, wherein the alkyl, cycloalkyl, phenyl, and aryl substituents are unsubstituted or substituted;
Z1 of Formula (VI) is, independently selected from -N(R10)-C(0)-Ci-io-alkyl. -N(Rio)-C(0)-(CH2)o-6-C3-7-cycloalkyl, -N(R1o)-C(0)-(CH2)&.6-phenyl, -N(R10)-C(0)(CH2)1_6-het, -C(0)-N(Ri )(RI2), -C(0)-0-C1-10-alkyl, -C(0)-0-(CH2)1-6-C3-7-cycloalkyl, -C(0)-(CH2)0_6-phenyl, -C(0)-0- (CH2)1_6-het, -0-C(0)-C1-10-alkyl, -0-C(0)-(CH2)i-6-cycloalkyl, -0-C(0)-(CH2)0.6-phenyl, - 0-C(0)-(CH2)1_6-het, wherein alkyl, cycloalkyl, and phenyl are unsubstituted or substituted;
het of Formula (VI) is, independently selected from a 5-7 member heterocyclic ring containing 1 -4 heteroatoms selected from N, 0, and S, or an 8-12 member fused ring system including at least one 5-7 member heterocyclic ring containing 1, 2, or heteroatoms selected from N, 0, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon or nitrogen atom;
Rio of Formula (VI) is selected from H, -CH3, -CF3, -CH2OH, or -CH2C1;
Ri and R12 of Formula (VI) are independently seleted from H, C3_7-cycloa1ky1, -(CH2)1_6-C3_7- cycloakyl, (CH2)o-6-phenyl, wherein alkyl, cycloalkyl, and phenyl are unsubstituted or substituted; or Rii and RI, together with the nitrogen form het, and U of Formula (VI) is, independently, as shown in Formula (VII):

Rs R.#
XIR,1 =====.µ
R6 \
X
Oth)õ""""Rd--, (VII), wherein:
each n of Formula (VII) is, independently selected from 0 to 5;
X of Formula (VII) is selected from the group -CH and N;
R. and RI). of Formula (VII) are independently selected from the group 0, S.
or N atom or Co-8-alkyl wherein one or more of the carbon atoms in the alkyl chain are optionally replaced by a heteroatom selected from 0, S. or N, and where each alkyl is, independently, either unsubstituted or substituted;
Rd of Formula (VII) is selected from the group Re-Q-(Rf)p(Rg)q, and Ar1-D-Ar2;
of Formula (VII) is selected from the group H or any Rc and Rd together form a cycloalkyl or het; where if Rc and Rd form a cycloalkyl or het, R5 is attached to the formed ring at a C or N atom;
p and q of Formula (VII) are independently selected from 0 or 1;
Re of Formula (VII) is selected from the group Ci_s-alkyl and alkylidene, and each Re is either unsubstituted or substituted;
Q is selected from the group N, 0, S, S(0), and S(0)2;
An and Ar2 of Formula (VII) are independently selected from the group of substituted or unsubstituted aryl and het;
Rf and Rg of Formula (VII) are independently selected from H. -C1-10-alkyl, Ci_io-alkylaryl, -OH, - (CH2)0.5-C3-7-cycloalky, -0-(CH2)G-6-aryl, phenyl, aryl, phenyl ¨
phenyl, -(CH2)1-6-het, -0-(CH2)1_6-het, -0R13. -C(0)-R13, -C(0)-N(R13)(R14), -N(R13)(R14), -S-R13, -S(0)-R13, -S(0)2-R13, -S(0)2- NRI3R14, -NR13-S(0)2-R14, -S-CE-lo-alkyl, aryl-C1-4-alkyl, or het-Ci4-alkyl, wherein alkyl, cycloalkyl, het, and aryl are unsubstituted or substituted, -S02-CI-2-alkyl, -S02-C1-2-alkylphenyl, -0-C14-a1kyl, or any Rg and Rf together form a ring selected from het or aryl;

D of Formula (VII) is selected from the group -CO-, -C(0)-CI4-alkylene or arylene, -CF2-, -0-, -S(0)r where r is 0-2, 1,3-dioxalane, or Ci4-alkyl-OH; where alkyl, alkylene, or arylene are unsubstituted or substituted with one or more halogens, OH, -0-C1_6-a1kyl, -S-C1-6-alkyl, or -CF3; or each D is, independently selected from N(Rh);
Rh is selected from the group H, unsubstituted or substituted CI 4-alkyl, aryl, unsubstituted or substituted -0-(C14-cycloalkyl), -C(0)-C1-10-alkyl, - C(0)-0040-alkyl-aryl, -C-0-Col-10-alkyl, -C-0-00_10-alkyl-aryl, -S02-C1_10-alkyI. or -S02-(C0-10- alkylary1);
R6, R7, R8, and R9 of Formula (VII) are, independently, selected from the group H, -C1-10-alkyl, -Ci_10-alkoxy, aryl-C1-10- alkoxy, -OH, -0-C140-alkyl, -(CH2)0-6-C3-7-cycloalkyl, -0-(CH2)0_6-aryl, phenyl, -(CH2)1-6-het, -0-(CH2)1.6-het, -OR 13, -C(0)-R 13, -C(0)-N(R13)(R14), -N(RI3)(R14), -S-R13, -S(0)-RI3, -S(0)2- RI3, -S(0)2-NR13R14, or -S(0)2-R14; wherein each alkyl, cycloalkyl, and aryl is unsubstituted or substituted; and any R6, R7, R8, and R9 optionally together form a ring system;
R13 and Ri4 of Formula (VII) are independently selected from the group H, Ci_10-alkyl, -(CH2)i).6-C34-cycloalkyl, -(CH2)0.5- (CH)04 -(aryl)i-2, -C(0)-C1-10-alkyl, -C(0)-(CH2)1-6-C34-cycloa1kyl, -C(0)-0-(CH2)a.6-aryl, - C(0)-(CH2)a-6-0-fluorenyl, -C(0)-NH-(CH2)0-6-aryl, -C(0)-(CH2)0.6-aryl, -C(0)-(CH2)o-6-het, - C(S)-C1-10-alkyl, -C(S)-(CH2)1-6-C3--7-cycloalkyl, -C(S)-0-(CH2)0.6-aryl, -C(S)-(CH2)-0-fluorenyl, -C(S)-NH-(CH2)0-6-aryl, -C(S)-(CH2)o-6-aryl, or -C(S)-(CH2)1-6-het, wherein each alkyl, cycloalkyl, and aryl is unsubstituted or substituted: or any RI3 and Ri4 together with a nitrogen atom form het;
wherein alkyl substituents of RI3 and Ri4 of Formula (VII) are unsubstituted or substituted and when substituted, are substituted by one or more substituents selected from Ci_io-alkyl, halogen. OH,- 0-C1_6-alkyl. -S-C1-6-alkyl, and -CF3; and substituted phenyl or aryl of R13 and Ri4 are substituted by one or more substituents selected from halogen, hydroxyl. Ci_4-alkyl, Ci_4-alkoxy, nitro, -CN, -0-C(0)-C14-alkyl, and -C(0)-0-C14-aryl;
or a pharmaceutically acceptable salt or hydrate thereof.
[0187] In any of the compounds described herein, the 1LM can have the structure of Formula (VIII), which is based on the IAP ligrands described in Ndubaku, C., et al. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists, ACS Chem. Biol., 557-566,4 (7) ( 2009), or an unnatural mimetic thereof:

H o1 õm, \
H
'NH
0' A2 (Al) (VIII), wherein each of Al and A2 of Formula (VIII) is independently selected from optionally substituted monocyclic, fused rings, aryls and hetoroaryls; and R of Formula (VIII) is selected from H or Me.
[0188] In a particular embodiment, the linker group L is attached to Al of Formula (VIII).
In another embodiment, the linker group L is attached to A2 of Formula (VIII).
[0189] In a particular embodiment, the ILM is selected from the group consisting of ..11 N H
N :)=( r\r 0 N H = H N

N
N
and (A) (B)
[0190] In any of the compounds described herein, the ILM can have the structure of Formula (IX), which is derived from the chemotypes cross-referenced in Mannhold, R., et al.
IAP antagonists: promising candidates for cancer therapy, Drug Discov. Today, 15 (5-6), 210-9 ( 2010), or an unnatural mimetic thereof:

H
i H _ -(IX), wherein R1 is selected from alkyl, cycloalkyl and heterocycloalkyl and, most preferably, from isopropyl, tert-butyl, cyclohexyl and tetrahydropyranyl , and R2 of Formula (IX) is selected from ¨0Ph or H.
[0191] In any of the compounds described herein, the ILM can have the structure of Formula (X), which is derived from the chemotypes cross-referenced in Mannhold, R., et al. IAP
antagonists: promising candidates for cancer therapy, Drug Discov. Today, 15 (5-6), 210-9 ( 2010), or an unnatural mimetic thereof:
w 0 x =r R3 N R4 t - N

(X), wherein:
R1 of Formula (X) is selected from H, ¨CH2OH, --CH2CH2OH, --CH2NH2, --CH2CH2NH2;
X of Formula (X) is selected from S or CH2;
R2 of Formula (X) is selected from:
Oil õ
N
.., I 0 iliv I*
R3 and R4 of Formula (X) are independently selected from H or Me
[0192] In any of the compounds described herein, the ILM can have the structure of Formula (XI), which is derived from the chemotypes cross-referenced in Mannhold, R., et al.
TAP antagonists: promising candidates for cancer therapy, Drug Discov. Today, 15 (5-6), 210-9 ( 2010), or an unnatural mimetic thereof:

i it 14111 0 R1rl-.'N 0 H
(XI), wherein R1 of Formula (XI) is selected from H or Me, and R2 of Formula (XI) is selected from H or S

N----H
0.e...N -1S
i
[0193] In any of the compounds described herein, the ILM can have the structure of Formula (XII), which is derived from the chemotypes cross-referenced in Mannhold, R., et al.
TAP antagonists: promising candidates for cancer therapy, Drug Discov. Today, 15 (5-6), 210-9 ( 2010), or an unnatural mimetic thereof:

0,..NH

N NE: 0 0 iej N N

(XII), wherein:
R1 of Formula (XII) is selected from:

ff'sN%(,) N AthiõN\
0 41.1) ; and R2 of Formula (XII) is selected from:
zg.õ.
[0194] In any of the compounds described herein, the IAP E3 ubiquitin ligase binding moiety is selected from the group consisting of:
Br = H
[0195] In any of the compounds described herein, the ILM can have the structure of Formula (XIII), which is based on the IAP ligands summarized in Flygare, J.A., et al. Small-molecule pan-IAP antagonists: a patent review, Expert Opin. Ther. Pat., 20 (2), 251-67 ( 2010), or an unnatural mimetic thereof:
0 n( N N
H

Z
n Tr- 0, 2 or, preferably, 1 wherein:
Z of Formula (XIII) is absent or 0;
R1 of Formula (XIII) is selected from:

/ \
...---* OH 0 , Rl 01 *
RR) of is selected from H, alkyl, or aryl;
X is selected from CH2 and 0; and is a nitrogen-containing heteroaryl.
[0196] In any of the compounds described herein, the ILM can have the structure of Formula (XIV), which is based on the TAP ligands summarized in Flygare, J.A., et al. Small-molecule pan-TAP antagonists: a patent review, Expert Opin. Ther. Pat., 20 (2), 251-67 ( 2010), or an unnatural mimetic thereof:
0 0 ................................ 'NH
- S
R
: H
...., z-. N ' H
(XIV), wherein:
Z of Formula (XIV) is absent or 0;
R3 and R4 of Formula (XIV) are independently selected from H or Me;
R1 of Formula (XIV) is selected from:

/ \
, Rl * ON
Rlo of is selected from H,\,alkyl, or aryl;
..."..4, X
,, X of is selected from CH2 and 0; and i \
.6-. õ
of '\
or is a nitrogen-containing heteraryl.
[0197] In any of the compounds described herein, the ILM is selected from the group consisting of:
H

/PMN
i H
H . and , which are derivatives of ligands disclose in US Patent Pub. No. 2008/0269140 and US
Pat. No. 7,244,851.
[0198] In any of the compounds described herein, the ILM can have the structure of Formula (XV), which was a derivative of the TAP ligand described in WO Pub.
No. 2008/128171, or an unnatural mimetic thereof:

H 0 ( 1L7'1 j'i, )..--z---k H
(XV) wherein:
Z of Formula (XV) is absent or 0;
R1 of Formula (XV) is selected from:
i \
R" X
*
*
*
, Ritl . 0 R1 of is selected from H, alkyl, or aryl;
",.õµ
X
* 1 ..,õ,.., 1 X of is selected from CH2 and 0; and Cs\,"
i .1..11.4..õ
, / \
of or is a nitrogen-containing heteraryl; and R2 of Formula (XV) selected from H, alkyl, or acyl;
[0199] In a particular embodiment, the ILM has the following structure:

/
\__e<
N ,..
_\....0 N ¨
k I
,õ,-.....-.
[0200] In any of the compounds described herein, the ILM can have the structure of Formula (XVI), which is based on the IAP ligand described in WO Pub. No.
2006/069063, or an unnatural mimetic thereof:
H 0 1;. r----\
,N ,L,N .,1 ..t4 /
.-- --?:-- ' '1r H A
ka VN )1 Ar (XVI), wherein:
R2 of Formula (XVI) is selected from alkyl, cycloalkyl and heterocycloalkyl;
more preferably, from isopropyl, tert-butyl, cyclohexyl and tetrahydropyranyl, most preferably from cyclohexyl;

\
s'(::!.) of Formula (XVI) is a 5- or 6-membered nitrogen-containing heteroaryl; more preferably, 5-membered nitrogen-containing heteroaryl, and most preferably thiazole; and Ar of Formula (XVI) is an aryl or a heteroaryl.
[0201] In any of the compounds described herein, the ILM can have the structure of Formula (XVII), which is based on the IAP ligands described in Cohen, F. et al., Antogonists of inhibitors of apoptosis proteins based on thiazole amide isosteres, Bioorg.
Med. Chem. Lett., 20(7), 2229-33 (2010), or an unnatural mimetic thereof:

\
Jõ.
( (XVII), wherein:
R1 of Formula (XVII) is selected from te group halogen (e.g. fluorine), cyano, /
.("/
/ /
o X of Formula (XVII) is selected from the group 0 or CH2.
[0202] In any of the compounds described herein, the ILM can have the structure of Formula (XVIII), which is based on the IAP ligands described in Cohen, F. et al., Antogonists of inhibitors of apoptosis proteins based on thiazole amide isosteres, Bioorg.
Med. Chem. Lett., 20(7), 2229-33 (2010), or an unnatural mimetic thereof:

z 6 s R
(XVIII), wherein R of Formula (XVIII) is selected from alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl or halogen (in variable substitution position).
[0203] In any of the compounds described herein, the ILM can have the structure of Formula (XIX), which is based on the IAP ligands described in Cohen, F. et al., Antogonists of inhibitors of apoptosis proteins based on thiazole amide isosteres, Bioorg.
Med. Chem. Lett., 20(7), 2229-33 (2010), or an unnatural mimetic thereof:

N N
N
H
0 'N
\\N
(XIX), N
wherein ----- is a 6-member nitrogen heteroaryl.
[0204] In a certain embodiment, the ILM of the composition is selected from the group consisting of:
0 ? r>
N r\r st4 = H H
0 t4 fro\
*
';rskµii N and \44
[0205] In certain embodiments, the ILM of the composition is selected from the group consisting of:

= H 0 Ni 1 z 0 "-= N H
S NLI\1=11 N
_= H

H

rej ro 0 ...-i 0 Nri...
N
H O N F S
H , and , Hi).L
N
N IQ
H
S IN
.
[0206] In any of the compounds described herein, the ILM can have the structure of Formula (XX), which is based on the TAP ligands described in WO Pub. No.
2007/101347, or an unnatural mimetic thereof:
c_,.

H
N
N
N

H
0 0)N
H (XX), wherein X of Formula (XX) is selected from CH2, 0, NH, or S.
[0207]
In any of the compounds described herein, the ILM can have the structure of Formula (XXI), which is based on the IAP ligands described in U.S. Pat. No.
7,345,081 and U.S.
Pat. No. 7,419,975, or an unnatural mimetic thereof:

===N

R- (XXI), wherein:
R2 of Formula (XXI) is selected from:

HN _____________________________________________________ R6 R5 of Formula (XXI) is selected from: 0 and \ _______ ; and W of Formula (XXI) is selected from CH or N; and HN ____________________________ R6 R6 of 0 and \ ___________________________________________________ are independently a mono- or bicyclic fused aryl or heteroaryl.
[0208]
In certain embodiments, the ILM of the compound is selected from the group consisting of:

0 = r\v!..1\
= .
,-N 14 H =
0 ==
, ,and
[0209] In any of the compounds described herein, the ILM can have the structure of Formula (XXII) or (XXIV), which are derived from the IAP ligands described in WO Pub. No.
2015/006524 and Perez HL, Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity. J. Med. Chem.
58(3), 1556-62 (2015), or an unnatural mimetic thereof, and the chemical linker to linker group L as shown:

"NH
wkirp.
HN, R2 N 1:%1 - 1 Linker (XXII);
'NH
, \:,N¨..wa Linker (XXIII); or NH

40-7µ..NH
Link er N
(XXIV), wherein:
R1 of Formula (XXII), (XXIII) or (XXIV) is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted aryl;
R2 of Formula (XXII), (XXIII) or (XXIV) is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted aryl;
or alternatively, R1 and R2 of Formula (XXII), (XXIII) or (XXIV) are independently selected from optionally substituted thioalkyl wherein the substituents attached to the S atom of the thioalkyl are optionally substituted alkyl, optionally substituted branched alkyl, optionally substituted heterocyclyl, -(CH2)vCOR20, -CH2CHR21COR22 or -CH2R23, wherein:
v is an integer from 1-3;
R2 and R22 of ¨(CH2)vCOR2 and -CH2R23 are independently selected from OH, or OR26;
R21 of -CH2CHR21COR2 is selected from NR24R25;
R23 of -CH2R23 is selected from optionally substituted aryl or optionally substituted heterocyclyl, wherein the optional substituents include alkyl and halogen;
R24 of NR24R25 is selected from hydrogen or optionally substituted alkyl;
R25 of NR24R25 is selected from hydrogen, optionally substituted alkyl, optionally substituted branched alkyl, optionally substituted arylalkyl, optionally substituted heterocyclyl, -CH2(OCH2CH20)õ,CH3, or a polyamine chain, such as spermine or spermidine;

R26 of OR26 is selected from optionally substituted alkyl, wherein the optional substituents are OH, halogen or NH2; and m is an integer from 1-8;
R3 and R4 of Formula (XXII), (XXIII) or (XXIV) are independently optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted heteroarylalkyl or optionally substituted heterocycloalkyl, wherein the substituents are alkyl, halogen or OH;
R5, R6, R7 and R8 of Formula (XXII), (XXIII) or (XXIV) are independently hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl; and/or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
[0210] In a particular embodiment, the ILM according to Formulas (XXII) through (XXIV):
R7 and R8 are selected from the H or Me;
R5 and R6 are selected from the group comprising:
y R3 and R4 are selected from the group comprising:
rTh 0 Ics,õ
[0211] In any of the compounds described herein, the ILM can have the structure of Formula (XXV), (XXVI), (XXVII), or (XXVIII), which are derived from the IAP
ligands described in WO Pub. No. 2014/055461 and Kim, KS, Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists. Bioorg. Med. Chem. Lett. 24(21), 5022-9 (2014), or an unnatural mimetic thereof, and the chemical linker to linker group L as shown:

R.8.
-HH
= c,.. .,0 R6s -T-'-r-A
)0 '---010),,,,.

Lihker (XXV);
R8.
-NH
HN
, .,...N, 4/.............,\
__________________________ Linker ', .. 4/
(XXVI);
R.Nil '") ________ 17 R2 S.....1 'NH
0 I)/
---=., N ______________________ Linker /

(xxvm; and fe.NH P
1,,...4 H2 e 4,i%.
R6 HN ...... < ,¨ --(, ,).
, s., d >/
o----.N _____________________ Linker /

(xxvim, wherein:

R2 of Formula (XXV) through (XXVIII) is selected from H, an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted aryl;
or alternatively;
R1 and R2 of Formula (XXV) and (XXVIII) are independently selected from H, an optionally substituted thioalkyl ¨CR6oR61,-,a 70 tc wherein R6 and R61 are selected from H or methyl, and R7 is an optionally substituted alkyl, optionally substituted branched alkyl, optionally substituted heterocyclyl, -(CH2)vCOR20, -CH2CHR21COR22 or -CH2R23;
wherein:
v is an integer from 1-3;
R2 and R22 of ¨(CH2)vCOR2 and -CH2CHR21COR22 are independently selected from OH, NR24R25 or OR26;
R21 of -CH2CHR21COR22 is selected from NR24R25;
R23 of -CH2R23 is selected from an optionally substituted aryl or optionally substituted heterocyclyl, where the optional substituents include alkyl and halogen;
R24 of NR24R25 is selected from hydrogen or optionally substituted alkyl;
R25 of NR24R25 is selected from hydrogen, optionally substituted alkyl, optionally substituted branched alkyl, optionally substituted arylalkyl, optionally substituted heterocyclyl, -CH2CH2(OCH2CH2)mCH3, or a polyamine chain [CH2CH2(CH2)81\TH]vCH2CH2(CH2)(75,NH2 , such as spermine or spermidine, wherein .3 = 0-2, Iv = 1-3, (75 = 0-2;
R26 of OR26 is an optionally substituted alkyl, wherein the optional substituents are OH, halogen or NH2, m is an integer from 1-8;
R6 and R8 of Formula (XXV) through (XXVIII) are independently selected from hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl; and R31 of Formulas (XXV) through (XXVIII) is selected from alkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl optionally further substituted, preferably selected form the group consisting of:

, A

E
, and
[0212] In any of the compounds described herein, the ILM can have the structure of Formula (XXIX) or (XXX), which are derived from the IAP ligands described in WO Pub. No.
2013/071039, or an unnatural mimetic thereof:

HN

N
H H
(XXIX), e 0 , 0 u : n X y -Fe. 1 x ) N
H H
0 0 R14 (XXX), wherein:
R43 and R44 of Formulas (XXIX) and (XXX) are independently selected from hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl further optionally substituted, and R6 and R8 of Formula (XXIX) and (XXX) are independently selected from hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl.
each X of Formulas (XXIX) and (XXX) is independently selected from:

0 0 N v N
H H 1N : 2 v N -1 -: 2 1µ = 2 -\ 0 401 HN 1 \)H N
).L 0 if3 N

N (s) 1 s 2 V A/ 1 H

N /
1 = 2 / 1v/ = 2 1 Nv&
7: 2 OTh H H 0 NI/\)%3 N 0µ%3 1 µ 2 II3 , If3 3 , 0 0 , HR) H
1 1 2 1 N 2 11¨N
0 7 , \)-N
(31if3 Oie3 2 3 , N &dt H
1 s 2 v N

3 0 o3 ,an d =
, 47.si ,- Nµ
I N
each Z of Formulas (XXIX) and (XXX) is selected from C , wherein each represents a point of attachment to the compound; and each Y is selected from:

H H

1 s N A
A N
* -.....- 1 0 *
dfzt H
H
N A
V Y

V y H
N A VNA
y 1 1V Y 1 i i ISI =
4 , 14 4 1$1 0 0.de4 H H
H N A VNA
N A V
V y 1 1 1 z 1.1 0 0 0A44N(N H
, , H
H VN A Y

H V
H A VN A
v N

0 r 1 / (:) Nk N el HN0 Aµ 01 4 H 4,c) 4 , 4 , H Me N A H
Ni A
V N A
_ HI),%4 0 N
* 1N :
z I. 0 = 4 0 ifzi H H
N,NA VN A
1 µ z 4 1 S

lx NH
H
N A
iv 'r H
ON_____\_ j--I4 41 ¨CH 1 ======,-=
V :

N=N , 2¨NH¨Il , /L1. , and 4 , wherein:
¨ I 1 represents a point of attachment to a ¨C=0 portion of the compound;
¨ I 2 represents a point of attachment to an amino portion of the compound;
- I 3 represents a first point of attachment to Z;
¨ I 4 represents a second point of attachment to Z; and A is selected from -C(0)R3 or 0 N N-N\ 0 HN-N, V \ N- \ NI' sN \1/4,11.... 0 vii.... /0 II 0 y.... S vO-OH
N1/4/L-z-IV N N NC-0 N
H H
OH
F el F
, or a tautomeric form of any of the foregoing, wherein:
R3 of -C(0)R3 is selected from OH, NHCN, NHSO2R10, NHOR11 or N(R12)(R13);
R1 and R11 of NHSO2R1 and NHOR11 are independently selected from -C1-C4 alkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, any of which are optionally substituted, and hydrogen;
each of R12 and R13 of N(R12)(R13) are independently selected from hydrogen, -Ci-C4 alkyl, -(Ci-C4 alkylene)-NH-(Ci-C4 alkyl), benzyl, -(Ci-C4 alkylene)-C(0)0H, -(Ci-C4 alkylene)-C(0)CH3, -CH(benzy1)-COOH, -Ci-C4 alkoxy, and -(Ci-C4 alkylene)-0-(C1-C4 hydroxyalkyl); or R12 and R13 of N(R12)(R13) are taken together with the nitrogen atom to which they are commonly bound to form a saturated heterocyclyl optionally comprising one additional heteroatom selected from N, 0 and S, and wherein the saturated heterocycle is optionally substituted with methyl.
[0213] In any of the compounds described herein, the ILM can have the structure of Formula (XXXI), which are derived from the IAP ligands described in WO Pub.
No.
2013/071039, or an unnatural mimetic thereof:
RI
i 1442 .rn \

(XXXI), wherein:
W1 of Formula (XXXI) is selected from 0, S, N-R', or C(R8a)(R8b);
W2 of Formula (XXXI) is selected from 0, S, N-R', or C(R8c)(R86 ); provided that W1 and W2 are not both 0, or both S;
R1 of Formula (XXXI) is selected from H, C1-C6alkyl, C3-C6cycloalkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from 0, N-R', S, S(0), or S(0)2, then X2 is C(R2aR2b);
or:
X1 of Formula (XXXI) is selected from CR2cR2d and )(2 is cR2a,sI(2b, and R2' and R2a together form a bond;
or:
X1 and X2 of Formula (XXXI) are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring;
or:

X1 of Formula (XXXI) is selected from CH2 and X2 is C=0, C=C(Rc)2, or C=NRc;
where each RC is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -C 1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
RA of N-R' is selected from H, C1-C6alkyl, -C(=0)C1-C2alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, R2b, R2c, R2d of cR2c-rsI(2d and CR2a's2b I( are independently selected from H, substituted or unsubstituted C 1-C6alkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3- C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heteroc yclo alkyl), -C1-C6alkyl- (substituted or unsubstituted aryl), -C
i-C6alkyl-(substituted or unsubstituted heteroaryl) and - C(=0)RB;
RB of - C(=0)RB is selected from substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3- C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heteroc yclo alkyl), -C1-C6alkyl- (substituted or unsubstituted aryl), -C
i-C6alkyl-(substituted or unsubstituted heteroaryl), or - NRDRE;
RD and RE of NRDRE are independently selected from H, substituted or unsubstituted C 1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl- (substituted or unsubstituted C3-C6cycloalkyl), -C 1-C6alkyl-( sub stituted or unsubstituted C2- C5heterocyclo alkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl- (substituted or unsubstituted heteroaryl);
m of Formula (XXXI) is selected from 0, 1 or 2;
-U- of Formula (XXXI) is selected from -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;

R3 of Formula (XXXI) is selected from C1-C3alkyl, or C1-C3fluoroalkyl;
R4 of Formula (XXXI) is selected from -NHR5, -N(R5)2, -N-F(R5)3 or -0R5;
each R5 of -NHR5, -N(R5)2, -N-F(R5)3 and -0R5 is independently selected from H, Ci-C3alkyl, C1-C3haloalkyl, C1-C3heteroalkyl and -Ci-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 of Formula (XXXI) together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 of Formula (XXXI) is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 of Formula (XXXI) is selected from -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS(=0)2NHR7, -(Ci-C3alkyl)-NHC(=0)R7, -(Ci-C3alkyl)-C(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 of -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS(=0)2NHR7, -(Ci-C3alkyl)-NHC(=0)R7, -(Ci-C3alkyl)-C(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2NHR7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-ClOcycloalkyl, a substituted or unsubstituted C2- Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl- (substituted or unsubstituted C2-C 10heterocyclo alkyl, -C 1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p of R7 is selected from 0, 1 or 2;

R8a, R8b, K ,s8c, and R8d of c(R8a)(R8bµ
) and C(R8c)(R8( ) are independently selected from H, Ci-C6a1kyl, C1-C6fluoroalkyl, Ci-C6 alkoxy, Cl-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
R8a and R8d are as defined above, and R8b and R8' together form a bond;
or:
R8a and R8d are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1 -3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8' and R8d are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated membered spirocycle or heterospirocycle comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8a and R8b are as defined above, and R8' and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated membered spirocycle or heterospirocycle comprising 1 -3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1 -3 R9; and each R9 of R8a, R8b, R8c and R8d is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4fluoroalkyl, Ci-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, - C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(Cl-C4alkyl)-0H, -NH(Ci-C4alkyl)-0-(C-C4alkyl), -0(Cl-C4alkyl)-NH2; -0(C1-C4alkyl)-NH-(C)-C4alkyl), and -0(Ci-C4alkyl)-N-(C)-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0214]
In any of the compounds described herein, the ILM can have the structure of Formula (XXXII), which are derived from the IAP ligands described in WO Pub.
No.
2013/071039, or an unnatural mimetic thereof:
..,X2 xl R 1 X'-' w2 W.õ ,U 1 y-Fe 0 IR'5 (XXXII), wherein:
W1 of Formula (XXXII) is 0, S, N-R', or C(R8a)(R8b);
W2 of Formula (XXXII) is 0, S, N-R', or C(R8c)(¨t( 86 ); provided that W1 and W2 are not both 0, or both S;
R1 of Formula (XXXII) is selected from H, C1-C6alkyl, C3-C6cycloalkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 of Formula (XXXII) is N-R', then X2 is C=0, or CR2c¨ 2d, _I( and X3 is CR2aR2b;
or:
when X1 of Formula (XXXII) is selected from S, S(0), or S(0)2, then X2 is cR2o_I(-s 2d, and X3 is cR2aR2b;
or:
when X1 of Formula (XXXII) is 0, then X2 is CR2' 2d _I( and N-R' and X3 is CR2aR2b;
or:
when X1 of Formula (XXXII) is CH3, then X2 is selected from 0, N-R', S, S(0), or S(0)2, and X3 is CR2aR2b;
when X1 of Formula (XXXII) is CR2e¨tc 2f and X2 is CR2' 2d, tc and R2e and R2c together form a bond, and X3 of Formula (XXXII) is CR2aR2b;
or:
X1 and X3 of Formula (XXXII) are both CH2 and X2 of Formula (XXXII) is C=0, C=C(Rc)2, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C 1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cyclo alkyl), -C1-C6a1kyl-(substituted or unsubstituted C2- C5heteroc yclo alkyl), -C -C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl- (substituted or unsubstituted heteroaryl);
or:
X1 and X2 of Formula (XXXII) are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 of Formula (XXXII) are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and XI of Formula (XXXII) is CR2'R2f;
RA of N-RA is selected from H, Ci-C6alkyl, -C(=0)Ci-C2alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, R2b, R2c, R2d, R2e, and R2f of CR2'R2d, 2b tc and CR2eR2f are independently selected from H, substituted or unsubstituted C1-C6a1kyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3- C6cyclo alkyl), -Ci-C6alkyl-(sub stituted or unsubstituted C2-05heterocyc lo alkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6a1kyl-(substituted or unsubstituted heteroaryl) and - C(=0)RB;
RB of -C(=0)RB is selected from substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(sub stituted or unsubstituted C3- C6cyclo alkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heteroc yclo alkyl) , -C1-C6alkyl- (substituted or unsubstituted aryl), -C i-C 6alkyl-(substituted or unsubstituted heteroaryl), or - NRDRE;
RD and RE of NRDRE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6a1kyl- (substituted or unsubstituted C3-C6cyclo alkyl) , -C
1-C6alkyl-( sub stituted or unsubstituted C2- C5heterocyclo alkyl) , -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl- (substituted or unsubstituted heteroaryl);
m of Formula (XXXII) is selected from 0, 1 or 2;
-U- of Formula (XXXII) is selected from -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 of Formula (XXXII) is selected from Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 of Formula (XXXII) is selected from -NHR5, -N(R5)2, -N-F(R5)3 or -0R5;
each R5 of -NHR5, -N(R5)2, -N-F(R5)3 and -0R5 is independently selected from H, C1-C3alkyl, C 1-C3halo alkyl, C 1-C3hetero alkyl and -C i-C3alkyl-(C3-05cyclo alkyl);
or:
R3 and R5 of Formula (XXXII) together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 of Formula (XXXII) is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 of Formula (XXXII) is selected from -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS(=0)2NHR7, -(Ci-C3alkyl)-NHC(=0)R7, 4Ci-C3alkyl)-C(=0)NHR7, -(C 1 -C3alkyl)-NHS (=0)2R7, -(C 1 -C3alkyl)-S (=0)2NHR7; -(C 1 -C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS (=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 of -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(Ci-C3alkyl)-NHC(=0)R7, -(Ci-C3alkyl)-C(=0)NHR7, -(C i-C3alkyl)-NHS (=0)2R7, -(C 1 -C3alkyl)-S (=0)2NHR7; -(C 1 -C3alkyl)-NHC(=0)NHR7, -(C 1 -C3alkyl)-NHS (=0)2NHR7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-Cl0cycloalkyl, a substituted or unsubstituted C2- Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-Ciocyc lo alkyl), -C1-C6alkyl- (substituted or unsubstituted C 2-C 10heteroc yclo alkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p of R7 is selected from 0, 1 or 2;
R8a, R8b, R8c, and R8d of c(R8a)(R8bµ
) and C(R8c)(R8( ) are independently selected from H, C 1-C6alkyl, C1-C6fluoroalkyl, Ci-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
R8a and R8d are as defined above, and R8b and R8' together form a bond;
or:
R8a and R8d are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1 -3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8' and R8d are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated membered spirocycle or heterospirocycle comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8a and R8b are as defined above, and R8' and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated membered spirocycle or heterospirocycle comprising 1 -3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1 -3 R9; and each R9 of R8a, K 8b, R8c and R8d is independently selected from halogen, -OH, -SH, (C=0), CN, C1-C4a1kyl, C1-C4fluoroalkyl, Ci-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(C1-C4alky1)2, - C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-0H, -NH(C1-C4alkyl)-0-(C-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C1-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(C1-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[0215] In any of the compounds described herein, the ILM can have the structure of Formula (XXXIII), which is derived from the IAP ligands described in WO Pub.
No.
2013/071039, or an unnatural mimetic thereof:
(,x3 XI
, - W2 -T. 'rim P-41 ' " \ =

n r`=
(XXXIII), wherein:
W1 of Formula (XXXIII) is selected from 0, S, N-R', or C(R8a)(R8b);
W2 of Formula (XXXIII) is selected from 0, S, N-R', or C(R8c)(''K 8( ); provided that W1 and W2 are not both 0, or both S;
R1 of Formula (XXXIII) is selected from H, C1-C6alkyl, C3-C6cycloalkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 of Formula (XXXIII) is selected from N-R', S, S(0), or S(0)2, then X2 of Formula (XXXIII) is CR2cR2d, and X3 of Formula (XXXIII) is CR2aR2b;
or:
when X1 of Formula (XXXIII) is 0, then X2 of Formula (XXXIII) is selected from 0, N-R' , S, S(0), or S(0)2, and X3 of Formula (XXXIII) is CR2aR2b;

or:
when X1 of Formula (XXXIII) is CR2eR2f and X2 of Formula (XXXIII) is CR2cR2d, and R2e and R2' together form a bond, and X3 of Formula (XXXIII) is CR2aR2b;
or:
X1 and X2 of Formula (XXXIII) are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 of Formula (XXXIII) is CR2aR2b;
or:
X2 and X3 of Formula (XXXIII) are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 of Formula (V11,1 I) is CR 2eR2f;
RA of N-RA is H, Ci-C6a1kyl, -C(=0)Ci-C2alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, R2b, R2c, R2d, R2e, and R2f of CR2cR2d, CR2aR2b and CR2eR2f are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3- C6cyclo alkyl), -C i-C6alkyl-(sub stituted or unsubstituted C2-05heterocyclo alkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6a1kyl-(substituted or unsubstituted heteroaryl) and - C(=0)RB;
RB of -C(=0)RB is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3- C6cycloalkyl), -C -C6alkyl-(substituted or unsubstituted Csheterocycloalkyl), -Ci-C6a1kyl- (substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), or - NRDRE;
RD and RE of NRDRE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6a1kyl- (substituted or unsubstituted C3-C6cyclo alkyl), -C1-C6alkyl-(sub stituted or unsubstituted C2- Csheterocyclo alkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl- (substituted or unsubstituted heteroaryl);
m of Formula (XXXIII) is 0, 1 or 2;
-U- of Formula (XXXIII) is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 of Formula (XXXIII) is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 of Formula (XXXIII) is -NHR5, -N(R5)2, -N-F(R5)3 or -0R5;
each R5 of -NHR5, -N(R5)2, -N-F(R5)3 and -0R5 is independently selected from H, C1-C3alkyl, C1-C3halo alkyl, C1-C3hetero alkyl and -Ci-C3alkyl-(C3-05cyclo alkyl);
or:
R3 and R5 of Formula (XXXIII) together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 of Formula (XXXIII) is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 of Formula (XXXIII) is selected from -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS(=0)2NHR7, -(Ci-C3alkyl)-NHC(=0)R7, -(Ci-C3alkyl)-C(=0)NHR7, -(C 1 -C3alkyl)-NHS(=0)2R7, -(C 1 -C3alkyl)-S(=0)2NHR7; -(C 1 -C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 of -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(Ci-C3alkyl)-NHC(=0)R7, -(Ci-C3alkyl)-C(=0)NHR7, -(Ci-C3alkyl)-NHS (=0)2R7, -(C 1 -C3alkyl)-S(=0)2NHR7; -(C 1 -C3alkyl)-NHC(=0)NHR7, -(C 1 -C3alkyl)-NHS (=0)2NHR7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-Cl0cycloalkyl, a substituted or unsubstituted C2- Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-Ciocyclo alkyl), -C1-C6alkyl- (substituted or unsubstituted C 2-C 10heteroc yclo alkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p of R7 is 0, 1 or 2;
R8a, R8b, R8c, and R8d of c(R8a)(R8bµ
) and C(R8c)(R8( ) are independently selected from H, C 1-C6alkyl, C1-C6fluoroalkyl, Ci-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
R8a and R8d are as defined above, and R8b and R8' together form a bond;
or:
R8a and R8d are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1 -3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8' and R8d are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated membered spirocycle or heterospirocycle comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8a and R8b are as defined above, and R8' and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated membered spirocycle or heterospirocycle comprising 1 -3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1 -3 R9; and each R9 of R8a, K=-= 813, R8c and R8d is independently selected from halogen, -OH, -SH, (C=0), CN, C1-C4a1kyl, C1-C4fluoroalkyl, Ci-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(Ci-C4a1kyl), -NH(C1-C4a1ky1)2, - C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-0H, -NH(C1-C4alkyl)-0-(C-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C1-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(C1-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[0216] In any of the compounds described herein, the ILM can have the structure of Formula (XXXIV), which is derived from the IAP ligands described in WO Pub.
No.
2013/071039, or an unnatural mimetic thereof:
4)(2 xl \ W3 R3 Li w2 T., (XXXIV), wherein:
W1 of Formula (XXXIV) is selected from 0, S, N-R', or C(R8a)(R8b);
W2 of Formula (XXXIV) is selected from 0, S, N-R', or C(R8c8c ); provided that W1 and h W2 are not both 0, or both S;
W3 of Formula (XXXIV) is selected from 0, S, N-R', or C(R8e)(R8f), providing that the ring comprising W1, W2, and W3 does not comprise two adjacent oxygen atoms or sulfer atoms;
R1 of Formula (XXXIV) is selected from H, C1-C6alkyl, C3-C6cycloalkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);

when X1 of Formula (XXXIV) is 0, then X2 of Formula (XXXIV) is selected from CR2cR2d and N-RA, and X3 of Formula (XXXIV) is CR2aR2b;
or:
when X1 of Formula (XXXIV) is CH2, then X2 of Formula (XXIV) is selected from 0, N-RA, S, S(0), or S(0)2, and X3 of Formula (XXXIV) is CR2aR2b;
or:
when X1 of Formula (XXXIV) is CR2e¨I( 2f and X2 of Formula (XXXIV) is CR2' 2d, tc and R2' and R2' together form a bond, and X3 of Formula (XXXIV) is CR2aR2b;
or:
X1 and X3 of Formula (XXXIV) are both CH2 and X2 of Formula (XXXIV) is C=0, C=C(Rc)2, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6a1kyl, substituted or unsubstituted C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6c yclo alkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6a1kyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
or:
X1 and X2 of Formula (XXXIV) are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 of Formula (XXXIV) is CR2aR2b;
or:
X2 and X3 of Formula (XXXIV) are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 340 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 of Formula (VLIV) is CR2122f;

RA of N-RA is selected from H, Ci-C6alkyl, -C(=0)Ci-C2alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, R2b, R2c, R2d, tc -=-= 2e, and R2f of CR2'R2d, cR2aR2b and cRK.2erN2f are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6a1kyl-(substituted or unsubstituted C3- C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl) and - C(=0)RB;
RB of -C(=0)RB is selected from substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3- C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl- (substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or - NRDRE;
RD and RE of NRDRE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6a1kyl- (substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2- C5heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl- (substituted or unsubstituted heteroaryl);
m of Formula (XXXIV) is selected from 0, 1 or 2;
-U- of Formula (XXXIV) is selected from -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 of Formula (XXXIV) is selected from Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 of Formula (XXXIV) is selected from -NHR5, -N(R5)2, -N-F(R5)3 or -0R5;
each R5 of -NHR5, -N(R5)2, -N-F(R5)3 and -0R5 is independently selected from H, Cl-C3alkyl, C1-C3haloalkyl, C1-C3heteroalkyl and -Ci-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 of Formula (XXXIV) together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;

or:
R3 of Formula (XXXIV) is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 of Formula (XXXIV) is selected from -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS(=0)2NHR7, -(Ci-C3alkyl)-NHC(=0)R7, -(Ci-C3alkyl)-C(=0)NHR7, -(C 1 -C3alkyl)-NHS(=0)2R7, -(C 1 -C3alkyl)-S(=0)2NHR7; -(C 1-C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 of -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(Ci-C3alkyl)-NHC(=0)R7, -(Ci-C3alkyl)-C(=0)NHR7, -(Ci-C3alkyl)-NHS (=0)2R7, -(C 1 -C3alkyl)-S(=0)2NHR7; -(C 1 -C3alkyl)-NHC(=0)NHR7, -(C 1 -C3alkyl)-NHS (=0)2NHR7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-ClOcycloalkyl, a substituted or unsubstituted C2- Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-Ciocyc lo alkyl), -Ci-C6alkyl- (substituted or unsubstituted C 2-C 10heteroc yclo alkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p of R7 is selected from 0, 1 or 2;
R8a, R8b, R8c, R8d, R8e, and R" of C(R8a)(R8b), C(R8c)(R8d) and C(R8e)(R8f) are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, Ci-C6 alkoxy, Ci-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
R8a, R8d, R8e, and R" of C(R8a)(R8b), C(R8c)(R8() and C(R8e)(R8f) are as defined above, and R8b and R8c together form a bond;
or:

R8a, R8b, R8d, and R8f of C(R8a)(R8b), c(R8c)(R8db ) and C(R8e)(R8f) are as defined above, and R8c and R8e together form a bond;
or:
R8a, R8d, R8e, and R8f of C(R8a)(R8b), c(R8c)(R8(b ) and C(R8e)(R8f) are as defined above, and R8b and R8c together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1 -3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8a, R8b, R8d, and R8f of C(R8a)(R8b), c(R8c)(R8(b ) and C(R8e)(R8f) are as defined above, and R8c and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1 -3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8c, R8d, R8e, and R8f of C(R8c)(R8() and C(R8e)(R8f)are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1 -3 heteroatoms selected from S, 0 and N;
or:
R8a, R8b, R8e, and R8f of C(R8a)(R8b) and C(R8e)(R8f) are as defined above, and R8c and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a, R8b, R8c, and R8d of C(R8a)(R8b) and C(R8c)(R8() are as defined above, and R8e and R8f together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;

or:
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1 -3 R9; and each R9 Of R8a, R8b, R8c, R8d R8e, and R8 tc8f a is independently selected from halogen, -OH, -SH, (C=0), CN, C1-C4a1kyl, C1-C4fluoroalkyl, Ci-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(Ci- C4a1kyl), -NH(C1-C4alky1)2, - C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-0H, -NH(Ci-C4alkyl)-0-(C-C4alkyl), -0(Ci-C4alkyl)-NH2;
-0(Ci-C4alkyl)-NH-(C1-C4alkyl), and -0(Ci-C4alkyl)-N-(C1-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[0217]
In any of the compounds described herein, the ILM can have the structure of Formula (XXXV), (XXXVI) or (XXXVII), which is derived from the IAP ligands described in Vamos, M., et al., Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP, ACS Chem. Biol., 8(4), 725-32 (2013), or an unnatural mimetic thereof:

n r. 0, (xxxv), 11 , N- N , H =
0 :
H
(XXXVI), R2 nk + X H
IA 9 I \,-.1- 1\ \
N L....-r-v---- ' C::----- ' N
H
n fa 0, 1 (XXXVII), wherein:
R2 of Formulas (XXXV) and (XXXVII) are independently selected from H or ME;
R3 and R4 of Formula (XXXV) are independently selected from H or ME;
X of Formulas (XXXV) and (XXXVII) is independently selected from 0 or S; and R1 of Formulas (XXXV) and (XXXVII) is selected from:
(1101 OP 0 Sp 0 * * *
tio *
[0218] In a particular embodiment, the ILM has a structure according to Formula (XXXVIII):
Ei 0 R3 X¨X.
I X
i\jN)IN( = Ho.
.., H
(XXXVIII), wherein R3 and R4 of Formula (XXXVIII) are independently selected from H or ME;
X ¨X.
I X
N
*' * =
is a 5-member heteocycle selected from:

S s R \
NR ,µ,õN>
* .
' X
* ,NR
*
[0219] In a particular embodiment, the of Formula (XXXVIII) is *
[0220] In a particular embodiment, the ILM has a structure and attached to a linker group L as shown below:
, 0 r---?.
H 11 r\?ir ...
- H
_ 0 NH
[0221] In any of the compounds described herein, the ILM can have the structure of Formula (XXXIX) or (XL), which is based on the IAP ligands described in Hennessy, EJ, et al., Discovery of aminopiperidine-based Smac mimetics as IAP antagonists, Bioorg.
Med. Chem.
Lett., 22(4), 1960-4 (2012), or an unnatural mimetic thereof:
0 RI R''' N A= 1 1,k, : H i n _ R'I
2 (XXXIX), , H
: H
u, R' 3 (XL), wherein:
R1 of Formulas (XXXIX) and (XL) is selected from:
1-------;
,_.,....õ.õ.
4: 1 R2 of Formulas (XXXIX) and (XL) is selected from H or Me;
R3 of Formulas (XXXIX) and (XL) is selected from:
$,¨, \ 0 , n izt 0,1, 2 /
in\
0, I 40" e==N n . 0 I 2 ---------------------------- ...' \
nO1 .. .4 ,.,.../ z Ott n = 0, 1 v , =
, X of is selected from H, halogen, methyl, methoxy, hydroxy, nitro or trifluoromethyl.
[0222] In any of the compounds described herein, the ILM can have the structure of and be chemically linked to the linker as shown in Formula (XLI) or (XLII), or an unnatural mimetic thereof:

N
RIõrõ,,L0 Linker FIN
(XLI), N
FN
R1õ,r-L H
0 Linker NHo HN
(XLII).
[0223] In any of the compounds described herein, the ILM can have the structure of Formula (XLIII), which is based on the IAP ligands described in Cohen, F, et al., Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold, J. Med. Chem., 52(6), 1723-30 (2009), or an unnatural mimetic thereof:
0 tr N N
N

HN
0 (XLIII) wherein:
R1 of Formulas (XLIII) is selected from:

...... ...,-;-,-L, , 6,-------,, --õ, x - , ,....--- ....õ--X of is selected from H, fluoro, methyl or methoxy.
[0224] In a particular embodiment, the ILM is represented by the following structure:

NH 11 tii,, N
z H Ff - 0 ...
, H N
/
0 'WI.
[0225] In a particular embodiment, the ILM is selected from the group consisting of, and which the chemical link between the ILM and linker group L is shown:
H
i \
- -, N ill Ht,41 ...-- 0 HN) ',' ; and ....ii., - N
¨ 0 ..=
HN
)----- I
[0226] In any of the compounds described herein, the ILM is selected from the group consisting of the structures below, which are based on the TAP ligands described in Asano, M, et al., Design, sterioselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists, Bioorg. Med. Chem., 21(18):
5725-37 (2013), or an unnatural mimetic thereof:
(0.
(47 0 Yirs N 0 N
H ii H
' N 0 : H H
¨ 0 , 0 N 0 t 0 N ----or .
[0227] In a particular embodiment, the ILM is selected from the group consisting of, and which the chemical link between the ILM and linker group L is shown:
. i,¨;õ L
¨NH 0 ( ) - RN ----- ,,01.--c ' ......L.;:._ ilr NH
\ '' = ¨L----- I. N
N N --, . co OF i----1 1::140,,IAzo, 0 HN,-<, 0 OTNH
HN ' "
; and 1
[0228] In any of the compounds described herein, the ILM can have the structure of Formula (XLIV), which is based on the TAP ligands described in Asano, M, et al., Design, sterioselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists, Bioorg. Med. Chem., 21(18): 5725-37 (2013), or an unnatural mimetic thereof:
X

.N N
XJ

H

(XLIV), wherein X of Formula (XLIV) is one or two sub stituents independently selected from H, halogen or cyano.
[0229] In any of the compounds described herein, the ILM can have the structure of and be chemically linked to the linker group L as shown in Formula (XLV) or (XLVI), or an unnatural mimetic thereof:

X L
\ /

........., 0 , H
(XLV) or X
,e(/-5 0 ----(r, ra...r2Cy NF1 0, NH
HN '1 i 1 (XLVI), wherein X of Formula (XLV) and (XLVI) is one or two substituents independently selected from H, halogen or cyano, and ; and L of Formulas (XLV) and (XLVI) is a linker group as described herein.
[0230] In any of the compounds described herein, the ILM can have the structure of Formula (XLVII), which is based on the IAP ligands described in Ardecky, RJ, et al., Design, sysnthesis and evaluation of inhibitor of apoptosis (IAP) antagonists that are highly selective for the BIR2 domain of XIAP, Bioorg. Med. Chem., 23(14): 4253-7 (2013), or an unnatural mimetic thereof:

(XL VII), wherein:

H
N
,,, =õ.....-11-,õ
R1 of Formula (XLVII) is a natural or unnatural amino acid; and *

41 kiliVe : õII Al IP
R2 of Formula (XLVII) is selected from: .
[0231] In any of the compounds described herein, the ILM can have the structure of and be chemically linked to the linker group L as shown in Formula (XLVIII) or (XLIX), or an unnatural mimetic thereof:
,...- -,.... -,;...õ

NH
--( 2, HN' 'IR'._, 0,. NH
I
HN -"' '''?
(XLVIII), or Hu HHH
Xr z - 0 R ......"
(XLIX), H
,N õI, R1 of Formulas (XLVIII) and (XLIX) is a natural or unnatural amino acid;
and L of Formula (XLVIII) and (XLIX) is a linker group as described herein.
[0232] In any of the compounds described herein, the ILM can have the structure selected from the group consisting of, which is based on the IAP ligands described in Wang, J, et al., Discovery of novel second mitochondrial-derived activator of caspase mimetics as selective inhibitor or apoptosis protein inhibitors, J. Pharmacol. Exp. Ther., 349(2):
319-29 (2014), or an unnatural mimetic thereof:
OH
NH

, and
[0233] In any of the compounds described herein, the ILM has a structure according to Formula (L), which is based on the TAP ligands described in Hird, AW, et al., Structure-based design and synthesis of tricyclic TAP (Inhibitors of Apoptosis Proteins) inhibitors, Bioorg. Med.
Chem. Lett., 24(7): 1820-4 (2014), or an unnatural mimetic thereof:
"

N
N N H

(L), wherein R of Formula (L) is selected from the group consisting of:
0 rc-hi I 0 n 0 , e- z HET

r .µ....õ, , : x ...õ.õ .,....., . ....,õ ...,,, R, R1 of is selected from H or Me;
s -R2 of is selected from alkyl or cycloalkyl;
0 n Ci 0 ...X.- . , %---7¨ X
_______________________________________________________ X
X of *
is 1-2 substitutents independently selected from halogen, hydroxy, methoxy, nitro and trifluoromethyl 'N'Il., Z of is 0 or NH;
HET
HET of ' is mono- or fused bicyclic heteroaryl; and --- of Formula (L) is an optional double bond.
[0234] In a particular embodiment, the ILM of the compound has a chemical structure selected from the group consisting of:

H j?
1\11\1.(N3.
H 0 H 0 0 NH 1.
NJI\IrN11-.
E H F S
)--:=N
N----A

(o N
H V
N'Cil )7--N
H W Iri0 E H
o o)---NH 0 NH
, 1\1::N
F F

H
N N
FN1 o '?C--- ) N
N,', 1\1) .

E H

0 N's 0 t H i \NH
\NH
0 ..." H- __ 0 HN N
...."110 0.--"4440 N
S
S õi-0 N
,-\>

, \NH \NH
11.0 0 HN HN
=õõ,,,, S N 1 S>....a ....N
N N
,---- .---' , .
Exemplary MLMs
[0235] In certain additional embodiments, the MLM of the bifunctional compound comprises chemical moieties such as substituted imidazolines, substituted spiro-indolinones, substituted pyrrolidines, substituted piperidinones, substituted morpholinones, substituted pyrrolopyrimidines, substituted imidazolopyridines, substituted thiazoloimidazoline, substituted pyrrolopyrrolidinones, and substituted isoquinolinones.
[0236] In additional embodiments, the MLM comprises the core structures mentioned above with adjacent bis-aryl substitutions positioned as cis- or trans-configurations.
[0237] In still additional embodiments, the MLM comprises part of structural features as in RG7112, RG7388, SAR405838, AMG-232, AM-7209, DS-5272, MK-8242, and NVP-CGM-097, and analogs or derivatives thereof.
[0238] In certain preferred embodiments, MLM is a derivative of substituted imidazoline represented as Formula (A-1), or thiazoloimidazoline represented as Formula (A-2), or spiro indolinone represented as Formula (A-3), or pyrollidine represented as Formula (A-4), or piperidinone / morphlinone represented as Formula (A-5), or isoquinolinone represented as Formula (A-6), or pyrollopyrimidine / imidazolopyridine represented as Formula (A-7), or pyrrolopyrrolidinone / imidazolopyrrolidinone represented as Formula (A-8).

R2 ,R4 ,R6 R2 4 )R

N
R
N

Formula (A-1) Formula (A-2) .1311 A "Ri3 R2'Q.""Rizt R1A" N R15 Formula (A-3) Formula (A-4) R16 .,J3 Ri 7 N
R-11 )X

Formula (A-5) Formula (A-6) R22 z .....-y 0 Y R27 II
¨R25 /
Nr-,N ,N N
R28 . R
, R3 26 Formula (A-7) Formula (A-8) wherein above Formula (A-1) through Formula (A-8):
X of Formula (A-1) through Formula (A-8) is selected from the group consisting of carbon, oxygen, sulfur, sulfoxide, sulfone, and N-Ra;
Ra is independently H or an alkyl group with carbon number 1 to 6;
Y and Z of Formula (A-1) through Formula (A-8) are independently carbon or nitrogen;
A, A' and A" of Formula (A-1) through Formula (A-8) are independently selected from C, N, 0 or S, can also be one or two atoms forming a fused bicyclic ring, or a 6,5-and 5,5-fused aromatic bicyclic group;
R1, R2 of Formula (A-1) through Formula (A-8) are independently selected from the group consisting of an aryl or heteroaryl group, a heteroaryl group having one or two heteroatoms independently selected from sulfur or nitrogen, wherein the aryl or heteroaryl group can be mono-cyclic or bi-cyclic, or unsubstituted or substituted with one to three substituents independently selected from the group consisting of:
halogen, -CN, Cl to C6 alkyl group, C3 to C6 cycloalkyl, -OH, alkoxy with 1 to carbons, fluorine substituted alkoxy with 1 to 6 carbons, sulfoxide with 1 to 6 carbons, sulfone with 1 to 6 carbons, ketone with 2 to 6 carbons, amides with 2 to 6 carbons, and dialkyl amine with 2 to 6 carbons;

R3, R4 of Formula (A-1) through Formula (A-8) are independently selected from the group consisting of H, methyl and Cl to C6 alkyl;
Rs of Formula (A-1) through Formula (A-8) is selected from the group consisting of an aryl or heteroaryl group, a heteroaryl group having one or two heteroatoms independently selected from sulfur or nitrogen, wherein the aryl or heteroaryl group can be mono-cyclic or bi-cyclic, or unsubstituted or substituted with one to three substituents independently selected from the group consisting of:
halogen, -CN, Cl to C6 alkyl group, C3 to C6 cycloalkyl, -OH, alkoxy with 1 to carbons, fluorine substituted alkoxy with 1 to 6 carbons, sulfoxide with 1 to 6 carbons, sulfone with 1 to 6 carbons, ketone with 2 to 6 carbons, amides with 2 to 6 carbons, dialkyl amine with 2 to 6 carbons, alkyl ether (C2 to C6), alkyl ketone (C3 to C6), morpholinyl, alkyl ester (C3 to C6), alkyl cyanide (C3 to C6);
R6 of Formula (A-1) through Formula (A-8) is H or ¨C(=0)Rb, wherein Rb of Formula (A-1) through Formula (A-8) is selected from the group consisting of alkyl, cycloalkyl, mono-, di- or tri-substituted aryl or heteroaryl, 4-morpholinyl, 1-(3-oxopiperazunyl), 1-piperidinyl, 4-N-Re-morpholinyl, 4-Re-l-piperidinyl, and 3-Re-1-piperidinyl, wherein Re of Formula (A-1) through Formula (A-8) is selected from the group consisting of alkyl, fluorine substituted alkyl, cyano alkyl, hydroxyl-substituted alkyl, cycloalkyl, alkoxyalkyl, amide alkyl, alkyl sulfone, alkyl sulfoxide, alkyl amide, aryl, heteroaryl, mono-, bis- and tri-substituted aryl or heteroaryl, CH2CH2Rd, and CH2CH2CH2Rd, wherein Rd of Formula (A-1) through Formula (A-8) is selected from the group consisting of alkoxy, alkyl sulfone, alkyl sulfoxide, N-substituted carboxamide, -NHC(0)-alkyl, -NH-S02-alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;
R7 of Formula (A-1) through Formula (A-8) is selected from the group consisting of H, Cl to C6 alkyl, cyclic alkyl, fluorine substituted alkyl, cyano substituted alkyl, 5-or 6-membered hetero aryl or aryl, substituted 5- or 6-membered hetero aryl or aryl;
R8 of Formula (A-1) through Formula (A-8) is selected from the group consisting of ¨Re-C(0)-W, -Re-alkoxy, -Re-aryl, -Re-heteroaryl, and -Re-C(0)-W-C(0)-Rg, wherein:
Re of Formula (A-1) through Formula (A-8) is an alkylene with 1 to 6 carbons, or a bond;

Rf of Formula (A-1) through Formula (A-8) is a substituted 4- to 7-membered heterocycle;
Rg of Formula (A-1) through Formula (A-8) is selected from the group consisting of aryl, hetero aryl, substituted aryl or heteroaryl, and 4- to 7-membered heterocycle;
R9 of Formula (A-1) through Formula (A-8) is selected from the group consisting of a mono-, bis- or tri-substituent on the fused bicyclic aromatic ring in Formula (A-3), wherein the substitutents are independently selected from the group consistin of halogen, alkene, alkyne, alkyl, unsubstituted or substituted with Cl or F;
Rio of Formula (A-1) through Formula (A-8) is selected from the group consistin of an aryl or heteroaryl group, wherein the heteroaryl group can contain one or two heteroatoms as sulfur or nitrogen, aryl or heteroaryl group can be mono-cyclic or bi-cyclic, the aryl or heteroaryl group can be unsubstituted or substituted with one to three substituents, including a halogen, F, Cl, -CN, alkene, alkyne, Cl to C6 alkyl group, Cl to C6 cycloalkyl, -OH, alkoxy with 1 to 6 carbons, fluorine substituted alkoxy with 1 to 6 carbons, sulfoxide with 1 to 6 carbons, sulfone with 1 to 6 carbons, ketone with 2 to 6 carbons;
Rii of Formula (A-1) through Formula (A-8) is -C(0)-N(Rh)(121), wherein Rh and 12' are selected from groups consisting of the following:
H; optionally substituted linear or branched Cl to C6 alkyl; alkoxy substituted alkyl;
mono- and di-hydroxy substituted alkyl (e.g., a C3 to C6), sulfone substituted alkyl;
optionally substituted aryl; optionally substituted heteraryl; mono-, bis- or tri-substituted aryl or heteroaryl; phenyl-4-carboxylic acid; substituted phenyl-4-carboxylic acid, alkyl carboxylic acid; optionally substituted heteroaryl carboxylic acid; alkyl carboxylic acid; fluorine substituted alkyl carboxylic acid;
optionally substituted cycloalky, 3-hydroxycyclobutane, 4-hydroxycyclohehexane, aryl substituted cycloalkyl; heteroaryl substituted cycloalkyl; or Rh and Ri taken together form a ring;
R12 and R13 of Formula (A-1) through Formula (A-8) are independently selected from H, lower alkyl (C1 to C6), lower alkenyl (C2 to C6), lower alkynyl (C2 to C6), cycloalkyl (4, 5 and 6-membered ring), substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, 5- and 6-membered aryl and heteroaryl, R12 and R13 can be connected to form a 5- and 6-membered ring with or without substitution on the ring;

R14 of Formula (A-1) through Formula (A-8) is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R15 of Formula (A-1) through Formula (A-8) is CN;
R16 of Formula (A-1) through Formula (A-8) is selected from the group consisting of C1-6 alkyl, C1-6 cycloalkyl, C2-6 alkenyl, C1-6 alkyl or C3-6 cycloalkyl with one or multiple hydrogens replaced by fluorine, alkyl or cycloalkyl with one CH2 replaced by S(=0), -S, or -S(=0)2, alkyl or cycloalkyl with terminal CH3 replaced by S(=0)2N(alkyl)(alkyl), -C(=0)N(alkyl)(alkyl), -N(alkyl)S(=0)2(alkyl), -C(=0)2(allkyl), -0(alkyl), C1-6 alkyl or alkyl-cycloalkyl with hydron replaced by hydroxyl group, a 3 to 7 membered cycloalkyl or heterocycloalkyl, optionally containing a -(C=0)- group, or a 5 to 6 membered aryl or heteroaryl group, which heterocycloalkyl or heteroaryl group can contain from one to three heteroatoms independently selected from 0, N or S, and the cycloalkyl, heterocycloalkyl, aryl or heteroaryl group can be unsubstituted or substituted with from one to three substituents independently selected from halogen, C1-6 alkyl groups, hydroxylated C1-6 alkyl, C1-6 alkyl containing thioether, ether, sulfone, sulfoxide, fluorine substituted ether or cyano group;
R17 of Formula (A-1) through Formula (A-8) is selected from the group consisting of (CH2)nC(0)NRkR1, wherein Rk and RI are independently selected from H, C1-6 alkyl, hydrxylated C1-6 alkyl, C1-6 alkoxy alkyl, C1-6 alkyl with one or multiple hydrogens replaced by fluorine, C1-6 alkyl with one carbon replaced by S(0), S(0)(0), C1-alkoxyalkyl with one or multiple hydrogens replaced by fluorine, C1-6 alkyl with hydrogen replaced by a cyano group, 5 and 6 membered aryl or heteroaryl, aklyl aryl with alkyl group containing 1-6 carbons, and alkyl heteroaryl with alkyl group containing 1-6 carbons, wherein the aryl or heteroaryl group can be further substituted;
R18 of Formula (A-1) through Formula (A-8) is selected from the group consisting of substituted aryl, heteroaryl, alkyl, cycloalkyl, the substitution is preferably -N(C1-4 alkyl)(cycloalkyl), -N(C1-4 alkyl)alkyl-cycloalkyl, and -N(C1-4 alkyl) [(alkyl)-(heterocycle-substituted)-cycloalkyl];

R19 of Formula (A-1) through Formula (A-8) is selected from the group consisting of aryl, heteroaryl, bicyclic heteroaryl, and these aryl or hetroaryl groups can be substituted with halogen, C1-6 alkyl, C1-6 cycloalkyl, CF3, F, CN, alkyne, alkyl sulfone, the halogen substitution can be mon- bis- or tri-substituted;
R20 and R21 of Formula (A-1) through Formula (A-8) are independently selected from C1-6 alkyl, C1-6 cycloalkyl, C1-6 alkoxy, hydoxylated C1-6 alkoxy, and fluorine substituted Cl-6 alkoxy, wherein R20 and R21 can further be connected to form a 5, 6 and 7-membered cyclic or heterocyclic ring, which can further be substituted;
R22 of Formula (A-1) through Formula (A-8) is selected from the group consisting of H, C1-6 alkyl, C1-6 cycloalkyl, carboxylic acid, carboxylic acid ester, amide, reverse amide, sulfonamide, reverse sulfonamide, N-acyl urea, nitrogen-containing 5-membered heterocycle, the 5-membered heterocycles can be further substituted with C1-6 alkyl, alkoxy, fluorine-substituted alkyl, CN, and alkylsulfone;
R23 of Formula (A-1) through Formula (A-8) is selected from aryl, heteroaryl, -0-aryl, -0-heteroaryl, -0-alkyl, -0-alkyl-cycloalkyl, -NH-alkyl, -NH-alkyl-cycloalkyl, -N(H)-aryl, -N(H)-heteroaryl, -N(alkyl)-aryl, -N(alkyl)-heteroaryl, the aryl or heteroaryl groups can be substituted with halogen, C1-6 alkyl, hydoxylated C1-6 alkyl, cycloalkyl, fluorine-substituted C1-6 alkyl, CN, alkoxy, alkyl sulfone, amide and sulfonamide;
R24 of Formula (A-1) through Formula (A-8) is selected from the group consisting of ¨CH2-(C1-6 alkyl), -CH2-cycloalkyl, -CH2-aryl, CH2-heteroaryl, where alkyl, cycloalkyl, aryl and heteroaryl can be substituted with halogen, alkoxy, hydoxylated alkyl, cyano-substituted alkyl, cycloalyl and substituted cycloalkyl;
R25 of Formula (A-1) through Formula (A-8) is selected from the group consisting of C1-6 alkyl, C1-6 alkyl-cycloalkyl, alkoxy-substituted alkyl, hydroxylated alkyl, aryl, heteroaryl, substituted aryl or heteroaryl, 5,6,and 7-membered nitrogen-containing saturated heterocycles, 5,6-fused and 6,6-fused nitrogen-containing saturated heterocycles and these saturated heterocycles can be substituted with C1-6 alkyl, fluorine-substituted C1-6 alkyl, alkoxy, aryl and heteroaryl group;
R26 of Formula (A-1) through Formula (A-8) is selected from the group consisting of C1-6 alkyl, C3-6 cycloalkyl, the alkyl or cycloalkyl can be substituted with ¨OH, alkoxy, fluorine-substituted alkoxy, fluorine-substituted alkyl, -NH2, -NH-alkyl, NH-C(0)alkyl, -NH-S(0)2-alkyl, and -S(0)2-alkyl;
R27 of Formula (A-1) through Formula (A-8) is selected from the group consisting of aryl, heteroaryl, bicyclic heteroaryl, wherein the aryl or heteroaryl groups can be substituted with C1-6 alkyl, alkoxy, NH2, NH-alkyl, halogen, or -CN, and the substitution can be independently mono-, bis- and tri-substitution;
R28 of Formula (A-1) through Formula (A-8) is selected from the group consisting of aryl, 5 and 6-membered heteroaryl, bicyclic heteroaryl, cycloalkyl, saturated heterocycle such as piperidine, piperidinone, tetrahydropyran, N-acyl-piperidine, wherein the cycloalkyl, saturated heterocycle, aryl or heteroaryl can be further substituted with ¨OH, alkoxy, mono-, bis- or tri-substitution including halogen, -CN, alkyl sulfone, and fluorine substituted alkyl groups; and Ri- of Formula (A-1) through Formula (A-8) is selected from the group consisting of H, alkyl, aryl substitituted alkyl, alkoxy substituted alkyl, cycloalkyl, aryl-substituted cycloalkyl, and alkoxy substituted cycloalkyl.
[0239] In certain embodiments, the heterocycles in Rf and Rg of Formula (A-1) through Formula (A-8) are substituted pyrrolidine, substituted piperidine, substituted piperizine.
[0240] More specifically, non-limiting examples of MLMs include those shown below as well as those 'hybrid' molecules that arise from the combination of 1 or more of the different features shown in the molecules below.
[0241] Using MLM in Formula A-1 through A-8, the following PROTACs can be prepared to target a particular protein for degradation, where 'L" is a connector (i.e. a linker group), and "PTM" is a ligand binding to a target protein.
[0242] In certain embodiments, the description provides a bifunctional molecule comprising a structure selected from the group consisting of:

f 8 R2 ,R4 ,R6 R2 F4 /R
---' N
PTM-L R1N-k---N R5 PTM-Lf R1N-k ----S I
-:3 N '143 N
, , Formula (A-9) Formula (A-10) Rii = Ri" _ .. Iii ,R1 D
PTM¨L "
õ,...C..1" N
¨io PTM¨L¨ R2...Q."R14 ¨E A'), Formula (A-11) Formula (A-12) 'N
Ri7 k 1 t R18N R20 i 1 PTM-4 i Ri'k<X i R4 PTM¨L
Rig R21 Formula (A-13) Formula (A-14) PTM¨L¨

R22 Z.,.--1(\ Y R--_ PTM_Lf R 'N ----NsR
N,rN
28 k _ -- 26 ,and , Formula (A-15) Formula (A-16) wherein X, Ra, Y, Z, A, A', A", Ri, R2, R3, R4, R5, R6, Rb, 12', Rd, R7, Re, Rf, Rg, R9, Rio, R11, R12, Ri3, Ri4, Ri5, R16, R17, Rk, RI, R18, R19, R20, R21, R22, R23,R24, R25, R26, R27, R28, and Ri- are as defined herein with regard to Formulas (A-1) through (A-8).
[0243] In certain embodiments, the description provides bifunctional or chimeric molecules with the structure: PTM-L-MLM, wherein PTM is a protein target binding moiety coupled to an MLM by L, wherein L is a bond (i.e., absent) or a chemical linker. In certain embodiments, the MLM has a structure selected from the group consisting of A-1-1, A-1-2, A-1-3, and A-1-4:

R1' R1' (I) N R3' N R4 H N \ = ' PTM-L- - R5, c....,, \ I / PTM-L- R5 (I) N R3' I
( / 10 R4' -(:) R6\7' R6' - ' Ri R2' _ (N ____________________________ \ r\li R4 _ N) \ -R,t -' N
PTM-L
I ( / o PTM-L-/ o \ I- -R2' R2' wherein:
R1' and R2' of Formulas A-1-1 throught A-1-4 (i.e., A-1-1, A-1-2, A-1-3, and A-1-4) are independently selected from the group consisting of F, Cl, Br, I, acetylene, CN, CF3 and NO2;
R3' is selected from the group consisting of -OCH3, -OCH2CH3, -OCH2CH2F, -OCH2CH2OCH3, and -OCH(CH3)2;
R4' of Formulas A-1-1 throught A-1-4 is selected from the group consisting of H, halogen, -CH3, -CF3, -OCH3, -C(CH3)3, -CH(CH3)2, -cyclopropyl, -CN, -C(CH3)20H, -C(CH3)20CH2CH3, -C(CH3)2CH2OH, -C(CH3)2CH2OCH2CH3, C(CH3)2CH2OCH2CH2OH, -C(CH3)2CH2OCH2CH3, -C(CH3)2CN, -C(CH3)2C(0)CH3, -C(CH3)2C(0)NHCH3, -C(CH3)2C(0)N(CH3)2, -SCH3, -SCH2CH3, -S(0)2CH3, -S(02)CH2CH3, -NHC(CH3)3, -N(CH3)2, pyrrolidinyl, and 4-morpholinyl;
R5' of Formulas A-1-1 throught A-1-4 is selected from the group consisting of halogen, -cyclopropyl, -S(0)2CH3, -S(0)2CH2CH3, 1-pyrrolidinyl, -NH2, -N(CH3)2, and -NHC(CH3)3; and R6' of Formulas A-1-1 throught A-1-4 is selected from the structures presented below where the linker connection point is indicated as Beside R6' as the point for linker attachment, R4' can also serve as the linker attachment position. In the case that R4' is the linker connection site, linker will be connected to the terminal atom of R4' groups shown above.
[0244] In certain embodiments, the linker connection position of Formulas throught A-1-4 is at least one of R4' or R6' or both.
[0245] In certain embodiments, R6' of Formulas A-1-1 throught A-1-4 is independently selected from the group consisting of H, F
\./ OH F
õ *
C<F ro-.......* , *
, , , , , , , K
1 1 1 , _ T -N N N N
F
Y y`OH yF y(F y-0 0,* 0,* 0,*
, , , , , N
, , N
-T-II
N
C 1O ( ) (N ) ( ) N N N
* * 1::* 0- I
--S

C, , 1 --- .
__ N N rN EN
\-----( N N N N
x 0-*

, , , , , I - 1 i T -N Al i N
N
\
Y
*
o* " CY
F F 0-*

, , 1 i 1 _ I
N N
C
r N (N L ) ) ====,N,---N aN
.=%".....LN
y 0 y ON
*
* 1 , , , , and wherein "*" indicates the point of attachment of the linker.
[0246] In certain embodiments, the linker of Formula A-4-1 through A-4-6 is attached to at least one of R1', R2', R3', R4', R5', R6', or a combination thereof.
[0247] In certain embodiments, the description provides bifunctional or chimeric molecules with the structure: PTM-L-MLM, wherein PTM is a protein target binding moiety coupled to an MLM by L, wherein L is a bond (i.e., absent) or a chemical linker. In certain embodiments, the MLM has a structure selected from the group consisting of A-4-1, A-4-2, A-4-3, A-4-4, A-4-5, and A-4-6:
z-)12' Z x,-,/ Ri 2' % _________________________________________________________ 1\1 R10\
N -R11' NH NH
0=

R7' ,õ R1" 0 ='.. R " C R
R7' -õ 1 - R7' -õ1"
\ N
\ - N
- /
-z PTM-L- .4,...--;,õ... N
PTM-L- .....c.,,,, N 1 PTM-L- .,...4,7< N
====;:õ.õ,, \=-= _ ''--....,, - - -R8' R8 R8' z i=i\j,Rii IR,,,z 12' / z /=µ/R12' NI\ N N
/( /(N1 NH NH
O=n-/ NH
R7' -õR1" R7' - --;õ R1"
R7' \0=('-... N,R1"
PTM-L- 4..x.,--..,, N 1PTM-L- .4.:-....S.,: N z ..z....
I 1 PTM-L- .iõ.7.,õ N

-====...,,,, y .......õ( _ - - R8 .....õ.õ...,),,,-- ' -R8' wherein:

R7' of Formula A-4-1 through A-4-6 (i.e., A-4-1, A-4-2, A-4-3, A-4-4, A-4-5, and A-4-6) is one or more (e.g., 1, 2, 3, or 4) halogens;
R8' of Formula A-4-1 through A-4-6 is one or more groups (e.g., 1, 2, 3, or 4 groups) selected from the group consisting of H, -F, -Cl, -Br, -I, -CN, -NO2, ethylnyl, cyclopropyl, methyl, ethyl, isopropyl, vinyl, methoxy, ethoxy, isopropoxy, -OH, other C1-6 alkyl, other C1-6 alkenyl, and C1-6 alkynyl, mono-, di- or tri-substituted;
R9' of Formula A-4-1 through A-4-6 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, hetero aryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted cycloalkenyl;
Z of Formula A-4-1 through A-4-6 is selected from the group consistin of H, -OCH3, -OCH2CH3, and halogen;
R10' and R11' of Formula A-4-1 through A-4-6 are each independently selected from the group consisting of H, (CH2)n-R', (CH2)n-NR'R", (CH2)n-NR'COR", (CH2)n-NR'SO2R", (CH2)n-COOH, (CH2)n-COOR', (CH)n-CONR'R", (CH2)n-OR', (CH2)n-SR', (CH2)n-SOW, (CH2)n-CH(OH)-W, (CH2)n-COR', (CH2)n-S 02R', (CH2)n-SONR'R", (CH2)n-SO2NR'R", (CH2CH20)m-(CH2)n-R', (CH2CH20)m-(CH2)n-OH, (CH2CH20)m-(CH2)n-OR', (CH2CH20)m-(CH2)n-NR'R", (CH2CH20)m-(CH2)n-NR'COR", (CH2CH20)m(CH2)n-NR'S 02R", (CH2CH20)m(CH2)n-COOH, (CH2CH20)m(CH2)n-COOR', (CH2CH20)m-(CH2)n-CONR'R", (CH2CH20)m-(CH2)n-S 02R', (CH2CH20)m-(CH2)n-COR', (CH2CH20)m-(CH2)n-SONR'R", (CH2CH20)m-(CH2)n-SO2NR'R", (CH2)p-(CH2CH20)m-(CH2),W, (CH2)p-(CH2CH20)m-(CH2)n-OH, (CH2)p-(CH2CH20)m-(CH2)n-OR', (CH2)p-(CH2CH20)m-(CH2).-NR'R", (CH2)p-(CH2CH20)m-(CH2)n-NR'COR", (CH2)p-(CH2CH20)m-(CH2)n-NR'S 02R", (CH2)p-(CH2CH20)m-(CH2)n-COOH, (CH2)p-(CH2CH20)m-(CH2)n-COOR', (CH2)p-(CH2CH20)m-(CH2)n-CONR'R", (CH2)p-(CH2CH20),,-(CH2),-SO2R', (CH2)p-(CH2CH20),,-(CH2),-COR', (CH2)p-(CH2CH20)m-(CH2),-SONR'R", (CH2)p-(CH2CH20),,-(CH2),-SO2NR'R", Aryl-(CH2)n-COOH, and heteroaryl-alkyl-CO-alkyl-NR'R"m, wherein the alkyl may be substituted with OR', and heteroary1-(CH2).-heterocycle wherein the heterocycle may optionally be substituted with alkyl, hydroxyl, COOR' and COW; wherein R' and R" are selected from H, alkyl, alkyl substituted with halogen, hydroxyl, NH2, NH(alkyl), N(alkyl)2, oxo, carboxy, cicloalkyl and heteroaryl;
m, n, and p are independently 0 to 6;
R12' of Formula A-4-1 through A-4-6 is selected from the group consisting of -0-(alkyl), -0-(alkyl)-akoxy, -C(0)-(alkyl), -C(OH)-alkyl-alkoxy, -C(0)-NH-(alkyl), -C(0)-N-(alkyl)2, -S(0)-(alkyl), S(0)2-(alkyl), -C(0)-(cyclic amine), and -O-aryl-(alkyl), -0-aryl-(alkoxy);
Rl" of Formula A-4-1 through A-4-6 is selected from the group consisting of H, alkyl, aryl substitituted alkyl, aloxy substituted alkyl, cycloalkyl, ary- substituted cycloalkyl, and alkoxy substituted cycloalkyl.
[0248] In any of the aspects or embodiments described herein, the alkyl, alkoxy or the like can be a lower alkyl or lower alkoxy.
[0249] In certain embodiments, the linker connection position of Formula A-4-1 through A-4-6 is at least one of Z, R8', R9', R10', R11", R12", or R1".
[0250] The method used to design chimeric molecules as presented in A-1-1 through A-1-4, A-4-1 through A-4-6 can be applied to MLM with formula A-2, A-3, A-5, A-6, A-7 and A-8, wherein the solvent exposed area in the MLM can be connected to linker "L"
which will be attached to target protein ligand "PTM", to construct PROTACs.
[0251] Exemplary MDM2 binding moieties include, but not limited, the following:
[0252] 1. The HDM2/MDM2 inhibitors identified in Vassilev, et al., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, SCIENCE vol:303, pag:844-848 (2004), and Schneekloth, et al., Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics, Bioorg. Med. Chem. Lett. 18 (2008) 5904-5908, including (or additionally) the compounds nutlin-3, nutlin-2, and nutlin-1 (derivatized) as described below, as well as all derivatives and analogs thereof:

CI
0 .

---k ---HN3N N"'1140 CI
-, 0 0 N

)------(derivatized where a linker group L or a ¨(L-MLM)group is attached, for example, at the methoxy group or as a hydroxyl group);
Br r----XN AN
H 0"-N--- N -I . N Br ..., (derivatized where a linker group L or a ¨(L-MLM) group is attached, for example, at the methoxy group or hydroxyl group);
CI

A --(NN ----..,,, =
CI
N
N

...,. 0 0 )-------(derivatized where a linker group L or a ¨(L-MLM) group is attached, for example, via the methoxy group or as a hydroxyl group); and
[0253] 2. Trans-4-Iodo-4'-Boranyl-Chalcone I 13,0H

OH
(derivatized where a linker group L or a a linker group L or a-(L-MLM) group is attached, for example, via a hydroxy group).
Exemplary Linkers
[0254] In certain embodiments, the compounds as described herein include one or more PTMs chemically linked or coupled to one or more ULMs (e.g., at least one of CLM, VLM, MLM, ILM, or a combination thereof) via a chemical linker (L). In certain embodiments, the linker group L is a group comprising one or more covalently connected structural units (e.g., -ALI ...(AL)q- or -(AL)q-), wherein Ai is a group coupled to PTM, and (AL)q is a group coupled to ULM.
[0255] In any aspect or embodiment described herein, the linker (L) to ULM (e.g., VLM, ILM, CLM, or MLM) connection or coupling is a stable L-ULM connection. For example, in any aspect or embodiment described herein, when a linker (L) and a ULM is connected via a heteroatom, any subsequent heteroatom, if present, is separated by at least one single carbon atom (e.g., -CH2-), such as with an acetal or aminal group. By way of further example, in any aspect or embodiment described herein, when a linker (L) and a ULM is connected via a heteroatom, the heteroatom is not part of a ester.
[0256] In any aspect or embodiment described herein, the linker group L
is a bond or a chemical linker group represented by the formula -(AL)q-, wherein A is a chemical moiety and q is an integer from 1-100 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100), and wherein L is covalently bound to the PTM and the ULM, and provides for sufficient binding of the PTM to the protein target and the ULM to an E3 ubiquitin ligase to result in target protein ubiquitination.
[0257]
In any aspect or embodiment described herein, the linker group L is-(AL)q, wherein:
(AL)q is a group which is connected to at least one of a ULM moiety, a PTM
moiety (e.g., a CLM or a VLM), or a combination thereof;
q of the linker is an integer greater than or equal to 1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100);
each AL is independently selected from the group consisting of, a bond, CRL1RI-2, 0, S, SO, SO2, NR13, SO2NR13, SONR13, CONR13, NRUCONRIA, NRI3S02NRIA, CO, cRLl_cRL2, CC, siRL1RL2, p(0µ r,)KL1, P(0)OR', NRI3C(=NCN)NRIA, NRI3C(=NCN), NRI-3C(=CNO2)NRL4, C34icycloalkyl optionally substituted with 0-6 RL1 and/or groups, C5-13 spirocycloalkyl optionally substituted with 0-9 121-1 and/or RI-2 groups, C3-llheterocyclyl optionally substituted with 0-6 121-1 and/or RI-2 groups, C5_13 spiroheterocycloalkyl optionally substituted with 0-8 121-1 and/or RI-2 groups, aryl optionally substituted with 0-6 121-1 and/or RI-2 groups, heteroaryl optionally substituted with 0-6 121-1 and/or RI-2 groups, where 121-1 or RI-2, each independently are optionally linked to other groups to form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 0-4 RI-5 groups; and Ru, RL2, r's L3, RL4 and RI-5 are, each independently, H, halo, C1_8alkyl, OC1_8alkyl, SC1_8alkyl, NHC1_8alkyl, N(C1-8alky1)2, C311cycloalkyl, aryl, heteroaryl, C3-11heterocyclyl, 0C3-8cyc10a1ky1, SC3_8cycloalkyl, NHC3_8cycloalkyl, N(C3_8cycloalky1)2, N(C3_ 8cycloalkyl)(Ci_8alkyl), OH, NH2, SH, SO2C1_8alkyl, P(0)(0C1_8alkyl)(C1_8alkyl), P(0)(0C1_8alky1)2, CC-Ci_8alkyl, CCH, CH=CH(C1_8alkyl), C(Ci_8alky1)=CH(Ci_8alkyl), C(C 1_8a11y1)=C(C 1_8a11y1)2, Si(OH)3, Si(C 1_8a1ky1)3, Si(OH)(C 1_8a1ky1)2, COC 1_8a1ky1, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHCi_8alkyl, SO2N(Ci_8alky1)2, SONHC i_8a11y1, SON(Cl_8alky1)2, CONHC 1_8a1ky1, CON(Ci_8alky1)2, N(C1-8alkyl)CONH(Ci_8alkyl), N(C 1_8a1ky1)CON(Cl_8a1ky1)2, NHCONH(Ci_8alkyl), NHCON(C 1_8a1ky1)2, NHCONH2, N(C 1_8a1ky1)S 02NH(C 1_8a1ky1), N(C 1_8a1ky1) SO2N(C1-8alky1)2, NH SO2NH(Ci_8alkyl), NH SO2N(Ci_8alky1)2, NH SO2NH2.
[0258]
In any aspect or embodiment described herein, q of the linker is an integer greater than or equal to 0. In certain embodiments, q is an integer greater than or equal to 1.
[0259]
In any aspect or embodiment described herein, e.g., where q of the linker is greater than 2, (AL)q is a group which is ALi and (AL)q, wherein the units AL
are couple a PTM to a ULM.
[0260]
In any aspect or embodiment described herein, e.g., where q of the linker is 2, (AL)q is a group which is connected to ALI and to a ULM.
[0261]
In any aspect or embodiment described herein, e.g., where q of the linker is 1, the structure of the linker group L is ¨ALI¨, and ALI is a group which is connected to a ULM moiety and a PTM moiety.
[0262]
In any aspect or embodiment described herein, the linker (L) comprises a group represented by a general structure selected from the group consisting of:
-NR(CH2),-(lower alkyl)-, -NR(CH2),-(lower alkoxyl)-, -NR(CH2),-(lower alkoxyl)-OCH2-, -NR(CH2),-(lower alkoxyl)-(lower alkyl)-OCH2-, -NR(CH2),-(cycloalkyl)-(lower alkyl)-OCH2-, -NR(CH2),-(hetero cycloalkyl)-, -NR(CH2CH20),-(lower alkyl)-0-CH2-, -NR(CH2CH20),-(hetero c yclo alkyl)-0 -CH2- , -NR(CH2CH20)n-Aryl-0 -CH2- , -NR(CH2CH20),-(hetero aryl)-0-CH2-, -NR(CH2CH20),-(cyclo alkyl)-0-(hetero ary1)-CH2-, -NR(CH2CH20),-(cyclo alkyl)-0-Aryl-0-CH2-, -NR(CH2CH20),-(lower alkyl)-NH-Ary1-0-CH2-, -NR(CH2CH20),-(lower alkyl)-0-Aryl-CH2, -NR(CH2CH20)n-cycloalky1-0-Aryl-, -NR(CH2CH20),-cyclo alkyl-0 -(hetero aryl)l- , -NR(CH2CH2)n-(cycloalkyl)-0-(heterocycle)-CH2, -NR(CH2CH2),-(heterocycle)-(heterocycle)-CH2, -N(R1R2)-(heterocycle)-CH2; wherein:
n of the linker can be 0 to 10;
R of the linker can be H, lower alkyl;
R1 and R2 of the linker can form a ring with the connecting N.
[0263]
In any aspect or embodiment described herein, the linker (L) comprises a group represented by a general structure selected from the group consisting of:
-N(R)-(CH2).-0(CH2),-0(CH2)0-0(CH2)p-0(CH2)q-0(CH2),-OCH2-, -0-(CH2).-0(CH2),-0(CH2)0-0(CH2)p-0(CH2)q-0(CH2),-OCH2-, -0-(CH2).-0(CH2),-0(CH2)0-0(CH2)p-0(CH2)q-0(CH2),-0-;
-N(R)-(CH2).-0(CH2),-0(CH2),-0(CH2)p-O(CH2)q-0(CH2),-0-;

-(CH2)m-0(CH2),-0(CH2)0-0(CH2)p-0(CH2)q-0(CH2),-0-;
-(CH2)m-0(CH2),-0(CH2)0-0(CH2)p-0(CH2)q-0(CH2),OCH2-;
-(CH2),0 N N (0H2)00 (CH2)p-\ __ -1-(CH2)m-N N¨(CH2)n-NH
-r(CH2)m-N N---(C1-12)n-0 µA, --:---(CH2)m0(CF12)n¨N N¨(CF12)0-NH
=
µ/.
--i--(CH2)m0(C1-12)n¨N N¨(C1-12)0-0 =
t(CH2)m0(CF12)n¨NNN¨(CF12)0-4µ.
--i--(CH2)m0(C1-12)n¨N/KN¨(C1-12)o-0µCµ
, (CH2)m -i-N 0 _______ 0 =
(bH2),,H-(CFA)n:1 ,(CH26 -:-( \N-(C1-12)m4H ; ;
i'10)µ =
C( H26 =
, r -or's _______________________________________________________ 0 N _________________________________________________ ______________________________ Ts- /¨

N N
/
/I- \
N N -(CH2),,C.) (CH2),,O(CH2)ACH2),-\ ______________________________________ =
41¨( )-0(CH2)m0(CH2)nO(CH2)p0(CH2)q0CH2 X =
-I-NH =
0(CH2),,O(CH2),,O(CH2)p0(CH2)q0CH2 -I-NH =
0(CH2),,O(CH2),,O(CH2)p0(CH2)q0CH2 -I-NH =
A o(cH2)m0(cH2)no(cH2)po(cH2)qocH2 -I-NH
0(CH2)m0(CH2)nOCH2 0(CH2)m0(CH2)nOCH2 X ;and N---(CH260CH2 =
wherein each m, n, o, p, q, and r of the linker is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;
when the number is zero, there is no N-0 or 0-0 bond R of the linker is H, methyl and ethyl;

X of the linker is H and F
N
(rsi-4 N¨k-21mn.,,,"rsi-4 Th where m of the linker can be 2, 3, 4, 5 N y w %/N
N \

s=sON /
ss= /\""

H , N
= 0 /
N =e%, H H H H
/0; '/N1C)0='()e%<
H H
/ , %/N 010%C iNIs NWOO' H H H
NJ =()==()\( ''NJ
H H

0õ0 NSO C):%!
H H H
%/NI N
,(:),,,, /'N \/) (:) ,<
/
H H H

/---/- -:-N-()/

H
., = \ 10 0-\ , A 'Fi'N' N
....0--N 0 0 -\ , __/ µ,\ 00, /
H
/
--/' N L...,/N...,/--/"- ..,' .,,... N
H H / N
H
N;(, H
1\v__Iy -;/, N ...0 401 ,:. .;/.;
H - H
H . /
`

0 ' . NO / 1 ,s,N ,..,c)N 0.
1 -/-N 110 N /). µx \-1.---1-NH ' H \ _____ t , H . ) /.
/ H A

/ 1-NH 0 , \

-1--N N 4 __ :
, \ ______________________________________________________ , "1/,_OeY'Itt 'ILL>00.r\
0 = 0 =
OH

µ111.
0 = =

,111.01HL00 rrrr ,tzL000j-,csr = .

,,,,,00j-Lcsss 0 = =
'ILL

0 rs cs' . .
\
\ 0 0 H
is' = 0 = \
N
00j=,, is' =

,iic N O/;
N 00 61j'.
= ''IL
N ,C)j is' , L,,,.../"--...- =-=,../-y'L'i-"tz,eY'Ll'`
nii,,,," . 0 = 0 rr ,Itz, 0 )==,s . 1,2, 0 0 j- a rr' = 0 '111.
-'1.. 4_ 0 0 \
; .
, X
\
N
I
/ I

OC)Ji . 0()A/ .

0 0)-/ .
; ; ;
, \
I I I

. ...-.,õ0 0 'A/ . OC)')/
, , ;
N

I 0 / , \ o..-^,,,.0j1..../ \ 0j-/ .

OC)j-/ .
; ; , N , 0,=,.õ.0,...),õ/ la 6 0 k et r/
;

N2.
0 µii N
0 i.si N
. NO
0 .
rN

4=,rN0j.-., scs5511 Nj4 0 ; ;

HO

_roA-Csss 1\1)-css=,r C) _N/¨\N_/ ______ AD\
N
1¨N N
0 ; 11/, \=N \__/
=
\
/¨ 5 /--\
1¨N N 1¨N N¨CN¨)i. -1¨N/¨\N¨CN-1-\_/ .
, , , µ. ' No 0 0 \ >I\10 1 H H H i 1 0õ)( -µ X

./,.. .
X x' X = H, F
H H
'NI. 0 ' ) :-H
. /
H ., ,µO 0õ , / -/, >N 40 \ \( H
- ' N 0 H
, H
N;;, ,/- H ';c1\10 0 , / 'hi Th=-"o 0 , \,, %-No 0 H "\_ :
= H 1 le y='µ`-, H H ' HTh I
N
X/,%
XY,%
, "N
H

XYN % N (), - N 0,' / H
' N µ..N.,,,..õ..--,õ,õ0õ,,,.T...
H \ H
N &
N N, 0 , X X
...
-H\-N-Ii=-(=1)-0 -1--H\N
ro\_:_ \ / \ / 0\ r0\_:_ N
1 i --NH * NI/--\71\r:¨ , --NH * 3 N \ri:_ 1 / ¨:¨N H
\ ¨ * N/¨ \N\ri _______________ \-0 N¨ 0¨:¨
\-0 --NH .
N N-1(_ j0¨µ

¨:¨N H / 0 --NH ¨1¨ = _ O¨ \ /0 ¨),( \ ____________________________________ I ¨ __ / __ ¨ ¨
I
¨:¨N H . _ _ 0 ¨µ,, rs H N N ' N 0 H
(Dy H ¨ N
N.
TII\l' "=*.m 0¨d ' fIN".-0..10¨d "F11\1' ""--0¨== 0 ¨0 /
I
xI N
X X = H, F
\ .
N
'-9¨U ¨µ¨)--\_ ANI.-0..'10-0¨\_ T¨TN."--0¨..0¨µ j-0 1 1 , Inv .

\ ' ,XNmiii10 1..0 1--N/----\
1 HNI"'.-CIN
H ss=
N \ / ' 0 ---- \
, ____________________________________ x:_ \----,____ \¨/ N NNJ

HN"0 ?\ HN'Or HN.-0"cb____ ?';---,'-- / \

N -/--....0,,,10,,, i0.0 HN / \ HN / \ HN = ,,,_ X
HN0-d it ,,_ I-11 H E I '--- v, v, X X
%0 veCaµ
, N0 /.
N
H lik \ , H 441k \ i --V 0 ' X 0 ' H H
0 \ /.... ,,N....,0, 0 \ ,_ , \
0 0 ' 0 0 ' µ. 0 0 ' .....,µO.a ' HN0-d ilk 0 r": -HIIN-__CiN . //\
"i--i I
HN

\
1-11\1 0 N.,/./ I-1-N
' ' '-''0 0 r-----N
-/-1\1/ 1\1 \...,.../N
H .

---.
/--\-( \ --N N N1 /' --N \XN-( N- --NN- ______ \ ,/
\__/ / / _____________________ /

.--/
--NN --NN -;-NXN-( N-' --NDCN-( / / I/
0-µ
N - \-- I HO HQ
/--\
-:-N N- __________________________________ /--\ j __________________ \ ); -I /--\
-:-N N 0- ` :-N N N
0-µ _ ________________________________________ - \ 11 - -- 0 I /--\ / \
1 /--\
HN Or\i \
-:-N N- j -:-N N
N
-:-N N- , -:-N N
N t. 0-:--;-N/-\N-( \-'7'' IIT\I--( \N-/- - \-HN
\/ / N

.i \, 11N-CN-(1 11N-CN-µ )-Ori -(IN-CN-µ )H-N N N
-I-NH 0 -.1.--\__\
/--\ ,/
ON-0"10 0-''' HNI"(-7 I\1 )rµ
-i.-- 0---\ =
/. N

H
I-IN --4 NI, µ.-N....,..------2\---=\,,.0;<

wherein each n and m of the linker can independently be 0, 1, 2, 3, 4, 5, 6.
[0264] many aspect or embodiment described herein, the linker (L) is selected from the group consisting of:

-= %

N
/----\ ' =f=-=,/"'N____N/-\N ,' _ 7"--\ _y--N NI
r---\ , I-D___Nr--\N
N-- = s, = ,0 \N--< =,,, , (\-)-0 =
\-----/ \
N / 1\1 / m = `
ro ' N
N õ0 N , /.........y' NO0 i Nz-1\1 NI/ N , , -1-0 .µ 0--7-NµsµNON,,,,, 1 /+)rNON -;
-,I-0 , =', ,=
N = -õO ---/-- NO-- Nr-- , f--N-----\ NTh , ,P----/---N____ /\ , c,- N = = N N-i =
-\-/I
, -N -N %,,N ' =
, m N/

'=
"m '0 rN1' MI-eNN N
N3-"IN
-,-\--i\I N,õ
õO ---7- NJ I `,,ONa7 rN NN
N = 4 N --NON.;

\ o ga 000,õ
/
WI WI N .
H ' H ' H

0....Ø--õ,..-ب.,r, 0 0 4.N 111F
H ; H =

Ai 0001.t'L
rt N WI 8 ric,N VI
H ' H ' F o o 0 oaõ...-..õ_õ.o, H ; H ' 4N ' 0".--.00.Thr.A H 00"---.--'"--0"---)-(A
0 ; 0 ;
=
0 tsc /
(:) N /.\C)./\.()ji H / =

/

H
0 ,ss / = H =
, , =
/
N
H
0 =-=õ,.
/ 0 0 0j.
j.,s N / . H
c5' = H 0 , , 0 r,s5NO H 0 0 , N O--/= rI / . r,"
= H =
, , , , 4N.--.......õ...0 0 H
N, r< 0 0 N 0 0.---Y\
N

N
H ; H ' H
5 ' /.., õ..."., õ,,,,.. õ0............."..

t 1\1 ......õ,,, H
-1ly\- Fswe ",õ.õ-----.--Thr' 0 ; 0 ; 0 ;

,-, -),"
.... - /
0 . H

; H
0 ' H

N
F 4(N''''''.---(31 "z1 H
OYµ 4N 101 c,,C),/,0,) c 0 /
' 0 ' H " ; H 0 ;

H 1 , ...
0-r \ H I
N isss,.. 0 0-rµ FNil rss' H
0 ; 0 1 ' 0 ; F .

0 SS\ N õ,....o\ 0 H
s 4C.../\------",=-==== ,...----\.õ-- ====)c, 0- ' ; H , =

0 0 0 4N------"---. 0 0/
/,,N.,-,...........".0,..".õ,.Ø..õ),...õ , H
sr . H
N i /
I F F = H z =

N, 4 N ......'"'"" =====.. N / N

H A H r ; H 0 4[10 `===, H i '-..
i 4 N H \
F F ; H

0 0 / -... , 4Ni0e N /
/ . H -----H H
H 0 ' 0 ' F .

0 .0' s 0 =- = A'N
\ ----'00Thrµ 0 H 4N
H 0 ; F ' H

Ario 0 '---. / 4 .0j:7A 1 .....y...Dõ, 'N .,..D.,....,11,,,,,, o N N .., N ..., N
F . H ' H ' H / ;

/
4N 0 IO I'0 \ 1:) .
/ =
FNI /

' H 0 rprr H E
F F

,z.....^.,,..0 FI H
/ro 1.. ---'¨'''''= 121 I ,is 4 N
_ r N .
F F F .

1.1 µ
4 N y \ Thq !C) 0 0 0 H
H H E \ ,4( =Cr \
,rps . 0 ,,,,, = Fls 0 oss. ;
F .

...cy.0 0 0.). , j ,s / H E
; H r.r.'" =

/
N:C) 0 0 E 0 'N.
1\1 0,X
H
4NI 0 / iCr 0 S rsis .õ0 I.
. H H VI:3 F F ; F ' H ' l'N1L3 ; H and H , wherein each m and n is independently selected from 0, 1, 2, 3, 4, 5,or 6.
[0265] In any aspect or embodiment described herein, the linker (L) is selected from the group consisting of:
N)2 N)2Z
c3,cN ,3zc N
c3za,,N
\sss!
N,sss! N1 c3zzN
N,sss!
N,sg cyze,, N N
N
N N,sss!
N/\
cz, )iN,sss!
N)\
\1\I

N
N
x ss- N,ss ck, N õ,=N
C)a0 xN xN
H
N
ss xN c3zz N N,sss!
C) /
H
N N
(32zNI N vz,N N,sss!
e /
1/\ ss(N/N/\
(3N N 0 N,sss!
N N ss'sN ''''µµµµµN
s'ss \/0 \N`sss!
ss(NN
ssssN ''''µµµµNN
0 N,ss AN N
0 N hc)¨ N/ \NA-\ /

in"'"N( /NI- ..----0--.NN/\ \zN
\NA
N \/ ) _______ N \/ z\ N 1 ____ 5 K N \/ ) N \/ /\ N
/) ) \

N N N _______________ /¨N, N NI-\ \ sry \ __ irs /) ) / ( 5 / / ( 5 N N N _______________ /¨N, N\ N
\ \ \
c sAIAP c ( 5 N\Z ) ________ NI( z(N ________ ,/r7NZ\ ) N\Z /N
/ \ 5 \ 5 -rN\ ) /) N N /¨N\ N NI-/ 'AI -µr /
5 /) /) \ \
-rNI\ N N /¨N ___ I \ N N-) / jv 'vs ) /
HO HO HO
______________________________________________________________ ( \
N\/ /N ______ ( z\ / (\ / N H N\ /N zN H N N
\ z /NA-HO HO
\
%, s /
-hN/ N ______ ( \N¨Y N \ N ______________ ( \ _______ / / \ __ / /
HO
/ 5 ( 5 _____ V --N N NI- N N/ NI-/ /
-hd N __ ( \ N ______ / l' \ \ c \ ________________ / \ 5 --N _____ N/ ) ____ H N N NI- N/ \NI-\ \ / \ /
N N \____ j -----\__N4 .µ..- NONO----\-- \/
1\1\

N µ3'2", Lk, O__.\ N1/2 N
V---1, , '", N
/ \ 5 / \ 5 / \
1-N\ /N¨C., 1-N No.---CN 1-N\ /Nw..0, N/ \ /
AN
Ne..
i-N3CN4 Ny AN
No N
AN AN
/ ____________________________________________________ \
= N
\ ____________________________________________________ /
NI/ \-0 Nk/ \,N4 \ ___________________ / \
.s4\s ________ NI/ \N¨h_,NN
1¨NN
cr0, N,s5s! c3zz,,N
N11:117 ,32(N t32c,N

jizrO)s! im.,õ\\01,s N N
c3zz,, N (322,, N

N
N
XN NA ' N ,sss , N
sss!
N
N
,sss! V \
N% N
'3zz, N
N\\ N\\
N N ...S
c3zz N cz,, N
N
.N\( ,3zcN
,32c N N ,s5s:s N ,ss5!

s / /\/N
\./N N.--1","
N¨F
c3zcN
L'a<N
N
N,sss!
.ziN Ny \N
AN ?s.N sssN
s'<.N
L3z2,N
ANNI-n0 NA NA
;rrrN%
?ssN N4 (z''N N--4 Ny Ny Ny µ?3µ1\I
Ny /11\1'32; N, (zr µos Ar nX ArN ====0>.' = Nt......¨ .0 228 Ao (:)-.0s a .N IN
<5 N?$-/\)i, NN NN
,(N ).i\N/ p,(N
NN N NN
OH OH OH
OH N.., OH N)', AN N ja cs ss 0 ss N,, N
N N', N/ V:)N
XC)N XC)N

N)C, ,css ?ssN
OH
N
,NN
NC)"C NC)OX

;s5so N c)e s's50 NC) OC) ?0 N() OC))( OO
NC)0C)C) ?0 )0 0 sss-5 .ss( N0c)0c)0\
.55s -ssso, - ss o , 340/\,zi, = o .=, o o %, )e0///.N
0 .' =, 0 = , % ......... 0 ........_....... 0 ..............."=%%%,..............õ. 0 ............õsõ.......N=N( N,...,....../ 0 ===.,.........................%%.......
.........===="................... 0,.......;
\ 0 \
[0266] In any aspect or embodiment described herein, the linker (L) is selected from the group consisting of:
o'' ' N(" N
HN-N.% , :v%1:) HI( , ...õ0,,õ,..za.,..v;
..õ0.7.7,.1\1%..-% % ,00 H
H
, ....0, .0, .vo 1100 o-1' õ

. H = H ;
, H . .
'0 -µ', . .
i \O N
NON.

'N I ; .
, >,..0 N.,...) ,"N
N 0 N. N 0 N
/ 0 =
-, , i 7'N .11'N

. ;
'0 N
;, Nis =
_.=. -...=-= -s..
H
N
N , S.
/ N =
, . 7` ,= .
, ,CDN
N
(:)0 c N
N (:)()()), .
H ;
, s'N-M.
cN ,=0-.0,N;µ' H
H = ;i'0 0;%
;
, , ./i N
#
, ,'N 1 %, õ...-...._ U (D/Y()%-%
c,N F F
i j F F
V
FE . .
, ,(ON
N I\1 c,N N1 UV ON-%% V 0/(N-%%
F F
H , FE H;
.
, N
it' ,\, 0 N ,=-=-) H
H F F =
, , N /1%N
N c,N (:)- x (:)A/c?;
N `
F F . FE H.
, , "N
N c,N I\1 U .
c,N (:)=y= x ON1.`
N `
.
FE H , .
H, , , , N
I . .
N;-V`
H . ' ' -, µC) H ;
`
, H
, OC)10sx OH OH =

OH
OH H
OH
;1001 = ; 0 0 H ;
Yo0C)ON:/
0 ; = =

H ;

N'' 01.4 =,- . H
' ¨

H = ''',ICOC)0C)'/ =

H ; ' =
= H , H
[0267] In any aspect or embodiment described herein, the linker (L) is selected from the group consisting of:

/ , \
sk\A _________ N\ 7 ( \/0)\ / ) N ____________ N-F) m \ ________________ / m \ /
n / \
%
ss ) N ss, (N \./0).4e, .
n o õ j/ )na ON (K
/ \ \ _ \
- -N ______ N ( \/0)e0 s - / \, ,X, A ( /N (lin m M 0 s 0 /sss --/
0)Css . s \ (/ --N __ N _____ N __ (1 / \ \
N i O/
\/ ci \ _____ / m \ , /
/ ) N/ _______ \ ___ ON (1/ ' sss< /'' ) \ ______ ON
n ______________________________________________ / (f"
- -N/
_ 0/C s>,,(0\/) m \ _____ / N/ \ i \
n N ( \./0r s.
\ N (/ ____ j o ss o \ __________ /

N ' ; ' )% ,-N,...... 0(//,,........,, )>:
''0.,....,.(......../õ...........,0)..., ......./...,, c...
s= =ci /H\ /sss:s m I 0 0 =
in n y,...ty,.0,......(./....õ, rs \
0 = = 0 ,,,/ ,'yN\K \r(k/' = M
III i n /
n n % H
;µN(:)),,, , m m, in % H
/ H
( \,õ.N.,......,...õ..........õ......õõ0 s=.-\.õ.N.,.........õ......,µ ,, \ii \ =
..,µ / / =:' \ ,..\ /112,õ
ilIA¨' n ---t N \ N 0 1 i M 0 n n N
/ N c , = "V
'l ................,,,* / N
m C\N = \
M 0 == \ m 0 _________________ N o 1 i A)>0 / \
____ N
o..../.;(...õ crosc c-r\
n ' n \ m N

I A, o N
=,/
. o' .
=:*, N .....,,,õõ.õ.. __ ,..õõ..........N*,,,:s ' \\(k ) N N ( m ____ n m __ n _____ H 1 _ -1--N __ N-- 1 / __ \ _______ 1( __ 1 / \
t \ __ / -!-N \ /N ( m --- !,N
1 \ /N ( /( i, N / \
¨1¨N
1 \ /N ( _______________________________________________ rm , \
-1--( N-- _ / l_i \ (C t_< IL
\ i __ NH t_ \ ( r -i \ / / __ (, < / m r¨ r¨

/ ___________________ \ / __ o / __ \ 1/ ____ N
_____________________________________ N N ( n / __ Nµ
/N ( 1 n / \ ______ /
0 ( )m '-, / m I-, ,--, o , o , n n H
\I\
/-', 0¨

¨
S''ON
/¨\ / \ n _( ie iill N\ /N

=,/ `õ/
e', N
0-- 0¨ ¨

=,,,,..,,,,..õ.1.,,,),õN,.......,...
___________________________________________ ov, 5:µ N
N'.5( n ,.................õ,,N/ `)(õN,........./....õ....
i N,....../.>

,5 F' e in S' fl:N
'4 .....,......,.õ,.-..,),,N,õ,,.,,,.

Xr1 N
S: Nµl<
n e ,B N N\ r ,,..........,...õ,N ....,,,z, i n m ;---, ril .õ0 \ 'Hil N1 N.L At NH,, M n Ni3zc, N \
d, in N F F
)( N 0(,,'r -'= / N...õ,..õ,..,,, = 0 ,s n m M m n N Xs -- N
\(\ ) 0 OH
n H
= 0 N N
N
:)(,0N.,õõ,...õ
)m \ _0_ -m / is( C F3 õ....N.,` \
OH N .
\ 0 = 0 .` N,.....,...õ ,\.=,õ
,,t...r.Thc..)r.õN,,,,..õ,,,..-n m n m n NN )s( --- \
= 0 N
'L07 \,- N
''-'0 ___ ON __ )nN\ / Z----.--.\ ( \
\
-- N / =N\,.õ,/' N
\¨ N
( n \ / ... ' N .-.../
, 0 n ................./(..õ)õ,,N..õ.....
..N
- M
N = µ
..., N\µ4'N
NµZ)Zt =,,...õõõ,,,N: 53..\,, S n OH
N
..õ,.,.,=,..õi.,),,N.,,õ,,,=õ,, / N
m n F ...õ..,...., (..õ...) N,.....s.=.õ,,,.,.-, ,1\ N/ , \,M\ .
= 0 , , m N
n \.....õ/N--.1_, s ''1-1'1--1 (' c'r,---'****
N
N ..-''''..****\. N'2'122, - ¨N n n N i N N
H ' N
µ21 N\ ' m o n F
õ/ N)s(= ,10 =,,.,.......,, N ,,,/
m i -M
m n N ---D- ......_ 1 i N i,' _ ¨N
i m , N---a_1 , m N
\ N
H n 0 _____ / N N \ ___________ ____2/

m 0 2/ ) m N N ___ n 0 __ r ------\
)4 m N00.-0 1 / A
0 0\, in sys, /\ )n ___________ N N
\ ___ / o m KN[ , srN1' \I" .11,,K
\ im (111 NaTN
,N1,!5 ,Nlge /Y.5 H 3 TL'r, r'N\
N,>
is N\ C, r1:4N1 ,N1Q.N) ,N1,e \N, N1,1, \ im 0 4:N
,Ncse 0 ,NI/e NN ,I
' m N =H r/;c) N H ,, I
:- '''\0' rN 1 rN)1 1 i % I n \-0 /

= , = 7-), N
0 ¨ : ¨
, .)-----/
/ ; - \--N = -I-O'n sCrV',N rN\
CN\ ' m l'\1 . , (N.-0-'-n 1 , NC)---Nr--N

.-, \ ,. kl-N N-:- \A,..`' . N\53sCY, .Q 1\11a<
--0-0-0 n \__/
,N.H) N,> m m N----z\ , 1 µ"-bN N
\ H "

\N_,_ \_____\_.
,/ N---9 " 1--\N
0---7-N \O---0-:- -b--0--N\_____/ ----\N-0,,, N N m , .
/-\
Nci ¨Ns...2,r , -01-yr Cri jµI'µ`

/---\
\ 4 NON2,_ , p.i_jr-N N ----N,:,:-}.._ Na(I %

_ rN ' 1-f)O-N N-;
\/
N-...N l'. ., ,-- mL. Ni/s ;
00t1000,)),(%
/ m n o P
q ,cw00t.i.00H),(%
r m n o P
, , 00t1.0f.( , H
0 N }c . , r m n o r m n i H
0 0 ON oeµ` )frr i H
/ m s n o P q , , H
OH0t1Ø1.N m)(,, / m n o P
%)(t00000' s , m n o p , m n o H , m n m H
, m m n H
% =)4Am-.00i-.
s m n o P
N
\00t10 , m n o \ % 0 Ot101.01.0(,ec s m n o P q 00t1.00.1,c%
m n o p H
N
% 0 m 11 o m n H
0.,)0tIN HX%
in n na n o H .
%).(r000N
s m n o P q H
(%0(,K=OtI0(,N
m n o p %)ON
m n o P
, \
N
, .
m n % 0 n 0 = n % m =

N .
8 Nai.r n , \ , = N,,,,.õ,õ,,,e 0 ..../ .

m m n 0 i''.41n n 0 p 0 , "0 m _ o n 0 p 0 \
, N,,,,o),\
,./
, m m o , ====,/ N\(,) / 11 N \ N 0 , m \ __ /

_ / N¨ . NI \ N- ¨
/
-N _ , n n \
""--'c ¨2 _______________________________________________________ N
/
N
m m =
N i \ ¨
N, i ).\ A /.... , _/\
0,1,...y.

-.
N ,/, s =
=
=

=
s m N
, N j s s M m = i', N
= 'm m , , , , / m m ¨N N - 4 \ 1 / \-( 0..=
N..õ,,,,..õ.....õ0 ,.........., \ _____________________________________ / i m N
m N.
=
/.=
0 0,,,,....õ...,,,õN
) ___________________________________________________ )`., ¨ / \ . N N
\/
0 0,,,,,....õ.., N.......õ.

. 0(.= \
_ . \ . / \, .
=
`,.., ; \
0 0,.,,,,,,,,,,,..õ...õ.õ0 iii .=
. : \ ________ /,, ,. .
i i / ________ \i.
\ , ___________ N ..,,,,.,,,,,Ø,õ,/,,,,,,ox< 0 0)C=
m i = / \
: \ /N __ \ / \ i m C'0 = 01 / m ' __ H
_ m 0 1 N no( ---------------------------------------------------- 0,(-Fd--,,, N---4E9 )rn ON¨es) o ,n / \ ..,.:ONõ.................õ 0-......1 i / N __ ON ¨C'N' )' x-0 .0'%s NH¨ ¨ ' 7(`/K
\ ___ / )sss m ;
, %
===,-, .......1-111 0/ n \
\ \µ..,I 4.y........... ,...,y \
il ) M __________________________ N
--A
\ 0 =

m n a \ N¨ ¨ --/ -5.--> \ N¨ ¨ ¨ _0 ________ /
/
N N
\ __ 0¨ ¨
--,/
/ \ / 0 N N __ )) m ____ N N __ n / \ ______ /

0 ________________________ 0 ¨
N
/ \ _____________ / __ N _________________________________________________ /
' _______ N N / \ __ /
/ \ ___________________________________________________________ /
N
is--/ \ ___ i n / ______ \ /1\1 \ s/ss / \

)()n \ /
/--, --,/
N
O\ A
N¨:¨
/ \ N c) N/ ) A \ /
c n \ m 0 __ --,/
/-'-, . _____________________________________________________ 0 i 0 ) / \
a N( ______________________________________________________________ /N¨ -- ¨0/ 0 __ ,....,0,........../.... ,, /'' N 0 \/N/\N
/\/ 0 01'' V.
nI\
0 __ vIN
i ____________ /N __ n 0 _____________________________ ill \s.)N N k:)(ii /N.
0¨ekn /
__________________________________________________________ N ___ NiFI's'' N 11, N __ Win JO I .) 0 ____________ /-µ111 \ - ,../ Nn __pi-----C(N ' / ) __ 7 - -_ p r - - - - = -0 /\ __ N n N
/ \ C)( NH
i /N n n N
H c '.
icrl 0 _____________________________________________________ n /'- /'=

= ) /'--0 ( km / ___ \- 0 ( kin \ ______ N N-\ ______ N 0 \ __________ / \-- N, \I N
0¨.-, ) / :
/ \ / i_ Q( N N __ n =-,/ --,/
, / \ __ I _ , 0 -' NrN --pri - - - --0 / jn N \ /N

n ijr- =
¨ / i 0 ___________________ c., m /
i'=
Y.' / ) __ Off ) n - ___________________________________ r 0 \O ( km \ - ¨ 0 N/ (N __ W
0 _______________________________________________ )(111 \ __ ( \ ______________________________ N N

f' / _____________________________________________________________ ) 0 , , N ' ____________ 0 .=,/ \___._.../N H A, /, ',,/
/',, n 1-=
/ ________________________________________________________________________ 1C1's 1 / \ 0)(ni 'ICN \ / .. 1 / \

________ N TN\ /N n''',Ir \ \
-k/ \
rN1' 1\1/ ,N16,4 N1-. \N, \ /m m 1 Ngt: m ,Nige m csss:
H
m ss --, ,....õ..Ø.,...
0 0 =
===' C) =
)'.....s.l.") IC' \
N.(n ,...,ZN \ =
0 n ::**0 S' 0 ).3C/N WoX
i --, =...õ.....a., Ns\, 0 m '..(...****)rs 0 m m cpNWO.
n \ 0 ;s / \
\s,õO 0 N''''' N

n in ..
in/
n in 0-..L
=¨=
\,....-' .... 0 N--.....7.------/
x ,......õ,....................,0 =

,.1 /
Lici = 0 ' 0 ,='==''.
vON =
.=' \
' 1 "c¨bN,.o.õ,ic,,rõ.o n ,.../...cr,O.,..........x.õ......õ,õ, N ,-..11 0 --4N = 7'-=N
s.:
I , , 0 n n o ...'''O/
µµ, = N -- 0 0 i ,....Ly `,/.... \,.
..".\
0 0 =
0 \ N
(j/ m n ..7:". 1 '....''ON, =
,......zr,,O,,E,,,......õ,.....,(.1:0),.......N
= 0 -'='.
H
m ---\.

;I
.
.)---j .
.
o ) ,s c.
.
\ / \
)--\
..
., z¨

%
. - -.
. 0 .
d i---6o cil l=-) R
8, ..
c, - )-- ?--- .-,A___ co-, _____________________ ..4,µ,._.
, .,.,,:
-k"
. --\-- --\ - -- \ 0`, . ' - \ . , .
I
0, , \ 0)._.\ 0 . ,-0 . . . 0 .
0)--i __________________________ I.) )__ _____ \
_______________________________________________________________________________ ____________ ) \ 0) \
z¨\ \ \ = zµ ____ / 0z __ 1 ) _________ / Iii \¨ \
i % .
,¨i i , X
c) 0 --1- . 0 0 0 . 0 ls.) ,-- , \ 0 0 0 8 0 =
.
.
c. z¨ z ..
'--1. --1---z ..

n ---0---, %,0 0 1 , .-- _._i NC
ON 0 \ N
0-..4..
s\ 0 N
0 0 \ N \
n \ 0 N
F,C
ON.......'' im , 0c)4 --- --F F
N., 0 - n n / N \
/ ..---ON - n 11,(..,0 .....,./.

s 0 1 n \ ...õ0,...õ,.0,..,, ....,./' s ON

NC
I
ON

F F
NX0C)><
..., ..,, F F

\\....:

_\......-4:74:1- 0 n ON____Ø----------------:-.----C) rr\O-7----%

0 N CF, W
ekit.n.0µ \
NN n m .), ......ZN .
s N
I
,''COON
,...............,N,O.,...õ,o NI,....:
0 S...-, 0 0 n F F F F
Li.,0,................Y.0,...,.......õ....õ0 .........zio,.............õ...õ,.........v0,......Y......õ.....õ,0 o CF, 0 \ ( \ /
in n n µ 0 0 n in in .*st\N =
n % OH
m ,14,1=õ,"..,...,..)=õ
ii.
m n 0,,(,.1õ,,.....i3O 0 =
m n / =
A
-- ' VC11171\
/
r....
, 0 , /
, No x ..,........"N
s ..=
j% Ci =
v C) ,,..., N NC
,/
/ 0 ...,,,,,..,...õ,N %s= 0 \
0 = v ,...,crõ0..,..,,, s<
N C) =
1 ../
/ 0 ..,,,,......,õõN
/ 00. =sf e..... \

=( 1 =./ Ci =
of 00 '====,....õ..., ...)::(0,.................

0 Ns\

,,i r''c) s,......,.......,,N
.( , i===,o õ....,,,,,.....74,,N
,,,...../...,õ N
NC
HO
N =,,, OX\
\ -ff oo'f \
,./
i',o ,,,...../...,õ N
...)::(0,................... =
`=
/ = Ci =
..o , ' 0 =/0 s,......,.....,õ N õ,,,...........õ N....., )&o 0 )::::r ==,......./...,Nõ,,,...,..,,,,..,,,....,,,,.....õ0õ...,.......0),.,:

N

,.
./
õN
i/) = , I

= 0 CF 3 == N
o1 =
02 \

CF3 \
)::1 = , .,.
i' )iii3 = , ;.c I %=-1 =,õ,..,,,.õ,==N /"µ
F F
)::::y = , 02\

., = , 02\
I
NCN
)( =
.....õ...,,,N,..........õ,,,N,,, I

AN %
.,,,,ON =
' n /
, f 0 N Wo%c F3C,,...,,,,,,.
N .
N
" \
n NW=,.
0 =
/
) ____________________________________________________ ,.. \
N ........:,..0 .
..,=\
N \ M
NW,.,\,= 0 0 \ 0 s==' ',,,cii ,=\

n 1 7C:r N)c /

,=\ '''\\ray 11.1.1'N
õi f\ro n ,=\
.),., 0 = 0 HO n = ' 0 ,...,,,e ,=\ '''Iiii,, n ))( =
oN
0 ' N' /'..0 0, NiVrNi r , n(,2)N .,,.,....N
0 ' n P
N N
r , N N,(.= 0)./1) (i N s n P
N N
r s n(,<N -,.......,,....õN,,,,/
, n / _______________________ NO\
o __ /
/ ____________________________________________________ NO
, c) o i.

/ ___ N Nn W I, 0 a I
I /

i 0 ( _______ NQ
) :
n , H
NN NCIN)s(%
H
m , O
' 0 o ir\ "/
H
N NN( N H ' m 1 0 'Clo ,1\ N
, 0 %
H %
N N s N
m N
. 0 H
N N rr0( N
m 1 0 113o ,I\ N
, 0 .Ø..--. ,,..--. 0 N N , oN
N X
N \
H
N

oN
0 coN
N
H , µ 0 r N 0):µ
N

rN=, N
N;4 =! w W
, 0 0 N\.3 OWOWO
r-X
.... .
i 0., %/isC)0() Cr ll' /.0W0W0."
s õ
:\N
wherein m, n, o, p, q, r, s are independently 0, 1,2, 3,4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
[0268] In any aspect or embodiment described herein, the linker (L) is selected from the group consisting of:
a--/¨\-0/¨\0- -= / \-0/0¨/¨Ck; /
, \ 0 ¨0¨/¨ o , ,,,¨\_ /¨\ //o¨\ / /¨\ /¨\ /-0\ /0¨\ /¨\
0 0¨/`-0 = ' `-0 0¨/ __________ `-0 0-- =
, , ,, __ \ P __________________ \_ i . ,,/ \ / . 1,/-- \ . /1- \ _ -- .
% ; ' \ __ / 5 U 5 5 \- - - 5 U 5 /1-- \- /- \ , \_ /- \ _/-N1,1-I /¨\_ /¨ j¨O HN---\__/ .
0 HN--- = ' 0 0 ` = ' 0 0 , , , ,/ __ \ /¨\ /-0\ /O¨\ / / _________ \ /¨\ /¨\
\-0 0¨/ \ __ NH = ' \-0 0¨/ ____ \-0 HN--- =
,/ ______________________________________________________________ \ /¨\ ¨/ /¨
0\ /0 ¨\ /¨\ r¨ N.-1 _ _ = _ _ _ _ = /
\-0 0 _________________ \-0 0¨/ , -- = = -- = %
-- * di . -- = or -- -- * 0/--\ -- * 0/ \- --;
= ______________ 0/ \ ' -' - . 0µ, __ =
0¨,,, = 0--, ; , , _ /--\ /--\_ ,, = \__,,, =
- -% /1¨f µ¨c) - 0¨
- o __ * 0-1 , , , 0 0-- -- . 0 0 ' , , II 0/0¨/¨ 0 \/0- - --5..0/¨\0_/-0\__/0¨\_d/
. .
__ . 0"-- \O ¨/¨ 0\ /0 ¨ \ ¨ \--\ ./
\-0/ 0- - -- i . 0 0¨' -- = 0/0 ¨/- - - - - * 0/ \¨di -- . a/ \¨o1 ; --; .
, = _____________ 0/ \ ________________ /o- - = 01--\ r-`0-- -- * 0- \, /

; ; .
, 0 0\ __ /0 - - 5,0 - \ r __ = ¨\ _______ P-- __ * \-0 . 0/ _______ \-01-`0-- -- = o/--\o¨/ \¨di -- * o/--\o¨/ \o--, ;
o = __________ o" ____ \-0/ ________________ \¨d/ -- 5,0/ \ / ¨\-01 - - <
\NJ¨ µ' _________________________________________________________ / .
- - < \ N / \O- - - - < N¨/ \
\ \_ 1/ < _/ \__/ - -/ / _______________ /
, , , / ___ \N _/¨ 0\ __/0 - \ N
/ ' / \N¨/¨ \ _______________________________________________ / \

- __ / < __ / \/ .
, , , /--\
-- = 0 N----(\¨di 0 ________________________________________ ro 0 - -LI, / _____________________________ / .
N--- - - = N N---\__/ ; \ __/ ;
, . N/¨\N¨ro\ /0-- = / ____________________ \
o ___________________________________________ \ i o =
, NJ
ii /--\
= __________ 0/ \ ___ 7 ____________ = 0,-\ __ /-N\ 7-; .
, /--\
N N--- N/ > - -- - = 0/-\0-/- \__/
j- ________________________________________________ = --0 0 \
, , rN--c)ON) -- = N/--\N ____________________________ / \O- -; \/ .
, CD/ -, 0---/Th 0-_ WI (:)(:) 0 C)00-, 0 .
-- ,0 , /--__/---0 0 .
'. 0 /--\ /
l "N_rN
< \N-rN
\ >
N _ _ 00 el - , . - - \ \__/ - -/ .
, / .
./
rN
-- \N-/ ______________________ -- \N-) -- \N-( \ 0 / / . / ,N--- . /1-\_0/-\0 ' , , __________ / , , /-\ j-0 HN---'-\_0/-\ 0\0/ /o¨_,, o o \NH
0 = 0 =

_ /-\ /-0\ /0-\ / _____________ ./
0 0-/ _______ \-0 HN--- =
, j-/-\ j-O\ /0-\j-N,H __ . N1-1 \-0 0 N = =

= 0/-\ 0 0-/- ______________ \
\\ = 0"0 -" \__/ N/H
0 = 0 =
, , -- =/
= 0/¨\0¨/¨Ck¨/ ¨\
\-0/ HN---, \ /O¨\ /¨\ j¨N,1-1, = 0/
= r -- _________ 0 /¨\ 0¨ \-0 0 0 ;, = 0 HN---\ , \\ / \ /
. (:)¨*/ ______________ N/1-1 = 0 /1 NH
0 ; o' o =
o o = o , >/ ____________ N/I-1 __ = HN--- -- 0 4. / _0 \ / =/
HN---0 =
, ; , __ = 0/¨\0¨/ =/ _______ * 0¨\ / ./
\-0 HN--- __ . 0/ \
; =
, 0 -- . 0/ \-01 -1,1 -- 41 01-`0-/
= 0 0 =
, , , 0 0¨), /
-- * o¨\ _____________ /o¨)/ N11-1 = \__/
o/ NH
0 =
, , \ ________________ . 0¨ /
\-0 )/ __ NH/ _ _ . 0/ H\N___ - - \ __ / I-1 N/
0 0 =

HN---, -- \ / __ -- . '\ \¨NH \ . õ
* j¨N1-1 0 = ; 5 5 -- \ /
NH
µ` -- * 0/¨\ __________________________ / 1-1 0 HN---, ; , = _____________ 0¨\ /-11\1 = 0 /
\ HN--- -- = 0¨/ ./
HN---, -- = 0/¨\0¨/ \0j¨NH
.

_ _ . 01 ___ \ _ 0/ ¨ \c) i¨ N,H, _ _ . 0/ ¨ \ /¨\0 j¨ NH
, o o . / ________ \ / \ /
--./ / \_ / \_ /
00¨¨o HN--- -- * 0 0 0 H N---=

= __________ 0/ __________ \ /o¨\_0/ __ II _ _ 1 \N j¨ 0\ AIN
\ N __________________________________________________________ / \ j\¨N,1-1 -\ __________________________________ / 0 , , 0 ; /

- - < \ N ¨ / \¨ / ./
0 H N--- - - < .
\N ¨ / \
¨/ NH
' __ / = ___ / 0 =
, , , < __ \N j¨ 0\ /0¨\ __< __ \ ro\
N H N¨f ro\ __ T
/ /
0 \O =

_________________ \j ___ 1\1,1-1 /
./
- - < / 0 ` -- < \N¨/¨ \¨/ \-0 H N---____ / / =
r\N
0 _____________ ,-0 N H 0 , 0, 0 1m H N - --- -N¨/¨\/ ¨/ -\--- N
/ 0 0 ;
, nr\ N
N H
N N
- - - - * 01 \-/-\jHC`
0 ; \/ =
, 7--/ H N NI/f /--\
0/¨\ /¨N 7 ¨)r /
--- . /-...\) \ - .._ _ _ 4.
0 N --._ N H
0 =
/--\
* 0/0 ¨/¨N\¨/N N/1-1/ - - * 0/¨\0¨/¨N/\ __ ) ¨1\11-1/
0 =0 =
, , N/¨\N N/\ ) 1 4, H
- - < \N¨/¨ \ ¨/ ¨/-1\1/1-1/ - - < \NJ¨

/ 0 / 0 =

/\
-- <N-<
\N-/ ___________ -i- ' N
NH' .N.r \N
/ / /
0 = \N) HN NH
., .

, , .
0 , - _________ * _______________ NH /,'\ r0\ HN--- , / / \

, %= 0 ,. :
, 0 HN--- =
, 0, iii--\ __ /-4(HN---;,/--\ _____________ >\-NH'/--\ j NH __ =0 N-0 , ; ' 0 , . =
., 0 , i_(,)-N--() __ _ * 0 ,, O \ ---- \ ._.-., , , VI
.. 0-/ - -. , 0 00N. 5 -R/- -- - * N-0 . -/ / --, .
, * 0 N-0 \----"No.,...NA). * ON.,....0N...õ__ / -- . N---, .
0 , ., . j)__ 0 N-C) OC) ---0(), =
., 0 , N---() OC)1(")-- -- IS (:)\----NO----\..,--___.
, * 0 , X0x11--C), -- *
CDNA--, ;
* 0 X0X, . 0 -- * \-----\, N-0 , ., 0 ;
N-C) ' OC) I / -- el N-C) , 0 'c)Q- -- .
. , 0 , - -e.\/* Q---, 0 .
., 0 , N ' O(DQ--- el C).'""..... .*:4 - -, .
N-C) - --, .
, i------\
N
. 1\1/-\N-0, -- 0 /Th j\--1N - =N \___11-\---N- , V......_/N . -- .
;
.._ .
-- 44Ik N .
. =
.._ --fik N \___ j i------\N
--\--0 0 -0 -, Is I /
N/ N/Th =
\N r\1\10 ' .
O

---\_,, __ . N \....... r"\ jN ----\---\,_.0 =
i--\ /- \0, /- \ /- 0\ p - - /- \ /- 0\ /0¨\ /
--o o--= --o 0¨' ,= --o 0¨' _________ ' = --o 0¨' \-0 ,=
, , , /--\ /¨o\ /0¨\ /¨\ /--\ /¨o\ /0¨\ /¨\ /¨ ON /-----o o-1 \-o o--= - -0 _______ o-1 \-o o-i , = --o =
, --01 \-0/;\o-1 ;--0/ \ ________________________________________ /0-, 0/--\o¨/
\o-, 0/¨\ /--\
0--;

/ ___ \_ / __ \_ / /--\ j _____ \_ / /¨\
--o o o = --o o o = --o o¨f . ,.
, , , r. 2¨\0_/ ___________________________ \o , . __ o/
, u , , /¨\ /¨o\ / _______________________________ \
/--\ _/ \ _____________________________________________________ / \
--o o¨I ,= o o-1 1 o--= --o o o o--=
, , , /--\ j ____ \_ /--\ / __ \ /o¨\ /--\
/ ______________________________________________________ \ __ /o __ ¨\ /--\
--o o o o--= --o \
\¨o o- oo--;
, , /--\ /¨\ /¨o\

3\1- . - -N N __ ' - /- ___ /- -/ \O - -; - - Or- 0/0 - -; - -NI \ 0 /¨\/ \/¨\ __________________________ / \¨ ii /¨\ /-0\ /0----N N¨ O-- --N N 0 --N N /
; \/ ; \__/ ;
;
/--\
/¨\ /¨N\ /N--- p¨\ /¨\ /¨o, ,o¨\ / __________________ \
--N N¨f , \¨N N¨/ ' ' \-0 \¨N N---\__/ \/
; ;
/P /--\
/¨ /¨ \
¨\¨/¨\¨N N--- --N \N _____________________ r 0\ r 0, ' --N N
\/ ; ; \__/ =
;
--N/--\N / \
\/
/ ______________________ \ /--\ /,/\
N --0 \¨N N¨/ ' --N N
, \/ . , / ¨\ /-0\ /
; ; ' ___________ /0- - .
. =
;
/--\ /--\
p__ --N\ 7¨\_0/ _________________________ \ /o-- __,\(--\
--N\ /N¨\ /0¨\ N¨¨P--; / ; ;
/--\ /--\ /--\
--N\ /N¨\ /¨N\ / ,N---. - -0, /¨N\ / /1\1¨\ o--= , .
, , ____________________________________________ o /¨\ /¨o\ HN--- /¨\ _/-0 0¨\
--0 /¨\ j-1\1-1 --0 0¨/ 0 0 \¨
NH/
. = - -0 0 . . 0 = 0 =
; ; ;

/¨\ /-0\ /0¨\ / /¨\ /¨o\ /o¨\ /¨\ i¨NH
--0 0¨/ _________________ \-0 HN ___ = --0 0¨/ \-0 0 ; ;
0 / __ \ HN-0/)/ ,p¨\ /¨\ /-0\ /0¨\ /¨\ N,I-1 0 \
µ NH
\-0 0 ; ; 0 =
;
o p _______ , JD _________ /
, ¨\ , / _______ \_ / /--\ / ___ "'c o \ /0 \ ¨NH
¨0 0 HN---= ¨0 0¨' HN---= --0/¨\ / I-N---= 0 =
; ; ; ;
/ \_ / \ / / 0 - -0 0 //NH0/¨\0¨ / ¨N1/1/-1 0/¨\¨¨NH/
/ ./
= - -0 HN---= = 0 0 ; ; ; ;
0 /-0, /
,-4-I µb¨/ \¨/ ¨N1/1-1 NO¨/ \o¨/ ¨1\1/F1 /--\
¨0 0 0 =
o b¨I

\¨o/ ¨NH µb¨/ \¨P¨)/ N'H /--\ i \ j¨NH
0 0 = - -0 0¨/ b \ .
, , , / __________________________________________________________________ \ /¨\
i¨N,1-1 /¨\ /-0\ ¨4-1 /¨\ /¨\ j¨NH
--0 \-0 0 ' = - -0 0¨/ ' 0 ; ;

rO\ )\-1\11 / __ \ /0¨\ \-1\iµFi /)\¨NH
0 \ ` 0 \-0. \ ______ , , , /¨\ _/¨\_)¨N\I-1 /¨\ / ___ \ / ___ 4( / \_ / \_ /
--0 0 - -0 0 0 HN--- ` = - -0 0¨/ \-0 HN--- = =
, , , 9 4) / _____ 0¨\ / 'K µ / /
--0 \ / \-0 HN--- = b¨f \¨/ ¨\¨o HN--- =
, , 'c b¨/ \-0/ \-0/ HN--- = 0¨/ \O¨/ \-0/ IL--- =
9 p ________________ / __ /< µ, \ ____ / __ \ /¨ /
HN--- U¨' " O¨ HN---rO\ / .µ rO\ /0¨\
0¨/ / HN 0¨/ HN---p p \o¨/ \¨/0¨\ _____ /¨i\dN µ0¨/ \¨ /--\ ______ /--\ 0 HN---0 0 /¨\ _/-0 HN---\ _/ \ \ _r()\__/¨\ _____ /-4 -N N \ __ /
\\
0 0 HN--- 0 HN--- \¨ 0 =
, % o ./( --N/--\N / \O¨i¨N\H` --N/--\N¨/ \-0/ 141--- - -1\1/--\N¨/ \¨/0¨)rN/1-1/
\__/ 0 =
, , , /¨\ /-0\ rO\ HN---/
--N N \¨ NH N N /
0 0 =
, , \_ --N/--\N_/-0\ / \c) j-1\1-µ1 --N/--\N J-0\ / /
.

; \__/ .
, /

/¨\ /-0\ /0¨\ / __________ ./ HN
__________________ \-0 HN--- ,o HN
_______ 0 /0¨\¨N/ --N N /
\/ \____/N
\ _____________________________________________________________ / =
, , , O I\17f /--\
/ ___ \ /¨\ i¨Np /......1f-- \ HN-- __0/--\ __ rN\__7¨)r r --0 \¨N N \N---/ NH
0 =

/--\
N/ __ /--\ /-N N-)r , 0 0-/ \- NH - -0 /--\ -/- \ __ ) - _r\i'Fil 0 0 =
; ;
/--\
/--\ /-N N / ->/_ --N N" \- NH --N N/\ )' -1\111-11 \/ . 0 \__/ 0 =
; ;
/-\ / ______ ( \N-\ il N N
/ `.rl--\N-K \N C) --N
--N ____ N ' i N \/ /
\/ 0 . N HN' NH
; - ' 0 =

`.0'. -.- , .0-- -; 0 =
;
N-C) . , ,0 I / --. ,.0 --; 0 =
---, 0 ; '00 =
;
N
v N-C) N--. õ0 -0 . ,,00.,)--; ; ;
N, --0\ N
\

!--. ,¨
, ;

-0, ) - 1.õ,r- ¨
0 =

-- , --.
, , -- - , --.owo . -0c)-, , -- , --'00c)-=
; , /--\ N-0 `.N N-õ
--N N-U
;=

NON--\_....0 N-0 N N-C) 'N N-o - -\_____c_...._. I
NC:,...,..,,,,-.11.)---1.,.....,,N.,.......o,....-.õ._,õ.-X.)--; , -0 ...... .......Nr3N,0N-0 .....
,,N \.....) -- / \
N ____ N \ ON -\ = and --NIN
, .
[0269] In any aspect or embodiment described herein, the linker (L) comprises a structure selected from, but not limited to the structure shown below, where a dashed line indicates the attachment point to the PTM or ULM moieties.
CO
(yL1) (yL1) 0_2 II 0_2 0 0 or , wherein:
Wu and WI-2 are each independently absent, a 4-8 membered ring with 0-4 heteroatoms, optionally substituted with RQ, each 12Q is independently a H, halo, OH, CN, CF3, Cl-C6 optionally substituted linear or branched alkyl, optionally substituted linear or branched C i-C6 alkoxy, or 2 12Q groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;
Yu is each independently a bond, optionally substituted linear or branched C1-C6 alkyl, and optionally one or more C atoms are replaced with 0; or optionally substituted linear or branched C1-C6 alkoxy;
n is 0-10; and indicates the attachment point to the PTM or ULM moieties.
[0270] In any aspect or embodiment described herein, the linker (L) comprises a structure selected from, but not limited to the structure shown below, where a dashed line indicates the attachment point to the PTM or ULM moieties.
(Re)0-6 (yLl )0_2 0 n i , (R Q)0-6 (yLl )0_2 aln , (RQ)0-6 of Li )0_2 QL (YU )0-2 n or (RQ)0-6 (yLi)0_2 , AO QL (YL1)0-2 n wherein:
Wu and WI-2 are each independently absent, aryl, heteroaryl, cyclic, heterocyclic, C1-6 alkyl and optionally one or more C atoms are replaced with 0, C1_6 alkene and optionally one or more C atoms are replaced with 0, C1_6 alkyne and optionally one or more C
atoms are replaced with 0, bicyclic, biaryl, biheteroaryl,or biheterocyclic, each optionally substituted with RQ, each 12Q is independently a H, halo, OH, CN, CF3, hydroxyl, nitro, C
CH, C2-6 alkenyl, C2-6 alkynyl, optionally substituted linear or branched C1-C6 alkyl, optionally substituted linear or branched C1-C6 alkoxy, optionally substituted OC1_3alkyl (e.g., optionally substituted by 1 or more -F), OH, NH2, NRY1RY2, CN, or 2 RQ
groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;
YL1 is each independently a bond, NRYL1, 0, S, NRYL2, CRYURYL2, C=0, SO, SO2, optionally substituted linear or branched C1-C6 alkyl and optionally one or more C atoms are replaced with 0; optionally substituted linear or branched C1-C6 alkoxy;
QL is a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally bridged, optionally substituted with 0-6 RQ, each RQ is independently H, optionally substituted linear or branched C1_6 alkyl (e.g., optionally substituted by 1 or more halo or C1-6 alkoxyl), or 2 RQ groups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;
Ryu, -YL2 tc are each independently H, OH, optionally substituted linear or branched C1_6 alkyl (e.g., optionally substituted by 1 or more halo or C1-6 alkoxyl), or R1, R2 together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;
n is 0-10; and indicates the attachment point to the PTM or ULM moieties.
[0271] In additional embodiments, the linker group is optionally substituted (poly)ethyleneglycol having between 1 and about 100 ethylene glycol units (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, etc., ethylene glycol units), between about 1 and about 50 ethylene glycol units, between 1 and about 25 ethylene glycol units, between about 1 and 10 ethylene glycol units, between 1 and about 8 ethylene glycol units and 1 and 6 ethylene glycol units, between 2 and 4 ethylene glycol units,or optionally substituted alkyl groups interdispersed with optionally substituted, 0, N, S, P or Si atoms. In certain embodiments, the linker is substituted with an aryl, phenyl, benzyl, alkyl, alkylene, or heterocycle group. In certain embodiments, the linker may be asymmetric or symmetrical.
[0272] In any of the embodiments of the compounds described herein, the linker group may be any suitable moiety as described herein. In one embodiment, the linker is a substituted or unsubstituted polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycol units.
[0273]
In any aspect or embodiment described herein, the linker (L) includes an optionally substituted Ci-Cioo alkyl (e.g., e.g., Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, CM, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C83, C84, C85, C86, C87, C88, C89, C90, C91, C92, C93, C94, C95, C96, C97, C98, C99, or Cioo alkyl), wherein each carbon is optionally substituted with (1) a heteroatom selected from N, S, P, or Si atoms that has an appropriate number of hydrogens, substitutions, or both to complete valency, (2) an optionally substituted cycloalkyl or bicyclic cycloalkly, (3) an optionally substituted heterocyloalkyl or bicyclic heterocyloalkyl, (4) an optionally substituted aryl or bicyclic aryl, or (5) optionally substituted heteroaryl or bicyclic heteroaryl. In any aspect or embodiment described herein, the linker (L) does not have heteroatom-heteroatom bonding (e.g., no heteroatoms are covalently linker or adjacently located).
[0274]
In any aspect or embodiment describe herein, the linker (L) includes an optionally substituted Ci-Cioo alkyl (e.g., Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C83, C84, C85, C86, C87, C88, C89, C90, C91, C92, C93, C94, C95, C96, C97, C98, C99, or Cioo alkyl), wherein:
each carbon is optionally substituted with CRLlRL2, 0, 5, SO, S02, NRI-3, S02NRI-3, SONRI-3, CONRI-3, NR1-3C0NRI-'4, NRI-3S02NRI-'4, CO, cRLi=cRL2, siRuRL2, P(0)R', P(0)OR', NRL
3C(=NCN)NRI-'4, NRI-3C(=NCN), NR1-3C(=CN02)NRIjI, C3-11cycloalkyl optionally substituted with 0-6 121-1 and/or RI-2 groups, C5-13 spirocycloalkyl optionally substituted with 0-9 121-1 and/or RI-2 groups, C3-11 heteocyclyl optionally substituted with 0-6 121-1 and/or RI-2 groups, C5-13 spiroheterocyclyl optionally substituted with 0-8 121-1 and/or RI-2 groups, aryl optionally substituted with 0-6 121-1 and/or RI-2 groups, heteroaryl optionally substituted with 0-6 121-1 and/or RL2 groups, where 121-1 or RI-2, each independently are optionally linked to other groups to form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 0-4 RI-5 groups; and Ru, RI-2, RI-3, RI-'4 and RI-5 are, each independently, H, halo, C1_8alkyl, OC1_8alkyl, SC1_8alkyl, NHC1_8alkyl, N(C1-8alky1)2, C3-licycloalkyl, aryl, heteroaryl, C3-liheterocyclyl, 0C3-8cyc10a1ky1, SC3_8cycloalkyl, NHC3_8cycloalkyl, N(C3_8cycloalky1)2, N(C3_ 8cycloalkyl)(Ci_8alkyl), OH, NH2, SH, SO2C1_8alkyl, P(0)(0C1_8alkyl)(C1_8alkyl), P(0)(0C1_8alky1)2, CC-C 1_8 alkyl, CCH, CH=CH(C 1_8 alkyl), C(C 1_8 alky1)=CH(C 1_8 alkyl), C(C 1_8 alky1)=C(C 1_8 alky1)2, Si(OH)3, Si(C 1_8 alky1)3, Si(OH)(C 1_8 alky1)2, COC 1_8 alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHCi_8alkyl, SO2N(C1_8alky02, SONHC 1_8 alkyl, SON(C1_8alky1)2, CONHC 1_8a1ky1, CON(Ci_8alky1)2, N(C 1-8a1ky1)CONH(C 1_8 alkyl), N(C1_8alkyl)CON(C1_8alky02, NHCONH(C 1_8 alkyl), NHCON(C 1_8 alky1)2, NHCONH2, N(C 1_8a1ky1)S 02NH(C 1_8a1ky1), N(C 1_8 alkyl) S 02N(C 1-8a1ky1)2, NH SO2NH(C1_8alkyl), NH SO2N(C1_8alky1)2, NH SO2NH2.
[0275]
In any aspect or embodiment described herein, the linker (L) does not have heteroatom-heteroatom bonding (e.g., no heteroatoms are covalently linker or adjacently located).
[0276]
In any aspect or embodiment described herein, the linker (L) includes about 1 to about 50 (e.g., 1,2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) alkylene glycol units that are optionally substituted, wherein carbon or oxygen may be substituted with a heteroatom selected from N, S, P, or Si atoms with an appropriate number of hydrogens to complete valency. For example, in any aspect or embodiment described herein, the linker (L) has a chemical structure selected from:

;
00t1000,)),(%
/ m n o P
q ,cw00t.i.00H),(%
r m n o P
, , 00t1.0f.( , H
0 N }c . , r m n o r m n i H
0 0 ON oeµ` )frr i H
/ m s n o P q , , H
OH0t1Ø1.N m)(,, / m n o P
%)(t00000' s , m n o p , m n o H , m n m H
, m m n H
% =)4Am-.00i-.
s m n o P
N
\00t10 , m n o \

wherein carbon or oxygen may be substituted with a heteroatom selected from N, S, P, or Si atoms with an appropriate number of hydrogens to complete valency, and m, n, o, p, q, r, and s are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.
[0277]
In any aspect or embodiment described herein, the present disclosure is directed to a compound which comprises a PTM group as described above, which binds to a target protein or polypeptide (e.g., RAF), which is ubiquitinated by an ubiquitin ligase and is chemically linked directly to the ULM group or through a linker moiety L, or PTM is alternatively a ULM' group which is also a ubiquitin ligase binding moiety, which may be the same or different than the ULM group as described above and is linked directly to the ULM
group directly or through the linker moiety; and L is a linker moiety as described above which may be present or absent and which chemically (covalently) links ULM to PTM, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.
[0278]
In any aspect or embodiment described herein, the linker group L is a group comprising one or more covalently connected structural units independently selected from the group consisting of:

/*
* I * *
X
K' * * *
* *

** / _ /* N)(* * * (:) 1 4,1\14, - _______________________ _ - 4< )1 The X is selected from the group consisting of 0, N, S, S(0) and S02; n is integer from 1-5, 5;
0 *
12I-1 is hydrogen or alkyl, * is a mono- or bicyclic aryl or heteroaryl optionally substituted with 1-3 substituents selected from alkyl, halogen, haloalkyl, hydroxy, alkoxy or 0 *
cyano; * is a mono- or bicyclic cycloalkyl or a heterocycloalkyl optionally substituted with 1-3 substituents selected from alkyl, halogen, haloalkyl, hydroxy, alkoxy or cyano; and the phenyl ring fragment can be optionally substituted with 1, 2 or 3 substituents selected from the grou consisting of alkyl, halogen, haloalkyl, hydroxy, alkoxy and cyano. In an embodiment, the linker group L comprises up to 10 covalently connected structural units, as described above.
[0279] Although the ULM group and PTM group may be covalently linked to the linker group through any group which is appropriate and stable to the chemistry of the linker, in preferred aspects of the present dislcosure, the linker is independently covalently bonded to the ULM group and the PTM group preferably through an amide, ester, thioester, keto group, carbamate (urethane), carbon or ether, each of which groups may be inserted anywhere on the ULM group and PTM group to provide maximum binding of the ULM group on the ubiquitin ligase and the PTM group on the target protein to be degraded. (It is noted that in certain aspects where the PTM group is a ULM group, the target protein for degradation may be the ubiquitin ligase itself). In certain preferred aspects, the linker may be linked to an optionally substituted alkyl, alkylene, alkene or alkyne group, an aryl group or a heterocyclic group on the ULM and/or PTM groups.
Exemplary PTMs
[0280] In preferred aspects of the disclosure, the PTM group is a group, which binds to target proteins. Targets of the PTM group are numerous in kind and are selected from proteins that are expressed in a cell such that at least a portion of the sequences is found in the cell and may bind to a PTM group. The term "protein" includes oligopeptides and polypeptide sequences of sufficient length that they can bind to a PTM group according to the present disclosore. Any protein in a eukaryotic system or a microbial system, including a virus, bacteria or fungus, as otherwise described herein, are targets for ubiquitination mediated by the compounds according to the present disclosure. Preferably, the target protein is a eukaryotic protein.
[0281] PTM groups according to the present disclosure include, for example, any moiety which binds to a protein specifically (binds to a target protein) and includes the following non-limiting examples of small molecule target protein moieties: RAF inhibitors, Hsp90 inhibitors, kinase inhibitors, HDM2 & MDM2 inhibitors, compounds targeting Human BET
Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, nuclear hormone receptor compounds, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others. The compositions described below exemplify some of the members of small molecule target protein binding moieties. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. These binding moieties are linked to the ubiquitin ligase binding moiety preferably through a linker in order to present a target protein (to which the protein target moiety is bound) in proximity to the ubiquitin ligase for ubiquitination and degradation.
[0282] Any protein, which can bind to a protein target moiety or PTM group and acted on or degraded by an ubiquitin ligase (e.g., RAF) is a target protein according to the present disclosure.
In general, target proteins may include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity, translation regulator activity. Proteins of interest can include proteins from eurkaryotes (e.g., c-RAF, A-RAF, and/or B-RAF) and prokaryotes including humans as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses (e.g., v-RAF and/or v-Mil), among numerous others.
[0283] The present disclosure may be used to treat a number of disease states and/or conditions, including any disease state and/or condition in which proteins are dysregulated and where a patient would benefit from the degradation of proteins.
[0284] In an additional aspect, the description provides therapeutic compositions comprising an effective amount of a compound as described herein or salt form thereof, and a pharmaceutically acceptable carrier, additive or excipient, and optionally an additional bioactive agent. The therapeutic compositions modulate protein degradation in a patient or subject, for example, an animal such as a human, and can be used for treating or ameliorating disease states or conditions which are modulated through the degraded protein. In certain embodiments, the therapeutic compositions as described herein may be used to effectuate the degradation of proteins of interest for the treatment or amelioration of a disease, e.g., cancer, cardiofaciocutaneous syndrome, neurofibromatosis type 1, Costello syndrome, Noonan Syndrome, LEOPARD syndrome. In certain additional embodiments, the disease is renal cell carcinoma, pancreatic cancer, colorectal cancer, lung cancer, ovarian cancer, thyroid cancer, pilocytic astrocytoma, prostate cancer, gastric cancer, hepatocellular carcinoma, and melanoma.
[0285] In alternative aspects, the present disclosure relates to a method for treating a disease state or ameliorating the symptoms of a disease or condition in a subject in need thereof by degrading a protein or polypeptide through which a disease state or condition is modulated comprising administering to said patient or subject an effective amount, e.g., a therapeutically effective amount, of at least one compound as described hereinabove, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient, and optionally an additional bioactive agent, wherein the composition is effective for treating or ameliorating the disease or disorder or symptom thereof in the subject. The method according to the present disclosure may be used to treat a large number of disease states or conditions including cancer, cardiofaciocutaneous syndrome, neurofibromatosis type 1, Costello syndrome, Noonan Syndrome, LEOPARD syndrome, by virtue of the administration of effective amounts of at least one compound described herein. The disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus (e.g., murine retrovirus or avian retrovirus, such as avian retrovirus MH2), bacteria, fungus, protozoa or other microbe or may be a disease state, which is caused by overexpression of a protein and/or the presence of a protein that is constitutively activated, which leads to a disease state and/or condition.
[0286] In another aspect, the description provides methods for identifying the effects of the degradation of proteins of interest in a biological system using compounds according to the present disclosure.
[0287] The term "target protein" is used to describe a protein or polypeptide, which is a target for binding to a compound according to the present disclosure and degradation by ubiquitin ligase hereunder. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. These binding moieties are linked to at least one ULM group (e.g. VLM, CLM, ILM, and/or MLM) through at least one linker group L.
[0288] Target proteins, which may be bound to the protein target moiety and degraded by the ligase to which the ubiquitin ligase binding moiety is bound, include any protein or peptide, including fragments thereof, analogues thereof, and/or homologues thereof.
Target proteins include proteins and peptides having any biological function or activity including structural, regulatory, hormonal, enzymatic, genetic, immunological, contractile, storage, transportation, and signal transduction. More specifically, a number of drug targets for human therapeutics represent protein targets to which protein target moiety may be bound and incorporated into compounds according to the present disclosure. These include proteins which may be used to restore function in numerous polygenic diseases, including for example B7.1 and B7, TINFR1m, TNFR2, NADPH oxidase, Bc1IBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1, cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5-lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinases, CD23, CD124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-alphaR, ICAM1, Cat+ channels, VCAM, VLA-4 integrin, selectins, CD40/CD4OL, newokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP Kinase, Ras/Raf/MEK-ERK pathway, interleukin-1 converting enzyme, caspase, HCV, N53 protease, HCV N53 RNA helicase, glycinamide ribonucleotide formyl transferase, rhinovirus 3C protease, herpes simplex virus-1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinases, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5 alpha reductase inhibitors, angiotensin 11, glycine receptor, noradrenaline reuptake receptor, endothelin receptors, neuropeptide Y and receptor, estrogen receptors, androgen receptors, adenosine receptors, adenosine kinase and AMP
deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), fames yltransferases, geranylgeranyl transferase, TrkA a receptor for NGF, beta-amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neu, telomerase inhibition, cytosolic phospholipaseA2 and EGF receptor tyrosine kinase. Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channels. Still further target proteins include Acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate-phosphate synthase.
[0289] These various protein targets may be used in screens that identify compound moieties which bind to the protein and by incorporation of the moiety into compounds according to the present disclosure, the level of activity of the protein may be altered for therapeutic end result.
[0290] The term "protein target moiety" or PTM is used to describe a small molecule which binds to a target protein or other protein or polypeptide of interest and places/presents that protein or polypeptide in proximity to an ubiquitin ligase such that degradation of the protein or polypeptide by ubiquitin ligase may occur. Non-limiting examples of small molecule target protein binding moieties include RAF inhibitors, Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC
inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others. The compositions described below exemplify some of the members of the small molecule target proteins.
[0291] Exemplary protein target moieties according to the present disclosure include, RAF
inhibitors, haloalkane halogenase inhibitors, Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC
inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR).
[0292] The compositions described below exemplify some of the members of these types of small molecule target protein binding moieties. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest.
References which are cited herein below are incorporated by reference herein in their entirety.
[0293] In any aspect or embodiment described herein, the PTM is a small molecule comprising a B-RAF protein targeting moiety.
[0294] In any aspect or embodiment described herein, the PTM targets and/or binds RAF.
For example, in any aspect or embodiment described herein, the PTM may comprise a chemical group selected from the group of chemical structures consisting of PTM-Ia or PTM-Ib:

v "pi-m/
WPTM-3 %\oµ
RPTM2 ii II Y ¨R
II ,/ PTM PTM3 V pi- 1 Z ,7 ZpTm / \
N
/ i ----__ HO N
PTM-Ia v /
"pi-m WPTM' 0 RPTM2 I I 0%
II \ Y
II ,,, PTM¨R PTM3 Vp-i-NIAI Z /7 Zpi-m \
RRPTM5 \ // H
.......--N Z / \
S
\ ¨_____ XPTM36 ....... XPTM38 N

PTM-Ib v "pi-m/
\NPTM-; µµ0%
IIII
Y ¨R
II , , PTM PTM3 Vpi-a Z /7 RPTM2a ZpTm / \RPTM2b -----_____.
N
PTM-Ic , wherein:
double dotted bonds are aromaric bonds;
VpTm, WpTM, XPTM, YPTM, ZPTM is one of the following combinations: C, CH, N, N, C; C, N, N, CH, C; C, 0, C, CH, C; C, S, C, CH, C; C, CH, C, 0, C; C, CH, C, S, C; C, CH, N, CH, C; N, CH, C, CH, C; C, CH, C, CH, N; N, N, C, CH, C; N, CH, C, N, C; C, CH, C, N, N; C, N, C, CH, N; C, N, C, N, C; and C, N, N, N, C;
Xplm35, XPTM36, XPTM37, and XPTM38 are independently selected from CH and N;
RpTM1 is covalently joined to a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof;
RPTM2 is hydrogen, halogen, aryl, methyl, ethyl, OCH3, NHCH3 or M1-CH2-CH2-M2, wherein Ml is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
RpTm2a and RPTM2b is hydrogen, OH, halogen;
RPTM3 is absent, hydrogen, aryl, methyl, ethyl, other alkyl, cyclic alkyl, OCH3, NHCH3 or M1-CH2-CH2-M2, wherein Ml is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
RpTM4 is hydrogen, halogen, aryl, methyl, ethyl, OCH3, NHCH3 or M1-CH2-CH2-M2, wherein Ml is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle; and RPTM5 is selected from the group consisting of F FN
N -------------------------- N --N..-----\
/N
\N \
/ -----) > -------------- ( /N -------------------- F ¨0-0 ---------------- F Ime¨ON ------- F ww--0- ------ F ________ ON
, F F
, N------\
\N 7 HO----) N N
/ HO HO\
HOV---j HO----....) /
HO
[0295] In any aspect or embodiment described herein, the PTM may comprise a chemical group selected from the group of chemical structures consisting of PTM-IIa or PTM-Ilb:
RPTM5a RPTM6a \ 0 RPTM7 1 \ XPTM3 RPTM9 f`PTM1% XPTM5 vRpTimi 0 RPTM6b /

/
RPTM6c PTM-IIa or RPTM6a RPTM5a RPTM8 \ 0 RPTM7 RPTM6b /

N
/
RPTM6c PTM-IIb , wherein:
XPTM1, XPTM2, XPTM3, XPTM4, XPTM5, and XpTM6 are independently selected from CH or N;
RpTm5a is selected from the group consisting of: bond, optionally substituted amine, optionally substituted amide (e.g., optionally substituted with an alkyl, methyl, ethyl, RPTM5 0 \ , /RPTM5b , \, S N/
- --, NH
, _ -propyl, or butyl group), H, ---"µ. - , ---.i. , -NHC(0)RpTm5;
RPTM5 is selected from the group consisting of F..............\ FN
N N --...------\ Fo_ F
N...-----\
/N
\N \

0 ------------- F Ime-ON ------- F ww-0.- ------- F _______ ON
..............\
, \, N------\ 7 HO'.....) , , F F

Z/
/N HO HO HO
\
HO'.....) /
HO
, RpTM5b is hydrogen or a linear or branched C1-C4 alkyl (e.g., methyl or ethyl);
Rm-m6a and RPTM6b are each independently selected from hydrogen, halogen, or optionally substituted linear or branched C1-C6 alkyl;
RpTM6 is absent, hydrogen, halogen, aryl, methyl, ethyl, OCH3, NHCH3 or M1-CH2-CH2-M2, wherein Ml is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
RpTM6c is hydrogen or a linear or branched C1-C4 alkyl (e.g., methyl or ethyl);
RpTM7 is absent, hydrogen, halogen, aryl, methyl, ethyl, 0CH3, NHCH3 or M1-CH2-CH2-M2, wherein Ml is CH2, 0 or NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
RpTmS, RPTM9 Or RPTM10 are independently selected from the group consisting of absent, hydrogen, halogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocycle, methyl, ethyl, 0CH3, NHCH3 or M1-CH2-CH2-M2, wherein Ml is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;

RpTmii is absent, hydrogen, halogen, methyl, ethyl, OCH3, NH CH3 or M 1-CH2-CH2-M2, wherein Ml is CH2, 0 or NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
and at least one of RPTM8, RPTM9 Or RPTM10 is modified to be covalently joined to a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof, or two of RPTM8, RPTM9, and RPTM10 are modified to form a polycyclic (e.g., bicyclic) fused ring with a chemical linker group.
[0296] In certain embodiments, the PTM may comprise a chemical group selected from the group of chemical structures consisting of:

\
" s, " ----NH
0 RPTM6a I

RPTM6 "PTM2 "PTM4 v 1 11 "PTM1 ........................,... _.,..õ. XPTM....5R Frmi 0 RPTM6b /

I
N

H
or \s, , 'NH
0 RPTM6a \.........../.=........ ,..,./. R PTM9 XPTM1....................õ,, N.,,................./"........
RPTM6b /

N

H
, wherein RPIM5, RPIM6a, RPIM6b, RpTM6, RpT1\47, Rpl-M8, RpTM9, Rp1M10, RpTmll are as described herein.
[0297] In some embodiments, when RpTm9 is the covalently joined position, RpTm7 and RpTms can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM7 and RPTM8 are attached.
[0298] In other embodiments, when RPTM8 is the covalently joined position, RPTM9 and RpTmlo can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM9 and RPTM10 are attached.
[0299] In further embodiments, when RPTM10 is the covalently joined position, RPTM8 and RpTm9 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM8 and RpTm9 are attached.
[0300] In any aspect or embodiment described herein, the PTM may comprise a chemical group selected from the group of chemical structures consisting of PTM-III:

\ .........,XPTM10 RPTM12 H oõ. XPTM17 0 RPTM17 XPTM1 .r XPTM9 i RPTM18 \ 1 1 y \
- -PTM20j XP-IN/..1.=,.............õ........ .../..XPTM....8 y 8 N XPTM 12 z,PTM19 x 11 I

\ N N

PTM-III
wherein:
XpTm7, XpTm8, XpTm9, XpT1\410, XPT1V111, XPTM12, XPTM13, XPTM14, XPT1VI15, XPT1VI16, XPTM17, XpTM18, XPTM19, XPTM20 are independently CH or N;
RpTm12, RPT1VI13, RPT1VI14, RPTM15, RPTM16, RPTM17, RPT1VI18, RPT1VI19 are independently selected from the group consisting of absent, hydrogen, halogen, aryl, heteroaryl, cycloalkyl, heterocycle, methyl, ethyl, other alkyl, OCH3, NHCH3 or M 1-CH2-CH2-M2, wherein Ml is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
RpTm20 is a small group containing less than four non-hydrogen atoms;

RpTA421 is selected from the group consisting of trifluoromethyl, chloro, bromo, fluoro, methyl, ethyl, propyl, isopropyl, tert-butyl, butyl, iso-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, OCH3, NHCH3, dimethylamino or M 1-CH2-CH2-M2, wherein Ml is CH2, 0 or NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle; and at least one of RPTM12, RPTM13 and RpTM16 is modified to be covalently joined to a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof.
[0301] In some embodiments, when RPTM12 is the covalently joined position, RPTM13 and RpTm14 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTm13 and Rplmi4 are attached; and/or Rplmi5 and RpTm16 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTm15 and RpTM16 are attached.
[0302] In other embodiments, when RPTM13 is the covalently joined position, RPTM12 and RpTm16 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTm12 and Rplmi6 are attached; and/or Rplmi5 and RpTm16 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTm15 and RpTM16 are attached.
[0303] In further embodiments, when RPTM16 is the covalently joined position, RPTM12 and RpTm13 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTm12 and Rplmi3 are attached; and/or Rplmi3 and RpTm14 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTm13 and RpTM14 are attached.
[0304] In any aspect or embodiment described herein, the PTM may comprise a chemical group selected from the group of chemical structures consisting of PTM-IVa or PTM-IVb:

\s, ,-- ------ NH
RPTM25a RPTM26 N
0 ..õ..- ' I /
RPTM25 ,,PTM29 ) \ ,, \

x \ N N .,..../ XPTM27 XPTM28 roo.
¨PTM22 .4"-4"--------RPTM25b XPTM26 RPTM30 /

_ 1 % APTM34 --------X733 XPTM25 \

/N \ II

RPTM23 \

PTM-IVa or \s, ,-- ----- NH
RPTM25a RPTM26 N

XPTM2 y .õ=0' .
I /

x \ N .....,..,XPTM27 XPTM28 Nizo ¨PT NM
22 "s"'"' / "PTM28 ----RPMT25b XPTM26 RPTM30 /

õ I
%.-----K APTM34---XPTM33 N
/ /

/ \

PTM-IVb , wherein:
XpTm21, XPTM22, XPTM23, XPTM24, XPTM25, XPTM26, XPTM27, XPTM28, XPTM29, XPTM30, XPTM31, XpTM32, XPTM33, XPTM34 are independently CH or N;
RpTm22 is selected from the group consisting of F....._____\ F
N.------\
N ------------------------ N --..-----N Fµc> F
--------------------------------------------------------------- /N
\N \

0 ---------------- Fiona-ON ------ Fmn.-0- -------- F _______ ON
/ HO F....._____\ F
, , N.-------\
\ '.......) /
N N
/ HO HO" HOZ/
HO'.......) /
HO
RPTM25a and RpTm25b are each independently selected from hydrogen, halogen, or Ci-C6 alkyl (linear, branched, optionally substituted);
RpTm23, RpTm24, RpTM28, RPTM29, RPTM30, RPTM31, RPTM32 are independently selected from the group consisting of absent, bond, hydrogen, halogen, aryl (optionally substituted), heteroaryl (optionally substituted), cycloalkyl (optionally substituted), heterocycle (optionally substituted), methyl, ethyl (optionally substituted), other alkyl (linear, branched, optionally substituted), OCH3, NHCH3 or M1-CH2-CH2-M2, wherein Ml is CH2, 0 and NH, and M2 is hydrogen, alkyl (linear, branched, optionally substituted), cyclic alkyl (optionally substituted), aryl (optionally substituted)or heterocycle (optionally substituted); and RpTM25 is absent, hydrogen, halogen, Ci-C6 alkyl (linear, branched, optionally substituted), OCH3, NHCH3 or SCH3;
RpTM26 is absent, hydrogen, halogen, Ci-C6 alkyl (linear, branched, optionally substituted), OCH3, NHCH3 or SCH3;
RpTm27 is selected from the group consisting of absent, hydrogen, halogen, Ci-C6 alkyl (linear, branched, optionally substituted), OCH3, NHCH3 or SCH3; and at least one of RPTM24, RPTM29, RPTM32 is modified to be covalently joined to a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof.
[0305] .In some embodiments, when RPTM24 is the covalently joined position, RPTM31 and RpTm32 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTm31 and RpTm32 are attached; or RPTM29 and RpTm30 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM29 and RPTM30 are attached.
[0306] In other embodiments, when RPTM29 is the covalently joined position, RPTM24 and RpTm32 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM24 and RpTm32 are attached; and/or RpTm3i and RpTm32 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTm31 and RpTM32 are attached.
[0307] In further embodiments, when RPTM32 is the covalently joined position, RPTM24 and RPTM29 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM24 and RPTM29 are attached; and/or RPTM29 and RPTM30 can be connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM29 and RpTM30 are attached.
[0308] In any aspect or embodiment described herein, the PTM may comprise a chemical group selected from the group of chemical structures consisting of PTM-Va or PTM-Vb:

\ XPTM36 /

(D PTM37 1'PTM37 H....,===******. "TM38 1 RPTM38 µ,,,,, or PTM-Va v 1 ,RPTM36 \ "PTM36 /

/
XPTM35 XPTM37 1'PTM37 1 v 1 N
^PTM38 v RPTM38 "PTM39 ., ,-, µ.., , PTM-Vb wherein:
XpTm35, XPTM36, XPTM37, XPTM38, and XPTM39 are independently CH or N;
RPTM33 is a halogen or a linear or branched C1-C4 haloalkyl;
RPTM34, Rpm, RPTM36, RPTM37, and RPTM38 are each independently selected from hydrogen, halogen, or linear or branched C1-C4 alkyl (e.g., methyl, ethyl, propyl, or butyl);
RpTm39 is an optionally substituted C4-C7 heterocycloalkyl (e.g., an optionally substituted C5 or C6 heterocycloalkyl); and N is the point of attachment with a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof.
[0309] In any aspect or embodiments described herein, the PTM is selected from the group consisting of chemical structures PTM-1, PTM-2, PTM-3, PTM-4, PTM-5, PTM-6, PTM-7, PTM-8, PTM-9, PTM-10, PTM-11, PTM-12, and PTM-13:

F, ,N N
HO N 0 ,-õ--IN N
H

P p s õ - NH õ
F N__--..,('6W 0 . NH 1 "

F H
N N F F
H

P
0\, H F
NH
SP" F 0 F
N õ 0 rN--N

N N
H

Nz-_¨\
/ 1 0\pH F
\S"
efit N
õ-- I
N 1 N F N\) F F
\N-$"-.1\1H
O F d F
I I
F /
N N N N
H H

, , , HO I N
I /N
/ \ H
CI O
CI
¨N

N
F F F (o)
[0310] .. In any aspect or embodiment described herein, the ULM is selected from the group consisting of:

-_ 0 __ _ _ - _ N N
,...14H 0 tIZH
0 .r1\1H

- - * = OH

- NR)r0 )r0 ---"\-\ 0 0 N `-' .rNH NH
OH

N /S

0 0 4 \I STh S
\--NH ---kd \ N
HN
OH
ii 0 .
bH

I
S \ N
lk D R14a "14a OH
0 Nv......0 ¨ = ONL.,.._ NH
H S ---\
0 R14a OH
OH
OH
N , N \ N
R14a OH
/ S
N-:-.--J
, wherein the R14a is a H, methyl or hydroxymethyl.
[0311] In any aspect or embodiment described herein, at least one of: (i) the PTM is selected from the PTMs of compounds 1-873 or 307-873 of the present disclosure; (ii) the chemical linker group (L) is selected from the linkers of compounds 1-873 or 307-873 of the present disclosure; (iii) the ULM is selected from the ULMs of compounds 1-873 or 307-873 of the present disclosure; (iv) the compound further comprises a prodrug chemical moiety selected from the PTMs of compounds 796-873, or (v) a combination thereof.
[0312] In any aspect or embodiment described herein, the ULM is selected from the group consisting of:

\o \ 00 00 'NH

..----\ F---No 00 N H
'NH

N )o N

R R

\,--\
0 0 )-----NO 0 0 NH 'NH

R R

0 0\ 1() 0 0 NH
'NH

R R

. 0 00' 00 NH CI 'NH

R R

F NH F NH
N ) 0 _________ N __ ? 0 R

NH N

R R

NH NH

R

NH R \ __ NH

\ __________________________________________________________________ NH

H
N

R R

NH _______________________________________ NH
Ni^-- ) __ 0 Niiii,.. \ ) __ 0 R R
HO\ OH

o 0 /-0 R N

i o1 H
NNH
N H

o pH p H

H

HN HN
F

H
NNH S S
\ \

pH gH QH

1\11-- .--I \I\I-;
, N
---- -N N - ------N
H H H

HN HN HN

S S S
\ \ N \

PH PH

-- N

HN HN
OH
110 1.
S S
N \ N \
pH pH pH

-----INN -'---IN -H H H
0HN/LO 0 0 0 1\fl HN HN ,/LO
OH

S S \ S
N \ N \ \ 0 N
pH pH

-'"--N ------N
H H

HN HN
/

S S
N \ N \

pH pH
0 p -- N
H H

HN HN
0--__ 7----../

110 o s s pH pH p H

- -----ININ *
H H H

S S S
N \ \ N \
N

pH pH

-----icli\ri-------jN
H H

HN HN

S s N \ \
\OH õ, pH
- \
I
N \
N.i NH NH
S fh \\ s .
\\ /
N/ N
CI CI
õ OH , õ, sOH
õ " \
\
Ni N Ni \

HN HN

S 4#
( / S *
( /
N N

H \OH \ \
N-0 N N-0 Ni HN HN

S * S 4#
N N
õ
N
N
=
P H \O
\
Ni HN HN H

S * S 4#
N N

\

S * S *
N N

\----\OH õµ
/ /NN
/
/N; N---N
--- N

NH NH
/S * /S *
/ /
N N

\/ HO,, ----,N
v C) tNi 0 0 HN
ro S
\ S
\----=---N
HO, C) HN

r0 .
-N
S
\---=----N

OH
, .--i INC
OH N".
--H

-- N

H
----N N
pH pH pH
, -- N
H H H

HN HN HN
OH
. \ .
N
N/ \
\ o pH o õIL

--- 1\---1-H

HN

S
N \

pH OH
H H

HN HN
0.....s.,..--...... ..,--. --...õ,,OH

0,..., S S
\ \
N N
OH pH
0 - 0 .õ
N.
H H

HN / HN

\ I
N and N .
Prodrug Bifunctional Compounds
[0313]
In any aspect or embodiment described herein, the bifunctional compound of the present disclosure or the prodrug thereof further includes a plurality of ethylene glycol units. In any aspect or embodiment described herein, the bifunctional compounds of the present disclosure or the prodrug thereof further includes at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more) polyethylene glycol (PEG) chain. In any aspect or embodiment described herein, the bifunctional compound of the present disclosure or the prodrug thereof further includes a plurality (e.g., 2, 3, 4, 5, 6, 7, 8, or more) polyethylene glycol chains that have uniform chain length or a mixture of chain lengths. In any aspect or embodiment described herein, the bifunctional compound or the prodrug thereof further includes a prodrug portion selected from exemplary compounds 796-873.
[0314] In any aspect or embodiment described herein, the bifunctional compound of the present disclosure or the prodrug thereof further includes at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more) polyethyelene glycol chain as described herein, wherein each polyethylene glycol chain is covalently linked to the bifunctional compound at the same point as the PEG
chain attachment in a compound selected from exemplary compounds 796-873. In any aspect or embodiment described herein, each PEG chain is attached directly or indirectly via a variable (e.g., via a methyl group or an 0) or in place of a variable of the VLM described herein (e.g., RP, R14a, R14b, W4, W5, RF, R2', R3'), the CLM described herein (e.g., G or G'), or a PTM as described herein (e.g., Rp1m6c). For example, in any aspect or embodiment described herein with a VLM, the RP, Ri4A, Ri4b, or a combination thereof is modified to be covalently linked (e.g., the hydroxyl group a of RP or RR1', the methyl group of R14, R14b, or W5 is modified to be covalently linked) directly or indirectly to a moiety that includes a PEG chain or is replaced with a moiety that includes a PEG chain. Additionally, in any aspect or embodiment described herein with a CLM, the G, G', or a combination thereof is modified to be covalently linked (e.g., they methyl of G or G' is modified to be covalently linked) directly or indirectly to a moiety that includes a PEG chain or is replaced with a moiety that includes a PEG chain.
[0315] In any aspect or embodiment described herein, the bifunctional compound of the present disclosure or the prodrug thereof includes at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more) ' '0A0C)OH ' -0)-LO -"I 0 L (jskOH - -13L0(3)`
k I r r r r r 0 r ., 0 00H
0 Or --1/y3sor 0 r 0 r 0 ' r 0 0) --1L40)' = ).
r r r r = , )=,0,0).
-,())0.(, Or I r \
I r N N =&./or - ,c)),r Nor ,,I.r N Vor '(.0) - "j-r k 0 r 0 r 0 r 0 r ,-1-0j-LN-03, 0 '0 H r H r r = ,(3,0j-N,C31) , lo J.N,t'(39 ,,k0j-LoO) I r I r r - ssN
N
r r , wherein r is an integer from 8 to 35 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35). For example, in any aspect or embodiment described herein with a VLM, the RP, R14A, R14b, or a combination thereof is modified to be a covalently linked (e.g., the hydroxyl group of RP, the methyl group of R14, R14b, or W5 is modified to be covalently linked) directly or indirectly to one of the above recited structures or is replaced with one of the above recited structures. Additionally, in any aspect or embodiment described herein with a CLM, the G, G', or a combination thereof is modified to be covalently linked (e.g., they methyl of G or G' is modified to be covalently linked) directly or indirectly to one of the above recited structures or is replaced with one of the above recited structures. For example, in any aspect or embodiment described herein, each PEG chain can be attached to the VLM, CLM, or PTM via a chemical group selected from:

'0 0' ,,LO, N
=
[0316] In any aspect or embodiment described herein, the polyethylene glycol chain of the bifunctional compound or prodrug thereof includes or is about 8 ethylene glycol units to about 35 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35), about 10 ethylene glycol units to about 35 ethylene glycol units (e.g., about 10 to about 35 ethylene glycol units, about 10 to about 30 ethylene glycol units, about 10 to about 25 ethylene glycol units, about 10 to about 20 ethylene glycol units, about 10 to about 15 ethylene glycol units, about 15 to about 35 ethylene glycol units, about 15 to about 30 ethylene glycol units, about 15 to about 25 ethylene glycol units, about 15 to about 20 ethylene glycol units, about 20 to about 35 ethylene glycol units, about 20 to about 30 ethylene glycol units, about 20 to about 25 ethylene glycol units, about 25 to about 35 ethylene glycol units, about 25 to about 30 ethylene glycol units, or about 30 to about 35 ethylene glycol units).
[0317] In any aspect or embodiment described herein, methoxy polyethylene glycol, or polyethylene-glycol capped with a methyl group on one end, having an average molecular weight of 1000 (such as mPEG-1000) may be used to prepare a prodrug bifunctional compounds of the present disclosure.
For example, in any aspect or embodiment, methoxy polyethylene glycol, or polyethylene-glycol capped with a methyl group on one end, having an average chain length of 22 units (such as mPEG-1000) may be used to prepare a prodrug bifunctional compounds of the present disclosure.
The methods described herein can be used to make longer or shorter PEG chains, of uniform or diverse chain lengths.
[0318] In any aspect or embodiment described herein, the prodrug bifunctional compound of the present disclosure has a percent release of at least about 10%. For example, in any aspect or embodiment described herein, the prodrug bifunctional compound of the present disclosure has a percent release of at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10%
to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 60% to about 90%, or about 60%
to about 80%, about 70% to about 90%, at about 30 minues, about 60 minues, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 4.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, or about 10 hours.
[0319] In any aspect or embodiment described herein, the prodrug bifunctional compound of the present disclosure has a half life of at least about 60 minutes. For example, in any aspect of embodiment described herein, the prodrug bifunctional compound of the present disclosure has a half life serum or plasma (e.g., human, cyano monkey, rat, mouse, pig, dog, cat, etc., serum or plasma) of less than or equal to about 1 minute, less than or equal to about 5 minutes, less than or equal to 10 minutes, less than or equal to about 15 minutes, less than or equal to about 30 minutes, less than or equal to about 45 minutes, less than or equal to about 1 hour, less than or equal to 1.5 hours, less than or equal to about 2 hours, less than or equal to about 2.5 hours, less than or equal to about 3 hours, less than or equal to about 3.5 hours, less than or equal to about 4 hours, less than or equal to 4.5 hours, less than or equal to about 5 hours, less than or equal to about 5.5 hours, less than or equal to about 6 hours, less than or equal to about 6.5 hours, less than or equal to about 7 hours, less than or equal to about 7.5 hours, less than or equal to about 8 hours, less than or equal to 8.5 hours, less than or equal to about 9 hours, less than or equal to 9.5 hours, less than or equal to about 10 hours, less than or equal to about 11 hours, less than or equal to about 12 hours, less than or equal to about 14 hours, less than or equal to about 16 hours, less than or equal to about 18 hours, less than or equal to about 20 hours, less than or equal to about 22 hours, less than or equal to about 24 hours, less than or equal to about 26 hours, less than or equal to about 28 hours, less than or equal to about 30 hours, less than or equal to about 32 hours, less than or equal to about 34 hours, less than or equal to about 36 hours, less than or equal to about 38 hours, less than or equal to about 40 hours, less than or equal to about 42 hours, less than or equal to about 44 hours, less than or equal to about 46 hours, less than or equal to about 48 hours, less than or equal to about 50 hours, about 15 seconds to about 50 hours, about 15 seconds to about 45 hours, about 15 seconds to about 40 hours, about 15 seconds to about 35 hours, about 15 seconds to about 30 hours, about 15 seconds to about 25 hours, about 15 seconds to about 20 hours, about 15 seconds to about 15 hours, about 15 seconds to about 10 hours, about 15 seconds to about 5 hours, about 30 seconds to about 50 hours, about 30 seconds to about 45 hours, about 30 seconds to about 40 hours, about 30 seconds to about 35 hours, about 30 seconds to about 30 hours, about 30 seconds to about 25 hours, about 30 seconds to about 20 hours, about 30 seconds to about 15 hours, about 30 seconds to about 10 hours, about 30 seconds to about 5 hours, about 1 minute to about 50 hours, about 1 minute to about 45 hours, about 1 minute to about 40 hours, about 1 minute to about 35 hours, about 1 minute to about 30 hours, about 1 minute to about 25 hours, about 1 minute to about 20 hours, about 1 minute to about 15 hours, about 1 minute to about 10 hours, about 1 minute to about 5 hours, about 1 to about 50 hours, about 1 to about 45 hours, about 1 to about 40 hours, about 1 to about 35 hours, about 1 to about 30 hours, about 1 to about 25 hours, about 1 to about 20 hours, about 1 to about 15 hours, about 1 to about 10 hours, about 1 to about 5 hours, about 5 to about 50 hours, about 5 to about 45 hours, about 5 to about 40 hours, about 5 to about 35 hours, about 5 to about 30 hours, about to about 25 hours, about 5 to about 20 hours, about 5 to about 15 hours, about 5 to about 10 hours, about 10 to about 50 hours, about 10 to about 45 hours, about 10 to about 40 hours, about to about 35 hours, about 10 to about 30 hours, about 10 to about 25 hours, about 10 to about 20 hours, about 15 to about 50 hours, about 15 to about 45 hours, about 15 to about 40 hours, about 15 to about 35 hours, about 15 to about 30 hours, about 15 to about 25 hours, about 20 to about 50 hours, about 20 to about 45 hours, about 20 to about 40 hours, about 20 to about 35 hours, about 20 to about 30 hours, about 25 to about 50 hours, about 25 to about 45 hours, about 25 to about 40 hours, about 25 to about 35 hours, about 30 to about 50 hours, about 30 to about 45 hours, about 30 to about 40 hours, about 35 to about 50 hours, about 35 to about 45 hours, about 40 to about 50 hours, in serum (e.g., human sera, monkey sera, dog sera, cat sera, pig sera, horse sera, etc.).
Therapeutic Compositions
[0320] Pharmaceutical compositions comprising combinations of an effective amount of at least one bifunctional compound as described herein, and one or more of the compounds otherwise described herein, all in effective amounts, in combination with a pharmaceutically effective amount of a carrier, additive or excipient, represents a further aspect of the present disclosure.
[0321] The present disclosure includes, where applicable, the compositions comprising the pharmaceutically acceptable salts, in particular, acid or base addition salts of compounds as described herein. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds useful according to this aspect are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3 naphthoate)[salts, among numerous others.
[0322] Pharmaceutically acceptable base addition salts may also be used to produce pharmaceutically acceptable salt forms of the compounds or derivatives according to the present disclosure. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of the present compounds that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (eg., potassium and sodium) and alkaline earth metal cations (eg, calcium, zinc and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines, among others.
[0323] The compounds as described herein may, in accordance with the disclosure, be administered in single or divided doses by the oral, parenteral or topical routes. Administration of the active compound may range from continuous (intravenous drip) to several oral administrations per day (for example, Q.I.D.) and may include oral, topical, parenteral, intramuscular, intravenous, sub-cutaneous, transdermal (which may include a penetration enhancement agent), buccal, sublingual and suppository administration, among other routes of administration. Enteric coated oral tablets may also be used to enhance bioavailability of the compounds from an oral route of administration. The most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen as well as the severity of disease in the patient. Administration of compounds according to the present disclosure as sprays, mists, or aerosols for intra-nasal, intra-tracheal or pulmonary administration may also be used. The present disclosure therefore also is directed to pharmaceutical compositions comprising an effective amount of compound as described herein, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient. Compounds according to the present disclosure may be administered in immediate release, intermediate release or sustained or controlled release forms. Sustained or controlled release forms are preferably administered orally, but also in suppository and transdermal or other topical forms.
Intramuscular injections in liposomal form may also be used to control or sustain the release of compound at an injection site.
[0324] The compositions as described herein may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and may also be administered in controlled-release formulations. Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[0325] The compositions as described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.
[0326] Sterile injectable forms of the compositions as described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol.
Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Hely or similar alcohol.
[0327] The pharmaceutical compositions as described herein may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
[0328] Alternatively, the pharmaceutical compositions as described herein may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient, which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
[0329] The pharmaceutical compositions as described herein may also be administered topically. Suitable topical formulations are readily prepared for each of these areas or organs.
Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-acceptable transdermal patches may also be used.
[0330] For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. In certain preferred aspects of the disclosure, the compounds may be coated onto a stent which is to be surgically implanted into a patient in order to inhibit or reduce the likelihood of occlusion occurring in the stent in the patient.
[0331] Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0332] For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
[0333] The pharmaceutical compositions as described herein may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
[0334] The amount of compound in a pharmaceutical composition as described herein that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host and disease treated, the particular mode of administration.
Preferably, the compositions should be formulated to contain between about 0.05 milligram to about 750 milligrams or more, more preferably about 1 milligram to about 600 milligrams, and even more preferably about 10 milligrams to about 500 milligrams of active ingredient, alone or in combination with at least one other compound according to the present disclosure.
[0335] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease or condition being treated.
[0336] A patient or subject in need of therapy using compounds according to the methods described herein can be treated by administering to the patient (subject) an effective amount of the compound according to the present disclosure including pharmaceutically acceptable salts, solvates or polymorphs, thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known erythopoiesis stimulating agents as otherwise identified herein.
[0337] These compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, including transdermally, in liquid, cream, gel, or solid form, or by aerosol form.
[0338] The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated. A
preferred dose of the active compound for all of the herein-mentioned conditions is in the range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient/patient per day. A typical topical dosage will range from 0.01-5% wt/wt in a suitable carrier.
[0339] The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing less than lmg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form. An oral dosage of about 25-250 mg is often convenient.
[0340] The active ingredient is preferably administered to achieve peak plasma concentrations of the active compound of about 0.00001-30 mM, preferably about 0.1-30 [tM.
This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient. Oral administration is also appropriate to generate effective plasma concentrations of active agent.
[0341] The concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
[0342] Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound or its prodrug derivative can be incorporated with excipients and used in the form of tablets, troches, or capsules.
Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
[0343] The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin;
or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
[0344] The active compound or pharmaceutically acceptable salt thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
[0345] The active compound or pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as erythropoietin stimulating agents, including EPO and darbapoietin alfa, among others. In certain preferred aspects of the disclosure, one or more compounds according to the present disclosure are coadministered with another bioactive agent, such as an erythropoietin stimulating agent or a would healing agent, including an antibiotic, as otherwise described herein.
[0346] Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens;
antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid;
buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[0347] If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
[0348] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
[0349] Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound are then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
Therapeutic Methods
[0350]
In an additional aspect, the description provides therapeutic compositions comprising an effective amount of a compound as described herein or salt form thereof, and a pharmaceutically acceptable carrier. The therapeutic compositions modulate protein degradation in a patient or subject, for example, an animal such as a human, and can be used for treating or ameliorating disease states or conditions which are modulated through the degraded protein.
[0351]
The terms "treat", "treating", and "treatment", etc., as used herein, refer to any action providing a benefit to a patient for which the present compounds may be administered, including the treatment of any disease state or condition which is modulated through the protein to which the present compounds bind.
Disease states or conditions, including cancer, cardiofaciocutaneous syndrome, neurofibromatosis type 1, Costello syndrome, Noonan Syndrome, LEOPARD (Lentigo, Electrocardiographic abnormalities, Ocular hypertelorism, or Pulmonary stenosis, Abnormal genitalia, Retarded growth, Deafness) syndrome, which may be treated using compounds according to the present disclosure are set forth hereinabove.
[0352]
The description provides therapeutic compositions as described herein for effectuating the degradation of proteins of interest for the treatment or amelioration of a disease, e.g., cancer, cardiofaciocutaneous syndrome, neurofibromatosis type 1, Costello syndrome, Noonan syndrome, or LEOPARD (Lentigo, Electrocardiographic abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retarded growth, Deafness) syndrome.
In certain additional embodiments, the disease is multiple myeloma. As such, in another aspect, the description provides a method of ubiquitinating/ degrading a target protein in a cell. In certain embodiments, the method comprises administering a bifunctional compound as described herein comprising, e.g., a ULM and a PTM, preferably linked through a linker moiety, as otherwise described herein, wherein the ULM is coupled to the PTM and wherein the ULM
recognizes a ubiquitin pathway protein (e.g., an ubiquitin ligase, such as an E3 ubiquitin ligase including cereblon, VHL, TAP, and/or MDM2) and the PTM recognizes the target protein such that degradation of the target protein will occur when the target protein is placed in proximity to the ubiquitin ligase, thus resulting in degradation/inhibition of the effects of the target protein and the control of protein levels. The control of protein levels afforded by the present disclosure provides treatment of a disease state or condition, which is modulated through the target protein by lowering the level of that protein in the cell, e.g., cell of a patient. In certain embodiments, the method comprises administering an effective amount of a compound as described herein, optionally including a pharamaceutically acceptable excipient, carrier, adjuvant, another bioactive agent or combination thereof.
[0353] In additional embodiments, the description provides methods for treating or ameliorating a disease, disorder or symptom thereof in a subject or a patient, e.g., an animal such as a human, comprising administering to a subject in need thereof a composition comprising an effective amount, e.g., a therapeutically effective amount, of a compound as described herein or salt form thereof, and a pharmaceutically acceptable excipient, carrier, adjuvant, another bioactive agent or combination thereof, wherein the composition is effective for treating or ameliorating the disease or disorder or symptom thereof in the subject.
[0354] In another aspect, the description provides methods for identifying the effects of the degradation of proteins of interest in a biological system using compounds according to the present disclosure.
[0355] In another embodiment, the present disclosure is directed to a method of treating a human patient in need for a disease state or condition modulated through a protein where the degradation of that protein will produce a therapeutic effect in the patient, the method comprising administering to a patient in need an effective amount of a compound according to the present disclosure, optionally in combination with another bioactive agent. The disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus, bacteria, fungus, protozoa or other microbe or may be a disease state, which is caused by overexpression and/or overactivation (e.g., a constitutively active) of a protein, which leads to a disease state and/or condition
[0356] The term "disease state or condition" is used to describe any disease state or condition wherein protein dysregulation (i.e., the amount of protein expressed in a patient is elevated) occurs and where degradation of one or more proteins in a patient may provide beneficial therapy or relief of symptoms to a patient in need thereof. In certain instances, the disease state or condition may be cured.
[0357] Disease states or conditions which may be treated using compounds according to the present disclosure include, for example, asthma, autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot¨Marie¨Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKD1) or 4 (PKD2) Prader¨
Willi syndrome, Sickle-cell disease, Tay¨Sachs disease, Turner syndrome.
[0358] The term "neoplasia" or "cancer" is used throughout the specification to refer to the pathological process that results in the formation and growth of a cancerous or malignant neoplasm, i.e., abnormal tissue that grows by cellular proliferation, often more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease. Malignant neoplasms show partial or complete lack of structural organization and functional coordination with the normal tissue and most invade surrounding tissues, metastasize to several sites, and are likely to recur after attempted removal and to cause the death of the patient unless adequately treated. As used herein, the term neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic and solid tumors. Exemplary cancers which may be treated by the present compounds either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas. Additional cancers which may be treated using compounds according to the present disclosure include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML.
[0359] The term "bioactive agent" is used to describe an agent, other than a compound according to the present disclosure, which is used in combination with the present compounds as an agent with biological activity to assist in effecting an intended therapy, inhibition and/or prevention/prophylaxis for which the present compounds are used. Preferred bioactive agents for use herein include those agents which have pharmacological activity similar to that for which the present compounds are used or administered and include for example, anti-cancer agents, antiviral agents, especially including anti-HIV agents, anti-retrovirus and anti-HCV agents, antimicrobial agents, antifungal agents, etc.
[0360] The term "additional anti-cancer agent" is used to describe an anti-cancer agent, which may be combined with compounds according to the present disclosure to treat cancer.
These agents include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK
inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bc1-2 inhibitor, an HDAC
inhbitor, a c-MET
inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK
inhibitor, an anti-HGF antibody, a PI3 kinase inhibitor, an AKT inhibitor, an mTORC1/2 inhibitor, a JAK/STAT inhibitor, a checkpoint-1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (mek) inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC
8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdRi KRX-0402, lucanthone, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib;
PD0325901, AZD-6244, capecitabine, L-Glutamic acid, N-[442-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d[pyrimidin-5-yl)ethyl[benzoyll-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHlR-258); 3-[5-(methylsulfonylpiperadinemethyl)- indolyl-quinolone, vatalanib, AG-013736, AVE-0005, goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW-572016, Ionafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951 , aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291 , squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox,gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS- 247550, BMS -310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR- 3339, ZK186619, topotecan, PTK787/ZK 222584, VX-745, PD
184352, rapamycin, 40-0-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-1 receptor antagonist, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa and mixtures thereof.
[0361] The term "anti-HIV agent", "anti-retroviral", or "additional anti-HIV agent" includes, for example, nucleoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptase inhibitors (i.e., those which are not representative of the present disclosure), protease inhibitors, fusion inhibitors, among others, exemplary compounds of which may include, for example, 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI
(Didanosine), ddC
(zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T
(Stavudine), Racivir, L-FddC, L-FD4C, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM
(Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV
(Nelfinavir), APV
(Amprenavir), LPV (Lopinavir), fusion inhibitors such as T20, among others, fuseon and mixtures thereof, including anti-HIV compounds presently in clinical trials or in development.
[0362] Other anti-HIV/anti-retrovirual agents which may be used in coadministration with compounds according to the present disclosure include, for example, other NNRTI' s (i.e., other than the NNRTI' s according to the present disclosure) may be selected from the group consisting of nevirapine (BI-R6-587), delavirdine (U-90152S/T), efavirenz (DMP-266), UC-781 (N-[4-chloro-3 -(3 -methyl-2-butenyloxy)phenyl] -2methy13-furancarbothiamide), etravirine (TMC 125), Trovirdine (Ly300046.HC1), MKC-442 (emivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II
(Methyl 3' ,3' -dichloro-4' ,4"-dimethoxy-5',5"-bis(methoxycarbony1)-6,6-diphenylhexenoate), Methyl 3-Bromo-5-(1-5-bromo-4-methoxy-3 -(methoxyc arb onyl)phenyl)hept-l-eny1)-2-methoxybenzoate (Alkenyldiarylmethane analog, Adam analog), (5-chloro-3-(phenylsulfiny1)-2'-indolecarboxamide), AAP-BHAP (U-104489 or PNU-104489), Capravirine (AG-1549, S-1153), atevirdine (U-87201E), aurin tricarboxylic acid (SD-095345), 1-[(6-cyano-2-indolyl)carbonyl] -4- [3 -(is oprop ylamino)-2-p yridinyl] piperazine, 1-[5-[[N-(methyl)methylsulfonylamino]-2-indolylcarbony1-4- [3 -(is oprop ylamino)-2-p yridinyl] piperazine, 1- [3 -(Ethylamino)-2- [pyridinyl] -4- [(5-hydroxy-2-indolyl)carbonyl]piperazine, 1-[(6-Formy1-2-indolyl)carbonyl]-443-(isopropylamino)-2-pyridinyl]piperazine, 1- [[5-(Methylsulfonyloxy)-2-indoyly)carbony1]-4- [3-(isopropylamino)-2-pyridinyl]piperazine, U8 8204E, Bis(2-nitrophenyl)sulfone (NSC 633001), Calanolide A (NSC675451), Calanolide B, 6-B enzy1-5-methy1-2-(cyclohexyloxy)pyrimidin-4-one (DABO-546), DPC 961, E-EBU, E-EBU-dm, E-EPSeU, E-EPU, Foscarnet (Foscavir), HEPT (1-[(2-Hydroxyethoxy)methy1]-6-(phenylthio)thymine), HEPT-M (1- [(2-Hydroxyethoxy)methyl] -6-(3-methylphenyl)thio)thymine), HEPT-S
(1-[(2-Hydroxyethoxy)methy1]-6-(phenylthio)-2-thiothymine), Inophyllum P, L-737,126, Michellamine A (NSC650898), Michellamine B (NSC649324), Michellamine F, 6-(3,5-Dimethylbenz y1)- 1- [(2-hydroxyethoxy)methyl] -5-isopropyluracil, 6-(3,5-Dimethylbenzy1)-1-(ethyoxymethyl)-5-isopropyluracil, NPPS, E-BPTU (NSC 648400), Oltipraz (4-Methy1-5-(pyraziny1)-3H-1,2-dithiole-3-thione), N-12-(2-Chloro-6-fluorophenethyl] -N' -(2-thiazolyl)thiourea (PETT Cl, F derivative), N-12-(2,6-Difluorophenethyl] -N' -[245-bromop yridyl)] thiourea 1PETT
derivative), N-12-(2,6-Difluorophenethyl] -N' - [245-methylpyridyNthiourea 1PETT Pyridyl derivative), N-[2-(3-Fluorofuranyl)ethyl]-N' - [245-chlorop yridyl)] thiourea, N- [2-(2-Fluoro-6-ethoxyphenethyl)] -N' - [2-(5-bromopyridy1)] thiourea, N-(2-Phenethyl)-N'-(2-thiazolyl)thiourea (LY-73497), L-697,639, L-697,593, L-697,661, 342-(4,7-Difluorobenzoxazol-2-yl)ethyl } -5-ethyl-6-methyl(pypridin-2(1H)-thione (2-Pyridinone Derivative), 3- [[(2-Methoxy-5,6-dimethy1-3-pyridyl)methyl] amine] -5-ethy1-6-methyl(pypridin-2(1H)-thione, R82150, R82913, R87232, R88703, R89439 (Loviride), R90385, S-2720, Suramin Sodium, TBZ (Thiazolobenzimidazole, NSC 625487), Thiazoloisoindo1-5-one, (+)(R)-9b-(3,5-Dimethylpheny1-2,3-dihydrothiazolo [2,3-a] isoindo1-5(9bH)-one, Tivirapine (R86183), UC -38 and UC-84, among others.
[0363] The term "pharmaceutically acceptable salt" is used throughout the specification to describe, where applicable, a salt form of one or more of the compounds described herein which are presented to increase the solubility of the compound in the gastic juices of the patient's gastrointestinal tract in order to promote dissolution and the bioavailability of the compounds.
Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids, where applicable. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, among numerous other acids and bases well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralization salts of the phosphates according to the present disclosure.
[0364] The term "pharmaceutically acceptable derivative" is used throughout the specification to describe any pharmaceutically acceptable prodrug form (such as an ester, amide other prodrug group), which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.
General Synthetic Approach
[0365] The synthetic realization and optimization of the bifunctional molecules as described herein may be approached in a step-wise or modular fashion. For example, identification of compounds that bind to the target molecules can involve high or medium throughput screening campaigns if no suitable ligands are immediately available. It is not unusual for initial ligands to require iterative design and optimization cycles to improve suboptimal aspects as identified by data from suitable in vitro and pharmacological and/or ADMET assays. Part of the optimization/SAR campaign would be to probe positions of the ligand that are tolerant of substitution and that might be suitable places on which to attach the linker chemistry previously referred to herein. Where crystallographic or NMR structural data are available, these can be used to focus such a synthetic effort.
[0366] In a very analogous way one can identify and optimize ligands for an E3 Ligase, i.e.
ULMs/ILMs/VLMs/CLMs/ILMs.
[0367] With PTMs and ULMs (e.g. ILMs, VLMs, CLMs, and/or ILMs) in hand, one skilled in the art can use known synthetic methods for their combination with or without a linker moiety.
Linker moieties can be synthesized with a range of compositions, lengths and flexibility and functionalized such that the PTM and ULM groups can be attached sequentially to distal ends of the linker. Thus a library of bifunctional molecules can be realized and profiled in in vitro and in vivo pharmacological and ADMET/PK studies. As with the PTM and ULM groups, the final bifunctional molecules can be subject to iterative design and optimization cycles in order to identify molecules with desirable properties.
[0368] In some instances, protecting group strategies and/or functional group interconversions (FGIs) may be required to facilitate the preparation of the desired materials.
Such chemical processes are well known to the synthetic organic chemist and many of these may be found in texts such as "Greene's Protective Groups in Organic Synthesis"
Peter G. M. Wuts and Theodora W. Greene (Wiley), and "Organic Synthesis: The Disconnection Approach" Stuart Warren and Paul Wyatt (Wiley).
[0369] List of Abbreviations
[0370] AcOH, acetic acid
[0371] aq., aqueous
[0372] BINAP, 2,2 '-bis(diphenylphosphino)-1,1 '-binaphthalene
[0373] Boc, tert-butoxycarbonyl
[0374] Boc20, di-tert-butyl dicarbonate
[0375] BOP, (benzotriazol-1- yloxy)tris(dimethylamino)phosphonium hex afluoropho sphate
[0376] CDC13, deuteriochloroform
[0377] CD30D, deuteriomethanol
[0378] CH3CN, acetonitrile
[0379] CH3OH, methanol
[0380] CsF, cesium fluoride
[0381] Cs2CO3, cesium carbonate
[0382] Cu(OAc)2, copper (II) acetate
[0383] Cy2NMe, dicyclohexylmethylamine
[0384] DCM, dichloromethane
[0385] DIAD, diisopropyl azodicarboxylate
[0386] DIEA or DIPEA, diisopropylethylamine
[0387] DMAP, N,N-dimethylaminopyridine
[0388] DMF, N,N-dimethylformamide
[0389] DMSO, dimethylsulfoxide
[0390] DMSO-d6, hexadeuterodimethyl sulfoxide
[0391] Et2NH, diethylamine
[0392] Et0Ac or EA, ethyl acetate
[0393] HC1, hydrochloric acid
[0394] H20, water
[0395] HPLC, high performance liquid chromatography
[0396] IBX, 2-iodoxybenzoic acid
[0397] KOAc, potassium acetate
[0398] LCMS, liquid chromatography / mass spectrometry
[0399] Li0H, lithium hydroxide
[0400] Me0H, methanol
[0401] MsCl, methanesulfonyl chloride
[0402] N2, nitrogen
[0403] NaH, sodium hydride
[0404] NaBH3CN, sodium cyanoborohydride
[0405] NaBH(OAc)3, sodium triacetoxyborohydride
[0406] NaCl, sodium chloride
[0407] NaHCO3, sodium bicarbonate
[0408] NaI, sodium iodide
[0409] Na2SO4, sodium sulfate
[0410] n-BuLi, n-butyllithium
[0411] NH3, ammonia
[0412] NH4C1, ammonium chloride
[0413] NH2OH HC1, hydroxylamine hydrochloride
[0414] NMP, N-methylpyrrolidone
[0415] NMR, nuclear magnetic resonance
[0416] 02, oxygen
[0417] Pd(aMPhos)C12, bis(di-tert-buty1(4-dimethylaminophenyl)phosphine)dichloropalladium(II)
[0418] Pd2(dba)3, tris(dibenzylideneacetone)dipalladium(0)
[0419] Pd(dppf)C12, [1,11-bis(diphenylphosphino)ferrocene[dichloropalladium(II)
[0420] Pd(OH)2, palladium hydroxide
[0421] Pd(PPh3)4, tetrakis(triphenylphosphine)palladium(0)
[0422] PE, petroleum ether
[0423] Ph3P, triphenylphosphine
[0424] Py, pyridine
[0425] PyB OP, (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
[0426] rt, room temperature
[0427] TBAF, tetra-n-butylammonium fluoride
[0428] TBDPSC1, tert-butyldiphenylsilyl chloride
[0429] TB S, tert-butyldimethylsilyl
[0430] tBuOK, potassium tert-butoxide
[0431] [tBu3PH[BF4, tri-tert-butyl phosphonium tetrafluoroborate
[0432] TEA, triethylamine
[0433] THF, tetrahydrofuran
[0434] TLC, thin layer chromatography
[0435] TMS OTf, trimethylsilyl trifluoromethanesulfonate
[0436] TsCl, p-toluenesufonyl chloride
[0437] Ts0H, p-toluenesulfonic acid
[0438] Scheme 1A.
F., F
c2N- 2 0 s, ii N
0 H F , i m' + __ M-Ar-L ________________ G-PG .. _ / \
HN
I N II
F
F
---- F
---HN
Ar-L-GH
III IV N-F

op N_ a 0 ,0 F
;S/, Y
X-L' V 0/ N

HN / \ Ar-L-Gre-L'ia Y' VI n N-[0430] A compound of formula I may be reacted with a reagent II
(commercially available or readily prepared using standard reaction techniques known to one skilled in the art) under palladium-catalyzed cross-coupling conditions, e.g. with a suitable palladium catalyst such as bis(di-tert-buty1(4-dimethylaminophenyl)phosphine)dichloropalladium(II), suitable base such as cesium fluoride, suitable solvent such as mixtures of 1,4-dioxane and water, at a suitable temperature such as 100 C, with or without microwave irradiation to produce a compound of formula III. One of M or M' represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane; the other of M
or M' represents a functional group capable of undergoing palladium-catalyzed oxidative addition, e.g. an iodide, bromide, chloride, or trifluoromethanesulfonate; Ar represents an aromatic or heteroaromatic ring system; L represents an optional linker or portion of a linker, GI¨PG represents a primary or secondary amine, optionally cyclized into a 4 to 8 membered heterocyclic ring, wherein PG represents a suitable protecting group, including but not limited to t-butoxycarbonyl or benzyl. Compounds of formula III may be converted to a compound of formula IV by treatment with a reagent suitable for the removal of PG, e.g.
hydrogen chloride in 1,4-dioxane when PG is t-butoxycarbonyl. Compound IV may then be reacted with compound V
to produce compound VI, wherein L' represents an optional linker or portion of a linker, Y is CH2 or C=0, and X is either a suitable leaving group (e.g. OMs, OTs, Cl, etc.) or an aldehyde (CHO). When X is a leaving group, n is 0, and suitable reaction conditions are those for an alkylation reaction, e.g. diisopropylethylamine, potassium iodide, DMSO or acetonitrile, 80 C.
When X is an aldehyde, n is 1, and suitable reaction conditions are those for a reductive amination reaction, e.g. sodium cyanoborohydride, methanol, dichloromethane, acetic acid, room temperature.
[0440] Scheme 1B.

s, o N
+ M-Ar-L¨G-PG _____________________________________________________ /
I
Z'' N
F
F
ZI F _______________________________ ) I
Z
..--- F
----,N / \ Ar-L¨GH
N-III IV N-O F
R
r( N-W
X -L' ,S/, F

i 0 R 0 ________________ . Z F
--- N-W
VI /
N / \ Ar-L¨G-H-L' /.-Y
Z' n N-[0441] A compound of formula I may be reacted with a reagent II
(commercially available or readily prepared using standard reaction techniques known to one skilled in the art) under palladium-catalyzed cross-coupling conditions, e.g. with a suitable palladium catalyst such as bis(di-tert-buty1(4-dimethylaminophenyl)phosphine)dichloropalladium(II), suitable base such as cesium fluoride, suitable solvent such as mixtures of 1,4-dioxane and water, at a suitable temperature such as 100 C, with or without microwave irradiation to produce a compound of formula III. One of M or M' represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane; the other of M
or M' represents a functional group capable of undergoing palladium-catalyzed oxidative addition, e.g. an iodide, bromide, chloride, or trifluoromethanesulfonate; Z
and Z' are each independently H or a suitable protecting group such as t-butoxycarbonyl; Ar represents an aromatic or heteroaromatic ring system; L represents an optional linker or portion of a linker, GI¨PG represents a primary or secondary amine, optionally cyclized into a 4 to 8 membered heterocyclic ring and/or fused to Ar, wherein PG represents a suitable protecting group, including but not limited to t-butoxycarbonyl or benzyl. Compounds of formula III may be converted to a compound of formula IV by treatment with a reagent suitable for the removal of PG, e.g. hydrogen chloride in 1,4-dioxane when PG is t-butoxycarbonyl.
Compound IV may then be reacted with compound V to produce compound VI, wherein L' represents an optional linker or portion of a linker, Y is CH2 or C=0, X is either a suitable leaving group (e.g. OMs, OTs, Cl, etc.) or an aldehyde (CHO), and R is an optional substituent (e.g. F
or OCH3), and W is:
CD,N H2 H

-- or 0 .
[0442] When X is a leaving group, n is 0, and suitable reaction conditions are those for an alkylation reaction, e.g. diisopropylethylamine, potassium iodide, DMSO or acetonitrile, 80 C.
When X is an aldehyde, n is 1, and suitable reaction conditions are those for a reductive amination reaction, e.g. sodium cyanoborohydride, methanol, dichloromethane, acetic acid, room temperature. As needed, mixtures of enantiomers or diastereomers of any compounds IV, V, or VI may be resolved into their constituent enantiomers or diastereomers using techniques known to one skilled in the art, including but not limited to preparative high performance liquid chromatography or preparative supercritical fluid chromatography.

[0443] In cases where W is 0 , the compound VI may be treated with conditions suitable for imide cyclization, e.g. benzenesulfonic acid in acetonitrile or N-methylpyrrolidone at 100 C to afford a different compound of formula VI where W is H

j -- .
[0444] In cases where one or both of Z or Z' are a protecting group, such protecting group may be removed from a compound VI, e.g. by treatment with trifluoroacetic acid when Z and/or Z' are t-butoxycarbonyl, to afford a different compound of formula VI wherein Z and Z' are H.
[0445] It will further be apparent to one skilled in the art that the positions of GI-PG in II
and X in V may be reversed throughout the synthetic sequence, such that the positions of G
and - \ 1- are reversed in compound VI. In such cases, X may also be CH2OH or an aldehyde protected e.g. as its acetal, and may be converted to a compound where X is CHO by oxidation of the alcohol, e.g. with Dess-Martin periodinane, or deprotection of the acetal, e.g. with Amberlyst 15 in acetone and water at reflux, prior to reaction with V.
[0446] Scheme 2.

as /0 X
VII
HN Ar-L-G1H
IV N-W
CL,N 0 HN Ar-L-G1/ Y
VIII
N-[0447] A
compound of formula IV may also be reacted with a compound of formula VII to provide compounds of formula VIII, wherein X is a suitable leaving group such as fluorine or chlorine, Y is C=0, R represents one or more optional substituents, W is H or CH3, and reaction conditions are those for a nucleophilic aromatic substitution, e.g.
triethylamine, DMSO, 70 C.
[0448] Scheme 3A.

F_, F
+ M-Ar-L-r S, HN
I N IX
F F
H H
________________________________________ ----- \ j---0 --- j-OH
HN / Ar-L HN / \ Ar-L
X N- XI Z
N-N
H
HO"' N(:) c?--- ,N

;Si, F OH
-Oi N 0 >cNH2 XII H
F
----HN / \ Ar-L 0 Z
N-4.
XIII
S \
N
[0449] A compound of formula I may be reacted with a reagent IX
(commercially available or readily prepared using standard reaction techniques known to one skilled in the art) under palladium-catalyzed cross-coupling conditions, e.g. as shown in Scheme 1A or 1B, to produce a compound of formula X. One of M or M' represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane; the other of M or M' represents a functional group capable of undergoing palladium-catalyzed oxidative addition, e.g. an iodide, bromide, chloride, or trifluoromethanesulfonate; Ar represents an aromatic or heteroaromatic ring system; L represents an optional linker or portion of a linker, and PG represents a suitable ester protecting group, e.g. methyl, ethyl, or t-butyl. Compounds of formula X may be converted to a compound of formula XI by treatment with a reagent suitable for the removal of PG, e.g. hydrogen chloride in 1,4-dioxane when PG is t-butyl. Compound XI

may then be reacted with compound XII, wherein Z is an optional substituent, e.g. H, methyl, or hydroxymethyl, to produce compounds of formula XIII under amide formation conditions, e.g.
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate, diisopropylethylamine, DMF, room temperature.
[0450] Scheme 3B.
F., F
c:N, 2 0 S, + M-Ar-L-)_ N , W
F F
I H
W F 0 PG ___________ ).

..--. d ..--. j-OH
WN / \ Ar-L---"-- HN / \ Ar-L
N-O R F
H / Y
HO-e: 0 a, ,;0 F OH
,S
)cXNH2 XII H F 0 0 .--,-NH 0 HN
Ar-L sZ
N-41tR
XIII
Y
[0451] A compound of formula I' may be reacted with a reagent IX
(commercially available or readily prepared using standard reaction techniques known to one skilled in the art) under palladium-catalyzed cross-coupling conditions, e.g. as shown in Scheme 1A or 1B, to produce a compound of formula X. One of M or M' represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane; the other of M or M' represents a functional group capable of undergoing palladium-catalyzed oxidative addition, e.g. an iodide, bromide, chloride, or trifluoromethanesulfonate; Ar represents an aromatic or heteroaromatic ring system; L represents an optional linker or portion of a linker;
PG represents a suitable ester protecting group, e.g. methyl, ethyl, or t-butyl; and W represents an optional protecting group, e.g. 2-(trimethylsilyl)ethoxymethyl. Where necessary, e.g. when L
contains a primary or secondary amine or an alcohol, such functional groups may be optionally protected with a suitable protecting group, e.g. t-butoxycarbonyl when the functional group is an amine or t-butyldimethylsilyl when the functional group is an alcohol.
Compounds of formula X
may be converted to a compound of formula XI by treatment with a reagent suitable for the removal of the optional W, e.g. hydrogen chloride in 1,4-dioxane and methanol or ethylenediamine and tetra-n-butylammonium fluoride when W is 2-(trimethylsilyl)ethoxymethyl;
followed by treatment with a reagent suitable for the removal of PG, e.g.
hydrogen chloride in 1,4-dioxane when PG is t-butyl. Compound XI may then be reacted with compound XII, wherein Z is an optionally substituted carbon, e.g. CH2, CD2, CH(Me), CH(CH2OH), C(CH3)2, R
is an optional substituent, e.g. F or CH2OH, and Y is an optional substituent, e.g. halogen, CN, or optionally substituted aryl or heterocyclyl, to produce compounds of formula XIII under amide formation conditions, e.g. (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate, diisopropylethylamine, DMF, room temperature. It will be apparent to one skilled in the art that when L contains a protected amine or alcohol, such protecting group may be removed as needed at the stage of compound X, XI, or XIII, e.g. by treatment with trifluoroacetic acid when said protecting group is t-butoxycarbonyl or hydrochloric acid in methanol when said protecting group is t-butyldimethylsilyl.
[0452] Scheme 4A.
OH
_ M-Ar-L->1_ M-Ar-L
R -)r _,.... OH + XII -,- M-Ar-L Z

IX XIV XV .
S \
L, N
I
__________ . XIII

[0453] Alternatively, a compound of formula IX may be converted to a compound of formula XIV by using conditions analogous to those for the conversion of X to XI in Scheme 3A
or 3B. A compound of formula XIV may be converted to a compound of formula XV
by using conditions analogous to those for the conversion of XI to XIII in Scheme 3A or 3B. A
compound of formula XV may then be converted to a compound of formula XIII by reaction with a compound of formula I using conditions analogous to those for the conversion of I and IX
to X in Scheme 3A or 3B.
[0454] Scheme 4B.
OH

j-NEI 0 HN
0 OH + X I I M-Ar-L
0 'PG 0 IX XIV XV
XIII
[0455] Alternatively, a compound of formula IX may be converted to a compound of formula XIV by using conditions analogous to those for the conversion of X to XI in Scheme 3A
or 3B. A compound of formula XIV may be converted to a compound of formula XV
by using conditions analogous to those for the conversion of XI to XIII in Scheme 3A or 3B. A
compound of formula XV may then be converted to a compound of formula XIII by reaction with a compound of formula I' using conditions analogous to those for the conversion of I' and IX to X, followed by optional deprotection of W, in Scheme 3B.

[0456] Scheme 5.
Br Br N
,NH + M'Ar -L-G-PG _________________________ , r-----\-r----\
---.. N-Ar-L-GI-PG ..- -..
N

N N
XVI II' XVII
M-Ar' Arr____\
Ar' XVIII e N-Ar-L-GH

XIX XX

1101 X ,N-- 0 NH
Y Ar 1101 , N-t 0 -- Y
VII
-... ,N-Ar-L-G
I N
_________________ ..-N/
XXI
[0457] A compound of formula XVI may be reacted with a reagent II' (commercially available or readily prepared using standard reaction techniques known to one skilled in the art) under Chan-Lam cross-coupling conditions, e.g. copper (II) acetate, pyridine or diethylamine or triethylamine, 100 C, to produce a compound of formula XVII. M' represents a boronic acid or boronic ester; Ar represents an aromatic or heteroaromatic ring system; L
represents an optional linker, 5-PG represents a primary or secondary amine, optionally cyclized into a 4 to 8 membered heterocyclic ring, wherein PG represents a suitable protecting group, including but not limited to t-butoxycarbonyl or benzyl. Compounds of formula XVII may be may be reacted with a reagent XVIII under palladium-catalyzed cross-coupling conditions, e.g.
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, tri-tert-butylphosphine tetrafluoroborate, cesium fluoride, 1,4-dioxane, 90 C, to produce a compound of formula XIX. M
represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane and Ar' represents an aromatic or heteroaromatic ring system with optional substituents. A compound of formula XIX may then be converted to a compound of formula XX by treatment with a reagent suitable for the removal of PG, e.g.
hydrogen chloride in 1,4-dioxane or methanol when PG is t-butyl. A compound of formula XX may also be reacted with a compound of formula VII to provide compounds of formula XXI, wherein X is a suitable leaving group such as fluorine or chlorine, Y is C=0, the aromatic ring of VII may have further optional substituents, and reaction conditions are those for a nucleophilic aromatic substitution, e.g. triethylamine, DMSO, 80 C. In cases where the group Ar' contains optional substituents, e.g. a ketone, these may undergo further functionalization, e.g.
by treatment with hydroxylamine hydrochloride and pyridine at room temperature, to provide further compounds of formula XXI.
[0458] Scheme 6.
Br Br -PG _______ ,N-Ar-L-G1 ,N-Ar-L-G1 N N
XXII
XVII

XVIII
,N1_,\-NH
Br XXI
VII
N

XXIII
[0459] Alternatively, a compound of formula XVII may be converted to a compound of formula XXII by using conditions analogous to those for the conversion of XIX
to XX in Scheme 5. A compound of formula XXII may then be treated with a compound of formula VII
as defined in Scheme 5 to produce a compound of formula XXIII. The compound of formula XXIII may then be treated with a reagent XVIII as defined in Scheme 5 to produce a compound of formula XXI. In cases where the group Ar' contains optional substituents, e.g. a ketone, these may undergo further functionalization, e.g. by treatment with hydroxylamine hydrochloride and pyridine at room temperature, to provide further compounds of formula XXI.

[0460] Scheme 7.

0 y,N-tiO NH
0Br HC-L' (110 ,N_.\- 0 Y
, ,N-Ar-L-CHO X BrXV i-ND-L' N ___________________________________ .
N-Ar-L
\ ---N=
N / I
N / XXVI
XXIV

_ti:11-1 401 ,N 0 Ar' XVIII
_________________ ).- , ,N-Ar-L
N
I
N / XXVII
[0461] A compound of formula XXIV (prepared in an analogous manner to the preparation of XVII from XVI and II' in Scheme 5, with additional functional group transformations as necessary, which are well known to one skilled in the art) may be reacted with a compound of formula XXV to prepare a compound of formula XXVI under reductive amination conditions, e.g. sodium cyanoborohydride, acetic acid, methanol, room temperature. Herein Ar represents an aromatic or heteroaromatic ring system; L and L' represent an optional linker or portion of a linker, HO represents a primary or secondary amine, optionally cyclized into a 4 to 8 membered heterocyclic ring, and Y is CH2 or C=0. A compound of formula XXVI
may then be treated with a reagent XVIII as defined in Scheme 5 to produce a compound of formula XXVII.
In cases where the group Ar' contains optional substituents, e.g. a ketone, these may undergo further functionalization, e.g. by treatment with hydroxylamine hydrochloride and pyridine at room temperature, to provide further compounds of formula XVII.

[0462] Scheme 8.

/\
$10 y,N- 01 tiO _tNH
N ,N 0 Br OHC-L' Br Y
-- XXVIII
N-Ar-L-GH ___________________________________________ /0 L' ,.. , ..-1 \ N

N /
XXII XXVI' t_ NH
1110 ,N 0 /\ Y
Ar XVIII At /GI L' __________________ .-- , N-Ar-L
, N
I
N / XXVII' [0463] Alternatively, a compound of formula XXII may be treated with a compound of formula XXVIII under reductive amination conditions, e.g. as in Scheme 7, to provide a compound of formula XXVI'. Herein Ar, L, L', GH, and Y are defined as in Scheme 7. A
compound of formula XXVI' may then be treated with a reagent XVIII as defined in Scheme 5 to produce a compound of formula XXVII'. In cases where the group Ar' contains optional substituents, e.g. a ketone, these may undergo further functionalization, e.g.
by treatment with hydroxylamine hydrochloride and pyridine at room temperature, to provide further compounds of formula XVII'.
[0464] Scheme 9.

N N 7 0 iii0 H

*
CINH F
VII /--\
No 10 Y,t0 N
/----\ N
/ \ N
XXX
XIX
[0465] A compound of formula XIX may be reacted with a compound of formula VII to provide compounds of formula XXX, wherein X is a suitable leaving group such as fluorine or chlorine, Y is C=0, the aromatic ring of VII may have further optional sub stituents, and reaction conditions are those for a nucleophilic aromatic substitution, e.g.
diisopropylethylamine, NMP, 130 C, with or without microwave irradiation.
[0466] Scheme 10.

I N
N H F
N XXVIII vAl---j ,S-N F 7---\
0"P H F / \ N ,S-N
01) H F
N---j XIX
XXXI
[0467] Alternatively, a compound of formula XIX may be treated with a compound of formula XXVIII to provide a compound of formula XXXI under reductive amination conditions, e.g. sodium triacetoxyborohydride, ethanol, dichloromethane, room temperature.

[0468] Scheme 11.
I
N
F V
I

ii , N 'Lr ¨ 0 0"6 H F
N=:::-/
)0(XI I HO, c)f I Z
HN
NoF V 0 AI
XII I ,1_7(1\1H , N
7-----\ N
¨ 0 0114 ,S-.-N
0"P H F \
/ N
N-:---/ S
\----::N
XXXII!
or I
N
F H
N ON-1_7((:) 7-----\ 14I , N3........\ 0 Ss--N
0/bH F i \N
N-_-.1----/
)0(XI I
HO
N.-''e I
No F V -----LO -Z R

_________________ I. 41, , N 'LVIN HN
H
7--\ N
¨ 0 1 IS--N
0"6 H F \
/ N Y
NIs--/
xxxiii [0469] Alternatively, a compound of formula XXXII, prepared from a compound of formula XIX through simple transformations well-known by one skilled in the art, e.g.
alkylation or reductive amination, may be reacted with a compound of formula XII to provide a compound of formula XXXIII under amide formation conditions, e.g. (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate, diisopropylethylamine, DMF, room temperature [0470] Scheme 12A.

0 Ni ,_-\¨NH NH
0 + M-Ar-L-X . ,N-¨ 0 ____________________________________________ ..-Y Y
HO M-Ar-L-0 XXXIV XXXV
XXXVI
F
, I Oi N 0 0 0 _____________ ...- H
F NH

Y
HN --- / \ Ar¨L-0 ,N_,\¨
)(XXVII N¨

[0471] A compound of formula XXXIV may be reacted with a reagent XXXV
(commercially available or readily prepared using standard reaction techniques known to one skilled in the art) under nucleophilic substitution conditions, e.g. potassium carbonate, potassium iodide, DMSO, 60 C, to produce a compound of formula XXXVI. Alternatively, the reaction conditions may be those for a Mitsunobu reaction, e.g. triphenylphosphine, diethylazodicarboxylate, THF. Herein Y is CH2 or C=0; one of M or M' represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane; the other of M or M' represents a functional group capable of undergoing palladium-catalyzed oxidative addition, e.g. an iodide, bromide, chloride, or trifluoromethanesulfonate; Ar represents an aromatic or heteroaromatic ring system; and L
represents a linker. When the reaction is a nucleophilic substitution reaction, X represents a suitable leaving group, e.g. p-toluenesulfonate, methanesulfonate, iodide, bromide, or chloride;
when the reaction is a Mitsunobu reaction, X is OH. A compound of formula XXXVI may then be further transformed by reaction with compound I under palladium-catalyzed cross-coupling conditions, e.g. with a suitable palladium catalyst such as bis(di-tert-buty1(4-dimethylaminophenyl)phosphine)dichloropalladium(II), suitable base such as cesium fluoride, suitable solvent such as mixtures of 1,4-dioxane and water, at a suitable temperature such as 100 C, with or without microwave irradiation to produce a compound of formula XXX
VII.
[0472] Scheme 12B.

R
M-Ar-L-X R R.
R" M-Ar-L-Z' R"
XXXIV XXXV
XXXVI
a, ,0 NH
,N
xxxvii Z' N-A compound of formula XXXIV may be reacted with a reagent XXXV (commercially available or readily prepared using standard reaction techniques known to one skilled in the art) to prepare a compound of formula XXXVI. In all cases, M represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane; or alternatively M represents a functional group capable of undergoing palladium-catalyzed oxidative addition, e.g. an iodide, bromide, chloride, or trifluoromethanesulfonate; Ar represents an aromatic or heteroaromatic ring system; L represents a linker; R represents one or more optional substituents; and R' and R" are either both carboxylic esters, e.g. CO2CH2CH3, R is a carboxylic ester e.g. CO2CH3 and R' is CN, or together R and R' form either:

0 or -' Y , wherein Y is either CH2 or C=0.
In some cases, X is a primary or secondary amine, optionally cyclized into a 4 to 8 membered heterocyclic ring, Y is a suitable leaving group such as fluorine or chlorine, and reaction conditions are those for a nucleophilic aromatic substitution, e.g.
triethylamine, DMSO, 70 C.
In these cases, Z becomes the corresponding secondary or tertiary amine derived from X.
In other cases, X is a suitable leaving group, e.g. p-toluenesulfonate, methanesulfonate, iodide, bromide, or chloride, Y is OH, and reaction conditions are those for a nucleophilic substitution, e.g. potassium carbonate, potassium iodide, DMSO, 60 C. In these cases, Z is 0.
In other cases, X is OH, Y is OH, and reaction conditions may be those for a Mitsunobu reaction, e.g. triphenylphosphine, diethylazodicarboxylate, THF. In these cases, Z is 0.

A compound of formula XXXVI may be further transformed into a different compound of formula XXXVI. When R' is a carboxylic ester and R" is CN, reduction of R" to CHO may be accomplished, e.g. by treatment with sodium hypophosphite and Raney nickel in a mixture of ,,,.....\

pyridine, acetic acid, and water. When R' and R" together form 0 , solvolysis e.g. with sodium hydroxide in an alcoholic solvent and tetrahydrofuran may afford a compound where R' is a carboxylic ester and R" is CH2OH. This compound may be further oxidized, e.g. with manganese dioxide, to afford an equivalent compound XXXVI where R' is a carboxylic ester and R" is CHO. Such compounds where R' is a carboxylic ester and R" is CHO may then be reacted with 3-aminoglutarimide in the presence of e.g. sodium triacetoxyborohydride, diisopropylethylamine, and acetic acid in methanol and dichloromethane to afford a new ,N1 0 compound of formula XXXVI wherein R' and R" together are -- Y , wherein Y
is CH2.
A compound of formula XXXVI may then be further transformed by reaction with a compound I
under palladium-catalyzed cross-coupling conditions, e.g. with a suitable palladium catalyst such as bis(di-tert-buty1(4-dimethylaminophenyl)phosphine)dichloropalladium(II), suitable base such as cesium fluoride, suitable solvent such as mixtures of 1,4-dioxane and water, at a suitable temperature such as 100 C, with or without microwave irradiation to produce a compound of formula XXXVII. Herein M', Z, and Z' are as defined in Scheme 1B.
In cases where one or both of Z or Z' are a protecting group, such protecting group may be removed from a compound XXXVII, e.g. by treatment with trifluoroacetic acid when Z and/or Z' are t-butoxycarbonyl, to afford a different compound of formula XXXVII wherein Z and Z' are H.
[0473] In cases where in R' and R" are both carboxylic esters in a compound XXXVII, hydrolysis e.g. with sodium hydroxide in methanol and water may afford a different compound XXXVII where R' and R" are CO2H. Such a compound may subsequently be reacted with e.g.
3-aminoglutarimide, (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate, and diisopropylamine in N,N-dimethylformamide to afford a new µ=1,-1( _tNH
3\1 0 compound of formula XXXVII wherein R' and R" together are -' Y
, wherein Y
is C=0.
[0474] Scheme 13A.
F F
M-Ar-L
I
0,PG ___________________________ bN P 0 \ o N

i N-0 0 HN ....-XXXVIII N
)00(IX
F F
s, OH
o N
______________ _ Ni N-0 0 H , N
XL
Z

N pH
H V N
P
HO"' NH Sj/ F 0 bi--11N
1 Ar-L N 0 H -N i\ f"
......

__________________________ ...-XLII Z
µs 1 N
[0475] A compound of formula I may be reacted with a reagent XXX VIII
(readily prepared using standard reaction techniques known to one skilled in the art) under palladium-catalyzed cross-coupling conditions, e.g. [1,11-bis(diphenylphosphino)ferrocene[dichloropalladium(II), sodium carbonate, in a suitable solvent such as 1,4-dioxane / water mixture, at a suitable temperature such as 100 C, with or without microwave heating, to produce a compound of formula XXXIX. One of M or M' represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane; the other of M or M' represents a functional group capable of undergoing palladium-catalyzed oxidative addition, e.g. an iodide, bromide, chloride, or trifluoromethanesulfonate; Ar represents an aromatic or heteroaromatic ring system; L represents an optional linker or portion of a linker, and PG represents a suitable ester protecting group, e.g. methyl, ethyl, or t-butyl. Compounds of formula XXXIX may be converted to a compound of formula XL by treatment with a reagent suitable for the removal of PG, e.g. sodium hydroxide in methanol and water at 40 C when PG
is methyl or ethyl. Compound XL may then be reacted with compound XLI, wherein Z is an optional substituent, e.g. H, methyl, or hydroxymethyl, to produce compounds of formula XLII
under amide formation conditions, e.g. N-Rdimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-l-ylmethylenel-N-methylmethanaminium hexafluorophosphate N-oxide, diisopropylethylamine, DMF, room temperature.
[0476] Scheme 13B.
F F
r o,PG ____________________________ bl, P 0 M-Ar-L \ o N

N , XXXVIII W
' N
XXXIX
F F
bN, P 0 S, OH
o N
HN ,-N
XL
Z

F
\N

HO"' NH Sji N

N kr 0 __________________________ )-Z
XLII S

N

[0477] A compound of formula I' may be reacted with a reagent XXX VIII
(readily prepared using standard reaction techniques known to one skilled in the art) under palladium-catalyzed cross-coupling conditions, e.g. [1,11-bis(diphenylphosphino)ferrocene[dichloropalladium(II), sodium carbonate, in a suitable solvent such as 1,4-dioxane / water mixture, at a suitable temperature such as 100 C, with or without microwave heating, to produce a compound of formula XXXIX. One of M or M' represents a functional group capable of undergoing palladium-catalyzed transmetallation, e.g. a boronic acid, boronic ester, or trialkylstannane; the other of M or M' represents a functional group capable of undergoing palladium-catalyzed oxidative addition, e.g. an iodide, bromide, chloride, or trifluoromethanesulfonate; Ar represents an aromatic or heteroaromatic ring system; L represents an optional linker or portion of a linker;
PG represents a suitable ester protecting group, e.g. methyl, ethyl, or t-butyl; W represents an optional protecting group, e.g. 2-(trimethylsilyl)ethoxymethyl; and the isoxazole of compound XXX VIII and following structures may have an optional substituent. Compounds of formula XXXIX may be converted to a compound of formula XL by treatment with a reagent suitable for the removal of the optional W, e.g. hydrogen chloride in 1,4-dioxane and methanol or ethylenediamine and tetra-n-butylammonium fluoride when W is 2-(trimethylsilyl)ethoxymethyl;
followed by treatment with a reagent suitable for the removal of PG, e.g.
sodium hydroxide in methanol and water at 40 C when PG is methyl or ethyl. Compound XL may then be reacted with compound XLI, wherein Z is an optional substituent, e.g. H, methyl, or hydroxymethyl, to produce compounds of formula XLII under amide formation conditions, e.g. N-Rdimethylamino)-1H-1,2,3-triazolo-[4,5-b[pyridin-l-ylmethylene[-N-methylmethanaminium hexafluorophosphate N-oxide, diisopropylethylamine, DMF, room temperature.
Optionally, as will be apparent to one skilled in the art, the order of the amide coupling and palladium-catalyzed cross-coupling steps may be reversed in the reaction sequence via suitable manipulations of M, M', and PG.
[0478] Scheme 14.

N Br N N
,N-Ar-oH N-Ar-0/ -)r0, N
XLV
XLIII XLIV
Br N-Ar-O OH XII

N
XLVI
HO
HO
Br µ1(113 At' N-Ar-O HN
XVIII

N N
XLVII S XLVIII S
[0479] A compound of formula XLIII may be reacted with a reagent XLIV
(commercially available or readily prepared using standard reaction techniques known to one skilled in the art) under nucleophilic substitution conditions, e.g. cesium carbonate, DMF, 75 C, to produce a compound of formula XLV. Ar represents an aromatic or heteroaromatic ring system; X
represents a suitable leaving group, e.g. p-toluenesulfonate, methanesulfonate, iodide, bromide, or chloride; L represents an optional linker; and PG represents a suitable ester protecting group, e.g. methyl, ethyl, or t-butyl. Compounds of formula XLV may be converted to a compound of formula XLVI by treatment with a reagent suitable for the removal of PG, e.g.
3 N hydrochloric acid in 1,4-dioxane at room temperature when PG is t-butyl. Compound XLVI may then be reacted with compounds XII as defined in Scheme 3A or 3B to produce compounds of formula XLVII under amide formation conditions, e.g. (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate, diisopropylethylamine, DMF, room temperature. The compound of formula XLVII may then be treated with a reagent XVIII as defined in Scheme 5 to produce a compound of formula XLVIII. In cases where the group Ar' contains optional substituents, e.g.
a ketone, these may undergo further functionalization, e.g. by treatment with hydroxylamine hydrochloride and pyridine at room temperature, to provide further compounds of formula XL VIII.
[0480] Intermediate 1: (3R)-N-[3-([5-bromo-1H-pyrrolo[2,3-b[pyridin-3-ylicarbony1)-2,4-difluorophenyll-3-fluoropyrrolidine-1-sulfonamide 0õ0 X F
....01 N

F
---HN / \ Br N-[0481] Step A: 2,6-difluoro-3-nitrobenzoyl chloride.

F

[0483] Into a 150-mL round-bottom flask, was placed 2,6-difluoro-3-nitrobenzoic acid (15.0 g, 73.8 mmol, 1.0 equiv), toluene (80 mL), thionyl chloride (80 mL). The resulting mixture was stirred at 80 C overnight and concentrated under reduced pressure. This resulted in 14.1 g (86%) of 2,6-difluoro-3-nitrobenzoyl chloride as a brown oil.
[0484] Step B: 5-bromo-3-[(2,6-difluoro-3-nitrophenyl)carbony11-1H-pyrrolo[2,3-b[pyridine.
F

Br I
N N
H
[0485] 5-bromo-1H-pyrrolo[2,3-b]pyridine (11.0 g, 55.8 mmol, 1.1 equiv) was mixed with 200 mL of chloromethane and aluminum trichloride (42.0 g, 318.2 mmol, 6.4 equiv) was added portionwise. The reaction was stirred at room temperature for 1 hour and 2,6-difluoro-3-nitrobenzoyl chloride (11.0 g, 49.6 mmol, 1.0 equiv) was added. The reaction was heated at 50 C overnight, then reaction mixture was cooled to room temperature and poured to ice-water (500 mL), extracted with ethyl acetate (500 mL x 3). The combined organic layer was washed with brine (500 mL x 2), dried over anhydrous sodium sulfate. The solvent was concentrated to give (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-y1)(2,6-difluoro-3-nitrophenyl) methanone (12.2 g) as a yellow solid, which was directly used to the next step without further purification. LCMS
(ES): m/z 381.30 [M+H] +.
[0486] Step C: 3-([5-bromo-1H-pyrrolo[2,3-b[pyridin-3-ylicarbony1)-2,4-difluoroaniline.
F

Br 1 \ F NH2 N "
H
[0487] A mixture of (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-y1)(2,6-difluoro-3-nitrophenyl)methanone (7.8 g, 20.4 mmol, 1.0 equiv), iron (5.6 g, 100.2 mmol, 4.9 equiv), ammonium chloride (3.6 g , 68 mmol), hydrochloric acid (25.0 mL) in ethanol (40 mL) and tetrahydrofuran (40 mL) was refluxed overnight. After cooling to room temperature, the mixture was filtered via a pad of Celite. The filtrate was concentrated in vacuo and the residue was purified by column chromatography on silica gel (petroleum ether /ethyl acetate = 1/2) to give (3-amino-2,6-difluorophenyl)(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone (4.3 g, 60%
yield) as a yellow solid. LCMS (ES): m/z 351.80 [M+H] +.
[0488] Step D: (R)-3-fluoropyrrolidine-1-sulfonyl chloride.
CI
k.
.--N
FI') [0489] An oven dried flask was charged with (R)-3-fluoropyrrolidine hydrochloride (3.0 g, 24 mmol). tRiethylamine (7.2 g, 72 mmol) and dichloromethane (150 mL). The mixture was stirred for 15 minutes at room temperature and then cooled to about -30 C in a dryice/acetonitrile bath for 10 minutes. Sulfuryl chloride (6.0 g, 48 mmol) was added dropwise over 10 minutes. The reaction mixture was stirred at about -30 C for an hour, then stirred at room temperature for 5 hours. The reaction mixture was diluted with aqueous HC1 (1 N, 70 mL).
The layers were separated and the aqueous layers were extracted with dichloromethane (50 mL x 3). The combined organic layer was washed with aqueous HC1 (1 N, 50 mL) and brine (50 mL), dried over anhydrous sodium sulfate. The solvent was concentrated to give (R)-fluoropyrrolidine-l-sulfonyl chloride (4.5 g) as a white solid, which was directly used to the next step without further purification.
[0490] Step E: (3R)-N-1-3-([5-bromo-1H-pyrrolo[2,3-blpyridin-3-ylicarbony1)-2,4-difluoropheny11-3-fluoropyrrolidine-1-sulfonamide.
0\ 0 ....01 N

F
.----HN / \ Br N¨

[0491] To a solution of (3-amino-2,6-difluorophenyl)(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone (8.0 g, 22.79 mmol, 1.0 eq) in pyridine (25.0 g) was added (R)-3-fluoropyrrolidine-1-sulfonyl chloride (4.6 g, 24.60 mmol, 1.08 eq) and 4-dimethylaminopyridine (560.0 mg, 4.59 mmol, 0.2 eq). The reaction mixture was stirred for 12 hours at 40 C. The solvent was removed and water (20 mL) was added, adjusted pH=7-8 with aqueous sodium bicarbonate, extracted with ethyl acetate (100 mL x 2). The combined organic layer was washed with brine (50 mL x 2), dried over anhydrous sodium sulfate. The solvent was removed in vacuo and the residue was purified by column chromatography on silica gel with ethyl acetate/petroleum ether (3:1) to give (R)-N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (6.4 g) as a yellow solid LCMS (ES):
m/z 505.05 [M+H]t [0492] Intermediate 2: (R)-N-(2,4-difluoro-3-(5-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1H-pyrrolo [2,3-blpyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine-1-sulfonamide 0\ 0 ....01 N

F
...--N¨ 0 [0493] Step A: (R)-N-(2,4-difluoro-3-(5-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1H-pyrrolo[2,3-blpyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine-1-sulfonamide [0494] To a solution of (R)-N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (1.0 g, 2.0 mmol) in 1,4-dioxane were added KOAc (392.0 mg, 4.0 mmol), Pd(dppf)C12 (163.0 mg, 0.2 mmol), and 4,4,4',4',5,5,5',5'-octamethy1-2,2'-bi(1,3,2-dioxaborolane) (1.02 g, 4.0 mmol) subsequently. The resulting solution was heated to 90 C overnight under N2. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel eluting with ethyl acetate/petroleum ether (1:1). This resulted in 551.0 mg (50%) (R)-N-(2,4-difluoro-3-(5-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine -1-sulfonamide as a light brown solid.
LCMS (ES): m/z 551.15 [M+H] .
[0495] Intermediate 3: N-(3-[5-bromo-1H-pyrrolo[2,3-blpyridine-3-carbony11-2,4-difluoropheny1)-2-(dimethylamino)ethane-1-sulfonamide \\Sõ/
N

HN Br N¨

[0496] Step A: N-(3-1-5-bromo-1H-pyrrolo[2,3-blpyridine-3-carbony11-2,4-difluorophenyflethene-1-sulfonamide 0 \ 0 \Sõ/

HN ¨
Br N
[0497] Into a 100 mL round-bottom flask, was placed 345-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoroaniline (500 mg, 1.42 mmol, 1 equiv), pyridine (20 mL, 248.47 mmol, 174.99 equiv), DMAP (35 mg, 0.29 mmol, 0.20 equiv), ethenesulfonyl chloride (360 mg, 2.84 mmol, 2.00 equiv), dichloromethane (20 mL). The resulting solution was stirred for 0.5 hour at room temperature. The reaction mixture was concentrated under reduced pressure.
The residue was applied onto a silica gel column eluting with ethyl acetate/petroleum ether (1:1).
This resulted in 300 mg (48%) of N-(345-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl)ethene-1-sulfonamide as a white solid. LCMS (ES): m/z 443.80[M+H] .

[0498] Step B: N-(3- [5-bromo-1H-pyrrolo[2,3-blpyridine-3-carbony11-2,4-difluoropheny1)-2-(dimethylamino)ethane-1-sulfonamide N

HN Br N¨

[0499] Into a 100 mL round-bottom flask, was placed N-(345-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl)ethene-1-sulfonamide (300 mg, 0.68 mmol, 1 equiv), dichloromethane (20 mL), dimethylamine (2.0 mL). The resulting solution was stirred for 2 hours at room temperature. The reaction mixture was concentrated under reduced pressure. This resulted in 360 mg (crude) of N-(345-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoropheny1)-2-(dimethylamino)ethane-1-sulfonamide as a white solid. LCMS
(ES): m/z 488.85 [M+H] .
[0500] Intermediate 4: N-(3-[5-bromo-1H-pyrrolo[2,3-blpyridine-3-carbony11-2,4-difluoropheny1)-2,3-dihydroxypropane-1-sulfonamide "S'N Br Hoc--ro H F /
OH
N N
[0501] Step A: N-(3-1-5-bromo-1H-pyrrolo[2,3-blpyridine-3-carbony11-2,4-difluorophenyl)prop-2-ene-1-sulfonamide rB
N
[0502] Into a 25 mL round-bottom flask, was placed 345-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoroaniline (500 mg, 1.42 mmol, 1 equiv), pyridine (2 mL, 15 equiv), prop-2-ene- 1-sulfonyl chloride (399.2 mg, 2.84 mmol, 2 equiv), DMAP (52.0 mg, 0.43 mmol, 0.3 equiv). The resulting solution was stirred overnight at 45 C in an oil bath.
The resulting mixture was concentrated. The residue was applied onto a silica gel column eluting with ethyl acetate/petroleum ether (1/1). This resulted in 480 mg (74%) of N-(345-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl)prop-2-ene-1-sulfonamide as a yellow solid.
[0503] Step B: N-(3-1-5-bromo-1H-pyrrolo1-2,3-blpyridine-3-carbony11-2,4-difluoropheny1)-2,3-dihydroxypropane-1-sulfonamide F

ii S-1,1 HO/-{-011 H- F Br / 1 OH
N N
H
[0504] Into a 50 mL round-bottom flask, was placed N-(345-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl)prop-2-ene-1-sulfonamide (430 mg, 0.94 mmol, 1 equiv), acetone (20 mL), N-methylmorpholine N-oxide (226 mg), water (5 mL), tetraoxoosmium (4 mL). The resulting solution was stirred overnight at room temperature. The reaction was then quenched by the addition of water (20 mL). The resulting solution was extracted with ethyl acetate (30 mL x 3). The resulting mixture was washed with brine (20 mL x 1), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was applied onto a silica gel column eluting with ethyl acetate/petroleum ether (1/1).
This resulted in 377 mg (82%) of N-(345-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoropheny1)-2,3-dihydroxypropane-1-sulfonamide as a white solid.
[0505] Intermediate 5: (R)-N-(3-(5-bromo-1H-pyrrolo1-2,3-blpyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-carboxamide /
F
/
NH / \ Br N-[0506] To the solution of (3-amino-2,6-difluorophenyl)(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone(2.0 g, 5.70 mmol, 1.00 equiv), triethylamine (8.6 g, 85.5 mmol, 15.00 equiv) in dichloromethane (80 mL) was slowly added a solution of bis(trichloromethyl) carbonate (2.5 g, 8.55 mmol, 1.50 equiv) in dichloromethane (40 mL), followed by dropwise addition of a solution of (R)-3-fluoropyrrolidine (761.0 mg, 8.55 mmol, 1.50 equiv) in dichloromethane (40 mL) at 0 C. The resulting solution was stirred for 30 minutes at 0 C in a water/ice bath. The resulting solution was quenched by the aqueous solution of ammonium chloride (40 mL), extracted with dichloromethane (40 mL x2). Then the organic layers were combined and concentrated. The residue was applied onto a silica gel column with chloroform/methanol (10:1).
This resulted in 541.0 mg (20%) of (R)-N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-l-carboxamide as a tawny solid. LCMS (ES):
m/z 467.10 [M+H] .
[0507] Scheme 15.
0 N'.1 0 N
I

N I T,..,N 1 XLIV H
H

- -'.., CY Nu H 0 N N
XL IX C ) L C ) F3C 0 izi ' 0- Nu OH
N
LI C ) XII rL 1 (3,1_',N6LAN
_,..

N HN
( ) Z

\
Y
[0508] A compound of formula XLIX (readily prepared using standard reaction techniques known to one skilled in the art) may be reacted with a compound of formula.

[0509] A compound of formula XLIX may be reacted with a reagent XLIV under nucleophilic substitution conditions, e.g. diisopropylethylamine, potassium iodide, acetonitrile, 100 C, to produce a compound of formula L. L' represents an optional linker or portion of a linker; Nu-H represents a suitable nucleophile such as an alcohol or secondary amine; X
represents a suitable leaving group, e.g. p-toluenesulfonate, methanesulfonate, iodide, bromide, or chloride; L represents an optional linker; and PG represents a suitable ester protecting group, e.g. methyl, ethyl, or t-butyl. Compounds of formula L may be converted to a compound of formula LI by treatment with a reagent suitable for the removal of PG, e.g.
trifluoroacetic acid, dichloromethane, 30 C when PG is t-butyl. Compound LI may then be reacted with compounds XII as defined in Scheme 3A or 3B to produce compounds of formula LII under amide formation conditions, e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 1-hydroxybenzotriazole, triethylamine, DMF, 30 C.
[0510] Scheme 16.

I R
r,\---k F3 isN 0 N-W
N-W
XLIX + c r _,...
X¨LAY' N
V ( ) LIII

[0511] A compound of formula XLIX as defined in Scheme 15 may be reacted with compound V to produce compound LIII, wherein L represents an optional linker or portion of a linker, Y is CH2 or C=0, X is either a suitable leaving group (e.g. OMs, OTs, Cl, etc.) or an aldehyde (CHO); R is an optional substituent (e.g. F or OCH3); and W is:
H
OIN:0 -' when Y is C=0; or 0,N H2 0 when Y is CH2.
[0512] When X is a leaving group, n is 0, Nu-H is a primary or secondary amine or alcohol, and suitable reaction conditions are those for an alkylation reaction, e.g.
potassium carbonate, DMF, 70 C. When X is an aldehyde, n is 1, Nu-H is a primary or secondary amine, and suitable reaction conditions are those for a reductive amination reaction, e.g. sodium cyanoborohydride, methanol, dichloromethane, acetic acid, room temperature. It will be apparent to one skilled in the art that the positions of Nu-H in XLIX and X in V' may also be reversed, such that the positions of Nu and (CH2)n are reversed in compound LIII. A compound of formula LIII where W is in an open chain form may be further transformed to another compound of formula LIII
where W is a glutarimide by cyclization under appropriate conditions, e.g.
benzenesulfonic acid, acetonitrile, 100 C.
[0513] Scheme 17.
F OH
H F 0 HN, HI\D--L' Z
--- X HN / \ Ar-L- + µ

LIV LV Y
OH
F

X
N N
H
liR
LVI Y
[0514] A compound of formula LIV (prepared using standard conditions known to one skilled in the art, analogous to the synthesis of compounds III in Scheme lA or 1B) may be reacted with a compound of formula LV (prepared using standard conditions known to one skilled in the art, analogous to the synthesis of compounds XV in Scheme 2) under reductive amination conditions, e.g. sodium triacetoxyborohydride, triethylamine, dichloroethane, 30 C, to produce a compound of formula LVI. Herein, Ar is an aromatic or heteroaromatic ring system; L and L' are an optional linker or portion of a linker; X is H or an optional substituent, which may be optionally cyclized into L to form a ring; G-H
represents a primary or secondary amine, optionally cyclized into a 4 to 8 membered heterocyclic ring; and R, Z, and Y
are as defined for compound XII in Scheme 3B. It will be apparent to one skilled in the art that the positions of C(0)X in LIV and G-H =
in LV may be reversed, with X optionally cyclized into L' to form a ring, such that the positions of CHX and G are reversed in compound LVI.
[0515] Scheme 18.
F
OH
HND--L' \ X I\II al ,0 HN 0 õ,. FH Ar-L N L /N
i Z ---, \
I N
\z9-' \ X OH

i LVII LVIII
I A, Y R
[0516] A compound of formula LIV (prepared using standard conditions known to one skilled in the art, analogous to the synthesis of compounds III in Scheme lA
or 1B) may be reacted with a compound of formula LVII (prepared using standard conditions known to one skilled in the art) under reductive amination conditions, e.g. sodium triacetoxyborohydride, acetic acid, dichloromethane, methanol, 30 C, to produce a compound of formula LVIII.
Herein, Ar is an aromatic or heteroaromatic ring system; L and L' are an optional linker or portion of a linker; X is H or an optional substituent, which may be optionally cyclized into L to form a ring;
= G-H
represents a primary or secondary amine, optionally cyclized into a 4 to 8 membered heterocyclic ring; R, Z, and Y are as defined for compound XII in Scheme 3B; and the isoxazole of compound LVII and following structures may have an optional substituent. It will be apparent to one skilled in the art that the positions of C(0)X in LIV
and G-H in LVII
may be reversed, with X optionally cyclized into L' to form a ring, such that the positions of CHX and G are reversed in compound LVIII.
[0517] Example synthesis of Compound 86 F
f rN NH
F
0 N) 0 0 bN..../s/....N
I
N N
H
[0518] Step A: (R)-tert-butyl 4-(4-(3-(2,6-difluoro-3-(3-fluoropyrrolidine-sulfonamido)benzoy1)-1H-pyrrolo[2,3-blpyridin-5-yl)phenyl)piperazine-1-carboxylate.
F F rN,Boc N N
H
[0519] A solution of (R)-N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (0.50 g, 1.0 mmol) in 1,4-dioxane/H20 (20 mL/2 mL), was added tert-butyl 4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate (0.43 g, 1.2 mmol), cesium fluoride (0.23 g, 1.5 mmol) and Pd(aMPhos)C12 (0.11 g, 0.15 mmol) under an argon atmosphere. The mixture was stirred at 100 C for 3 hours. After being cooled to room temperature, water was added. The aqueous phase was extracted with ethyl acetate (20 mL x 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by silica gel (dichloromethane/methanol = 12:1) to give compound (R)-tert-butyl 4-(4-(3-(2,6-difluoro-3-(3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazine-1-carboxylate (0.39 g, 57%) as a yellow solid. LCMS: m/z 685.2 [M+H];
1H NMR (400 MHz, DMSO-d6) 6 1.43 (9H, s), 2.06-2.12 (1H, m), 3.18-3.20 (4H, m), 3.26-3.30 (1H, m), 3.37-3.53 (8H, m), 5.30 (1H, d, J = 52.0 Hz), 7.10 (2H, d, J = 8.8 Hz), 7.28 (1H, t, J =
8.4 Hz), 7.60-7.64 (3H, m), 8.09 (1H, d, J =2.8 Hz), 8.55 (1H, brs.), 8.66 (1H, d, J = 2.4 Hz), 9.87 (1H, s), 12.93 (1H, s).
[0520] Step B: (R)-N-(2,4-difluoro-3-(5-(4-(piperazin-1-yl)pheny1)-1H-pyrrolo[2,3-blpyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine-1-sulfonamide.

F r NH
F

t\ P
N-i/ N
' N N
H
[0521] To a solution of (R)-tert-butyl 4-(4-(3-(2,6-difluoro-3-(3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b[pyridin-5-yl)phenyl)piperazine-1-carboxylate (0.39 g, 0.57 mmol) in hydrochloric acid/1,4-dioxane (5 mL, 4.0 N) was stirred at room temperature for 3 hours. Then the solvent was directly removed, then water (10 mL) was added and the pH of the mixture was adjusted to 8-9 by saturated sodium bicarbonate. The aqueous phase was extracted with ethyl acetate (10 mL x 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give (R)-N-(2,4-difluoro-3-(5-(4-(piperazin-1-yl)pheny1)-1H-pyrrolo[2,3-b[pyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine-1-sulfonamide (0.30 g, 91%) as a yellow solid.
[0522] Step C: 2-(2-chloroethoxy)ethyl 4-methylbenzenesulfonate.
,-, 0 CI
cr 0 [0523] The mixture of 2-(2-chloroethoxy)ethanol (0.5 g, 4.0 mmol), tosyl chloride (0.8 g, 4.0 mmol) and triethylamine (810 mg, 8.1 mmol) in dichloromethane (10 mL) was stirred at room temperature overnight. The mixture was poured into saturated sodium bicarbonate solution (20 mL) and extracted with dichloromethane (20 mL x 3). The combined organic phase was concentrated in vacuo and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 10/1) to give 2-(2-chloroethoxy)ethyl 4-methylbenzenesulfonate (0.9 g, 80% yield) as colorless oil. LCMS: m/z 279.1 [M+H]t [0524] Step D: 5-(2-(2-chloroethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.

[0525] The mixture of 2-(2-chloroethoxy)ethyl 4-methylbenzenesulfonate (100 mg, 0.36 mmol), 2-(2,6-dioxopiperidin-3-y1)-5-hydroxyisoindoline-1,3-dione (98 mg, 0.36 mmol), ethyldiisopropylamine (93 mg, 0.72 mmol) and potassium iodide (59 mg, 0.36 mmol) in dimethyl sulfoxide (5 mL) was heated at 45 C for 2 hours and then cooled to room temperature.
The reaction mixture was poured into water (10 mL) and extracted with dichloromethane (15 mL
x 3). The combined organic phase was concentrated in vacuo and the residue was purified by column chromatography on silica gel (dichloromethane/methanol = 20/1) to give 5-(2-(2-chloroethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (48 mg, 35% yield) as a white solid. LCMS: m/z 381.2 [M+H]t [0526] Step E: (3R) N (3 (5 (4 (4 (2 (2 (2 (2,6 dioxopiperidin-3-y1)-1,3-dioxoisoindolin-5-yloxy)ethoxy)ethyl)piperazin-l-yl)pheny1)-1H-pyrrolo[2,3-b[pyridine-3-carbonyl)-2,4-difluoropheny1)-3-fluoropyrrolidine-l-sulfonamide.

0 N) 0 /

k, I
IN N
[0527] The mixture of 5-(2-(2-chloroethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (40 mg, 0.11 mmol), (R)-N-(2,4-difluoro-3-(5-(4-(piperazin-1-yl)pheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine-1-sulfonamide (61 mg, 0.11 mmol), ethyldiisopropylamine (28 mg, 0.22 mmol) and potassium iodide (18 mg, 0.11 mmol) in dimethyl sulfoxide (5 mL) was heated at 80 C overnight. The mixture was poured into water (10 mL) and extracted with dichloromethane (10 mL x 3). The organic phase was concentrated in vacuo and the residue was purified by pre-HPLC to give (3R)-N-(3-(5-(4-(4-(2-(2-(2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-5-yloxy)ethoxy)ethyl)piperazin-1-yl)pheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (31 mg, 30% yield) as a yellow solid. LCMS: m/z 929.3 [M+H]; 1H NMR (400 MHz, DMSO-d6) 6 1.95-2.10 (3H, m), 2.53-2.59 (8H, m), 3.18-3.23 (4H, m), 3.24-3.31 (2H, m), 3.36-3.39 (2H, m), 3.47 (1H, s), 3.64 (2H, t, J = 6.0 Hz), 3.80 (2H, t, J =4.0 Hz), 4.35 (2H, t, J = 4.0 Hz), 5.12 (1H, dd, J = 5.6, 9.6 Hz), 5.29 (1H, d, J = 12.8 Hz), 7.05 (2H, d, J = 8.8 Hz), 7.26 (1H, d, J = 8.8 Hz), 7.39 (1H, dd, J = 2.0, 8.4 Hz), 7.48 (1H, d, J = 2.4 Hz), 7.58-7.65 (3H, m), 7.85 (1H, d, J =
8.4 Hz), 8.07 (1H, s), 8.53 (1H, d, J = 2.4 Hz), 8.65 (1H, d, J = 2.4 Hz), 9.85 (1H, brs), 11.1 (1H, s), 12.9 (1H, s).
[0528] Compounds 87-90 may be prepared in an analogous manner.
[0529] Example synthesis of compound 91 F rN NH
0 0c3.N 0 0 F)---/ N N
H
[0530] Step A: 2-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethanol.
0 (:)01:DH
)0B

[0531] To a solution of 2-(2-chloroethoxy)ethanol (2.0 g, 16.1 mmol) in N,N-dimethylformamide (15.0 mL) was added 4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenol (3.54 g, 16.1 mmol), cesium carbonate (10.5 g, 32.2 mmol) and potassium iodide (267 mg, 1.61 mmol). The reaction mixture was stirred at 60 C overnight. Then water (50 mL) was added and extracted with ethyl acetate (50 mL x 3), washed with brine (5 mL x 4). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel (petroleum ether/ethyl acetate = 2:1) to give 2-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethanol (2.1 g, 42%) as yellow oil. 1H
NMR (400 MHz, DMSO-d6) 6 1.28 (12H, s), 3.49-3.52 (4H, m), 3.74 (2H, t, J =
4.8 Hz), 4.10-4.12 (2H, m), 4.62-4.64 (1H, m), 6.93 (2H, d, J = 9.2 Hz), 7.60 (2H, d, J =
8.4 Hz).
[0532] Step B: 2-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethyl methanesulfonate.
Is (:)().0Ms [0533] To a solution of 2-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethanol (350 mg, 1.14 mmol) in dichloromethane (15.0 mL) was added triethylamine (231 mg, 2.28 mmol) and methanesulfonyl chloride (157 mg, 1.37 mmol) under nitrogen. The resulting reaction mixture was stirred at room temperature for 1 hour. Then aq.
sodium bicarbonate (20.0 mL) was added and extracted with dichloromethane (20 mL x 3), washed by brine, dried and concentrated in vacuo to give crude 2-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethyl methanesulfonate as yellow oil, which was used for the next step without further purification. LCMS: m/z 404.2 [M+18] .
[0534] Step C: tert-butyl 4-(2-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethyl)piperazine-1-carboxylate.
r ,Boc N
opi 0c)N
O
[0535] To a solution of 2-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethyl methanesulfonate (1.14 mmol) in acetonitrile (20 mL) was added potassium carbonate (315 mg, 2.28 mmol) and tert-butyl piperazine-l-carboxylate (234 mg, 1.25 mmol). The resulting reaction mixture was stirred at 80 C overnight. The solvent was concentrated in vacuo. The residue was extracted with ethyl acetate (20 mL x 3) and water (20 mL). The organic phase was dried and concentrated in vacuo. The residue was purified by preparative TLC (petroleum ether/ethyl acetate = 1:2) to give tert-butyl 4-(2-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethyl)piperazine-1-carboxylate (280 mg, 52% for two steps) as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) 6 1.27 (12H, s), 1.38 (9H, s), 2.35 (4H, t, J = 5.2 Hz), 2.47-2.50 (2H, m), 3.25-3.26 (4H, m), 3.57 (2H, t, J = 6.0 Hz), 3.70-3.73 (2H, m), 4.10-4.12 (2H, m), 6.92 (2H, d, J = 8.8 Hz), 7.59 (2H, d, J
= 8.4 Hz).
[0536] Step D: (R)-tert-butyl 4-(2-(2-(4-(3-(2,6-difluoro-3-(3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-blpyridin-5-yl)phenoxy)ethoxy)ethyl)piperazine-1-carboxylate.

F F rN,Boc 0 0c)N
Oz.-IN
)----/ N N"--H
[0537] To a solution of tert-butyl 4-(2-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethyl)piperazine- 1-carboxylate (114 mg, 0.238 mmol) in 1, 4-dioxane/water (10 mL/1 mL) was added (R)-N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (120 mg, 0.238 mmol), cesium fluoride (72.4 mg, 0.476 mmol) and Pd(aMPhos)C12 (16.9 mg, 0.0238 mmol). The resulting reaction mixture was stirred at 95 C for 16 hours. After cooling, water (20 mL) was added and extracted with ethyl acetate (15 mL x 3). The organic phase was dried and concentrated in vacuo. The residue was purified by preparative TLC (dichloromethane/methano1=20:1) to give (R)-tert-butyl 4-(2-(2-(4-(3-(2,6-difluoro-3-(3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenoxy)ethoxy)ethyl)piperazine- 1-carboxylate (60 mg, 33%) as a pale yellow solid.
LCMS: m/z 773.3 [M+H]t [0538] Step E: (R)-N-(2,4-difluoro-3 (5 (4 (2 (2 (piperazin- 1-yl)ethoxy)ethoxy)pheny1)-1H-pyrrolo[2,3-blpyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine-l-sulfonamide hydrochloride F F rNHHCI
0 OoN
r Nj 11 F / 1 H
[0539] A solution of (R)-tert-butyl 4-(2-(2-(4-(3-(2,6-difluoro-3-(3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenoxy)ethoxy)ethyl)piperazine-1-carboxylate (60 mg, 0.0517 mmol) in hydrochloric acid/1,4-dioxane (5 mL, 4 M) was stirred at room temperature for 1 hour. The solvent was concentrated in vacuo to give compound (R)-N-(2,4-difluoro-3-(5-(4-(2-(2-(piperazin-1-yl)ethoxy)ethoxy)pheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine- 1-sulfonamide hydrochloride as a pale yellow solid, which was used to next step without further purification. LCMS: m/z 673.2 [M+H]t [0540] Step F: (3R) N (3 (5 (4 (2 (2 (4 (2 (2,6 dioxopiperidin-3-y1)-1,3-dioxoisoindolin-5-yl)piperazin-l-yl)ethoxy)ethoxy)pheny1)-1H-pyrrolo[2,3-b[pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-l-sulfonamide N-0 0c3.N 0 0 F)----/ N N
H
[0541] To a solution of (R)-N-(2,4-difluoro-3-(5-(4-(2-(2-(piperazin-1-yl)ethoxy)ethoxy)pheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)pheny1)-3-fluoropyrrolidine-1-sulfonamide hydrochloride (0.0517 mmol) in dimethyl sulfoxide (3 mL) was added 2-(2,6-dioxopiperidin-3-y1)-5-fluoroisoindoline-1,3-dione (14.3 mg, 0.0517 mmol) and triethylamine (10.5 mg, 0.104 mmol). The reaction mixture was stirred at 70 C for 24 hours.
After cooling to room temperature, water (10 mL) was added and extracted with ethyl acetate (10.0 mL x 3). The combined organic phase was washed with brine (2.0 mL x 4), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC
(dichloromethane/methano1=20:1) twice to give (3R)-N-(3-(5-(4-(2-(2-(4-(2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethoxy)ethoxy)pheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (6.7 mg, 14%) as a yellow solid. LCMS: m/z 929.3 [M+H]t 1H NMR (400 MHz, DMSO-d6) 6 1.96-2.13 (3H, m), 2.58 (7H, s), 2.83-2.92 (1H, m), 3.26-3.30 (2H, m), 3.40-3.43 (6H, m), 3.48 (1H, s), 3.63-3.67 (2H, m), 3.76-3.80 (2H, m), 4.17-4.19 (2H, m), 5.05-5.09 (1H, m), 5.23-5.36 (1H, m), 7.11 (2H, d, J =
8.4 Hz), 7.24-7.29 (2H, m), 7.34 (1H, s), 7.60-7.69 (4H, m), 8.10 (1H, s), 8.57 (1H, brs), 8.66 (1H, d, J = 2.4 Hz), 9.88 (1H, s), 11.09 (1H, s), 12.95 (1H, s).
[0542] Compounds 92-97 may be prepared in an analogous manner.
[0543] Example synthesis of compound 99 gH

rNrC))LIµTcf i\o N -s_N
N N S
H µN \
[0544] Step A: tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate Br . N/¨\NBoc [0545] To a solution of 1,4-dibromobenzene (5.0 g, 21.2 mmol) in toluene (100 mL) were added tert-butyl piperazine-l-carboxylate (3.04 g, 16.3 mmol), Pd2(dba)3 (485 mg, 0.53 mmol), t-BuOK (5.95 g, 53 mmol) and BINAP (485 mg, 0.53 mmol). The resulting solution was stirred at 90 C for 3 hours under N2 atmosphere. After cooling to room temperature, the reaction was quenched with H20 (50 mL), and the mixture was extracted with EA. The combined organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel to afford the desired product (1.2 g, 17% yield) as a white solid. 1H NMR
(400 MHz, CDC13): 6 7.35 (d, J = 8.8 Hz, 2H), 6.78 (d, J = 9.2 Hz, 2H), 3.57 (t, J = 4.8 Hz, 4H), 3.09 (t, J = 4.8 Hz, 4H), 1.48 (s, 9H).
[0546] Step B: tert-butyl 4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate .4.7µ13 = Nr¨\NBoc [0547] To a solution of tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate (1.2 g, 3.53 mmol) in 1,4-dioxane (24 mL) were added 4,4,4',4',5,5,5',5'-octamethy1-2,2'-bi(1,3,2-dioxaborolane) (1.8 g, 7.06 mmol), Pd(dppf)C12 (258 mg, 0.35 mmol) and KOAc (1.04 g, 10.59 mmol). The resulting solution was stirred at 90 C overnight under N2 atmosphere. TLC showed the reaction was completed. After cooled to room temperature, the reaction was diluted with 50 mL of EA, and the mixture was washed with water and brine. The organic phase was dried over anhydrous sodium sulfate. The residue was purified by chromatography column to afford the desired product (1.0 g, 73% yield). LCMS (ES): m/z 482Ø
[0548] Step C: tert-butyl 2-(2-(4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethoxy)acetate ( 0 NB 11 N/¨\N¨r [0549] To a solution of tert-butyl 4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate (550 mg, 1.42 mmol) in DCM (5 mL) was added TFA (1.5 mL, 20.2 mmol). The resulting solution was stirred at 5 C for 2 hours. The solvent was removed under vacuum to afford a residue (547 mg, calculated), which was used directly in next step. To a solution of the residue (547 mg, 1.42 mmol) in dry DMF (5 mL) were added K2CO3 (977 mg, 7.08 mmol), KI (470 mg, 2.83 mmol) and tert-butyl 2-(2-chloroethoxy)acetate (550 mg, 2.83 mmol). The resulting solution was stirred at 90 C for 3 hours. After cooling to room temperature, the reaction was quenched with 20 mL of saturated NaCl solution, and the mixture was extracted with EA twice. The combined organic layer was concentration in vacuo, and the residue was purified by silica gel to afford the desired product (300 mg, 47%
yield in two steps) as oil. 1H NMR (400 MHz, CDC13): 6 7.70 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.01 (m, 3H), 3.69 (m, 4H), 3.30 (m, 4H), 2.68 (m, 6H), 1.48 (s, 9H), 1.32 (s, 12H).
[0550] Step D: (R)-tert-butyl 2-(2-(4-(4-(3-(2,6-difluoro-3-(3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b[pyridin-5-yl)phenyl)piperazin-1-yl)ethoxy)acetate 0 ?I J
F\C

N
H F I
N N
[0551] To a solution of tert-butyl 2-(2-(4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethoxy)acetate (100 mg, 0.20 mmol) in 1,4-dioxane/
H20 (10 ml/ 1 mL) were added (3R)-N-[3-([5-bromo-1H-pyrrolo[2,3-b[pyridin-3-yl] carbony1)-2,4-difluorophenyll-3-fluoropyrrolidine-1-sulfonamide (134 mg, 0.36 mmol), Pd(aMphos)C12 (15 mg, 0.02 mmol) and CsF (121 mg, 0.80 mmol). The resulting solution was stirred at 95 C for 3 hours under N2 atmosphere. TLC showed the reaction was completed. After cooling to room temperature, the reaction was diluted with 50 mL of EA, and the mixture was washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by chromatography column to afford the desired product (100 mg, 66% yield).
LCMS (ES): m/z 743.2 [M+H-16] .
[0552] Step E: (25,4R)-1-((S)-2 (2 (2 (4 (4 (3 (2,6-difluoro-3-((R)-3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b[pyridin-5-yl)phenyl)piperazin-l-yl)ethoxy)acetamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide OH

rN7vC))L1\7\rcN

HN

N N S
H \
[0553] To a solution of (R)-tert-butyl 2-(2-(4-(4-(3-(2,6-difluoro-3-(3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)ethoxy)acetate compound with methanol (100 mg, 0.13 mmol) in 1,4-dioxane (2 mL) was added HC1 (g), 1,4-dioxane (1 mL, 8 M). The resulting solution was stirred at 50 C for 3 hours.
TLC showed the reaction was completed. After cooled to room temperature, the reaction mixture was concentrated to afford a crude product (93 mg, 100% yield, calculated), which was used into next reaction. To a solution of crude product (93 mg, 0.13 mmol) in dry NMP (5 mL) were added (2S,4R)-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-amino-3,3-dimethylbutanoy1)-4-hydroxypyrrolidine-2-carboxamide hydrochloride (91 mg, 0.19 mmol), DIEA (167 mg, 1.30 mmol) and PyBOP (203 mg, 0.39 mmol) subsequently. The resulting solution was stirred at 10 C for 1 hour. After the reaction was quenched with brine (20 mL), the mixture was extracted with EA twice. The organic layers was concentrated, and the residue was purified by silica gel and preparative HPLC to afford the desired product (39 mg, 27% yield in two steps) as a yellow solid. 1H NMR (400 MHz, CD30D): 6 8.80 (s, 1H), 8.65 (s, 1H), 8.56 (s, 1H), 7.89 (s, 1H), 7.73 (m, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.44 (d, J = 7.6 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.07-7.14 (m, 3H), 5.13 - 5.30 (m, 1H), 4.71 (s, 1H), 4.50 - 4.65 (m, 4H), 4.34 (d, J =
15.6 Hz, 1H), 4.12 (m, 2H), 3.78-3.95 (m, 4H), 3.40-3.65 (m, 9H), 3.10 (m, 6H), 2.42 (s, 3H), 2.00-2.30 (m, 4H), 1.04 (s, 9H); LCMS (ES): m/z 550.3 [M/2+H]t [0554] Compounds 98, 100-101, 102, 103-106, and 223-252 may be prepared in an analogous manner.
[0555] Example synthesis of compound 114 OH
0\P F
\,SI, F F j\-NH 0 HN
/ r----Ni ...-CN
HN N
/ \ N\___J
-41, S \
1.----z-N
[0556] Step A: 1-(azetidin-3-y1)-4-(4-bromophenyl)piperazine hydrochloride r -N
Br 410 NNõ) HCI
[0557] To a solution of1-(4-bromophenyl)piperazine hydrochloride (2.0 g, 7.21 mmol) in CH3OH/DCM (v/v =1/1, 30 mL) was added KOAc (1.4 g, 14.4 mmol) and cat. AcOH
(0.1 mL) at room temperature. After stirring for 30 minutes, NaBH(OAc)3 (7.6 g, 36.1 mmol). The mixture was stirred at 30 C overnight. After the reaction was quenched with aqu.NaHCO3 (50 mL), the mixture was extracted with DCM (100 mL x 2). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated under vacuum to afford crude the desired product (2.5 g) as a light brown solid, which was used to next step without further purification. To a solution of the above intermediates in methanol (20 mL) was added HC1(g)/CH3OH (10 mL). The resulting solution was stirred for 2 hours at room temperature. The solvent was removed under vacuum. The residue was triturated with DCM and filtered to afford the desired product 1-(azetidin-3-y1)-4-(4-bromophenyl)piperazine hydrochloride (2.0 g) as a brown solid.

[0558] Step B: ethyl 2-(3-(4-(4-bromophenyl)piperazin-1-yl)azetidin-1-y1)acetate (NNN= orC) NN
Br [0559] To a solution of 1-(azetidin-3-y1)-4-(4-bromophenyl)piperazine hydrochloride (2.0 g, 6.01 mmol) in CH3OH/DCM (v/v =1/1, 10 mL) was added KOAc (1.2 g, 12.1 mmol) and cat.
AcOH (0.1 mL) at room temperature. After stirring for 30 minutes, NaBH(OAc)3 (6.3 g, 30.1 mmol). The mixture was stirred at 30 C overnight. After the reaction was quenched with aq.
NaHCO3(30 mL), the mixture was extracted with DCM (50 mL x 3). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated under vacuum to afford the desired product ethyl 2-(3-(4-(4-bromophenyl)piperazin-1-yl)azetidin- 1-yl)acetate (1.0 g, crude) as a light brown solid, which was used to next step without further purification. LCMS (ES): m/z 384.1; 382.1 [M+H] +.
[0560] Step C: methyl 2-(3-(4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)piperazin -1-yl)azetidin-1-y1)acetate 4b, [0561] To a solution of ethyl 2-(3-(4-(4-bromophenyl)piperazin-1-yl)azetidin-1-y1) acetate (1.0 g, crude) in methanol (20 mL) was added HC1 (g)/CH3OH (10 mL). The resulting solution was stirred at 60 C for 2 hours. The solvent was removed under vacuum. The residue was taken up with DCM (100 mL), and the mixture was washed with NaHCO3 (30 mL x 3). The organic phase was concentrated under vacuum. The residue (500 mg) was used into next reaction without further purification. To a solution of the above intermediates (500 mg, 1.4 mmol) in 1,4-dioxane (20 mL) was added KOAc (267 mg, 2.8 mmol), Pd(dppf)C12 (190 mg, 0.14 mmol), 4,4,5,5-tetramethy1-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1, 3,2-dioxaborolane (700 mg, 2.8 mmol). The resulting solution was purged with N2 at room temperature for 10 minutes to remove the excess 02. The mixture was stirred at 100 C overnight. After cooling to room temperature, the reaction was taken up with Et0Ac. The organic phase was concentrated under vacuum. The residue was purified by silica gel with PE/EA (10-1/1) to afford the desired product methyl 2-(3-(4-(4-(4,4,5,5-tetramethy1-1,3,2- dioxaborolan-2-yl)phenyl)piperazin-1-yl)azetidin-1-y1)acetate (300 mg) as a brown solid. LCMS (ES): m/z 416.3 [M+H] +.
[0562] Step D: (2S,4R)-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((S)-3,3-dimethyl-2-(2-(3-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y1)phenyl)piperazin-1-y1)azetidin-y1)acetamido)butanoy1)-4-hydroxypyrrolidine-2-carboxamide OH

o ¨1\0(iHN
0 AIL Nr-\N-N-)\--1\11-\I3 Mr \____-/
ci =
s \
N
[0563] To a solution of methyl 2-(3-(4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)azetidin-1-y1)acetate (300 mg, 0.72mmo1) in H20/THF
(v/v=1/5, 5 mL) was added LiOH (34 mg, 1.5 mmol).The resulting solution was stirred at room temperature for 1 hour. Then the solvent was removed under vacuum. The residue was used into next reaction without further purification. To a solution of the above intermediates in DMF
(5.0 mL) were added DIEA (300 mg, 2.2 mmol), (2S,4R)-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-amino-3,3-dimethylbutanoy1)-4-hydroxypyrrolidine-2-carboxamide hydrochloride (338 mg, 0.72 mmol) and PyBOP (564 mg, 1.1 mmol) at room temperature. The resulting solution was stirred at 20 C
for 2 hours. The reaction was quenched with H20 (10 mL), and the mixture was extracted with Et0Ac (20 mL x 3). The combined organic layer was concentrated under vacuum.
The residue was purified by preparative TLC with DCM/CH3OH (20/1) to afford the desired product (2S,4R)-1-((S)-3,3-dimethy1-2-(2-(3-(4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)phenyl)piperazin-1-y1)azetidin-1-y1)acetamido) butanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (80 mg) as a light brown solid. LCMS
(ES): m/z 814.4 [M+H] +.
[0564] Step E: (25,4R)-N-(4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2 (2 (3 (4 (4 (3 (2,6-difluoro-3-((R)-3-fluoropyrrolidine-1-sulfonamido)benzoy1)-1H-pyrrolo12,3-blpyridin-5-yl)phenyl)piperazin-l-yl)azetidin-1-y1)acetamido)-3,3-dimethylbutanoy1)-4-hydroxypyrrolidine-2-carboxamide OH
0,P F
F F j\-NH 0 HN
i-----\
/
N N----N
N-S \
N
[0565] To a solution of (2S,4R)-1-((S)-3,3-dimethy1-2-(2-(3-(4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)phenyl)piperazin-1-y1)azetidin-1-y1)acetamido)butanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (80 mg, 0.098 mmol) in H20/1,4-dioxane (v/v=1/5, 5.0 mL) were added CsF (45 mg, 0.29mmo1), Pd(amphos)C12 (8 mg, 0.01mmol), (R)-N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (70 mg, 0.14 mmol) at room temperature. The solution was purged with N2 at room temperature for 10 minutes to remove the excess 02. The resulting solution was stirred at 80 C overnight. After cooling to room temperature, the reaction was taken up with Et0Ac. The combined organic layer was concentrated under vacuum. The residue was purified by preparative TLC with DCM/CH3OH (20/1) to afford the desired product (2S,4R)-1-((S)-2-(2-(3-(4-(4-(3-(2,6-difluoro-3-(((R)-3-fluoro -pyrrolidine)-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-l-yl)azetidin-l-y1)acetamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (35 mg) as a light yellow solid. 1H NMR
(400 MHz, DMSO-d6): 6 9.02 (s, 1H), 8.71-8.75 (m, 2H), 8.68 (br, 1H), 8.12 (s, 1H), 7.61-7.66 (m, 4H), 7.42-7.46 (m, 5H), 7.19-7.21 (m, 2H), 7.06 (d, J = 8.0 Hz, 2H), 5.33-5.35 (m, 0.5H), 5.22-5.23 (m, 0.5 H), 5.16 (d, J = 7.2 Hz, 1H), 4.53 (d, J = 9.6 Hz, 1H), 4.34-4.47 (m, 5H), 4.24-4.29 (m, 1H), 4.04 (s, 1H), 3.65-3.66 (m, 3H), 3.51-.3.61 (m, 5H), 3.22-3.34 (m, 6H), 3.08 (br, 3H), 2.41-2.47 (m, 3H), 1.93-2.07 (m, 5H), 0.94 (s, 9H); LCMS (ES): m/z 1111.3 [M+H], 1108.3 [M-H]t [0566] Compounds 107-113, 115, 116, and 253-269 may be prepared in an analogous manner.

[0567] Example synthesis of compound 117 HO-N
\
---N 41 Ni---\N 0 ---- ---N' \----/ N)=(NH
I
N Z 0 o [0568] Step A: tert-butyl 4-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazine-1-carboxylate Br , N \ / \N A 0 1 N
N
>0 [0569] The mixture of 4-(4-bromo-1H-pyrazol-3-yl)pyridine (5.0 g, 22.3 mmol) (previously described in Bioorg. Med. Chem. Lett. 2008, 18, 4692-4695), tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-l-carboxylate (8.7 g, 22.3 mmol) and cupric acetate (4.0 g, 22.3 mmol) in pyridine (30 mL) was stirred at 100 C overnight. The mixture was concentrated in vacuo and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 5/1) to give tert-butyl 4-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazine-l-carboxylate (10.8 g, 70% yield) as a brown solid.
[0570] Step B: tert-butyl 4-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazine-1-carboxylate Nr---\____/N4 ..--N . 0 NI
N ---[0571] The mixture of tert-butyl 4-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-yl)phenyl)piperazine-1-carboxylate (2.4 g, 5.0 mmol), 5-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-2,3-dihydro-1H-inden-1-one (1.3 g, 5.0 mmol), [1,1'-bis(diphenylphosphino)ferrocene[dichloropalladium (366 mg, 0.5 mmol). tri-tert-butylphosphine tetrafluoroborate (145 mg, 0.5 mmol) and cesium fluoride (2.3 g, 15.0 mmol) in 1,4-dioxane/water (20 mL, 10/1) was stirred at 90 C overnight. The mixture was poured into water (30 mL) and extracted with dichloromethane (30 mL x3). The combined organic phase was concentrated in vacuo and the residue was purified by column chromatography on silica gel (dichloromethane/methanol = 20/1) to give tert-butyl 4-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazine-1-carboxylate (1.6 g, 60% yield) as a yellow solid. LCMS: m/z 536.3 [M+H]t [0572] Step C: 5-(1-(4-(piperazin-1-yl)pheny1)-3-(pyridin-4-y1)-1H-pyrazol-4-y1)-2,3-dihydro-1H-inden-1-one hydrochloride /--\ ---HN N . NsNõ....
i N
=HCI I
-- N
[0573] The solution of tert-butyl 4-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazine-1-carboxylate (1.6 g, 3.0 mmol) in dry hydrochloride acid/methanol (30 mL, 1.0 M.) was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo to give 5-(1-(4-(piperazin-1-yl)pheny1)-3-(pyridin-4-y1)-1H-pyrazol-4-y1)-2,3-dihydro-1H-inden-1-one hydrochloride (1.0 g, 80% yield) as a white solid, which was directly used to the next step without further purification.
[0574] Step D: 2-(2,6-dioxopiperidin-3-y1)-5 (4 (4 (4 (1 oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)isoindoline-1,3-dione N) 0 / y \N
[0575] The mixture of 5-(1-(4-(piperazin-1-yl)pheny1)-3-(pyridin-4-y1)-1H-pyrazol-4-y1)-2,3-dihydro-1H-inden-1-one hydrochloride (1.0 g, 2.3 mmol), 2-(2,6-dioxopiperidin-3-y1)-5-fluoroisoindoline-1,3-dione (635 mg, 2.3 mmol) and triethylamine (697 mg, 6.9 mmol) in dimethyl sulfoxide (10 mL) was stirred at 80 C overnight. The mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phase was concentrated in vacuo and the residue was purified by column chromatography on silica gel (dichloromethane/methanol = 20/1) to give 2-(2,6-dioxopiperidin-3-y1)-5-(4-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)isoindoline-1,3-dione (1.1 g, 70% yield) as a yellow solid. LCMS: m/z 692.3 [M+H]t [0576] Step E: (E)-2-(2,6-dioxopiperidin-3-y1)-5-(4-(4-(4-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)isoindoline-1,3-dione HON
N=

Nr-\N 0 Nj.(NH

[0577] The mixture of 2-(2,6-dioxopiperidin-3-y1)-5-(4-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)isoindoline-1,3-dione (300 mg, 0.43 mmol) and hydroxylamine hydrochloride (300 mg, 4.3 mmol) in pyridine (10 mL) was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was purified by preparative HPLC to give (E)-2-(2,6-dioxopiperidin-3-y1)-5-(4-(4-(4-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)isoindoline-1,3-dione (182 mg, 60% yield) as a yellow solid. LCMS: m/z 707.3 [M+H];

1H NMR (400 MHz, DMSO-d6) 6 2.01-2.07 (1H, m), 2.54-2.61 (2H, m), 2.80-2.89 (3H, m), 2.98-3.02 (2H, m), 3.39 (4H, brs), 3.66 (4H, brs), 5.06-5.11 (1H, m), 7.16 (2H, d, J = 8.8 Hz), 7.21 (1H, d, J = 7.6 Hz), 7.33-7.35 (1H, m), 7.42 (2H, d, J = 8.0 Hz), 7.47 (2H, dd, J = 5.6, 1.6 Hz), 7.55 (1H, J = 7.6 Hz), 7.72 (1H, d, J = 8.4 Hz), 7.83 (2H, d, J = 8.8 Hz), 8.57 (2H, dd, J =
4.4, 1.2 Hz), 8.73 (1H, s), 10.9 (1H, s), 11.0-11.1 (1H. m).
[0578] Compounds 118-132 and 271 may be prepared in an analogous manner.
[0579] Example synthesis of compound 137 NH
HO-N

/ N
[0580] Step A: tert-butyl (2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)(methyl)carbamate BocN¨

Br *0 N
N
[0581] To a solution of tert-butyl methyl(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)carbamate (3.57 g, 9.47 mmol) and 4-(4-bromo-1H-pyrazol-3-yl)pyridine (2.12 g, 9.47 mmol) in DCM(20 mL) were added Et2NH(6.91 g, 94.72 mmol), Cu(0Ac)2(1.72 g, 9.47 mmol).The resulting mixture was stirred at 30 C for 16 hours under the atmosphere of 02 The mixture was diluted with DCM (30 mL), and then the mixture was washed with NH3-1-120 thrice.
The organic phase was evaporated under reduced pressure, The residue was purified by silica gel column chromatography on silica gel(DCM/Me0H= 80/1) to afford tert-butyl (2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-y1) phenoxy)ethyl)(methyl)carbamate (3.0 g, 66.9%
yield) as a brown oil.
[0582] Step B: 2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)-N-methylethan-1-amine H
Br -/N¨

Or N
N
[0583] To a solution of tert-butyl (2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)(methyl)carbamate (1.56 g, 3.31 mmol) in Me0H (6 mL) was added HC1/Dioxane(6 N, 10 mL) at room temperature slowly. The mixture was stirred at room temperature for 2 hours .The mixture was evaporated under reduced pressure to afford 2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)-N-methylethan-1-amine as a colorless solid (1.23 g, 100% yield).
[0584] Step C: 5-((2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Br 0 of---/ 0 N

[0585] To a solution of 2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)-N-methylethan-1-amine (400 mg, 1.07 mmol) and 2-(2,6-dioxopiperidin-3-y1)-5-fluoroisoindoline-1,3-dione (591.9 mg, 2.14 mmol) in NMP(2 mL) was added DIPEA(1.38 g, 10.7 mmol). The resulting mixture was stirred at 130 C for 12 hours under the atmosphere of N2 The mixture was diluted with EA (30 mL), and then the mixture was washed with brine twice. The organic phase was evaporated under reduced pressure, The residue was purified by column chromatography on silica gel (PE/Et0Ac= 1/3) to afford 5-((2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (500 mg, 74.1% yield).
[0586] Step D: 2-(2,6-dioxopiperidin-3-y1)-5-(methyl(2-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-y1)phenoxy)ethyl)amino)isoindoline-1,3-dione ON

/ N
[0587] To a solution of 5-((2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (500 mg, 0.79 mmol) and 5-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-2,3-dihydro-1H-inden-1-one (307.6 mg, 1.19 mmol) in 1,4-dioxane/H20(9 mL,8:1) were added t-Bu3PHBF4(92.2 mg, 0.32 mmol), CsF(483.3 mg, 3.18 mmol),Cy2NMe(5 drop) and Pd2(dba)3(145.6 mg, 0.16 mmol). The resulting mixture was stirred at 100 C for 2 hour under the atmosphere of N2 The solvent was evaporated under reduced pressure. The residue was diluted with EA (30 mL), and then the mixture was washed with brine twice. The organic phase was evaporated under reduced pressure, The residue was purified by column chromatography on silica gel (PE/DCM/Me0H, 800/200/25) to afford 2-(2,6-dioxopiperidin-3-y1)-5-(methyl(2-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)amino)isoindoline-1,3-dione (500 mg, 92.4% yield).
[0588] Step E: (E)-2-(2,6-dioxopiperidin-3-y1)-5-((2-(4-(4-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)(methyl)amino)isoindoline-1,3-dione ON NH
N-t HO-N

/ N
[0589] To a solution of 2-(2,6-dioxopiperidin-3-y1)-5-(methyl(2-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)amino)isoindoline-1,3-dione (200 mg, 0.294 mmol) in CH3CN/Py(3 mL/3 mL) was added NH2OH-HC1(200 mg, 2.877 mmol),the mixture was stirred at 40 C for 0.5 hour. The mixture was diluted with DCM (30 mL),washed with brine twice. The organic layer was evaporated under reduced pressure. The residue was purified by TLC(DCM/EA/Me0H=50/100/15) to afford (E)-2-(2,6-dioxopiperidin-3-y1)-5-[0590] ((2-(4-(4-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethyl)(methyl)amino)isoindoline-1,3-dione as a yellow-green solid (103 mg, 49.9% yield). 1H NMR (400 MHz, CDC13): 6 8.56 (d, J = 4.0 Hz, 2H), 8.16 (s, 1H), 7.94 (s, 1H), 7.66 ¨ 7.72 (m, 4H), 7.50 (d, J = 4.8 Hz, 2H), 7.43 (s, 1H), 7.29 (s, 1H), 7.19 ¨ 7.26 (m, 2H), 6.93 ¨ 6.98 (m, 3H), 4.92 ¨ 4.96 (m, 1H), 4.24 (t, J = 4.8 Hz, 2H), 3.94 (t, J =10 Hz, 2H), 3.23 (s, 3H), 3.00¨ 3.04 (m, 4H), 2.77 ¨2.92 (m, 4H), 2.12 ¨ 2.15 (d, J =8.4 Hz, 1H); LCMS
(ES): m/z 696.2 [M+H] +.
[0591] Compounds 133-136, 138-149, and 273-281 may be prepared in an analogous manner.
[0592] Example synthesis of compound 150 /Th H0 =7......./--Nv_./N
' NI\ 0 -7-/ N =N 0 c*IF-1 \ /

[0593] Step A: 4-(4-bromo-1-(4-(2-(3-((tert-butyldimethylsilyl)oxy)propoxy)ethoxy)pheny1)-1H-pyrazol-3-y1)pyridine Br ---N = ONOOTBS
----. N
I
N /
[0594] To a solution of 2-(3-((tert-butyldimethylsilyl)oxy)propoxy)ethy14-methylbenzene-esulfonate (420 mg, 1.08 mmol) in dry DMF (10 mL) were added K2CO3 (299 mg, 2.16 mmol) and 4-(4-bromo-1H-pyrazol-3-yl)pyridine (342 mg, 1.08 mmol) subsequently. The resulting solution was stirred at 80 C for 3 hours. The reaction mixture was diluted with EA (30 mL) and washed with brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified to afford the desired product 4-(4-bromo-1-(4-(2-(3-((tert-butyldimethylsilyl)oxy)propoxy) ethoxy) phenyl)-1H-pyrazol-3-y1)pyridine (DCM:Me0H
= 20:1) (430 mg) as colorless solid. 1H NMR (400 MHz, CDC13): 6 8.66 (br, 2H), 7.89-7.93 (m, 3H), 7.55 (d, J = 8.8 Hz, 2H), 6.96-6.98 (m, 2H), 4.04-4.14 (m, 2H), 3.76 (d, J = 4.8 Hz, 2H), 3.67 (d, J = 6 Hz, 3H), 3.58 (d, J = 6.4 Hz, 2H), 1.71-1.79 (m, 2H), 0.84 (s, 9H), 0.0 (s, 6H).
[0595] Step B: 3-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propan-1-ol Br ---N 4I 'OOH
------_ N
I
N Z
[0596] To a solution of 4-(4-bromo-1-(4-(2-(3-((tert-butyldimethylsilyl)oxy) propoxy)ethoxy)pheny1)-1H-pyrazol-3-y1)pyridine (430 mg, 0.808 mmol) in 1,4-dioxane (2 mL) was added 6 M HC1 in 1,4-dioxane (4 mL). The resulting solution was stirred at 25 C for 1 hour.
The solvent was removed under reduced pressure to afford crude the desired product 3-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propan-1-ol (270 mg crude), which was used in next step without further purification. LCMS (ES): m/z 420.0 [M+H]
+.
[0597] Step C: 3-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propanal Br 411 n N
---...
I
N /
[0598] To a solution of 3-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propan-1-ol (135 mg, 0.32 mmol), IBX (136 mg, 0.48 mmol) in CH3CN (4 mL) was added at room temperature. The mixture was stirred at 80 C for 2 hours. After the reaction was completed, the mixture was filtrated. The filtrate was concentrated under vacuum to afford crude desired product 3-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy) ethoxy)propanal (140 mg crude), which was used in next step without further purification.
LCMS (ES): m/z 416.0 [M+H] +.
[0599] Step D: tert-butyl 4-(2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)piperazine-1-carboxylate N_Z-NH 0 N C ) N

Boc [0600] To a solution of tert-butyl piperazine-l-carboxylate (1.35 g, 7.25 mmol) in NMP (10 mL) were added 2-(2,6-dioxopiperidin-3-y1)-4-fluoroisoindoline-1,3-dione (1 g, 3.62 mmol) and DIEA (1.87 g, 14.5 mmol). The resulting solution was stirred at 90 C under N2 for 4 hours. The reaction mixture was diluted with EA (30 mL) and washed with brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified to afford the desired product tert-butyl 4-(2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)piperazine-1-carboxylate (DCM:EA = 1:1) (1.4 g) as yellow solid. 1H NMR
(400 MHz, DMSO-d6): 6 7.73 (d, J = 7.2 Hz, 1H), 7.35-7.41 (m, 2H), 5.09-5.13 (m, 1H), 3.52 (s, 4H), 3.26 (s, 4H), 2.84-2.89 (m, 1H), 2.56-2.63 (m, 2H), 2.00-2.05 (m, 2H), 1.45 (s, 9H).
[0601] Step E: 2-(2,6-Dioxopiperidin-3-y1)-4-(piperazin-1-yl)isoindoline-1,3-dione hydrochloride N_Z-NH 0 N _____________________________________ EN) H HCI
[0602] To a solution of tert-butyl 4-(2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)piperazine-1-carboxylate (1.4 g, 3.16 mmol) in 1,4-dioxane (4 mL) was added 6 M HC1 in 1,4-dioxane (6 mL). The resulting solution was stirred at 25 C for 1 hour.
The solution was concentrated under reduced pressure. The residue afforded the desired product 2-(2,6-dioxopiperidin-3-y1)-4-(piperazin-1-yl)isoindoline-1,3-dione hydrochloride (1.4 g crude), which was used in next step without further purification. LCMS (ES): m/z 343.1 [M+H]
+.
[0603] Step F: 4 (4 (3 (2 (4 (4 bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propyl)piperazin-l-y1)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione NON
. 0 /---C/

B rT N N 0 ( / cCrIF-I

[0604] To a solution of 3-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propanal (140 mg crude, 0.32 mmol), 2-(2,6-dioxopiperidin-3-y1)-4-(piperazin- 1-y1) isoindoline-1,3-dione (123 mg, 0.32 mmol), NaBH3CN (41 mg, 0.64 mmol), acetic acid (3.8 mg, 0.062 mmol) in Me0H. The resulting solution was stirred atrt for overnight.
The mixture was diluted with EA, washed with water, and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified to afford the desired product 4-(4-(3-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-yl)phenoxy)ethoxy)propyl)piperazin-1-y1)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (DCM:Me0H = 15:1) (70 mg) as yellow solid. LCMS (ES): m/z 742.1 [M+H] +.
[0605] Step G: 2-(2,6-dioxopiperidin-3-y1)-4-(4-(3-(2-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propyl)piperazin-l-yl)isoindoline-1,3-dione /.........7"-N7¨\
0 *0 ¨NI 0 c*CrIF:1 \ /

[0606] To a solution of 4-(4-(3-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-yl)phenoxy)ethoxy)propyl)piperazin-1-y1)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (70 mg, 0.094 mmol), 5-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-2,3-dihydro-1H-inden-1-one (191 mg, 0.74 mmol), Pd2(dba)3 (181 mg, 0.198 mmol), CsF (300 mg, 1.97 mmol).
tri-tert-butylphosphine tetrafluoroborate (115 mg, 0.39 mmol), N,N-dicyclohexylmethylamine (9 mg, 0.047 mmol) in 1,4-dioxane/H20 (6 mL, 10/1). The resulting solution was irradiated at 100 C
with microwave under N2 for 2 hours. After cooling to room temperature, the mixture was diluted with EA, washed with water, and brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified to afford the desired product 2-(2,6-dioxopiperidin-3-y1)-4-(4-(3-(2-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propyl)piperazin-l-yl)isoindoline-1,3-dione (DCM:Me0H = 20:1) (33 mg) as yellow solid. LCMS (ES): m/z 795.3 [M-FH] +.
[0607] Step H: (E)-2-(2,6-dioxopiperidin-3-y1)-4-(4-(3-(2-(4-(4-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propyl)piperazin-l-yl)isoindoline-1,3-dione 7.--\
/___7-N\_____iN
HO -N\ 0..x-0 cCr11:1 \ /

[0608] To a solution of 2-(2,6-dioxopiperidin-3-y1)-4-(4-(3-(2-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propyl)piperazin-l-yl)isoindoline-1,3-dione (33 mg, 0.042 mmol) in acetonitrile (2 mL) and pyridine (1.5 mL), added hydroxylamine hydrochloride (27 mg, 0.42 mmol). The mixture was stirred at 40 C for 20 minutes, and it was diluted with DCM 20mL, washed with brine (10 mL). The organic layer was concentrated and purified by preparative TLC to afford (E)-2-(2,6-dioxopiperidin-3-y1)-4-(4-(3-(2-(4-(4-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)propyl)piperazin-l-yl)isoindoline-1,3-dione (22 mg, 66.6%
yield) as yellow solid. 1H NMR (400 MHz, CDC13): 6 8.56 (d, J = 5.6 Hz, 2H), 8.37 (s, 1H), 7.94 (s, 1H), 7.68 (d, J = 9.2 Hz, 3H), 7.55-7.57 (m, 1H), 7.51 (d, J = 5.6 Hz, 2H), 7.38-7.40 (m, 1H), 7.21-7.28 (m, 2H), 7.15 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 8.8 Hz, 2H), 4.91-4.98 (m, 1H), 4.18 (d, J = 4.8 Hz, 2H), 3.82-3.84 (m, 2H), 3.63 (d, J = 6.4 Hz, 2H), 3.49 (s, 2H), 3.36-3.38 (m, 4H), 3.02 (d, J = 10.8 Hz, 4H), 2.69-2.87 (m, 8H), 2.52-2.56 (m, 2H), 1.85-1.88 (m, 1H);
LCMS (ES):
m/z 810.2 [M-FH] +.
[0609] Compounds 151-172 and 282-284 may be prepared in an analogous manner.
[0610] Example synthesis of compound 174 HO-N H o N
\ 0 N .

¨NI
, 0 \
N /
[0611] Step A: 4-(benzyloxy)butyl 4-methylbenzenesulfonate ,--............,-.....õ.õ.0 Bn0 Ts [0612] To a solution of 4-(benzyloxy)butyl 4-methylbenzenesulfonate (5 g, 27.76 mmol), DMAP (0.34 g, 2.78 mmol) and TEA (8.4 g, 83.28 mmol) in DCM (50 mL) was added TsC1 (7.94 g, 41.64 mmol) batches. The resulting solution was stirred at 15 C for 2 hours. The reaction was quenched by addition of saturated NH4C1 (50 mL). The mixture was extracted with DCM (50 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate, concentrated under vacuum. The residue was purified by silica gel to afford desired product 4-(benzyloxy)butyl 4-methylbenzenesulfonate (5.6 g, 60% yield) as a light yellow oil. 1H NMR
(400 MHz, CDC13): 6 7.77 (d, J = 8.4 Hz, 2H), 7.26-7.33 (m, 7H), 4.45 (s, 2H), 4.05 (t, J = 6.4 Hz, 2H), 3.42 (t, J = 6.4 Hz, 2H), 2.44 (s, 3H), 1.59-1.78 (m, 4H).
[0613] Step B: (S)-tert-butyl 5-amino-4-(4-(4-(benzyloxy)butoxy)-1,3-dioxoisoindolin-2-y1)-5-oxopentanoate Bn0¨\ r0 N,/
\

>0 [0614] To a solution of 4-(benzyloxy)butyl 4-methylbenzenesulfonate (0.63 g, 1.87 mmol) in dry DMF (8.0 mL) was added K2C 03 (0.4 g, 2.88 mmol), tert-butyl (S)-5-amino-4-(4-hydroxy-1,3-dioxoisoindolin-2-y1)-5-oxopentanoate (0.5 g, 1.44 mmol) subsequently. The resulting solution was stirred at 70 C for 2 hours. After cooling to room temperature, the reaction was quenched with water (30 mL), and the mixture was extracted with EA (40 mL x 2). The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, concentrated under vacuum. The residue was purified by silica gel column to afford (S)-tert-butyl 5-amino-4-(4-(4-(benzyloxy)butoxy)-1,3-dioxoisoindolin-2-y1)-5-oxopentanoate (0.4 g, 55% yield). 1H NMR (400 MHz, CDC13): 6 7.63 (t, J = 8.4 Hz, 1H), 7.43 (m, 1H), 7.25-7.40 (m, 5H), 7.18 (s, 1H), 6.41 (br, 1H), 5.66 (br, 1H), 4.79 (m, 1H), 4.52 (s, 2H), 4.19 (t, J = 6.4 Hz, 2H), 3.58 (t, J = 6.4 Hz, 2H), 3.47 (m, 2H), 2.50 (m, 2H), 2.25 (m, 2H), 2.00 (m, 2H), 1.85 (m, 1H), 1.43 (s, 9H).
[0615] Step C: (S)-2-(2,6-dioxopiperidin-3-y1)-4-(4-hydroxybutoxy)isoindoline-1,3-dione N __________________________________________ )-NH

[0616] To a solution of (S)-Tert-butyl 5-amino-4-(4-(4-(benzyloxy)butoxy)-1,3-dioxoisoindolin-2-y1)-5-oxopentanoate (400 mg, 0.784 mmol) in acetonitrile (5 mL) was added Ts0H H20 (1.48 g, 7.84 mmol). The resulting solution was stirred at 80 C for 2 hours. The reaction was quenched by saturated NaHCO3 and extracted with EA. The organic layer was dried over anhydrous sodium sulfate, concentrated and purified by column to afford (S)-4-(4-(benzyloxy)butoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (370 mg).
To a solution of (S)-4-(4-(benzyloxy)butoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (370 mg, 0.85 mmol) in THF / Me0H (4 mL / 1 mL) was added Pd(OH)2 (185 mg) and two drops of concentrated HC1. The resulting mixture was stirred at 20 C for 1 hour under H2 1 atm. The resulting solution was filtered and evaporated. The residue was purified by preparative TLC to afford the desired product (S)-2-(2,6-dioxopiperidin-3-y1)-4-(4-hydroxybutoxy)isoindoline-1,3-dione (250 mg, 92% yield in two steps). LCMS (ES, Neg): m/z 345.0 [M-H]
[0617] Step D: (S)-4-((2-(2,6-Dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)oxy)butanal N

[0618] To a solution of (S)-2-(2,6-dioxopiperidin-3-y1)-4-(4-hydroxybutoxy)isoindoline-1,3-dione (0.25 g, 0.72 mmol) in CH3CN (5 mL) was added IBX (607 mg, 2.16 mmol).
The resulting solution was stirred at 75 C for 1 hour. After cooling to room temperature, the reaction mixture was filtered and concentrated under vacuum to afford crude desired product (240 mg crude, calculated, 100% yield), which was used in next step directly.

[0619] Step E: (S)-4-(4-(4-(4-(4-Bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)butoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Br , 11 Nn\1 H
N -\
---_, N \--/ \ ONO
I \ 0 N 7 N ) [0620] To a solution of (S)-4-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)oxy)butanal (240 mg crude, 0.72 mmol) in Me0H (6 mL) was added 1-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazine (276 mg, 0.72 mmol) and two drops of AcOH.
Then NaBH3CN (134 mg, 2.16 mmol) was added. The resulting solution was stirred at 18 C for 2 hours. After quenched with water (30 mL), and the mixture was extracted with EA (40 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column to afford desired product (S)-4-(4-(4-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)butoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (350 mg, 68% yield in two steps).
LCMS (ES): m/z 713.1 [M+H] +.
[0621] Step F: (S)-2-(2,6-Dioxopiperidin-3-y1)-4 (4 (4 (4 (4 (1 oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)butoxy)isoindoline-1,3-dione ---N 41 r-\ H
N ,., co N õeu -----.. N /N -\ __ \ 0 1 \-0 N , [0622] To a solution of (S)-4-(4-(4-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-yl)phenyl)piperazin-l-yl)butoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (0.35 g, 0.52 mmol) and 5-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-2,3-dihydro-1H-inden-1-one (147 mg, 0.57 mmol) in 1,4-dioxane (15 mL)/ H20 (1.5 mL) was added CsF (316 mg, 2.08 mmol), Pd2(dba)3 (190 mg, 0.21 mmol). tri-tert-butylphosphine tetrafluoroborate (121 mg, 0.42 mmol) and two drops of N-cyclohexyl-N-methylcyclohexanamine subsequently. The reaction was heated to 100 C for 2 hour under N2 atmosphere. After cooling to room temperature, the reaction was quenched with water (20 mL), and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column to afford desired product (S)-2-(2,6-dioxopiperidin-3-y1)-4-(4-(4-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-l-yl)butoxy)isoindoline-1,3-dione (0.3 g, 80%
yield) as yellow solid. LCMS (ES+): m/z 382.8 [(M+H)/2] .
[0623] Step G: (S,E)-2-(2,6-dioxopiperidin-3-y1)-4 (4 (4 (4 (4 (1 (hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)butoxy)isoindoline-1,3-dione HO-N H
=
r'N 0 o N
[0624] To a solution of (S)-2-(2,6-dioxopiperidin-3-y1)-4-(4-(4-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-l-yl)butoxy)isoindoline-1,3-dione (165 mg, 0.22 mmol) in acetonitrile / pyridine (6 ml /3 ml) was added hydroxylamine hydrochloride (150 mg, 2.16 mmol). The mixture was stirred at 45 C for 1 hour.
The solvent was removed under vacuum, and the residue was purified by preparative TLC with DCM /
Me0H (20 / 1) to afford the desired product (S,E)-2-(2,6-dioxopiperidin-3-y1)-4-(4-(4-(4-(4-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenyl)piperazin-1-yl)butoxy)isoindoline-1,3-dione (60 mg, 38% yield) as a white solid. 1H NMR
(400 MHz, DMSO-d6): 6 11.11 (s, 1H), 10.88 (d, J = 3.6 Hz, 1H), 8.69 (s, 1H), 8.56 (m, 2H), 7.81 (m, 3H), 7.35-7.62 (m, 6H), 7.20 (s, 1H), 7.09 (m, 2H), 5.10 (m, 1H), 4.25 (t, J = 6.4 Hz, 2H), 3.32 (m, 4H), 3.19 (m, 4H), 2.75-3.05 (m, 5H), 2.40 (m, 2H), 1.60-2.10 (m, 8H); LCMS
(ES+): m/z 779.3 [M+H] .
[0625] Compounds 173 and 175-181 may be prepared in an analogous manner.
[0626] Example synthesis of compound 182 N)WN\J
Fo N
[0627] Step A: N-(3-(5-((1-(2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)piperidin-4-y1)(methyl)amino)-3-(pyrimidin-5- y1)-1H-pyrrolo [3 ,2-b1 pyridin-1- y1)-2,4-difluorophenyl)propane-1-sulfonamide N N
F

[0628] A mixture of N-(2,4-difluoro-3-(5-(methyl(piperidin-4-yl)amino)-3-(pyrimidin- 5-y1)-1H-pyrrolo[3,2-b[pyridin-1-yl)phenyl)propane-1-sulfonamide (100.0 mg, 0.18mmol) (previously described in W02012/104388), 2-(2,6-dioxopiperidin-3-y1)-4-fluoroisoindoline-1,3-dione (102 mg, 0.36 mmol), DIEA(239 mg, 1.80 mmol) in anhydrous NMP (2.0 mL) was radiated at 130 C
with microwave for 1 hour. After cooling to room temperature, the reaction was quenched with water, and the mixture was extracted with EA (10 mL x 3). The combined organic layer was washed with water (10 mL x 3), brine (20 mL), dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by preparative TLC to afford the desired product N-(3-(5-((1-(2-(2,6-dioxopiperidin-3-y1)- 1,3-dioxoisoindolin-4-yl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-y1)-1H- pyrrolo[3,2-b[pyridin-1-y1)-2,4-difluorophenyl)propane-1-sulfonamide ( DCM : Me0H = 10:1) (45 mg, yield =
30.6%) as white solid. 1H NMR (400 MHz, CDC13): 6 9.58 (s, 1H), 9.10 (s, 1H), 8.03 (s, 1H), 7.67-7.59 (m, 2H), 7.42 (d, J =7.2 Hz, 1H), 7.34 (d, J =8 Hz, 1H), 7.23-7.18 (m, 1H), 6.66 (d, J
=12 Hz, 1H), 5.02-4.81 (m, 1H), 3.90-3.89 (m, 1H), 3.18-3.14 (m, 3H), 3.05 (s, 2H), 2.96-2.87 (m, 3H), 2.13 (dd, J
=2.8 Hz,4 Hz, 2 H), 2.00-1.90 (m, 3H), 1.30 (s, 8H), 1.09 (t, J =12.0 Hz, 3H), 0.84-.088 (m, 4H);
LCMS (ES): m/z 798.2 [M+H]t [0629] Compound 183 may be prepared in an analogous manner.
[0630] Example synthesis of compound 184 cin = N N N 0 0 N p [0631] Step A: tert-butyl (S)-5-amino-4-(4-(2-(benzyloxy)ethoxy)-1,3-dioxoisoindolin-2-y1)-5-oxopentanoate \¨NH2 N _____________________________________ , :
\ _____________________________________________ Y
0 0 & 0 ) 0 Bn0 [0632] A mixture of tert-butyl (S)-5-amino-4-(4-hydroxy-1,3-dioxoisoindolin-2 -y1)-5-oxopentanoate (1.22 g, 3.51mmol), 2-(benzyloxy)ethyl methanesulfonate (900 mg, 3.91 mmol), K2CO3(1.08 g, 7.83 mmol) in DMF (10 mL) was stirred at 70 C for 6 hours.
After quenched with water, the mixture was extracted with EA. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified to afford the desired product tert-butyl (S)-5-amino-4-(4-(2- (benzyloxy)ethoxy)-1,3-dioxoisoindolin-2-y1)-5-oxopentanoate (PE:Et0Ac = 1:5) (907 mg).
[0633] Step B: (S)-4-(2-(benzyloxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione ro Bnaj [0634] To a solution of tert-butyl (S)-5-amino-4-(4-(2-(benzyloxy)ethoxy)-1,3 -dioxoisoindolin-2-y1)-5-oxopentanoate (907 mg, 1.88 mmol), p-Ts0H (1.5 g, 7.89 mmol) in MeCN (10 mL) was stirred with at 80 C for 8 hours. After quenched with water, the mixture was diluted with EA, washed with water, brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified to afford the desired product (S)-4-(2-(benzyloxy)ethoxy)-2-(2,6- dioxopiperidin-3-yl)isoindoline-1,3-dione (PE:Et0Ac = 1:1) (1.23 g, crude).
[0635] Step C: (S)-2-(2,6-dioxopiperidin-3-y1)-4-(2-hydroxyethoxy)isoindoline-1,3-dione HO' HO--/
[0636] To a solution of (S)-4-(2-(benzyloxy)ethoxy)-2-(2,6-dioxopiperidin-3-y1) isoindoline-1,3-dione (1.23 g, 3.01 mmol), Pd(OH)2/C(0.7 g), HC1/dioxane (6N, 6 drops) in Me0H/Et0Ac (1:1, 40 mL) was stirred with at room temperature for 12 hours under H2 1 atm.
The mixture was filtered through Celite and the filtrate was concentrated under vacuum to afford the desired product (S)-2-(2,6-dioxopiperidin-3-y1)-4-(2- hydroxyethoxy)isoindoline-1,3-dione (700 mg, crude).
[0637] Step D: (S)-2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)oxy)acetaldehyde NH
r 0 0 [0638] To a solution of (S)-2-(2,6-dioxopiperidin-3-y1)-4-(2-hydroxyethoxy)isoindoline -1,3-dione (200 mg, 0.63 mmol) in CH3CN (10 mL) was added IBX (352 mg, 1.26 mmol).
The resulting solution was stirred at 80 C for 2 hours. After cooling to room temperature, the mixture was filtered, and the filtrate was concentrated under vacuum to afford crude desired product (S)-2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)oxy) acetaldehyde (200 mg crude) as yellow solid, which was used into next reaction without further purification.

[0639] Step E: N-(3-(5-((1-(2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)piperidin-4-y1)(methyl)amino)-3-(pyrimidin-5-y1)-1H-pyrrolo [3 ,2-111 pyridin-l-y1)-2,4-difluorophenyl)propane-l-sulfonamide . NNOO
N ,0 [0640] To a solution of (S)-2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin- 4-yl)oxy)acetaldehyde (200 mg crude, 0.631 mmol), N-(2,4-difluoro-3-(5-(methyl (piperidin-4-yl)amino)-3-(pyrimidin-5 -y1)-1H-pyrrolo [3 ,2-b] pyridin-l-yl)phenyl)prop ane-l-sulfonamide hydrochloride (80 mg, 0.148 mmol), CH3COOH (3.8 mg, 0.062 mmol) in Et0H/DCM(v/v =1/1, 20 mL) was added NaBH(OAc)3 (400 mg, 1.88 mmol). The resulting solution was stirred at room temperature overnight. After quenched with water, the mixture was extracted with Et0Ac.
The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was purified by prep-TLC (DCM/Et0Ac/Me0H=10/1/1) to afford the desired product (S)-N-(3-(5- ((1-(2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-y1)-oxy)ethyl)piperidin- 4-y1)(methyl)amino)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-b[pyridin-1-y1)-2,4-difluorophenyl)propane-1-sulfonamide (20.1 mg) as white solid. 1H NMR (400 MHz, DMSO-d6) 6 11.07 (s, 1H), 9.80¨ 10.02 (m, 1H), 9.66 (s, 1H), 9.01 (s, 1H), 8.40 (s, 1H), 7.80 ¨ 7.89 (m, 1H), 7.61-7.63 (m, 2H), 7.44-7.48 (m, 2H), 6.76 (d, J = 9.3 Hz, 1H), 5.08 (dd, J = 12.9, 5.2 Hz, 1H), 4.33 ¨ 4.49 (m, 3H), 3.45 (s, 6H), 3.06 ¨ 3.25 (m, 3H), 2.94 (s, 2H), 2.83 (s, 2H), 2.55 ¨
2.73 (m, 4H), 2.29 (d, J = 10.3 Hz, 2H), 1.77 (m, 2H), 1.68 (d, J = 10.1 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H); LC-MS: (ES): m/z 842.3 [M-FH] +.
[0641] Compounds 185-189 may be prepared in an analogous manner.
[0642] Example synthesis of compound 191 I OH
z-F nN 0 --Th it N__N1 N e-0J-1\.µr NI-TI
-.
Os__N H o 0 z.-OH F / \ ...._\ N HN
N:-_-.--/
S
N \
[0643] Step A: tert-butyl 2-(2-(2-oxoethoxy)ethoxy)acetate o0-'()')0 [0644] To a solution of tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)acetate (1 g, 4.55 mmol) in CH3CN (15 mL) was added IBX (3.8 g, 13.64 mmol). The resulting solution was stirred at 75 C
for 1 hour. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated under vacuum to afford crude desired product tert-butyl 2-(2-(2-oxoethoxy)ethoxy)acetate (1 g crude, 100% yield), which was used in next step directly. 1H
NMR (400 MHz, CDC13): 6 9.75 (s, 1H), 4.18 (s, 2H), 4.03 (s, 2H), 3.77 (s, 4H), 1.48 (s, 9H).
[0645] Step B: tert-buty1-2-(2-(2-(4-((1-(2,6-difluoro-3-(propylsulfonamido)pheny1)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-blpyridin-5-y1)(methyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetate N
__'\) 410 N \ N N .e-0j-e=K
0:-..-p_N -OH F
N-:.---/
[0646] To a solution of tert-butyl 2-(2-(2-oxoethoxy)ethoxy)acetate (181 mg crude, 0.83 mmol) in Et0H / DCM (1 / 1) was added N-(2,4-difluoro-3-(5-(methyl(piperidin -4-yl)amino)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-b]pyridin-1-y1)phenyl)propane-1-sulfonamide hydrochloride (150 mg, 0.28 mmol) and cat. AcOH. KOAc was added if pH was below 5-6. After stirring for 30 minutes, NaBH(OAc)3 (235 mg, 1.11 mmol) was added. The resulting solution was stirred at 30 C for 1 hour. After quenched with water (20 mL), the mixture was extracted with DCM (30 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column to afford desired product 2-(2-(2-(4-((1-(2,6-difluoro-3-(propylsulfonamido)pheny1)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-b[pyridin-5-y1)(methyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetate (120 mg, 58%
yield).
LCMS: (ES): m/z 744.3 [M-FH] +.
[0647] Step C: 2-(2-(2-(4-((1-(2,6-difluoro-3-(propylsulfonamido)pheny1)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-b[pyridin-5-y1)(methyl)amino)piperidin-1-y1)ethoxy)ethoxy)acetic acid F nN 0 ---- . ). N \ N N
0--zs_N
OH F
N--.:j [0648] To a solution of tert-butyl 2-(2-(2-(4-((1-(2,6-difluoro-3-(propylsulfonamido)phenyl) -3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-b[pyridin-5-y1)(methyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetate (0.12 g, 0.16 mmol) in DCM (3 mL) was added TFA (1 mL). The resulting solution was stirred at 30 C for 1 hour. The solvent was removed under vacuum to afford the desired product 2-(2-(2-(4-((1-(2,6-difluoro-3-(propylsulfonamido)pheny1)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-b[pyridin-5-y1)(methyl)amino)piperidin-1-y1)ethoxy)ethoxy)acetic acid (111 mg crude, calculated), which was used into next reaction without further purification. LCMS: (ES): m/z 688.2 [M-FH] +.
[0649] Step D: (25,4R)-1-((S)-2 (2 (2 (2 (4 ((1-(2,6-difluoro-3-(propylsulfonamido)pheny1)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-blpyridin-5-y1)(methyl)amino)piperidin-1-y1)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-y1)benzyl)pyrrolidine-2-carboxamide I OH
z--Th it N....N___\ \N ()0A1\(.rN TI
I--.
Oz.-s__N H o o ¨
OH F / \ N HN
N:-..-.--/
S
N \
[0650] To a solution of 2-(2-(2-(4-((1-(2,6-difluoro-3-(propylsulfonamido)pheny1)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-b]pyridin-5-y1)(methyl)amino)piperidin-1-y1)ethoxy)ethoxy)acetic acid (111 mg crude, 0.16 mmol) in DCM (10 mL) was added (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (150 mg, 0.32 mmol), D1PEA (209 mg, 1.62 mmol) and PyBOP
(250 mg, 0.48 mmol) subsequently. After stirring at 30 C for 1 hour, the reaction mixture was diluted with DCM (30 mL), washed with water (10 mL x 2), brine (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by column (DCM / Me0H 19/1) first and further purified by prep-HPLC
to afford the desired product (2S,4R)-1-((S)-2-(2-(2-(2-(4-((1-(2,6-difluoro-3-(propylsulfonamido)pheny1)-3-(pyrimidin-5-y1)-1H-pyrrolo[3,2-b]pyridin-5-y1)(methyl)amino)piperidin-1-y1)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-y1)benzyl)pyrrolidine-2-carboxamide (55 mg, 31% yield in two steps) as white solid. 1H NMR
(400 MHz, DMSO-d6): 6 9.65 (s, 2H), 9.02 (s, 1H), 8.94 (s, 1H), 8.57 (t, J =
4.8 Hz, 1H), 8.40 (m, 1H), 7.55-7.65 (m, 1H), 7.35-7.50 (m, 7H), 6.74 (d, J = 9.2 Hz, 1H), 4.57 (d, J = 9.6 Hz, 1H), 4.20-4.50 (m, 5H), 4.00 (s, 2H), 3.50-3.70 (m, 2H), 3.00-3.20 (m, 7H), 2.93 (s, 3H), 2.50-2.70 (m, 4H), 2.43 (s, 3H), 1.60-2.25 (m, 13H), 0.90-1.05 (m, 12H); LCMS: (ES): m/z 1101.4 [M+H] +.
[0651] Compounds 190 and 192 may be prepared in an analogous manner.
[0652] Example synthesis of compound 195 [(3R) N (3 (5 (4 (2 (2 (2,6 dioxopiperidin-3-y1)-1,3-dioxoisoindolin-5-yloxy)ethoxy)pheny1)-1H-pyrrolo[2,3-b[pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamidel ,Th N
[0653] Step A: ethyl 2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)acetate o [0654] To a solution of 4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenol (5 g, 22.7 mmol) in N,N-dimethylformamide (50 mL) was added ethyl 2-bromoacetate (4.52 g, 27.2 mmol) and potassium carbonate (6.27 g, 45.4 mmol). The mixture was stirred overnight under nitrogen gas. The reaction mixture was added to water (200 mL), and extracted with ethyl acetate (150 mL x 3). The organic layer was washed with brine (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give ethyl 2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)acetate (5.2 g, 75%) as colorless oil.
[0655] Step B: methyl 2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethanol o0H
B.
[0656] To a solution of ethyl 2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-yl)phenoxy)acetate (1 g, 3.27 mmol) in tetrahydrofuran/ethanol (10 mL/10 mL) was added sodium borohydride (124 mg, 3.27 mmol) under ice-water bath. The mixture was allowed to warm to room temperature and stirred for 2 hours. The mixture was partitioned between ethyl acetate (100 mL) and water (50 mL). The organic layer was separated, washed with brine (20 mL

x 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give methyl 2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethanol (0.8 g, 93%) as colorless oil.
[0657] Step C: 2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl methanesulfonate 00Ms 1.1 ,B, [0658] To a solution of 2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethanol (200 mg, 0.76 mmol) and ehyldiisopropylamine (293 mg, 2.27 mol) in dichloromethane (10.0 mL) was added methanesulfonyl chloride (105 mg, 0.91 mmol) under cooling, and the mixture was stirred at 0 C for 30 minutes. The mixture was quenched with cold water (10.0 mL), the organic layer was washed with sodium bicarbonate solution (10.0 mL x 3) and brine (10.0 mL x 3), dried over anhydrous saturated sodium sulfate, filtered and concentrated in vacuo to afford (2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl methanesulfonate which was used for next step directly.
[0659] Step D: 2-(2,6-dioxopiperidin-3-y1)-5-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)isoindoline-1,3-dione 0 0, 0,B 0 10 1\1-¨Nli 0 -)-(!) 0 [0660] The mixture of (2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl methanesulfonate (260 mg, 0.76 mmol), potassium carbonate (210 mg, 1.52 mol), potassium iodide (126 mg, 0.76 mmol) and 2-(2,6-dioxopiperidin-3-y1)-5-hydroxyisoindoline-1,3-dione (208 mg, 0.76 mmol) in dimethyl sulfoxide (10 mL) was stirred at 60 C
overnight. The resulting mixture was cooled down to room temperature. Water (20 mL) and ethyl acetate (20 mL) was added. The organic layer was separated, washed with brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give the crude product which was purified by pre-TLC(dichloromethane/ methano1=20:1) to give 2-(2,6-dioxopiperidin-3-y1)-5-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)isoindoline-1,3-dione (140 mg, 36% two steps) as a white solid. LCMS (ES): m/z 521.2 [M+H], 538.2 [M+18] .
[0661] Step E: (3R) N (3 (5 (4 (2 (2 (2,6 dioxopiperidin-3-y1)-1,3-dioxoisoindolin-5-yloxy)ethoxy)pheny1)-1H-pyrrolo[2,3-blpyridine-3-carbony1)-2,4-difluoropheny1)-fluoropyrrolidine-1-sulfonamide F

F)----/ N N
H
[0662] To a solution of 2-(2,6-dioxopiperidin-3-y1)-5-(2-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)isoindoline-1,3-dione (136 mg, 0.26 mmol), (R)-N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (120 mg, 0.24 mmol) and CsF (0.18 mg , 0.012 mmol) in 1,4-dioxane (10 mL) and water (2 mL) was added Pd(aMPhos)C12 (17 mg, 0.024 mmol) under argon atmosphere, and the mixture was stirred at 100 C for 6 hours. When it was cooled to room temperature, water (20 mL) was added and the resultant mixture was extracted by EA (20 mL x 3), washed by brine (10 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by pre-HPLC to give (3R)-N-(3-(5-(4-(2-(2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-5-yloxy)ethoxy)pheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoropheny1)-3-fluoropyrrolidine-1-sulfonamide (8.1 mg, 4% yield) as a white solid. LCMS
(ES): m/z 817.2 [M+H]; 1H NMR (400 MHz, DMSO-d6) 6 2.06-2.09 (3H, m), 2.55-2.62 (2H, m), 2.85-2.93 (1H, m), 3.24-3.27 (1H, m), 3.38-3.50 (3H, m), 4.42-4.46 (2H, m), 4.58-4.62 (2H, m), 5.12-5.16 (1H, m), 5.23-5.36 (1H, m), 7.15 (2H, d, J= 8.8 Hz), 7.25 (1H, t, J= 8.8 Hz), 7.45 (1H, dd, J= 2.4, 8.4 Hz), 7.55 (1H, d, J= 2.0 Hz), 7.59-7.63 (1H, m), 7.70 (2H, d, J= 8.4 Hz), 7.87 (1H, d, J= 8.4 Hz), 8.10 (1H, s), 8.58 (1H, s), 8.68 (1H, d, J=2.4 Hz), 9.89 (1H, brs.), 11.14 (1H, s), 12.96 (1H, brs.).
[0663] Compounds 194 and 195 may be prepared in an analogous manner.
[0664] Example synthesis of compound 2851-(25,4R)-1-((S)-2 (3 (2 (4 (4 (3 (2,6-difluoro-3-(((R)-3-fluoropyrrolidine)-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-blpyridin-5-yl)phenyl)piperazin-l-yflethoxy)isoxazol-5-y1)-3-methylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamidel and compound 286 [(2S,4R)-14(R)-2-(3-(2-(4-(4-(3-(2,6-difluoro-3-(((R)-3-fluoropyrrolidine)-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-blpyridin-5-y1)phenyl)piperazin-1-yflethoxy)isoxazol-5-y1)-3-methylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamidel F r N 0c,rµii, .,,OH

il I-1 F / 1 NH
F -----/ N N
H S
\\ /
N
and F r N 0sN
\.01,1 .,,OH

F-----/ N N
H SOJ
\\ /
N
[0665] Step A: 2-(3-hydroxy-1,2-oxazol-5-y1)-3-methylbutanoic acid / \
OH
N,0 [0666] Into a 100 mL round-bottom flask, was placed 2-(3-methoxy-1,2-oxazol-5-y1)-3-methylbutanoic acid (1.0 g, 5.02 mmol, 1.0 equiv) and a solution of hydrobromic acid (11.9 g, 147.07 mmol, 29.30 equiv) in acetic acid (20 mL). The resulting solution was stirred overnight at 60 C in an oil bath. The reaction mixture was concentrated under reduced pressure. This resulted in 650.0 mg (crude) of 2-(3-hydroxy-1, 2-oxazol-5-y1)-3-methylbutanoic acid as a white solid.
[0667] LCMS (ES): m/z 186.05 [M+H]t [0668] Step B: ethyl 2-(3-hydroxy-1,2-oxazol-5-y1)-3-methylbutanoate HO

/ \ /----N, 0 [0669] Into a 50 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-(3-hydroxy-1,2-oxazol-5-y1)-3-methylbutanoic acid (650.0 mg, 3.51 mmol, 1.00 equiv) in ethanol (30 mL), sulfuric acid (1 mL). The resulting solution was stirred overnight at 70 C. The reaction mixture was then quenched by the addition of 20 mL
water and extracted with ethyl acetate (20 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate. Filtered and the filtrate was concentrated under reduced pressure.
This resulted in 720.0 mg (96%) of ethyl 2-(3-hydroxy-1,2-oxazol-5-y1)-3-methylbutanoate as light yellow oil.
[0670] Step C: ethyl 2-[3-(2-bromoethoxy)-1,2-oxazol-5-y11-3-methylbutanoate BrO \
I \
Ng 0µ
\------[0671] Into a 50 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of ethyl 2-(3-hydroxy-1,2-oxazol-5-y1)-3-methylbutanoate (380.0 mg, 1.78 mmo1,1.00 equiv) in acetone (15 mL), 1,2-dibromoethane (994.8 mg, 5.30 mmol, 3.00 equiv), Cs2CO3(1.17 g, 3.59 mmol, 2.00 equiv). The resulting mixture was stirred overnight at room temperature. The reaction mixture was then quenched by the addition of water (15 mL), and extracted with ethyl acetate (20 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was applied onto a silica gel column eluting with ethyl acetate/petroleum ether (1:5).
This resulted in 450.0 mg (79%) of ethyl 243-(2-bromoethoxy)-1,2-oxazol-5-y1]-3-methylbutanoate as a colorless solid.
[0672] Step D: 1-[4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenylipiperazine 40N IB4100 Nr¨NH
0/ \--/
[0673] Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl 444-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-l-carboxylate (1.6 g, 4.12 mmol, 1.00 equiv) in dichloromethane (40 mL), followed by the addition of TMSOTf (1.5 g, 6.75 mmol, 1.60 equiv) dropwise with stirring at 0 C. To the above solution was added 6-dimethylpyridine (132.5 mg, 1.00 mmol, 0.30 equiv).
The resulting solution was stirred for 3 hours at room temperature. The reaction was then quenched by the addition of 50 mL of saturated sodium bicarbonate aqueous. The resulting solution was extracted with ethyl acetate (30 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was applied onto a silica gel column eluting with dichloromethane/methanol (10:1).
This resulted in 854.0 mg (72%) of 144-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl]piperazine as off-white solid. LCMS (ES): m/z 289.15 [M+H]t [0674] Step E: ethyl 3-methyl-2 [3 (2 [4 [4 (tetramethy1-1,3,2-dioxaborolan-2-yl)phenyllpiperazin-l-yllethoxy)-1,2-oxazol-5-yllbutanoate rNC) N I \

0 \---[06751 Into a 30 mL sealed tube purged and maintained with an inert atmosphere of nitrogen, was placed a solution of ethyl 243-(2-bromoethoxy)-1,2-oxazol-5-y11-3-methylbutanoate (576.0 mg, 1.80 mmol, 1.00 equiv) in N,N-dimethylformamide (6 mL), 1-[4-(tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl]piperazine (624.0 mg, 2.17 mmol, 1.20 equiv), DIEA
(17 mL), NaI
(20 mg). The resulting solution was stirred for 16 hours at 130 C. The reaction mixture was then quenched by the addition of 30 mL of water. The resulting solution was extracted with ethyl acetate (30 mL x 3). The combined organic layer was washed with brine (30 mL x 3), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was applied onto a silica gel column eluting with ethyl acetate/petroleum ether (1:2).
This resulted in 720.0 mg (76%) of ethyl 3-methy1-2-[3-(2-[4-[4-(tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl]piperazin-1-yl]ethoxy)-1,2-oxazol-5-yl]butanoate as a light yellow solid. LCMS (ES):
m/z 528.25 [M+H]t [0676] Step F: ethyl 2-(3- [2-[4-(4-amino] phenyl)carbony11-1H-pyrrolo[2,3-b[pyridin-5-yllphenyl)piperazin-l-yllethoxyl -1,2-oxazol-5-y1)-3-methylbutanoate 0 N N-0 OEt Oz.-s"....N
H
[0677] r [0678] Into a 30 mL sealed tube purged and maintained with an inert atmosphere of nitrogen, was placed a solution of ethyl 3-methy1-2-[3-(2-[4-[4-(tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl]piperazin-1-yl]ethoxy)-1,2-oxazol-5-yl]butanoate (527.0 mg, 1.00 mmol, 1.00 equiv) in 20 mL of 1,4-dioxane/water(4:1), (3R)-N-[3-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylcarbony1)-2,4-difluoropheny1]-3-fluoropyrrolidine-1-sulfonamide (503.0 mg, 1.00 mmol, 1.00 equiv), sodium carbonate (318.0 mg, 3.00 mmol, 3.00 equiv), Pd(dppf)C12 (82.0 mg, 0.10 mmol, 0.10 equiv). The reaction mixture was reacted under microwave radiation for 2 hours at 100 C.
The reaction mixture was then quenched by the addition of 20 mL of water. The resulting solution was extracted with ethyl acetate (30 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was applied onto a silica gel column eluting with dichloromethane/methanol (10:1).
This resulted in 460.0 mg (56%) of ethyl 2-(3-[2-[4-(4-[3-[(2,6-difluoro-3-[[(3R)-3-fluoropyrrolidine-1-sulfonyl]amino]phenyl)carbony1]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl)piperazin-1-yl]ethoxy]-1,2-oxazol-5-y1)-3-methylbutanoate as a light yellow solid. LCMS (ES): m/z 824.15 [M+H]t Step G: 2-(3-[2-[4-(4-[3-[(2,6-difluoro-3-[[(3R)-3-fluoropyrrolidine-1-sulfonyllaminolphenyl)carbony11-1H-pyrrolo[2,3-blpyridin-5-yllphenyl)piperazin-1-yllethoxyl-1,2-oxazol-5-y1)-3-methylbutanoic acid I \

, P 0 -----./ N N
H
F
[0679] Into a 50 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of ethyl 2-(3-[2-[4-(4-[3-[(2,6-difluoro-3-[[(3R)-3-fluoropyrrolidine-1-sulfonyl]amino]phenyl)carbony1]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl)piperazin-1-yl]ethoxy]-1,2-oxazol-5-y1)-3-methylbutanoate (420.0 mg, 0.51 mmol, 1.00 equiv) in methanol (10 mL) and then a solution of sodium hydroxide (102.0 mg, 2.55 mmol, 5.00 equiv) in water (2 mL) was added. The resulting solution was stirred at 40 C for 5 hours.
The pH value of the solution was adjusted to pH 6 with hydrogen chloride (1 mol/L). The solids were collected by filtration. The solid was dried in an oven under reduced pressure. This resulted in 366.0 mg (90%) of 2-(3-[2-[4-(4-[3-[(2,6-difluoro-3-[[(3R)-3-fluoropyrrolidine-1-sulfonyl]amino]phenyl)carbony1]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl)piperazin-1-yl]ethoxy]-1,2-oxazol-5-y1)-3-methylbutanoic acid as a solid. LCMS (ES): m/z 796.10 [M+H]t [0680] Step H: (25,4R)-1 [2 (3 [2 [4 (4 [3 [(2,6-difluoro-3-[[(3R)-3-fluoropyrrolidine-1-sulfonyll aminolphenyl)carbonyll -1H-pyrrolo[2,3-b[pyridin-5-yllphenyl)piperazin-l-yllethoxyl -1,2-oxazol-5-y1)-3-methylbutanoy11-4-hydroxy-N-[[4-(4-methy1-1,3-thiazol-5-yl)phenyl-methyllpyrrolidine-2-carboxamide ..,OH
0 N N-o N.i , P
k.).1_N
i 00 F . \
r-- F ' I NH
IL--/ N N S
H
\\ /
N ' [0681] To a solution of 2-(3-[2-[4-(4-[3-[(2,6-difluoro-3-[[(3R)-3-fluoropyrrolidine- 1-sulfonyl]amino]phenyl)carbony1]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl)piperazin-1-yl]ethoxy]-1,2-oxazol-5-y1)-3-methylbutanoic acid (300.0 mg, 0.38 mmol, 1.00 equiv) and (25,4R)-4-hydroxy-N-[4-(4-methy1-1,3-thiazol-5-y1)phenyl]methylpyrrolidine-2-carboxamide hydrochloride (199.9 mg, 0.56 mmol, 1.50 equiv) in N,N-dimethylformamide (10 mL), was added DIEA (3.0 mL) and BOP (200.3 mg, 0.45 mmol, 1.20 equiv). The resulting mixture was stirred for 1 hour at room temperature. The reaction was then quenched by the addition of 20 mL
of water. The resulting solution was extracted with ethyl acetate (30 mL x 3).
The combined organic layer was washed with brine (30 mL x 3), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was applied onto a silica gel column eluting with dichloromethane/methanol (10:1). This resulted in 265.0 mg (64%) of (2S,4R)-1-[2-(3-[2-[4-(4-[3-[(2,6-difluoro-3-[[(3R)-3-fluoropyrrolidine-1-sulfonyl]amino]phenyl)carbony1]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl)piperazin-1-yl]ethoxy]-1,2-oxazol-5-y1)-3-methylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-y1)phenyl]methyl]pyrrolidine-2-carboxamide as a solid.
LCMS (ES): m/z 1095.30 [M+H]t [0682] Step I: (2S,4R)-4-hydroxy-N-[[4-(4-methy1-1,3-thiazol-5-y1)phenyllmethyll-1-(2-[3-[2-(methylamino)ethoxyl-1,2-oxazol-5-yllbutanoyl)pyrrolidine-2-carboxamide F r N Ocr i i . .,\OH

, P 0 ,..,:si_N

F -----/ N N
H ,S
\\ /
N
and 0 N N-0 N.i ii 0 0:...¨s_N

A
F)----/ N NOJ
H vS
\\ /
N
[0683] (2S,4R)-1-[2-(3-[2-[4-(4-[3-[(2,6-difluoro-3-[[(3R)-3-fluoropyrrolidine-1-sulfonyl]amino]phenyl)carbony1]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl)piperazin-1-yl]ethoxy]-1,2-oxazol-5-y1)-3-methylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-y1)phenyl]methyl]pyrrolidine-2-carboxamide was separated by chiral HPLC
resulting in:

[0684] 25.7 mg (10%) of (2S,4R)-1-((S)-2-(3-(2-(4-(4-(3-(2,6-difluoro-3-(((R)-3-fluoropyrrolidine)-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)ethoxy)isoxazol-5-y1)-3-methylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6): 69.10-8.97 (m, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.60-8.53 (m, 2H), 8.10-8.07 (m, 1H), 7.70-7.56 (m, 3H), 7.51-7.21 (m, 5H), 7.18-7.07 (m, 2H), 6.18-6.12 (m, 1H), 5.38-5.21 (m, 1H), 4.44-4.31 (m, 6H), 3.78 (d, J = 8.6 Hz, 1H), 3.62-3.45 (m, 4H), 3.32-3.01 (m, 8H), 2.98-2.60 (m, 4H), 2.55-2.43 (m, 3H), 2.34-1.82 (m, 6H), 0.97-0.62 (m, 6H). LCMS (ES): m/z 1095.60 [M+H]t [0685] 57.5 mg (22%) of (2S,4R)-1-((R)-2-(3-(2-(4-(4-(3-(2,6-difluoro-3-(((R)-3-fluoropyrrolidine)-1-sulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)ethoxy)isoxazol-5-y1)-3-methylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6): M2.90 (brs, 1H), 9.84 (brs, 1H), 8.99-8.95 (m, 1H), 8.69-8.66 (m, 1H), 8.60-8.53 (m, 2H), 8.07 (s, 1H), 7.70-7.61 (m, 3H), 7.54-7.39 (m, 4H), 7.387.30 (m, 1H), 7.21-7.08 (m, 2H), 6.18-5.80 (m, 1H), 5.40-5.15 (m, 1H), 4.74-4.28 (m, 6H), 3.90-3.62 (m ,6H),3.41-3.22 (m, 7H), 3.21-2.81 (m, 5H) 2.45-2.42 (m, 3H), 2.32-2.20 (m, 1H), 2.17-1.80 (m, 4H), 0.95 (d, J= 6.5 Hz, 3H), 0.81 (d, J= 6.7 Hz, 3H).
LCMS (ES): m/z 1095.60 [M+H]t [0686] Exemplary compounds 287 and 288 may be prepared in an analogous manner.
[0687] Example synthesis of compound 291 [(2S,4R)-4-hydroxy-14(S)-2 (2 (2 (4 (4 ((E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)-3,3-dimethylbutanoy1)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamidel HO,N OH
I
- . i0---,-- 0 HN
,N /----1 N
lik S
N\

[0688] Step A: tert-butyl 2-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetatethoxy)acetate Br ¨

NI \ \N-N 40 [0689] To a solution of tert-butyl 2-(2-chloroethoxy)acetate (400 mg, 2.06 mmol) and C S2C 03 in DMF (15 mL) was added tert-butyl 4-(4-bromo-3-(pyridin-4-y1) -1H-pyrazol-1-yl)phenol (525 mg, 1.66 mmol). The mixture was stirred at 75 C for 3 hours.
The solution was diluted with EA (100 mL). The mixture was washed with water, brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford 2-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-y1) phenoxy)ethoxy)acetatethoxy)acetate (290 mg, 0.62 mmol). LCMS
(ES): m/z 475.21 [M+H], 476.1 [M+2H]t [0690] Step B: (2S,4R)-1-((S)-2-(2-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide OH
z Br ¨ ________________________ \
NI \ NN'N 0 o//

S
µN \
[0691] To a solution of 2-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-y1) phenoxy)ethoxy)acetatethoxy)acetate (290 mg, 0.61 mmol) in 1,4-dioxane (5 mL) was added HC1 (g) in 1,4-dioxane (3 M, 5 mL). The reaction was stirred at room temperature for 2 hours.
The solvent was removed under reduced pressure. The residue was dissolved in DCM (20 mL).
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4- methylthiazol-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (394 mg, 0.92 mmol), DIPEA
(394 mg, 3.05 mmol) and PyBOP (954 g, 1.83 mmol) were added to the solution subsequently.
After stirring 30 minutes, it was diluted with DCM (50 mL). The mixture was washed with water, brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford (2S,4R)-1-((S)-2-(2-(2- (4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (390 mg, 0.46 mmol). LCMS (ES): m/z 830.2 [M+H]t [0692] Step C: (25,4R)-1-((S)-3,3-dimethy1-2 (2 (2 (4 (4 (1 oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)butanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 0 )......1cIC

=
0----)\--F1 0 HN
x ,N /----/
i N 0 N
S
µN\
[0693] To a solution of (2S,4R)-1-((S)-2-(2-(2-(4-(4-bromo-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (390 mg,0.46 mmol) and 5-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-2,3-dihydro-1H-inden-1-one (248 mg, 0.92 mmol) in 1,4-dioxane/water (20 mL/1 mL) were added Pd(aMPhos)C12 (36 mg, 0.046 mmol), CsF (360 mg, 2.30 mmol) subsequently. The reaction mixture was stirred at 90 C overnight under nitrogen atmosphere.
After cooled to room temperature, it was diluted with ethyl acetate (100 mL).
The mixture was washed with brine (50 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography (DCM/Me0H) to afford (2S,4R)-1-((S)-3,3-dimethy1-2-(2-(2-(4-(4-(1-oxo-2,3 -dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)butanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (230 mg, 0.26 mmol).
LCMS (ES): m/z 882.3 [M+H] +.

[0694] Step D: (2S,4R)-4-hydroxy-1-((S)-2-(2-(2-(4-(4-((E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)-3,3-dimethylbutanoy1)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide HO,N OH
I
0 >.......,\(10 - 0 ,0----)\-- 0 HN
,N 7-----1 N
lik S
N\
[0695] To a solution of (25,4R)-14(S)-3,3-dimethy1-2-(2-(2-(4-(4-(1-oxo-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)butanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (230 mg, 0.26 mmol) in CH3CN
and pyridine (v/v = 1/1, 5 mL) was added NH2OH-HC1 (179 mg, 2.6 mmol). The solution was stirred at 20 C for 3 hours. The mixture was filtered through Celite. The filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography (DCM/Me0H) to afford (2S,4R)-4-hydroxy-1-((S)-2-(2-(2-(4-(4-((E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-y1)-3-(pyridin-4-y1)-1H-pyrazol-1-yl)phenoxy)ethoxy)acetamido)-3,3-dimethylbutanoy1)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (21 mg, 0.023 mmol). 1H
NMR (400 MHz, DMSO-d6): 6 10.89 (s, 1H), 8.97 (s, 1H), 8.72 (s, 1H),8.56- 8.58 (m, 3H), 7.86 (d, J = 8.4 Hz, 2H), 7.49-7.57 (m, 3H), 7.39 (m, 6H), 7.22 (s, 1H), 7.09-7.12 (m, 2H), 5.17 (m, 1H), 4.52-4.65 (m, 1H), 4.32-4.50 (m, 3H), 4.08-4.29 (s, 4H), 3.95-4.05 (m, 2H), 3.73-3.82 (m, 2H), 3.56-3.70 (m, 2H), 2.95-3.08 (m, 2H), 2.76-2.85 (s, 2H), 2.40-2.51 (m, 3H), 1.87-2.16 (s, 1H), 0.91-1.07 (s, 9H). LCMS (ES): m/z 898.4 [M+H]t [0696] Exemplary compounds 289, 290, 292, and 293 may be prepared in an analogous manner.

[0697] Example 15-Synthetic Scheme A: Compounds 305, 298, 299, 300, 301, 302, 514, and 303 Method A
FN1 N Cy P.

>% 47, , Cs2CO3/ DMF
N
0 OorCh< \
Br 0.3r Br ).riOl<
41111111Y1" OH
2(68%) 1(71%) TFA / DCM
N
N
PyBOP Et3N / DMF
\ FNi HN
0 =

3 (quantitative yieOlehl Z-3_40 Compound 305 (57%) F131\11 0 HN (45 4 IN;
[0698] tert-Butyl 4-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy)butanoate (1).
To a mixture of 4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenol (209.12 mg, 0.95 mmol) and tert-butyl 4-bromobutanoate (212 mg, 0.95 mmol) in N,N-Dimethylformamide (2 mL) was added Cs2CO3 (402.47 mg, 1.24 mmol). Reaction mixture was heated at 65 C for 12 hours (overnight) . By TLC small amounts of starting material (Hex:AcOEt, 7:3).
Crude product was purified by flash CC (5i02-25g, Hex:AcOEt, gradient 9:1 to 4:6) to give 198 mg (57% yield) of product as an oil: 1H NMR (500 MHz, DMSO-d6) 6 7.59 (d, J = 8.2 Hz, 2H), 6.91 (d, J = 7.9 Hz, 2H), 3.99 (t, J = 6.3 Hz, 2H), 2.35 (t, J = 7.3 Hz, 2H), 1.92 (p, J = 6.7 Hz, 2H), 1.39 (s, 9H), 1.27 (s, 12H). 13C NMR (101 MHz, dmso) 6 172.25, 161.56, 136.66, 114.37, 83.77, 80.12, 66.81, 31.72, 28.20, 25.12, 24.71. LC-MS (ESI); m/z [M+Na]: Calcd. for C20I-131B05Na, 385.2162.
Found 385.2194.
[0699] tert-Butyl 4-(4-(3-benzoy1-1H-pyrrolo[2,3-b[pyridin-5-yl)phenoxy)butanoate (2). To a solution of tert-butyl 4-[4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenoxy] -butanoate (72 mg, 0.2 mmol) and (5-bromo-1H-pyrrolo[2,3-b[pyridin-3-y1)-phenyl- -methanone (59.85 mg, 0.2 mmol) in Dioxane (6 mL) was de-gassed under vacuum and purged with argon.
Then K2CO3 (82.4 mg, 0.6 mmol) was added, follow by water (2 mL), the reaction mixture was de-gassed under vacuum and purged with argon again. Tricyclohexylphosphine (5.57 mg, 0.02 mmol) and Pd(dba)2 (5.71 mg, 0.01 mmol) was added into and the reaction mixture and the reaction mixture was de-gassed under vacuum and purged with argon again. Then reaction mixture was heated at 90 C for 2 hours. By TLC some SM (Hex:AcOEt, 3:7), an additional amounts of Tricyclohexylphosphine (5.57 mg, 0.02 mmol) and Pd(dba)2 (5.71 mg, 0.01 mmol) was added twice and reaction mixture stirred for an additional 2 hours. The reaction mixture was diluted with AcOEt (20 mL), dried (Na2SO4), and filtered in vacuum over a celite pad, filtrate was dried (Na2SO4) and concentrated under vacuum. The crude material was diluted in DCM
and purified by flash chromatography (5i02-40g, gradient Hex:AcOEt, gradient 9:1 to 100%
AcOEt) to give 69 mg (68%) of product as off-white solid. 1H NMR (500 MHz, DMSO-d6) 6 12.68 (s, 1H), 8.65 (s, 1H), 8.60 (s, 1H), 8.10 (s, 1H), 7.82 (d, J = 7.5 Hz, 2H), 7.58 (dt, J =
36.0, 7.9 Hz, 5H), 7.04 (d, J = 8.1 Hz, 2H), 4.16 - 3.83 (m, 2H), 2.37 (t, J = 6.5 Hz, 2H), 1.95 (dd, J = 11.4, 5.5 Hz, 2H), 1.39 (s, 9H). 13C NMR (126 MHz, dmso) 6 189.81, 171.86, 158.13, 148.26, 143.24, 139.62, 136.43, 131.45, 130.82, 130.66, 128.52, 128.48, 128.16, 127.01, 118.77, 115.13, 113.73, 79.68, 66.63, 31.36, 27.77, 24.37. LC-MS (ESI); m/z: [M+H[ Calcd. for C28H29N204, 457.2127. Found 457.2156.
[0700] 4-(4-(3-Benzoy1-1H-pyrrolo[2,3-b[pyridin-5-yl)phenoxy)butanoic acid (3). A solution of tert-butyl 4-(4-(3-(2,6-difluorobenzoy1)-1H-pyrrolo[2,3-b]pyridin-5-y1) -phenoxy)butanoate (30 mg, 0.06 mmol) in a mixture of TFA (1 ml, 13.46 mmol) and dichloromethane (3 ml) was stirred for 1 hour. Then the solvent was removed under vacuum and crude product was dried under high vacuum for 2 hours. Crude product was used in the next step without any further purification (26.5 mg, quantitative yield). LC-MS (ESI); m/z: [M+H[ Calcd.
for C24H21N204, 401.1501. Found 401.1420.
[0701] (2S,4R)-1-4S)-2-(4-(4-(3-benzoy1-1H-pyrrolo[2,3-b[pyridin-5-yl)phenoxy)butanamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (Compound 305). To a solution of 444-(3-benzoy1-1H-pyrrolo[2,3-b[pyridin-5-y1) -phenoxy[butanoic acid (26.5 mg, 0.07 mmol) and (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl- butanoy1]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;hydrochloride (30.91 mg, 0.07 mmol) in DMF(2 ml) was added TEA (0.2 ml, 1.43 mmol) and PyBOP (37.88 mg, 0.07 mmol) at room temperature. The reaction mixture was stirred for 12 hours (overnight) at the same temperature.
TLC (DCM:MeOH:NH4OH, 90:9:1) shows no starting materials. The DMF was removed under high vacuum. Crude product was filtered over a silica-carbonate cartridge (1g) using DCM:Me0H (9:1) as a eluent. Filtrate was evaporated under vacuum and crude product was purified by PTLC (MeOH:DCM, 9:1), to give 31 mg of product (58% yield). 1H NMR
(400 MHz, DMSO-d6) 6 12.70 (s, 1H), 8.97 (s, 1H), 8.68 (d, J = 2.2 Hz, 1H), 8.62 (d, J = 2.3 Hz, 1H), 8.60¨ 8.51 (m, 1H), 8.12 (s, 1H), 8.00 (d, J = 9.3 Hz, 1H), 7.90 ¨ 7.77 (m, 1H), 7.72 ¨ 7.51 (m, 5H), 7.48 ¨ 7.29 (m, 4H), 7.07 (d, J = 8.7 Hz, 2H), 5.15 (d, J = 3.5 Hz, 1H), 4.59 (d, J = 9.3 Hz, 1H), 4.50 ¨ 4.32 (m, 3H), 4.22 (dd, J = 15.9, 5.4 Hz, 1H), 4.03 (td, J = 6.5, 2.6 Hz, 2H), 3.80 ¨
3.60 (m, 2H), 2.44 (s, 3H), 2.48 ¨2.28 (m, 5H), 2.13 ¨ 1.84 (m, 4H), 0.96 (s, 9H). 13C NMR (101 MHz, dmso) 6 189.87, 172.00, 171.63, 169.69, 158.23, 151.48, 148.29, 147.73, 143.29, 139.64, 139.53, 136.54, 131.52, 131.19, 130.74, 129.65, 128.66, 128.58, 128.55, 128.21, 127.44, 127.05, 118.81, 115.19, 113.74, 68.93, 67.13, 58.75, 56.47, 48.64, 41.68, 38.01, 35.29, 31.33, 26.43, 25.08, 15.99. LC-MS (ESI); m/z [M+H]: Calcd. for C46H49N606S, 813.3434. Found 813.3478.
[0702] (2S,4S)-1-((S)-2-(4-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b]- pyridine-5-yl)phenoxy)butanamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-y1) -benzyl)pyrrolidine-2-carboxamide (Compound 514).
H F \ I
OSN H r`r FIN
0 (DNO

[0703] To a solution of 4-[4-[3-[2,6-difluoro-3-(propyl-sulfonylamino)benzoy1]-1H-pyrrolo[2,3-b[pyridin-5-yl[phenoxy[butanoic acid (4.08 mg, 0.00732 mmol) and (2S,4S)-1-((S)-2-amino-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzy1)-pyrrolidine-2-carboxamide (3.76 mg, 0.00873 mmol) in DMF(1.5 ml) was added TEA (0.200 mL, 1.43 mmol) and PyBOP (4.19 mg, 0.00805 mmol) at room temperature. The reaction mixture was stirred for 4 h at the same temperature. TLC (DCM:MB, 1:1) shows no starting materials. The DMF was removed under high vacuum (product is partially soluble in water).
Crude product was filtered over a silica-carbonate cartridge using DCM:Me0H (9:1) as a eluent. Filtrate was evaporated under vacuum and crude product was purified by PTLC
(DCM:MeOH:NH4OH, 90:9:1) to give 3.1 mg of product (43% yield). 1H (500 MHz, DMSO-d6) 6 12.83 (bs, 1H), 9.64 (bs, 1H), 8.96 (s, 1H), 8.77 - 8.41 (m, 3H), 8.18 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 8.5 Hz, 2H), 7.61 - 7.48 (m, 1H), 7.38 (q, J = 8.2 Hz, 4H), 7.26 (t, J = 8.7 Hz, 1H), 7.04 (d, J = 8.7 Hz, 2H), 5.43 (d, J = 7.2 Hz, 1H), 4.54 -4.31 (m, 3H), 4.30 - 4.15 (m, 2H), 4.08 - 3.88 (m, 3H), 3.50 - 3.40 (m, 1H), 3.16 - 3.02 (m, 2H), 2.44 - 2.26 (m, 3H), 2.42 (s, 3H), 2.04 - 1.88 (m, 2H), 1.79 - 1.63 (m, 3H), 0.95 (s, 9H), 0.94 (t, 3H). 13C NMR (151 MHz, DMSO-d6) 6 181.03 , 172.89, 172.34, 170.35, 158.75, 156.44 (dd, J = 246.1, 6.7 Hz), 152.78 (dd, J
= 249.5, 8.6 Hz), 151.89 , 148.94 , 148.15 , 144.15 , 139.63 , 139.07 , 131.74 , 131.55 , 130.82, 130.14 , 129.36 -129.11 (m), 129.08 , 128.68 , 127.86 , 126.85 , 122.35 (dd, J = 13.6, 3.4 Hz), 117.94 , 116.03 , 115.59 , 69.53 , 67.52, 58.95 , 57.24 , 56.04 , 53.86 , 42.21 , 37.36 , 35.11 , 31.62 , 26.82 , 25.42 , 17.26 , 16.37 , 13.04 . LC-MS (ESI); m/z [M+H]: Calcd. for C49H54F2N708S2, 970.3443.
Found 970.3422 [0704] Example 16-Synthetic Scheme B: 217, 220, 510, and 221 Method B
[21 N N N 1) Cy3P, Pc1Mba)2, K2CO3 Dioxane/water (56%)(5a) H õ
N
F I H F I
THF H \ I
0=S-N Br 0 j<
2.- 0 0 NH2 >%9 7(78%) j.) 0 j< F 6(71%) F

411111Yr NHBoc 2) TFA / DCM, (quantitative yield) TFA / DCM
H , N
N HO, F I PyBOP, Et3N / DMF \ F
J ___________________________________ oH
0 JLNFic, HN
0 H0,2 F
8 (quantitative yield)) Compound 217(29%) = ils1;
4 /N;
[0705] tert-B uty1(4-(3 -(2,6-difluoro-3 -(propylsulfonamido)benzoy1)-1H-pyrrolo [2,3 -blpyridin-5-yl)phenyl)carbamate (5a). To a solution of tert-butyl (4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)pheny1)-carbamate (50.99 mg, 0.16 mmol) in Dioxane (3 ml) was added N-[3-(5-bromo-1- H-pyrrolo [2,3 -b[pyridine-3 -c arbony1)-2,4-difluoro-phenyll propane-1- sulfonamide (0.06 ml, 0.13 mmol), K2C 03 (55.19 mg, 0.4 mmol), Tricyclohexylphosphine (3.73 mg, 0.01 mmol) and water (1 mL). Then the reaction mixture was de-gassed under vacuum and purged with argon, Pd(dba)2 (3.83 mg, 0.01 mmol) was added into and the reaction mixture was heated at 80 C for 3 hours. By TLC small amounts of SM (Hex:AcOEt, 3:7), the reaction mixture was filtered in vacuum over a celite pad, filtrate was poured onto an aqueous saturated solution of NaCl (20 mL) and the product was extracted with Et0Ac (2x20 mL). The Et0Ac layers were combined, dried (Na2SO4) and concentrated in vacuum. The crude material was diluted in DCM
and purified by flash chromatography (5i02-12g, Hexane:AcOEt, gradient 8:2 to 100% AcOEt) to give 47 mg (56%) of product as a off-white solid. 1H NMR (400 MHz, DMSO-d6) 6 12.96 (bs, 1H), 9.77 (bs, 1H), 9.49 (s, 1H), 8.68 (d, J = 2.1 Hz, 1H), 8.57 (bs, 1H), 8.21 (s, 1H), 7.79 ¨
7.46 (m, 5H), 7.28 (td, J = 8.7, 1.5 Hz, 1H), 3.19 ¨ 3.07 (m, 2H), 1.74 (dq, J
= 14.9, 7.4 Hz, 2H), 1.50 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, dmso) 6 180.61, 156.03 (dd, J =
246.5, 7.1 Hz), 152.77, 152.34 (dd, J = 249.5, 8.5 Hz), 148.60, 143.76, 139.22, 138.64, 131.66, 131.31, 128.79 (d, J = 9.7 Hz), 127.35, 126.38, 121.94 (dd, J = 13.7, 3.6 Hz), 118.66, 118.24 (t, J
= 23.5 Hz), 117.53, 115.63, 112.35 (dd, J = 22.6, 3.9 Hz), 79.19, 53.46, 28.15, 16.85, 12.62. LC-MS (ESI); m/z: [M+H] Calcd. for C28H29F2N4055, 571.1826. Found 571.1917.
[0706] N-(3 -(5-(4- aminopheny1)- 1H-p yrrolo [2,3 -hi p yridine-3 -c arbony1)-2,4-difluorophenyl)propane-l-sulfonamide (6). To a solution of tert-butyl (4-(3-(2,6-difluoro-3-(prop ylsulfonamido)benzoy1)-1H-p yrrolo - [2,3 -b] pyridin-5 -yl)phenyl)c arb amate (30 mg, 0.05 mmol) in TFE (2 mL) was heated at 140 C, for 3 hours under microwave assisted conditions. The reaction mixture was evaporated to dryness under vacuum, to give 23 mg of product in quantitative yields. The crude product was used in the next step without any further purification. LC-MS (ESI); m/z: [M+H] Calcd. for C23H21F2N4035, 471.1302.
Found 471.1351.
[0707] tert-B uty1-5-((4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)benzoy1)-1H-p yrrolo [2,3 -blpyridin-5-yl)phenyl)amino)-5-oxopentanoate (7). To a solution of tert-butyl 5-chloro-5-oxopentanoate (21.96 mg, 0.11 mmol) in THF (2 mL) was added N-(3-(5-(4-aminopheny1)-1H-pyrrolo [2,3-b] -pyridine-3 -c arbony1)-2,4-difluorophenyl)prop ane-1-sulfonamide (10 mg, 0.02 mmol). The resulting suspension was heated to reflux for 12 hours (overnight).
The reaction mixture was evaporated in vacuum and the crude product was purified by PTLC
(MB:DCM, 4:6) to give a white powder 10.7 mg (79% yield). 1H NMR (500 MHz, DMSO-d6) 6 12.96 (bs, 1H), 10.04 (s, 1H), 9.76 (bs, 1H), 8.69 (d, J = 2.2 Hz, 1H), 8.59 (s, 1H), 8.21 (s, 1H), 7.75 (d, J = 8.7 Hz, 2H), 7.69 (d, J = 8.6 Hz, 2H), 7.59 (td, J = 9.0, 5.8 Hz, 1H), 7.28 (t, J
= 9.2 Hz, 1H), 3.13 (dd, J = 8.7, 6.7 Hz, 2H), 2.39 (t, J = 7.4 Hz, 2H), 2.28 (t, J = 7.4 Hz, 2H), 1.83 (p, J = 7.4 Hz, 2H), 1.75 (h, J = 7.5 Hz, 2H), 1.41 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR
(101 MHz, dmso) 6 181.01, 172.37, 171.16, 156.02 (dd, J = 246.3, 7.0 Hz), 152.34 (dd, J =
249.5, 8.5 Hz), 149.05, 144.18, 139.30, 139.05, 133.00, 131.62, 128.77 (d, J = 9.5 Hz), 127.75, 126.88, 121.96 (dd, J =
13.7, 3.5 Hz), 120.04, 118.74¨ 117.84 (m), 117.94, 116.05, 112.34 (dd, J =
22.8, 3.0 Hz). 79.98, 53.89, 35.72, 34.53, 28.20, 20.93, 17.25, 13.02. LC-MS (EST); m/z: [M+H[
Calcd. for C32H35F2N406S, 641.2245. Found 641.2473.
[0708] 5-((4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b[pyridin-5-yl)phenyl)amino)-5-oxopentanoic acid (8). A solution oftert-butyl 5-((4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoyl) -1H-pyrrolo[2,3-b[pyridin-5-yl)phenyl)amino)-5-oxopentanoate (10.7 mg, 0.02 mmol) in a mixture of TFA (1 ml, 13.46 mmol) and Dichloromethane (2 ml) was stirred for 2 hours. Then the solvent was removed under vacuum and crude product was dried under high vacuum for 2 hours. Crude product was used in the next step without any further purification (9.7 mg, quantitative yield). LC-MS (ESI); m/z: [M-FH[ Calcd.
for C28H27F2N406S, 585.1619. Found 585.1636.
[0709] N1-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b[pyridin-5-yl)pheny1)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-l-y1)-3,3-dimethyl-1-oxobutan-2-y1)glutaramide (Compound 217). To a solution of 5-((4-(3-(2,6-difluoro-3-(propylsulfonamido) -benzoy1)-1H-pyrrolo[2,3-b[pyridin-5-yl)phenyl)amino)-5-oxopentanoic acid (9.7 mg, 0.02 mmol) and (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoy1]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl[methyl[pyrrolidine-2-carboxamide;hydrochloride (8.52 mg, 0.02 mmol) in DMF (1 ml) was added TEA (0.1 ml, 0.72 mmol) and PyBOP (9.5 mg, 0.02 mmol) at room temperature.
The reaction mixture was stirred for 4 hours at the same temperature. TLC
(DCM:MeOH:NH4OH, 90:9:1) shows no starting materials. The reaction mixture was diluted with Et0Ac (10 mL) and washed with brine (5 mL, 4x), organic phase was dried (Na2SO4), and evaporated under vacuum. Crude product was purified by PTLC (DCM:MeOH:NH4OH, 90:9:1) to give 4.8 mg of product (29% yield). 1H NMR (500 MHz, DMSO-d6) 6 10.02 (s, 1H), 8.97 (s, 1H), 8.68 (d, 1H), 8.64 ¨ 8.52 (m, 2H), 8.21 (s, 1H), 7.95 (d, J = 9.2 Hz, 1H), 7.72 (dd, J = 36.7, 8.5 Hz, 4H), 7.62 ¨ 7.54 (m, 1H), 7.40 (dd, 4H), 7.28 (t, J = 8.7 Hz, 1H), 5.16 (d, 2H), 4.56 (d, J
= 9.3 Hz, 1H), 4.50 ¨ 4.40 (m, 2H), 4.40 ¨ 4.33 (m, 1H), 4.22 (dd, J = 15.8, 5.3 Hz, 1H), 3.76 ¨
3.62 (m, 2H), 3.16 ¨3.05 (m, 2H), 2.44 (s, 3H), 2.41 ¨2.17 (m, 4H), 2.09 ¨
2.01 (m, 1H), 1.98 ¨

1.80 (m, 3H), 1.74 (dq, J = 14.9, 7.4 Hz, 2H), 0.96 (s, 9H), 0.95 (t, 3H). 13C
NMR (151 MHz, dmso) 6 181.06, 172.39, 172.17, 171.46, 170.15, 156.37 (dd, J = 246.6, 6.3 Hz), 152.73 (dd, J =
249.4, 8.1 Hz), 151.86, 149.05, 148.13, 144.19, 139.91, 139.37, 139.13, 132.97, 131.64, 131.59, 130.05, 129.22 (d, J = 14.7 Hz), 129.06, 127.84, 127.74, 126.89, 122.47 (d, J
= 14.1 Hz), 120.07, 119.02- 118.20 (m), 117.95, 116.06, 112.75 (dd, J = 23.4, 2.8 Hz), 69.34, 59.15, 56.90, 56.81, 53.87, 42.08, 38.38, 36.36, 35.63, 34.63, 26.85, 21.91, 17.27, 16.37, 13.04.
LC-MS (ESI); m/z [M+H]: Calcd. for C50H55F2N808S2, 997.3552. Found 997.3524.
[0710] N1-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b[pyridin-5-yl)phenyl) -N4-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-l-y1)-3,3-dimethyl-1-oxo -butan-2-y1)-N1-methylsuccinamide (Compound 510).
N " HO,,, F \ I
O'SN 0 N jirliN'----\0 HN
\O

I

N
[0711] To a solution of 4-[4-[3-[2,6-difluoro-3-(propylsulfonylamino)-benzoy1]-1H-pyrrolo[2,3-b]pyridin-5-y1]-N-methyl-anilino[-4-oxo-butanoic acid (33.7 mg, 0.06 mmol) and (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoy1]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;hydrochloride (4) (32.31 mg, 0.07 mmol) in DMF
(2 ml) was added TEA (0.2 ml, 1.43 mmol) and PyBOP (36 mg, 0.07 mmol) at room temperature. The reaction mixture was stirred for 4 h at the same temperature.
TLC
(DCM:MeOH:NH4OH, 90:9:1) shows some starting material (acid). The reaction mixture was evaporated to dryness under high vacuum. Crude product was purified by PTLC
(DCM:MeOH:NH4OH, 90:9:1) to give 4.6 mg of product (8 % yield). 1H NMR (400 MHz, DMSO-d6) 6 13.01 (bs, 1H), 9.70 (bs, 1H), 8.95 (s, 1H), 8.73 (d, J = 2.3 Hz, 1H), 8.66 (bs, 1H), 8.54 (t, J = 5.9 Hz, 1H), 8.22 (s, 1H), 7.84 (dd, J = 19.4, 8.6 Hz, 2H), 7.57 (td, J = 9.0, 6.1 Hz, 1H), 7.52 - 7.30 (m, 6H), 7.26 (t, J = 8.5 Hz, 1H), 5.08 (d, J = 3.2 Hz, 1H), 4.47 (d, J = 9.2 Hz, 1H), 4.44 - 4.25 (m, 3H), 4.19 (dd, J = 16.0, 5.4 Hz, 1H), 3.66- 3.54 (m, 2H), 3.19 (s, 3H), 3.16 -3.00 (m, 2H), 2.75 -2.16 (m, 4H), 2.42 (s, 3H), 2.06- 1.96 (m, 1H), 1.93 -1.80 (m, 1H), 1.79 - 1.64 (m, 2H), 0.94 (t, 3H), 0.90 (s, 9H). 13C NMR (151 MHz, DMSO-d6) 6 181.08, 172.37, 171.90, 171.57, 170.00, 156.45 (dd, J = 246.4, 7.0 Hz), 152.76 (dd, J = 249.3, 8.9 Hz), 151.88, 149.37 , 148.13 , 144.49, 143.73 , 139.91 , 139.34, 137.64, 131.59, 131.11 , 130.04, 129.53 -129.16 (m), 129.06, 127.84, 127.55, 122.35 (d, J = 15.0 Hz), 119.06- 118.23 (m), 117.93, 116.13 , 112.77 (d, J = 22.0 Hz), 69.31 , 59.13 , 56.87 , 56.75 , 53.86 ,42.07 , 38.32, 35.76, 30.61 , 29.66 , 26.77 , 22.93, 17.26, 16.37, 13.04 . LC-MS (ESI); m/z [M+H]:
Calcd. for C50f155F2N808S2, 997.3552. Found 997.3572.
[0712] Example 17-Synthetic Scheme C: Compound 218, 219, and 222 Method C
N N 1) RuPh_mFPX.:00()51)LHOMS
N
\---\ F <')1N; I
PyBOP, Et,N / DMF 1\1") ______ \--\
__________________________________ 0% F O's-N Br HN"-.1 0 10(68%) HOO 9b (71%) F 5 2) TFA / DCM, (quantitative yield) TFA / DCM
H HO
PyBOP, Et3N / DMF
0=S-N N-Th 0 0 0 0 HN

F 11 (quantitative yield)) 0_40 Compound 218(29%) /N;

4 ) [0713] tert-Butyl 4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)benzoy1)-1H-p yrrolo [2,3 -blpyridin-5-yl)piperazine- 1-carboxylate (9a). A solution of N43-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4- difluoro-phenyl]propane-l-sulfonamide (61 mg, 0.13 mmol) and tert-butyl piperazine-l-carboxylate (37.19 mg, 0.2 mmol) in THF (3 mL) was purged with argon (5x). RuPhos (18.63 mg, 0.04 mmol) and Pd(OAc)2 (2.99 mg, 0.01 mmol) were added followed by 1M LHMDS in THF (0.53 ml) The reaction mixture was heated to 60 C and stirred for 6 hours. The reaction was cooled and poured into an aqueous solution of oxalic acid (5%, 2 ml), then a saturated aqueous NaHCO3 solution was added (5 ml), the product was extracted with DCM (3x10 m1). Organic extracts were combined, dried (Na2SO4) and evaporated under vacuum. Crude product was purified by PTLC (DCM:MeOH:NH4OH, 90:9:1) (20 mg, 26%). 1H
NMR (400 MHz, DMSO-d6) 6 12.61 (bs, 1H), 9.73 (bs, 1H), 8.27 (d, J = 2.6 Hz, 1H), 8.03 (s, 1H), 7.94 (bs, 1H), 7.57 (td, J = 9.0, 5.9 Hz, 1H), 7.26 (td, J = 8.7, 1.5 Hz, 1H), 3.63 - 3.46 (m, 4H), 3.42 - 3.24 (m, 4H), 3.20 - 3.06 (m, 2H), 1.74 (dq, J = 15.0, 7.4 Hz, 2H), 1.43 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, dmso) 6 180.37, 155.96 (dd, J = 246.2, 7.2 Hz), 153.87, 152.31 (dd, J = 249.1, 8.6 Hz), 144.72, 144.31, 138.06, 137.78, 128.59 (d, J =
7.8 Hz), 121.94 (dd, J = 13.6, 3.7 Hz), 119.35 - 117.93 (m), 117.56, 115.58, 115.17, 112.25 (dd, J = 22.7, 3.8 Hz), 79.01, 53.49, 50.03, 43.56, 28.07, 16.84, 12.61. LC-MS (ESI); m/z: [M+H]
Calcd. for C26H32F2N505S, 564.2092. Found 564.2 [0714] N-(2,4-difluoro-3 -(5-(piperazin-1- y1)- 1H-p yrrolo [2,3 -Kip yridine-3 -carbonyl)phenyl)propane-l-sulfonamide (9b). A solution of tert-butyl 4-(3-(2,6-difluoro-3-(prop ylsulfonamido)benzoy1)-1H-p yrrolo- [2,3 -b] pyridin-5 -yl)piperazine-1 -c arboxylate (20 mg, 0.04 mmol) in a mixture of DCM:TFA (3 mL:1 mL) was stirred for 1 hour at room temperature.
By TLC no more starting material (DCM:MeOH:NH4OH, 90:9:1). 16.4 mg of product (quantitative yield), crude product was used in the next step without any further purification. LC-MS (ESI); m/z [M+H]: Calcd. for C21t124F2N503S, 464.1567. Found 464.1712.
[0715] tert-butyl 5-(4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)benzoy1)-1H-p yrrolo [2,3 -blpyridin-5-yl)piperazin-1-y1)-5-oxopentanoate (10). To a solution of N-(2,4-difluoro-3-(5-(piperazin- 1-y1)-1H-p yrrolo [2,3 -b] p yridine-3 -carbonyl) -phenyl)prop ane-1- sulfonamide (16.4 mg, 0.04 mmol) and 5-(tert-butoxy)-5-oxopentanoic acid (7.99 mg, 0.04 mmol) in DMF (2 ml) was added TEA (0.1 ml, 0.72 mmol) and PyBOP (20.25 mg, 0.04 mmol) at room temperature.
The reaction mixture was stirred for 3 hours at the same temperature. TLC
(DCM:MeOH:NH4OH, 90:9:1) shows no starting materials. The reaction mixture was dissolved in Et0Ac (10 mL) and washed with brine/water (3x5mL). Organic extract was concentrated under vacuum and crude product was purified by PTLC (DCM:MeOH:NH4OH, 90:9:1) to give 15.4 mg of product (69% yield). 1H NMR (400 MHz, DMSO-d6) 6 12.67 (bs, 1H), 9.71 (bs, 1H), 8.29 (s, 1H), 8.03 (s, 1H), 7.95 (s, 1H), 7.56 (q, J = 8.8 Hz, 1H), 7.26 (t, J
= 8.7 Hz, 1H), 3.71 -3.57 (m, 4H), 3.24 - 3.06 (m, 6H), 2.39 (t, J = 7.3 Hz, 2H), 2.26 (t, J = 7.3 Hz, 2H), 1.84 - 1.66 (m, 4H), 1.40 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, dmso) 6 180.79, 172.52, 170.57, 156.37 (dd, J = 246.4, 7.1 Hz), 152.72 (dd, J = 249.2, 8.7 Hz), 145.03, 144.70, 138.44, 138.20, 129.01 (d, J = 10.4 Hz), 122.34 (dd, J = 13.7, 3.7 Hz), 119.28 -118.29 (m), 117.97, 115.84, 115.58, 112.66 (dd, J = 22.8, 3.3 Hz), 79.92, 53.89, 50.66, 45.18, 41.39, 34.57, 31.72, 28.21, 20.83, 17.25, 13.02. LC-MS (ESI); m/z [M+H]: Calcd. for C30H38F2N506S, 634.2510.
Found 634.2621.
[0716] 5-((4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)benzo y1)-1H-p yrrolo [2,3 -b] p yridin-5-yflphenyl)amino)-5-oxopentanoic acid (11). A solution of tert-butyl 5-((4-(3-(2,6-difluoro-3-(prop ylsulfonamido)benzoyl) -1H-p yrrolo [2,3 -b] p yridin-5-yl)phenyl)amino)-5-oxopentanoate (10.7 mg, 0.02 mmol) in a mixture of TFA (1 ml, 13.46 mmol) and Dichloromethane (2 ml) was stirred for 2 hours at room temperature. Then the solvent was removed under vacuum and crude product was dried under high vacuum for 2 hours. Crude product was used in the next step without any further purification (9.7 mg, quantitative yield). LC-MS (ESI);
m/z: [M+H] Calcd.
for C28H27F2N406S, 585.1619. Found 585.1636.
[0717] (2S ,4R)-1-((S )-2-(5-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo [2,3 -b] pyridin-5-yl)piperazin-1- y1)-5-oxopentanamido)-3 ,3 -dimethylbutano y1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (Compound 218). To a solution of 5-(4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)-benzoy1)- 1H-p yrrolo [2,3 -b] pyridin-5-yl)piperazin-l-y1)-5-oxopentanoic acid (9.3 mg, 0.02 mmol) and (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoy1]-4-hydroxy-N-[[4-(4-methylthiazol -5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;hydrochloride (8.27 mg, 0.018 mmol) in DMF (1 ml) was added TEA
(0.1 ml, 0.72 mmol) and PyBOP (9.22 mg, 0.018 mmol) at room temperature. The reaction mixture was stirred for 4 hours at the same temperature. TLC (DCM:MeOH:NH4OH, 90:9:1) shows no starting materials. The reaction mixture was diluted with Et0Ac (10 mL) and washed with brine (5 mL, 4x), organic phase was dried (Na2SO4), and evaporated under vacuum.
Crude mixture did not show product by TLC, just some VHL starting material (4) (Product is soluble in water).
Water extracts were lyophilized for overnight, the solid residue was filtered using a mixture of DCM:MeOH:NH4OH (90:9:1, 30 mL). Filtrate was evaporated to dryness and crude product was purified by PTLC (DCM:MeOH:NH4OH, 90:9:1) to give 13 mg of product (81%
yield). 1H
NMR (500 MHz, DMSO-d6) 6 12.64 (bs, 1H), 9.74 (bs, 1H), 8.97 (s, 1H), 8.62 ¨
8.52 (m, 3H), 8.28 (d, J = 2.0 Hz, 1H), 8.00 (s, 1H), 7.95 (bs, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.59 ¨ 7.49 (m, 1H), 7.47 ¨ 7.27 (m, 4H), 7.20 (t, J = 8.7 Hz, 1H), 5.13 (bs, 1H), 4.56 (d, J
= 9.3 Hz, 1H), 4.48 ¨
4.32 (m, 3H), 4.22 (dd, J = 15.8, 5.3 Hz, 1H), 3.75 ¨ 3.57 (m, 5H), 3.23 ¨
3.02 (m, 7H), 2.44 (s, 3H), 2.41 ¨ 2.17 (m, 4H), 2.07 ¨ 2.01 (m, 1H), 1.96 ¨ 1.87 (m, 1H), 1.81 ¨
1.66 (m, 4H), 0.95 (s, 9H), 0.94 (t, 3H). 13C NMR (151 MHz, dmso) 6 180.70, 171.99, 171.92, 170.44, 169.75, 155.24 (dd, J = 248.1, 5.5 Hz), 152.12 (dd, J = 248.8, 8.5 Hz), 151.47, 147.73, 144.63, 144.31, 139.52, 138.02, 137.75, 131.19, 129.65, 128.65, 127.98 - 127.64 (m), 127.44, 123.91 -123.09 (m), 118.86- 117.72 (m), 117.60, 115.50, 115.23, 112.02 (dd, J = 22.6, 3.2 Hz), 68.92, 58.74, 56.47, 56.43, 53.44, 50.31, 50.18, 48.63, 44.86, 41.68, 41.00, 37.99, 34.28, 31.80, 26.43, 21.36, 16.99, 15.97, 12.72. LC-MS (ESI); m/z [M+H]: Calcd. for C48H58F2N908S2, 990.3817.
Found 990.3889.
[0718] Example 18-Synthetic Scheme C: compound 304, and 306 Method D
Ers1 N
N N
1.1 F I
N'Th 0 Et3N DMF F I
0 j,0,j< 0 F 12(48%) TFA / DCM
0,0 F N 0 HN
OOH
PyBOP Et3N / DMF
F I HN
N-Th 0 0 0 13 (quantitative yield)) N H N Compound 304 (52%) /\
(4) W
[0719] tert-Butyl 4-[4-[3-[2,6-difluoro-3-(propylsulfonylamino)benzoy11-1H-pyrrolo[2,3-b[pyridin-5-yllpiperazin-1-yllbutanoate (12). To a solution of methyl N-[2,4-difluoro-3-(5-piperazin-l-y1-1H-pyrrolo [2,3-b] -pyridine-3 -carbonyl)phenyl]propane-l-sulfonamide;2,2,2-trifluoroacetic acid (17.4 mg, 0.03 mmol) and tert-butyl 4-iodobutanoate (8.95 mg, 0.03 mmol) in DMF (1 ml) was added TEA (0.03 ml, 0.15 mmol), the resulting solution stirred for 16 hours at 50 C (overnight). The solvent was evaporated under high vacuum and the residue was filtered over a silica-carbonate cartridge (1g) using DCM:Me0H (9:1) as a eluent.
Filtrate was evaporated under vacuum and crude product was purified by PTLC
(DCM:MeOH:NH4OH, 90:9:1), to give 8.8 mg of product (48% yield). 1H NMR (400 MHz, DMSO-d6) 6 12.63 (bs, 1H), 9.73 (bs, 1H), 8.25 (d, J = 2.7 Hz, 1H), 8.00 (s, 1H), 7.89 (bs, 1H), 7.56 (td, J = 9.0, 6.0 Hz, 2H), 7.34 -7.16 (m, 1H), 3.25 - 3.04 (m, 6H), 2.68 -2.52 (m, 4H), 2.34 (t, J =
7.1 Hz, 2H), 2.24 (t, J = 7.2 Hz, 2H), 1.85 - 1.61 (m, 4H), 1.40 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) 6 180.34 , 172.23 , 155.99 (dd, J = 246.1, 7.0 Hz), 152.31 (dd, J = 249.3, 8.6 Hz), 144.80 , 143.96 , 137.64 , 137.36 , 128.60 (d, J = 9.9 Hz), 121.91 (dd, J
= 13.6, 3.7 Hz), 118.41 (t, J = 23.8 Hz), 117.63 , 115.12, 114.54 , 112.26 (dd, J = 22.8, 3.7 Hz), 56.95 , 53.47 , 52.70 , 49.72 , 32.69 , 27.83 , 21.79 , 16.86 , 12.63. LC-MS (ESI); m/z: [M+H]
Calcd. for C29H38F2N505S, 606.2561. Found 606.2504.
[0720] 4- [4- [3- [2,6-Difluoro-3 -(prop ylsulfonylamino)b enzoyll -1H-p yrrolo [2,3 -b[pyridin-5-yllpiperazin-1-yllbutanoic acid (13). A solution of tert-butyl 4-[4-[3-[2,6-difluoro-3-(prop ylsulfonylamino)benzo yl] - 1H-p yrrolo [2,3 -b] pyridin-5- yl]
piperazin-1- yl] butanoate (8.8 mg, 0.01 mmol) in a mixture of TFA (1 ml, 13.46 mmol) and Dichloromethane (3 ml) was stirred for 1 hour. Then the solvent was removed under vacuum and crude product was dried under high vacuum for 2 hours. Crude product was used in the next step without any further purification (7.9 mg, quantitative yield). LC-MS (ESI); m/z: [M+H]+ Calcd.
for C25H30F2N505S, 550.1936. Found 550.1865.
[0721] (2S ,4R)-1-((S )-2-(4-(4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)benzo y1)-1H-pyrrolo [2,3 -b[pyridin-5-yl)piperazin-1- yl)butanamido)-3 ,3 -dimethylbutanoy1)-4 -hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (Compound 304). To a solution of 4-[4-[3- [2,6-difluoro-3 -(prop ylsulfonyl -amino)benzoyl] - 1H-p yrrolo [2,3 -b]
pyridin-5-yl] piperazin-1-yl] butanoic acid (7.9 mg, 0.01 mmol) and (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoy1]-4-hydroxy-N-[[4-(4-methylthiazo-1-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;hydrochloride (7.38 mg, 0.02 mmol) in DMF (1 ml) was added TEA (0.1 ml, 0.72 mmol) and PyBOP
(8.23 mg, 0.02 mmol) at room temperature. The reaction mixture was stirred for 12 hours (overnight) at the same temperature. TLC (DCM:MeOH:NH4OH, 90:9:1) shows no starting materials. The reaction mixture was evaporated to dryness. Crude product was filtered over a silica-carbonate cartridge (1 g) using DCM:Me0H (9:1) as eluent (washed a few times, product has high affinity for the stationary phase). Filtrate was evaporated under vacuum and crude product was purified by PTLC (DCM:Me0H, 9:1) to give 7.2 mg of product (52% yield). 1H NMR (500 MHz, DMSO-d6) 6 12.66 (bs, 1H), 9.73 (bs, 1H), 8.96 (s, 1H), 8.61 - 8.50 (m, 1H), 8.25 (s, 1H), 8.00 (s, 1H), 7.93 (bs, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.63 - 7.49 (m, 1H), 7.40 (dd, 4H), 7.25 (t, J =
8.7 Hz, 1H), 5.14 (s, 1H), 4.56 (d, J = 9.1 Hz, 1H), 4.46 - 4.34 (m, 3H), 4.22 (dd, J = 15.8, 4.7 Hz, 1H), 3.75 - 3.60 (m, 2H), 3.23 - 3.14 (m, 4H), 3.13 - 3.08 (m, 2H), 2.65 -2.53 (m, 4H), 2.43 (s, 3H), 2.38 -2.31 (m, 2H), 2.31 -2.25 (m, 1H), 2.24 - 2.16 (m, 1H), 2.07 - 1.99 (m, 1H), 1.95 - 1.87 (m, 1H), 1.72 (dq, J = 16.3, 10.5, 8.9 Hz, 4H), 0.95 (t, J = 5.3 Hz, 3H), 0.95 (s, 9H). 13C NMR (151 MHz, DMSO-d6) 6 180.77 , 172.43 , 172.39 , 170.12 , 156.38 (dd, J =
246.2, 7.1 Hz), 152.75 (dd, J = 249.8, 9.0 Hz), 151.87 , 148.13 , 145.23 , 144.35 , 139.92 , 138.09 , 137.78 , 131.59 , 130.05 , 129.21 - 128.76 (m), 127.84 , 122.32 (d, J
= 13.1 Hz), 119.83 - 118.25 (m), 118.03 , 115.53 , 114.96 , 112.68 (d, J = 22.7 Hz), 69.30, 59.13 , 57.62, 56.79 , 55.33 , 53.88 , 53.06 , 50.11 , 42.07 , 38.38 , 35.68 , 33.27 , 26.83 , 23.09, 17.26, 16.37 , 13.04. LC-MS (EST); m/z [M+H]: Calcd. for C47H58F2N907S2, 962.3868. Found 962.3986.
[0722] Example 19-Synthetic Scheme E: compound 511, and 513 Method E
o HATU / DIPA
OH + DMF 0-B

14 (52%) N N
\--\H F \I; Pd(dba)2 / PCY3 o Br K2003, Dioxane-water H F \ I
N N
H H HN 1) TFA / DCM \
H F \ I

0 = kIV3E011-P-11/g10 Compound 511 (73%) 15 (69%) [0723] tert-butyl 3-(4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzamido)propanoate (14).

N

[0724] To a solution of 4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzoic acid (538 mg, 2.17 mmol) and tert-butyl 3-aminopropanoate (315 mg, 2.17 mmol) in N,N-Dimethylformamide (10 ml) was added N,N-Diisopropylethylamine (1.13 mL, 6.51 mmol) and 0-(7-Azabenzotriazol-1-y1)-N,N,N',N'-tetramethyluronium hexafluorophosphate (825 mg, 2.17 mmol) at room temperature. The reaction mixture was stirred for 4 h at the same temperature. TLC
(DCM:MeOH:NH4OH, 90:9:1) shows no starting materials. Reaction mixture was diluted with Et0Ac (50 mL), washed with water/brine (4x30 mL), dried (Na2SO4) and evaporated under vacuum. Crude product was purified by flash chromatography (SiO2-25g, gradient Hex:Et0Ac, 1:9 to 100% Et0Ac in 15 min), to give 471 mg of product (-90% pure by NMR, 52 % yield).
This product was used in the next step without any further purification. 1H
NMR (500 MHz, Chloroform-d) 6 7.86 (d, J = 7.9 Hz, 2H), 7.74 (d, J = 7.9 Hz, 2H), 6.87 (t, 1H)z 3.69 (q, J = 5.9 Hz, 2H), 2.56 (t, J = 5.8 Hz, 2H), 1.45 (s, 9H), 1.35 (s, 12H). LC-MS (ESI);
m/z [M+H]: Calcd.
for C20H31BN05, 376.2295. Found 376.2259.
[0725] tert-butyl 3-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)benza-mido)-propanoate (15).
H
N N
\----\ H F \ I
OS.N H
\O
0 N .rol<

[0726] To a solution of N- [3 -(5-bromo-1H-p yrrolo [2,3 -Il] p yridine-3 -c arbony1)-2,4-difluoro-phenyl[propane- 1-sulfonamide (5) (87.3 mg, 0.191 mmol) in Dioxane (6 ml) was added tert-butyl 2- [2- [2- [2- [444,4,5 ,5-tetramethyl- 1,3 ,2-diox aborolan-2-yl)phenoxy] ethoxyl ethoxyl ethoxyl acetate (14) (65.0 mg, 0.173 mmol), K2CO3 (71.8 mg, 0.520 mmol), Tricyclohexyl phosphine (4.86 mg, 0.017 mmol) and water (2 mL). Then the reaction mixture was de-gassed under vacuum and purged with argon (5x), Pd(dba)2 (4.98 mg, 0.080 mmol) was added into and the reaction mixture was heated at 90 C for 3 h. By TLC small amounts of SM (Hex:Et0Ac, 3:7), the reaction mixture was filtered in vacuum over a celite pad, filtrate was poured into an aqueous saturated solution of NaCl (20 mL) and the product was extracted with Et0Ac (2x20 mL). The Et0Ac layers were combined, dried (Na2SO4) and concentrated in vacuum. The crude material was diluted in CH2C12 and purified by flash chromatography (5i02-12g, Hexane:Et0Ac, 9:1 to 100% Et0Ac in 15 min) to give 75 mg (71%) of product. 13C NMR (101 MHz, DMSO-d6) 6 181.08, 171.05, 166.24, 156.44 (dd, J
= 246.3, 6.9 Hz), 152.76 (dd, J = 249.7, 8.2 Hz), 149.55 , 144.57 , 141.15 , 139.40 , 133.71 , 130.98 , 129.65 - 128.79 (m), 128.43 , 127.64 , 127.55 - 126.10 (m), 122.66 - 122.12 (m), 119.00 -118.20 (m), 117.93 , 116.15 , 112.78 (dd, J = 22.9, 3.5 Hz), 80.28 , 53.88 , 36.10 , 35.45 ,28.17 , 17.25 , 13.03 . 1H NMR (500 MHz, DMSO-d6) 6 13.03 (bs, 1H), 9.76 (bs, 1H), 8.78 (s, 1H), 8.69 (s, 1H), 8.61 (t, J = 4.6 Hz, 1H), 8.26 (s, 1H), 7.98 (d, J = 7.1 Hz, 2H), 7.87 (d, J = 7.2 Hz, 2H), 7.59 (q, J = 7.6 Hz, 1H), 7.29 (t, J = 8.7 Hz, 1H), 3.50 (q, J = 5.7 Hz, 2H), 3.13 (t, 2H), 2.64 - 2.44 (m, 2H), 1.74 (dq, J = 13.9, 7.3 Hz, 2H), 1.40 (s, 9H), 0.96 (t, J =
7.4 Hz, 3H). LC-MS
(ESI); m/z [M+H]: Calcd. for C31t133F2N406S, 627.2088. Found 627.2485.
[0727] (2S ,4R)-1-((S )-2-(3 -(4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)benzo y1)-1H-pyrrolo [2,3 -b[pyridin-5-y1) -benzamido)propanamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrole -dine-2-carboxamide (Compound 511).
n-S-N
- - \ H
µ0 0 H nHN

/
N
[0728] A solution of tert-butyl 44443 -benzoy1-1H-pyrrolo [2,3 -b]pyridin-5-yl)phenoxy]butanoate (15) (26.0 mg, 0.0415 mmol) in a mixture of TFA (1 ml, 13.46 mmol) and Dichloromethane (3 ml) was stirred for 1.5 h. Then the solvent was removed under vacuum and crude product was dried under high vacuum for 2 h. Crude product was used in the next step without any further purification (23.5 mg, quantitative yield). LS-MS (ESI);
m/z: [M+H] Calcd.
for C27t125F2N406S, 571.1462. Found 571.1812. To a solution of crude product from above; 4-[4- [3- [2,6-difluoro-3-(propylsulfonylamino)benzoyl] -1H-p yrrolo [2,3 -b]
pyridin-5-yl] -N-methyl-anilino] -4-oxo-butanoic acid (23.5 mg, 0.0402 mmol) and (2S ,4R)- 1- [(2S )-2-amino-3 ,3 -dimethyl-butano y1]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;hydrochloride (4) (21.0 mg, 0.0450 mmol) in DMF (1 ml) was added TEA (0.139 mL, 1.00 mmol) and PyBOP (23.4 mg, 0.0450 mmol) at room temperature. The reaction mixture was stirred for 4 h at the same temperature. TLC (DCM:MB, 1:1) shows no starting material (acid). The reaction mixture was evaporated to dryness under high vacuum (Product may be soluble in water). Crude product was filtered over a silica-carbonate cartridge (100 mg) using DCM:Me0H (9:1) as a eluent. Filtrate was evaporated under vacuum and crude product was purified by PTLC (MBLDCM, 1:1). A second purification was performed by PTLC
(DCM:MeOH:NH4OH, 90:9:1), to give 27 mg of product (73% yield). 11-1NMR (500 MHz, DMSO-d6) 6 13.03 (bs, 1H), 9.77 (bs, 1H), 8.96 (s, 1H), 8.77 (s, 1H), 8.69 (s, 1H), 8.57 (t, J =
5.7 Hz, 1H), 8.53 (t, J = 4.9 Hz, 1H), 8.26 (s, 1H), 8.03 (d, J = 9.1 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.59 (q, J = 8.8 Hz, 1H), 7.40 (dd, 4H), 7.28 (t, J = 8.6 Hz, 1H), 5.16 (d, J = 2.8 Hz, 1H), 4.58 (d, J = 9.1 Hz, 1H), 4.50 - 4.34 (m, 3H), 4.22 (dd, J = 15.8, 5.1 Hz, 1H), 3.80- 3.61 (m, 2H), 3.58 - 3.40 (m, 2H), 3.15 - 3.06 (m, 2H), 2.69 -2.49 (m, 2H), 2.43 (s, 3H), 2.11 - 1.99 (m, 1H), 1.96 - 1.86 (m, 1H), 1.83 - 1.66 (m, 2H), 0.95 (t, 3H), 0.94 (s, 9H).
13C NMR (151 MHz, DMSO-d6) 6 180.69 , 171.95 , 170.40, 169.62, 165.76 , 156.00 (dd, J =
246.6, 6.9 Hz), 152.34 (dd, J = 249.4, 8.3 Hz), 151.42 , 149.13 , 147.71 , 144.14 , 140.67 , 139.50 , 138.99 , 133.39 , 131.16 , 130.58 , 129.64 , 128.81 (d, J = 9.8 Hz), 128.64 , 128.03 , 127.42, 127.23 , 126.91 , 122.26- 121.63 (m), 118.52- 117.80 (m), 117.52, 115.75, 112.77 -111.89 (m), 68.92 , 58.75 , 56.53 , 56.40, 53.47 , 41.67 , 37.97 , 36.32 , 35.26 , 34.89 , 26.40, 16.85 , 15.95 , 12.63 . LC-MS (ESI); rniz [M+H]: Calcd. for C49H53F2N808S2, 983.3395.
Found 983.3963.
[0729] Example 20-Synthetic Scheme F: compound 512, 513, and 516 Method F
Pd(dba)2/ P0y3 H N
N N
H F \ I K2CO3, Dioxane-water H F \ I TFA / DCM H F
\ I
0"-r-qcoN Br 90 C 0,voN

Th 1-s) B
16(83%) 1 (quantitative yield) Br.jak THF
N
H F \ I
OT'Vo-N HO, N
0 0 --1 N 1) TFA / DCM
H F \ I
z\ 2) VHL-ligand 0.'"SN
PyBOP / TEA
Compoune 512 (64%) DMF
F 18(68%) 103)(0-j<

[0730] tert-butyl 4-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl) -piperazine-l-carboxylate (16).
H , F NI,.r0<
\ 0 [0731] To a solution of N43-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbony1)-2,4-difluoro-phenyl]propane- 1-sulfonamide (5) (70.8 mg, 0.155 mmol) in Dioxane (6 ml) was added tert-butyl 4-(4-(4,4,5 ,5-tetramethyl- 1,3 ,2-diox aborolan-2- yl)phenyl)piperazine-l-c arboxylate (60.0 mg, 0.155 mmol), K2CO3 (64.2 mg, 0.465 mmol), Tricyclohexyl phosphine (4.33 mg, 0.0155 mmol)and water (2 mL). Then the reaction mixture was de-gassed under vacuum and purged with argon (5x), Pd(dba)2 (4.44 mg, 0.00773 mmol) was added into and the reaction mixture was heated at 90 C for 3 h. By TLC small amounts of SM (Hex:AcOEt, 3:7), the reaction mixture was filtered in vacuum over a celite pad, filtrate was poured into an aqueous saturated solution of NaCl (20 mL) and the product was extracted with Et0Ac (2x20 mL). The Et0Ac layers were combined, dried (Na2SO4) and concentrated in vacuum. The crude material was diluted in CH2C12 and purified by flash chromatography (Si02-12g, Hexane:Et0Ac, 9:1 to 100% Et0Ac in 15 min) to give 82 mg (83%) of product. 13C NMR (151 MHz, DMSO-d6) 6 180.61 , 156.04 (dd, J = 246.5, 6.9 Hz), 153.88 , 152.34 (dd, J = 249.4, 8.6 Hz), 150.35 , 148.44 , 143.61 , 138.60 , 131.47 , 128.92 - 128.75 (m), 128.19 (d, J = 161.3 Hz), 126.05 , 121.94 (dd, J
= 13.6, 3.6 Hz), 118.96 - 117.87 (m), 117.60 , 116.33 , 115.61 , 112.36 (dd, J = 22.6, 3.2 Hz), 79.03 , 53.42 , 48.08 , 43.72 , 42.58 , 28.09, 16.87 , 12.64 . 1H NMR (500 MHz, DMSO-d6) 6 12.92 (bs, 1H), 9.76 (bs, 1H), 8.66 (d, J = 2.2 Hz, 1H), 8.55 (s, 1H), 8.19 (s, 1H), 7.75 -7.46 (m, 3H), 7.28 (t, J
= 8.7 Hz, 1H), 7.10 (d, J = 8.7 Hz, 2H), 3.49 (t, 4H), 3.19 (t, J = 5.2 Hz, 4H), 3.16 - 3.05 (m, 2H), 1.74 (h, J = 7.5 Hz, 2H), 1.43 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H). LC-MS
(ESI); m/z [M+H]:
Calcd. for C32H36F2N5055, 640.2405. Found 640.2541.
[0732] N-(2,4-difluoro-3-(5-(4-(piperazin-1-yl)pheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl)propane-1-sulfonamide (17).

H
N
H F \
n-S-N

[0733] A solution of tert-butyl 4-[4-[3-[2,6-difluoro-3-(propylsulfonylamino)benzoy1]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]piperazine-1-carboxylate (16) (28.0 mg, 0.0438 mmol) in a mixture of DCM/TFA (3:1, 4 mL) was stirred for lh at room temperature (by TLC
no SM "A").
The solvent was removed under vacuum and the residue was dried under high vacuum foe 2h (23 mg of product, quantitative yield). Crude product was used in the next step without any further purification. LC-MS (ESI); m/z [M+H]: Calcd. for C27t128F2N5035, 540.1880.
Found 540.1949.
[0734] tert-butyl 2-(4-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-y1)-phenyl) piperazin-l-yl)acetate (18).
H
N 1"
H F \
n-S-N

Nj-Lo<
[0735] To a solution of N- [2,4-difluoro-3- [5-(4-piperazin-1- ylpheny1)-1H-p yrrolo [2,3 -b] pyridine-3 -carbonyl] -phenyl] prop ane- 1-sulfonamide (17) (23.0 mg, 0.0426 mmol) and TEA
(0.0594 mL, 0.426 mmol) in DMF (1 ml) was added tert-butyl 2-bromoacetate (9.15 mg, 0.0469 mmol) and the resulting solution stirred for 3 h at rt. The reaction mixture was evaporated under vacuum. Crude product was purified by PTLC (DCM:MeOH:NH4OH, 90:9:1, 2x) to give 19 mg of pure product (69% yield). 1H NMR (500 MHz, DMSO-d6) 6 12.92 (bs, 1H), 9.76 (bs, 1H), 8.65 (t, J = 2.6 Hz, 1H), 8.55 (s, 1H), 8.18 (s, 1H), 7.76 - 7.42 (m, 3H), 7.28 (t, J = 8.3 Hz, 1H), 7.07 (d, J = 6.5 Hz, 2H), 3.33 (s, 2H), 3.30 - 3.16 (m, 4H), 3.16 - 3.04 (m, 2H), 2.81 - 2.55 (m, 4H), 1.84 - 1.67 (m, 2H), 1.43 (s, 9H), 0.96 (t, J = 7.2 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) 6 180.57 , 169.22 , 156.02 (dd, J = 246.3, 7.0 Hz), 152.33 (dd, J = 249.4, 8.6 Hz), 150.42 , 148.37 , 143.55 , 138.50, 131.53 , 128.75 (d, J = 9.6 Hz), 128.17 , 127.58 , 125.93 , 121.92 (dd, J = 13.6, 3.6 Hz), 118.25 (t, J = 23.6 Hz), 117.58 , 115.80 , 115.58 , 112.33 (dd, J = 21.9, 3.0 Hz), 80.23 , 59.21 , 53.44 , 51.81 , 47.93 , 27.82 , 16.84 , 12.62 . LC-MS
(ESI); m/z [M+H]:
Calcd. for C33H38F2N505S, 654.2561. Found 654.2675.
[0736] (2S,4R)-1-((S)-2 (2 (4 (4 (3 (2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo [2,3 -b[pyridin-5-yl)phenyl)piperazin- 1-y1) acetamido)-3 ,3 -dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benz yl)p yrrolidine-2-c arboxamide (Compound 512).

H , n¨S¨N

HN
. 0 /7\

N
A solution oftert-butyl 2-(4-(4-(3 - (2,6-difluoro-3 - (prop yl s ulfonamido)benzoy1)-1H-p yrrolo [2,3 -b]pyridin-5-yl)phenyl)piperazin-1-yl)acetate (18) (20.0 mg, 0.0306 mmol) in a mixture of TFA
(2 ml, 13.46 mmol) and Dichloromethane (2 ml) was stirred for 5 h. Then the solvent was removed under vacuum and crude product was dried under high vacuum for 1 h.
Crude product was used in the next step without any further purification (18.3 mg, quantitative yield). LC-MS
(ESI); m/z: [M+H] Calcd. for C29H30F2N505S, 598.1935. Found 598.1953. To a solution of crude product from above; 2-(4- (4- (3 -(2,6-difluoro-3 -(prop yl sulfonamido)benzoy1)- 1H-pyrrolo [2,3 -b] pyridin-5-yl)phenyl) -piperazin- 1-y1) acetic acid (18.3 mg, 0.0306 mmol) and(2S ,4R)-1- [(2S )-2-amino-3 ,3 -dimethyl-butanoyl] -4-hydroxy-N- [
[4- (4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;hydrochloride (4) (17.2 mg, 0.0367 mmol) in DMF (1 ml) was added TEA (0.106 mL, 0.762 mmol) and PyBOP (19.1 mg, 0.0367 mmol) at room temperature. The reaction mixture was stirred for 4 h at the same temperature. TLC
(DCM:MeOH:NH4OH, 90:9:1) shows no starting material (acid). The reaction mixture was evaporated to dryness under high vacuum. Crude product was diluted with Et0Ac (10 mL) and washed with a saturated-aqueous solution of NaHCO3 (2x5 mL), organic extract was dried (Na2SO4), and evaporated under vacuum. Crude product was purified by PTLC
DCM:MeOH:NH4OH, 90:9:1, 2x) to give 20 mg of product (65% yield). 1H NMR (500 MHz, DMSO-d6) 6 12.92 (bs, 1H), 9.76 (bs, 1H), 8.91 (s, 1H), 8.66 (s, 1H), 8.65 ¨
8.45 (m, 2H), 7.85 (d, J = 9.1 Hz, 1H), 7.74 - 7.52 (m, 3H), 7.49 - 7.32 (m, 4H), 7.28 (t, J =
8.6 Hz, 1H), 7.09 (d, J
= 8.5 Hz, 2H), 5.16 (d, J = 3.0 Hz, 1H), 4.54 (d, J = 9.6 Hz, 1H), 4.52 - 4.32 (m, 3H), 4.26 (dd, J
= 15.7, 5.4 Hz, 1H), 3.76 - 3.58 (m, 2H), 3.27 (s, 4H), 3.21 - 2.95 (m, 4H), 2.68 (s, 4H), 2.40 (s, 3H), 2.07 (dd, J = 12.9, 7.7 Hz, 1H), 1.92 (ddd, J = 13.1, 9.0, 4.6 Hz, 1H), 1.75 (h, J = 7.5 Hz, 2H), 0.97 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) 6 180.56, 171.77 , 169.28, 168.48, 156.02 (dd, J = 246.6, 7.0 Hz), 152.37 (dd, J = 240.8, 8.8 Hz), 151.30, 150.27, 148.38 , 147.68 , 143.55 , 139.42 , 138.47 , 131.48 , 131.12 , 129.68 , 129.10 - 128.66 (m), 128.63 , 128.33 , 127.57 , 127.51 , 125.96 , 121.92 (dd, J = 13.7, 3.6 Hz), 118.60- 117.95 (m), 117.57 , 115.84 , 115.59 , 112.32 (dd, J = 23.0, 2.7 Hz), 68.91 , 60.59 , 58.81 , 56.56 , 55.86 , 48.16 , 41.67 , 37.87 , 35.80 , 26.26, 16.83 , 15.90, 12.61. LC-MS (ESI); m/z [M+H]: Calcd.
for C51t158F2N907S2, 1010.3868. Found 1010.4036 [0737] (2S ,4R)-1-((S )-2-(4-(4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)benzo y1)-1H-pyrrolo [2,3 -bi -pyridine-5-yl)benzamido)butanamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (Compound 513).
H
N "
µ0 N N[i HN
0 NI-1, . 0 ....õ---...,..
/
N
[0738] To a solution of crude product from SJF-0633; 4-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamido)butanoic acid (29.0 mg, 0.0496 mmol) and (2S ,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoy1]-4-hydroxy-N4[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;hydrochloride (27.8 mg, 0.0595 mmol) in DMF (2 ml) was added TEA (0.172 mL, 1.23 mmol) and PyBOP (31.0 mg, 0.0595 mmol) at room temperature. The reaction mixture was stirred for 4 h at the same temperature.
TLC (DCM:MeOH:NH4OH, 90:9:1) shows no starting material (acid). The reaction mixture was evaporated to dryness under high vacuum. Crude product was filtered over a silica-carbonate cartridge (1g) using DCM:Me0H (9:1) as a eluent. Filtrate was evaporated under vacuum and crude product was purified by PTLC (DCM:MeOH:NH4OH, 85:14:1) to give 35 mg of product (71% yield). 1t1 NMR (400 MHz, DMSO-d6) 6 12.96 (bs, 1H), 9.70 (bs, 1H), 8.97 (s, 1H), 8.77 (d, J = 2.0 Hz, 1H), 8.69 (bs, 1H), 8.56 (t, J = 5.6 Hz, 2H), 8.26 (s, 1H), 8.08 - 7.92 (m, 3H), 7.86 (d, J = 8.2 Hz, 2H), 7.65 - 7.53 (m, 1H), 7.40 (dd, J = 8.2 Hz, 4H), 7.29 (t, J = 8.7 Hz, 1H), 5.14 (d, J = 3.5 Hz, 1H), 4.57 (d, J = 9.3 Hz, 1H), 4.51 -4.31 (m, 3H), 4.22 (dd, J = 15.9, 5.4 Hz, 1H), 3.77 - 3.59 (m, 2H), 3.32- 3.21 (m, 2H), 3.17 - 3.05 (m, 2H), 2.44 (s, 3H), 2.42 - 2.14 (m, 2H), 2.08 - 1.98 (m, 1H), 1.97 - 1.84 (m, 1H), 1.88 - 1.61 (m, 4H), 0.96 (s, 9H), 0.95 (t, 3H).
13C NMR (151 MHz, DMSO-d6) 6 181.11 , 172.38 , 172.30, 170.10, 166.19 , 156.45 (dd, J =
246.3, 7.1 Hz), 152.78 (dd, J = 249.6, 8.2 Hz), 151.86 , 149.54 , 148.13 , 144.57 , 141.04 , 139.92 , 139.43 , 133.94 , 131.59 , 131.04 , 130.05 , 129.46 - 129.15 (m), 129.06 , 128.49 , 127.84 , 127.63 , 127.32 , 122.35 (dd, J = 13.4, 3.8 Hz), 118.94 - 118.30 (m), 117.94 , 116.15 , 112.79 (d, J = 22.6 Hz), 69.32 , 59.14 , 56.87 , 56.82 , 53.87 , 42.08 , 40.46 , 38.39 , 35.69 , 33.08 , 26.84 , 26.10 , 17.26 , 16.38 , 13.04. LC-MS (ESI); m/z [M+H]: Calcd.
for C50H55F2N808S2, 997.3552. Found 997.2761.
[0739] (2S ,4S )-1-((S )-2-(2-(4-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)- 1H-pyrrolo I-2,3 -bl pyridin-5-yl)phenyl)piperazin- 1-yl)acetamido)-3 ,3 -dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benz yl)p yrrolidine-2-c arboxamide (Compound 516).

H , N 1"

F Nj=LNI-1, ----\HN
- 0 _ z ........--....õ, N
[0740] To a solution of crude product from SJF-0660; 2-(4-(4-(3-(2,6-difluoro-3-(prop ylsulfonamido)benzoy1)-1H-p yrrolo [2,3 -b] pyridin-5-yl)phenyl) -piperazin-l-yl)acetic acid (5.70 mg, 0.00954 mmol) and (2S,4S)-1-((S)-2-amino-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (5.35 mg, 0.0124 mmol) in DMF (1 ml) was added TEA (0.1 mL, 0.762 mmol) and PyBOP (5.96 mg, 0.0114 mmol) at room temperature. The reaction mixture was stirred for 4 h at the same temperature.
TLC
(DCM:MeOH:NH4OH, 85:14:1) shows no starting material (acid). The reaction mixture was evaporated to dryness under high vacuum (Product may be soluble in water).
Crude product was filtered over a silica-carbonate cartridge (100 mg) using DCM:Me0H (9:1) as a eluent and evaporated under vacuum.. Crude product was purified by PTLC (DCM:MeOH:NH4OH, 85:14:1) to give 6.1 mg of product (63% yield). 1t1 NMR (500 MHz, DMSO-d6) 6 12.93 (bs, 1H), 9.76 (bs, 1H), 8.93 (s, 1H), 8.69 (t, J = 5.8 Hz, 1H), 8.66 (s, 1H), 8.56 (bs, 1H), 8.18 (s, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.65 - 7.50 (m, 3H), 7.51 - 7.32 (m, 4H), 7.28 (t, J
= 8.7 Hz, 1H), 7.09 (d, J = 8.2 Hz, 2H), 5.48 (d, J = 7.2 Hz, 1H), 4.49 (d, J = 9.2 Hz, 1H), 4.46 -4.33 (m, 2H), 4.32 -4.18 (m, 2H), 3.96 - 3.88 (m, 1H), 3.54 - 3.42 (m, 1H), 3.30 - 3.19 (m, 4H), 3.17 - 3.00 (m, 4H), 2.78 - 2.56 (m, 4H), 2.41 (s, 3H), 2.39 - 2.30 (m, 1H), 1.82 - 1.68 (m, 3H), 0.98 (s, 9H), 0.95 (t, 3H). 13C NMR (151 MHz, DMSO-d6) 6 180.60, 172.29, 169.55, 168.84, 156.04 (dd, J
= 246.5, 6.9 Hz), 152.38 (dd, J = 249.4, 8.3 Hz), 151.40 , 150.29 , 148.40 , 147.75 , 143.57 , 139.16 , 138.53 , 131.50 , 131.12 , 129.79 , 128.78 (d, J = 7.4 Hz), 128.70 , 128.36 , 127.54 , 125.99 , 121.93 (dd, J = 13.4, 3.6 Hz), 118.52 - 117.94 (m), 117.59 , 115.87 , 115.60 , 112.35 (dd, J = 23.0, 3.9 Hz), 69.09 , 60.50 , 58.62 , 56.01 , 55.63 , 53.46 , 52.70 , 48.17 , 41.83 , 36.90, 35.21 , 26.25 , 16.85 , 15.93 , 12.63 . LC-MS (ESI); rniz [M-Ft1] : Calcd.
for C51t158F2N907S2, 1010.3868. Found 1010.3542.
[0741] Example 21-Synthetic Scheme G: compound 515 Method G
Br Br X-PHOS, KOAc MgC12, (Boc)2 0 B
OH
t-BuOH 0 0 Pd(OAc)2, Dioxane 0 0 h<
19(20%) _ 0 0 B-Bis In-situ formation N = N
F \ I Pd(dba)2/

o Br K2CO3, Dioxane-water N = N HO, =
H F \ N N
NO 0 '2) VHL-ligand 0 PyBOP / TEA 0 DMF
Compound 515 (64%) F 20 (32%) 0 0 I
\
[0742] tert-butyl 5-(4-bromopheny1)-5-oxopentanoate (19).

Br 0<

[0743] In a flask equipped with a magnetic stirring bar, 5-(4-bromopheny1)-5-oxopentanoic acid (0.460 g, 1.70 mmol), and Boc Anhydride (0.481 g, 2.21 mmol) were dissolved in t-Butanol (1.00 mL, 10.5 mmol) and then Magnesium Chloride (0.0162 g, 0.170 mmol) was added into.
The mixture was stirred at 40 C for 16 h (overnight). The crude reaction mixture was diluted with Et0Ac (100 mL), washed with water (2x100 mL), aqueous NaHCO3 (2x100 mL), dried (Na2SO4) and evaporated by rotary evaporation. Crude product was purified by flash chromatography (SiO2-25g, Gradient Hex 100% to Hex:Et0Ac, 1:1, in 15 min) to give 198 mg of product (35% yield). 1H NMR (500 MHz, Chloroform-d) 6 7.82 (d, J = 8.3 Hz, 2H), 7.60 (d, J
= 8.4 Hz, 2H), 2.99 (t, J = 7.2 Hz, 2H), 2.33 (t, J = 7.1 Hz, 2H), 2.01 (p, J
= 7.2 Hz, 2H), 1.44 (s, 9H). 13C NMR (101 MHz, cdc13) 6 198.68, 172.67, 135.69, 132.04, 129.72, 128.33, 80.54, 37.64, 34.68, 28.27, 19.68. LC-MS (ESI); m/z [M+Na]: Calcd. for C15tl19BrO3Na, 349.0415.
Found 349.0676, and 351.0609.
[0744] tert-Butyl 5-(4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoy1)-1H-pyrrolo[2,3-b]pyridin-5-yl)pheny1)-5-oxopentanoate (20).
H
N N
, µ0 I
/ ONic.

I \

[0745] To a solution of tert-butyl 5-(4-bromopheny1)-5-oxo-pentanoate (19) (74.0 mg, 0.226 mmol) in Dioxane (5 mL) was added 4,4,5,5-tetramethy1-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1,3,2-dioxaborolane (63.2 mg, 0.249 mmol), CH3CO2K (66.6 mg, 0.678 mmol), and the reaction mixture was degassed under argon. X-PHOS (16.2 mg, 0.0339 mmol) and Palladium(II) acetate (2.54 mg, 0.0113 mmol) were added and the reaction mixture was stirred at 100 C (external temperature) for 1 h. under a argon atmosphere. After 1 h. the temperature of the heating bath was turned down to 90 C and the flask was raised out of the heating bath, but continued stirring. N- [3 -(5-bro mo-1H-p yrrolo [2,3 -b]
pyridine-3 -c arbony1)-2,4-difluoro-phenyl[propane-l-sulfonamide (5) (104 mg, 0.226 mmol) and Potassium carbonate (93.8 mg, 0.678 mmol) were added, followed by water (2.00 m1). Tricyclohexyl phosphine (6.34 mg, 0.0226 mmol, 2x) and Pd(dba)2 (6.50 mg, 0.0113 mmol) were added, and the reaction mixture was heated with vigorous stirring at 90 C and stirred for 3 h, then the reaction mixture was cooled to ambient temperature. The reaction mixture was diluted with Et0Ac (30 mL) and poured into brine (20 mL), the organic extract was dried (Na2SO4), and evaporated under vacuum. Crude product was purified by flash chromatography (SiO2-40g, gradient Hex:Et0Ac, 1:9 to 100% Et0Ac in 20 min). Product was about 85% pure, it was purified again by PTLC
(DCM:MeOH:NH4OH, 90:9:1) to give 45 mg of product (32% yield). 1H NMR (500 MHz, DMSO-d6) 6 12.98 (bs, 1H), 9.68 (bs, 1H), 8.78 (s, 1H), 8.69 (s, 1H), 8.26 (s, 1H), 8.07 (d, J =
8.3 Hz, 2H), 7.92 (d, J = 8.3 Hz, 2H), 7.65 - 7.49 (m, 1H), 7.27 (t, J = 8.7 Hz, 1H), 3.10 (q, J =
7.8, 7.3 Hz, 4H), 2.29 (t, J = 7.4 Hz, 2H), 1.85 (p, J = 7.3, 6.8 Hz, 2H), 1.79 - 1.62 (m, 2H), 1.39 (s, 9H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) 6 199.09 , 180.72, 172.08 , 156.04 (dd, J = 246.5, 6.9 Hz), 152.37 (dd, J = 249.6, 8.5 Hz), 149.29, 144.21 , 142.60, 139.11 , 135.42, 130.30, 128.97 - 128.74 (m), 128.78 , 127.40, 127.35 , 122.00 (dd, J =
13.6, 3.7 Hz), 118.66- 117.86 (m), 117.55, 115.79, 112.38 (dd, J = 22.7, 3.8 Hz), 79.61 , 53.48 , 37.08 , 34.03 , 27.80 , 19.46 , 16.86 , 12.64.
LC-MS (ES I) ; m/z: [M+H]+ Calcd.
for C32H34F2N306S, 626.2136. Found 626.2191.
[0746] (2S ,4R)-1-((S )-2-(5-(4-(3 -(2,6-difluoro-3 -(prop ylsulfonamido)benzo y1)-1H-pyrrolo [2,3 -bi pyridin-5-y1) -pheny1)-5-oxopentanamido)-3,3-dimethylbutanoy1)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl) -pyrrolidine-2-carboxamide (Compound 515).
H m HO
,,.
µ0 I
HN

N
[0747]
A solution of tert-butyl 5-(4-(3-(2,6-difluoro-3-(propyl -sulfonamido)benzoy1)-pyrrolo[2,3-b]pyridin-5-yl)pheny1)-5-oxopentanoate (20) (22.0 mg, 0.0352 mmol) in a mixture of TFA (1.50 mL, 20.2 mmol) and Dichloromethane (3 ml) was stirred for 2 h at room temperature. Then the solvent was removed under vacuum and crude product was dried under high vacuum for 2 h. Crude product was used in the next step without any further purification (19.9 mg, quantitative yield). LC-MS (EST); m/z: [M+H] Calcd. for C28H26F2N306S, 570.1510.

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:

Claims (42)

WO 2020/051564 PCT/US2019/050114What Is Claimed Is:
1. A bifunctional compound having the chemical structure:
ULM¨L¨PTM, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph or prodrug thereof, wherein:
the ULM is a small molecule E3 ubiquitin ligase binding moiety that binds an ubiquitin ligase;
the PTM is a small molecule comprising a rapidly accelerated fibrosarcoma (RAF) protein targeting moiety; and the L is a bond or a chemical linking moiety connecting the ULM and the PTM.
2. The bifunctional compound according to claim 1, wherein the E3 ubiquitin ligase binding moiety that targets an E3 ubiquitin ligase selected from the group consisting of Von Hippel-Lindau (VLM), cereblon (CLM), mouse double-minute homolog2 (MLM), and IAP
(ILM).
3. The bifunctional compound according to claim 1 or 2, wherein the PTM is represented by chemical structure PTM-Ia or PTM-Ib:
111='TM1 y /
/pTivi R WPTM' %%0 %

,%,/ YPTM ¨ RPTM3 Vpi-a ... ,7 ZpTivi / \
N
/ al, ----._ HO N
PTM-Ia 11:4)-1M1 v /
zµpTm WPTM' %µ=
R i i PTM2 =%%
1 1 ,,,YPTM¨RPTM3 ZpTm \

S
v \ XPTM38 ^PTM36 ........XPTM37 PTM-Ib v /
zp-rm WPTM." µµµ%%

1 1 YPTM¨RPTM3 Vp-ra ::: ,7 RPTM2a ZpTm RPTM2b RPTM4 / \
---.........
N
PTM-Ic , wherein:
double dotted bonds are aromaric bonds;
Vp1m, WPTM, XPTM, YPTM, ZPTm is one of the following combinations: C, CH, N, N, C; C, N, N, CH, C; C, 0, C, CH, C; C, S, C, CH, C; C, CH, C, 0, C; C, CH, C, S, C; C, CH, N, CH, C; N, CH, C, CH, C; C, CH, C, CH, N; N, N, C, CH, C; N, CH, C, N, C; C, CH, C, N, N; C, N, C, CH, N; C, N, C, N, C; and C, N, N, N, C;
Xplm35, XPTM36, XPTM37, and XPTM38 are independently selected from CH and N;
Rp1m1 is covalently joined to a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof;

RPTM2 is hydrogen, halogen, aryl, methyl, ethyl, OCH3, NHCH3 or M 1-CH2-CH2-M2, wherein M1 is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
RpTM2a and RPTM2b is hydrogen, OH, halogen;
RpTm3 is absent, hydrogen, aryl, methyl, ethyl, other alkyl, cyclic alkyl, OCH3, NHCH3 or M 1-CH2-CH2-M2, wherein M1 is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
RpTM4 is hydrogen, halogen, aryl, methyl, ethyl, OCH3, NHCH3 or M 1-CH2-CH2-M2, wherein M1 is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle; and RpTm5 is selected from the group consisting of F......_____\ FN.---"*"..\
N ----------- N
\N
/ -------> --- > ------- K\ /N ------------------- F-0.-0 --- F me..=-=ON ---- F limm=-<>- ---- F _______ ON
, .--------\
, "......) ,,,, F F
......_____\
N -------------------------------------------------------------- N
N _____________________________________________________________ / HO
HO\ HO
HO"......) /
HO
4. The bifunctional compound according to claim 1 or 2, wherein the PTM is represented by chemical structure PTM-IIa or PTM-IIb:

RPTM5a RPTM6a \ 0 RPTM 1 7\ XPTM3 RPTM9 =`171TM1 XPTM5 vRPTI\A10 RPTM6b /

/
RPTM6c PTM-IIa or RPTM6a RPTM5a RPTM8 \ 0 RPTM7 RPTM6b /

/
RPTM6c PTM-IIb , wherein:
XPTM1, XPTM2, XPIM3, XPIM4, XPTM5, and XPTM6 are independently selected frorn CH or N;

RipTA45a is selected from the group consisting of: H, optionally substituted amide (e.g., optionally substituted with an alkyl, methyl, ethyl, propyl, or butyl group), optionally \ , / rRPTM5b --.........N/
0 \
substituted amine, , -NHC(0)Rm-ms;
RipTm5 is selected from the group consisting of F......_____\ FN.---"*"..\
N --------------------- N --N...---'...\
-------j NI:11) /N
> ______________________________________ \ K ----------------------------------- )N
N F-0.-/ --------- ------->
0 --------------- F N --- F Illm.0- ------- F _______ ON
F......_____\
/ F.--------\

/
"......) i , /
N ----------------------------------------------------------- N
N ___________________________________________________________ / HO __ HO\ HO
HO".......) __ / --HO
, RpTM5b is hydrogen or a linear or branched C1-C4 alkyl (e.g., methyl or ethyl);
RpTM6a and RPTM6b are each independently selected from hydrogen, halogen, or optionally substituted linear or branched Ci-C6 alkyl;
RpTA46 is either of the following groups: absent, hydrogen, halogen, aryl, methyl, ethyl, OCH3, NHCH3 or M 1-CH2-CH2-M2, wherein M1 is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle.
RpTM6c is hydrogen or a linear or branched C1-C4 alkyl (e.g., methyl or ethyl);

RpTM7 is absent, hydrogen, halogen, aryl, methyl, ethyl, OCH3, NHCH3 or M1-CH2-CH2-M2, wherein M1 is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle.
RpTm8, RPTM9 Or RPTM10 are independently selected from the group consisting of absent, hydrogen, halogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocycle, methyl, ethyl, OCH3, NHCH3 or M1-CH2-CH2-M2, wherein M1 is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle; and Rpn411 is absent, hydrogen, halogen, methyl, ethyl, OCH3, NHCH3 or M1-CH2-CH2-M2 in which Ml, wherein CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle.
at least one of RPTM8, RPTM9, Or RPTM10 is modified to be covalently joined to a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof, or two of RPTM8, RPTM9, and RPTM10 are modified to form a polycyclic (e.g., bicyclic) fused ring with a chemical linker group.
5. The bifunctional compound according to claim 4, wherein:
when RpTm9 is the covalently joined position, RPTM7 and RPTM8 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM7 and RPTM8 are attached; or when RpTm8 is the covalently joined position, RPTM9 and RPTM10 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM9 and RPTM10 are attached; or when RPTM10 is the covalently joined position, RPTM8 and RPTM9 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM8 and RPTM9 are attached.
6. The bifunctional compound according to claim 1 or 2, wherein the PTM is represented by chemical structure PTM-III:

\ .....4:,XPTM10 RPTM12 H oõ. XPTM 17 0 RPTM 17 XPTM 1"r XPTM9 RPTM 18 i \

y \
- ....,1 XPTfc.14......./............. .......... XPTfZ
y 8 N XPTM 12 ',PIM 19 x 11 I

\ N N

PTM-III
wherein:
XpTm7, XpTm8, XpTim9, XpTM10, XPTM11, XPTM12, XPTM13, XPTM14, XPTM15, XPTM16, XPTM17, XpTM18, XPTM19, XPTM20 are independently CH or N;
RpTm12, RPTM13, RPTM14, RPTM15, RPTM16, RPTM17, RPTM18, RPTM19 are independently selected from the group consisting of absent, hydrogen, halogen, aryl, heteroaryl, cycloalkyl, heterocycle, methyl, ethyl, other alkyl, OCH3, NHCH3 or M 1-CH2-CH2-M2, wherein M1 is CH2, 0 and NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle;
RpTm20 is a small group containing less than four non-hydrogen atoms;
RpTm21 is selected from the group consisting of trifluoromethyl, chloro, bromo, fluoro, methyl, ethyl, propyl, isopropyl, tert-butyl, butyl, iso-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, OCH3, NHCH3, dimethylamino or M 1-CH2-CH2-M2, wherein M1 is CH2, 0 or NH, and M2 is hydrogen, alkyl, cyclic alkyl, aryl or heterocycle; and at least one of RPTM12, RPTM13 and RPTM16 is modified to be covalently joined to a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof.
7. The compound according to claim 6, wherein:
when RpTh412 is the covalently joined position, RpTm13 and RpTh414 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM13 and RPTM14 are attached, and/or RPTM15 and RPTM16 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which Rplmis and RPTM16 are attached;

when RpTA413 is the covalently joined position, RPTA412 and Rm-m16 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM12 and RPTM16 are attached, and/or RPTM15 and RPTM16 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RpTmis and RPTM16 are attached; or when RpTh416 is the covalently joined position, RpTA412 and RpTh413 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM12 and RPTM13 are attached, and/or RPTM13 and RPTM14 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM13 and RPTM14 are attached
8. The bifunctional compound according to claim 1 or 2, wherein the PTM is represented by chemical structure PTM-IVa or PTM-IVb:

\s, ff ----NH
RPTM25a RPTM26 x .......õ

XPTM21 I\PTM23 XPTM28 Np 1 ¨PTM28 -----RPTM25b XPTM26 RPTM30 /

v I
,4 APTM34=----XPTM33 XPTM25 \ - Rp-rm24 / x -----XPTM31 RPTM23 ¨PTM30 / \

PTM-IVa or \s, , ------ NH
RPTM26N ......,...N
0 RPTM25a RPTM25 XPTM21--'''''' ) / \ \
I
XPTM21 v f\PTM23 ..
x \ N/ N ....õ.0 XPTM27 XPTM28 p ¨PTM22 ----""
/ . ,PTM28 ------RPMT25b XPTM26 RPTM30 1RPTM29 ,-- I
---/( v "PTM34--XPTM33 XPTM25 N \ RPTM24 / /

RPTM23 \

PTM-IVb , wherein:
XpTm21, XPTM22, XPTM23, XPTM24, XPTM25, XPTM26, XPTM27, XPTM28, XPTM29, XPTM30, XpT1VB1, XpE\432, XPTM33, XPTM34 are independently CH or N;
RpTm22 is selected from the group consisting of F....._____\ F
N..------\
N --------------------- N --..-----N Fµc> F
------------------------------------------------------------ /N
\N
/ -------> --- > ------- ( /\

0 ------------- F Ime-ON ------------------ F Imm-0- _______ F ON
, , N.---------\
F F
---......) /
N N --N __________________________________ ss=\/
Z/
/ HO He HO
HO-) /
HO
RPTM25a and RpTh425b are each independently selected from hydrogen, halogen, or C1-C6 alkyl (linear, branched, optionally substituted);
RpTA423, RpTA424, RpTM28, RPTM29, RPTM30, RPTM31, RPTM32 are independently selected from the group consisting of absent, bond, hydrogen, halogen, aryl (optionally substituted), heteroaryl (optionally substituted), cycloalkyl (optionally substituted), heterocycle (optionally substituted), methyl, ethyl (optionally substituted), other alkyl (linear, branched, optionally substituted), OCH3, NHCH3 or M1-CH2-CH2-M2, wherein M1 is CH2, 0 and NH, and M2 is hydrogen, alkyl (linear, branched, optionally substituted), cyclic alkyl (optionally substituted), aryl (optionally substituted)or heterocycle (optionally substituted); and RpTm25 iS selected from absent, hydrogen, halogen, Ci-C6 alkyl (linear, branched, optionally substituted), OCH3, NHCH3 or SCH3;
RpTm26 iS selected from absent, hydrogen, halogen, Ci-C6 alkyl (linear, branched, optionally substituted), OCH3, NHCH3 or SCH3;

RpTm27 is selected from the group consisting of absent, hydrogen, halogen, Ci-C6 alkyl (linear, branched, optionally substituted), OCH3, NHCH3 or SCH3; and at least one of RPTM24, RPTM29, RPTM32 is modified to be covalently joined to a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof.
9. The bifunctional compound according to claim 8, wherein:
when RpTm24 is the covalently joined position, Rpm/131 and RpTm32 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM31 and RPTM32 are attached, or RPTM29 and RPTM30 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM29 and RPTM30 are attached;
or when RpTm29 is the covalently joined position, RpTm24 and RpTm32 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM24 and RPTM32 are attached, and/or RPTM31 and RPTM32 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM31 and RPTM32 are attached; or when RpTm32 is the covalently joined position, RPTM24 and RPTM29 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM24 and RPTM29 are attached, and/or RPTM29 and RPTM30 are connected together via a covalent bond in a way to form a bicyclic group with the ring to which RPTM29 and RPTM30 are attached.
10. The bifunctional compound according to claiml or 2, wherein the PTM is represented by chemical structur PTM-Va:

\ XPTM36 /

H....,===******. "TM38 1 RPTM38 %,,,, or PTM-Va \v 1 ,RPTM36 ^PTM36 /

1 v 1 N
^PTM38 v RPTM38 ^PTM39 ,,, ., ,-, µ.., , PTM-Vb wherein:
Xplm35, XPTM36, XPTM37, XPE\438, and XPTM39 are independently CH or N;
RpTM33 is a halogen or a linear or branched C1-C4 haloalkyl;
Rplm34, RpTm35, RPTM36, RPTM37, and RPTM38 are each independently selected from hydrogen, halogen, or linear or branched C1-C4 alkyl (e.g., methyl, ethyl, propyl, or butyl);
RpTm39 is an optionally substituted C4-C7 heterocycloalkyl (e.g., an optionally substituted C5 or C6 heterocycloalkyl); and %%= is the point of attachment with a ULM, a chemical linker group (L), a CLM, an ILM, a VLM, MLM, a ULM', a CLM', a ILM', a VLM', a MLM', or combination thereof.
11. The bifunctional compound according to claims 1-10, wherein the PTM is selected from the group consisting of PTM-1, PTM-2, PTM-3, PTM-4, PTM-5, PTM-6, PTM-7, PTM-8, PTM-9, PTM-10, PTM-11, PTM-12, and PTM-13:

F\

, c/1\13-NH
/ \ 0 F
- A\1 0 HO N N ------N N
H

p õ----NH
F N.,-,...('6' 0 = NH 1 F H
N N F F
H

k N)1 0,P H F \ / ...-_-,\ N
ir-NH
-\--/ = N 0 , N ri\I
I I\1) F \
N
I' N N
H

N.-z_-\
0,P H F
\S" / = N \--/ = N-.---- N N------ I

N I

F F
N--C-?/ _NH \NI
0 F d -NH F

I I /

N N N N
H H
PTM-9 PTM-10 , IV O
I ;NI N
HO
l i, N
/ \ H
CI O
-N / \
CI
-N

0 f HI N
N y, rN
F F F
L

PTM-13 .
12. The bifunctional compound according to any of claims 1-11, wherein the ULM is selected from the group consisting of:

- , N
0 _.,ZH tIZH 0 tl4H )ro 0 0 ,.µr -- * - - * OH
61 N O N ,,1( ---NH
õ .
NH .rNH9 OH

N / S

0 0 N.;:j S---, S
\I
\ N
HN

IL)L
ii 0 .
bH

N O NH
S S ---, i 4_1(NI II
\ N
= D R14a "14a OH
HN N , 0 N\...-0 - / 0 NH
- ,1\1 II
0 R14a OH
OH
OH
, 0:,\LNH
\ II
N \ N
R14a OH
/ S
N-.7.--1- , wherein the Ri4a is a methyl or hydroxymethyl.
13. The bifunctional compound according to any of claims 1-11, wherein ULM is a Von Hippel-Lindau (VHL) ligase-binding moiety (VLM) with a chemical structure represented by:
r7..--R
P
41 X1'NY
\Aft , wherein:
Xi, X2 are each independently selected from the group of a bond, 0, NRY3, CRY3RY4, C=0, C=S, SO, and S02;

RY3, RY4 are each independently selected from the group of H, linear or branched C1-6 alkyl (optionally substituted by 1 or more halo), optionally substituted C1-6 alkoxyl (e.g., optionally substituted by 0-3 RP groups);
RP is 0, 1, 2, or 3 groups, each independently selected from H, halo, -OH, C1-3 alkyl, C=0;
W3 is selected from the group of an optionally substituted T, an optionally substituted ¨T-N(R 1 aRlbµ,,3 )A, optionally substituted ¨T-N(RlaR) lb,µ optionally substituted ¨T-Aryl, an optionally substituted ¨T-Heteroaryl, an optionally substituted T-biheteroaryl, an optionally substituted ¨T-Heterocycle, an optionally substituted ¨T-biheterocycle, an optionally substituted -NR1-T-Aryl, an optionally substituted -NR1-T-Heteroaryl or an optionally substituted -NR1-T-Heterocycle;
X3 of Formula ULM-a is C=0, Ri, Ria; Rib;
Ri; tc ¨ ia;
Rib are each independently selected from the group consisting of H, linear or branched Ci-C6 alkyl group optionally substituted by 1 or more halo or -OH
groups, RY3C=0, RY3C=S, RY3S0, RY3S02, N(RY3RY4)C=0, N(RY3RY4)C=S, N(RY3RY4)S0, and N(RY3RY4)S 02;
T is selected from the group of an optionally substituted alkyl, ¨(CH2).-group, wherein each one of the methylene groups is optionally substituted with one or two substituents selected from the group of halogen, methyl, optionally substituted alkoxy, a linear or branched Ci-C6 alkyl group optionally substituted by 1 or more halogen, C(0) NR1Ria , or NR1Ria or Ri and Ria are joined to form an optionally substituted heterocycle, or -OH
groups or an amino acid side chain optionally substituted; and n is 0 to 6, Ri4a , Ri4a 14b14a '=//10 ¨14b 1µ

w4 is R15 R15 , or , Fr , N

R15 ;

Ri4a, R14b, are each independently selected from the group of H, haloalkyl, optionally substituted alkoxy, optionally substituted hydroxyl alkyl, -(CH2)m,C(=0)(CH2)m,C(=0)(OH), (CH2)m'OCOCH2(CH2)m,OCH2(CH2)m,CO(CH2)m,OH, (CH2)m'OCOCH2(CH2)m,CO(CH2)m,OH, or optionally substituted linear or branched alkyl optionally with one or more carbons replaced with an oxygen;
R1 is H, linear or branched C1-C6 alkyl group optionally substituted by 1 or more halo or -OH
groups;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);
W5 is selected from the group of an optionally substituted phenyl, an optionally substituted 5-membered heteroaryl, W6 is an optionally substituted 8-14 membered bicyclic heterocycle;
Ris is selected from the group of H, halogen, CN, OH, NO2, N R14aR14b, OR14a, CONR14aR14b, NR14aCOR14b, SO2NR14aR14b, NRi4a SO2R14b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl; and the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM') or a chemical linker moiety coupling at least one PTM or a ULM' or both to ULM.
14. The bifunctional compound according to any of claims 1-1 1, wherein ULM is a Von Hippel-Lindau (VHL) ligase-binding moiety (VLM) with a chemical structure represented by:
_ ¨
HO, HO iRi . _________________________________________ --; R14a H R14a N N -00R14b w3o 0 ,L 0 411) (R16)0 R15 (R16)0 ¨ ¨ or ¨ ¨
, wherein:

W3 is selected from the group of an optionally substituted aryl, optionally substituted 1¨eRio heteroaryl, or R11 ;
R9 and Rio are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl, or R9, Rio, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;
Ri 1 is selected from the group of an optionally substituted heterocyclic, optionally substituted 1 ¨N:
alkoxy, optionally substituted heteroaryl, optionally substituted aryl, R13 , 1¨N \....---(R18)p or /¨N j-(R18)p N =
, R12 is selected from the group of H or optionally substituted alkyl;
Ri3 is selected from the group of H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;
Ri is H, linear or branched C 1-C6 alkyl group optionally substituted by 1 or more halo or -OH
groups;
R14a, R14b, are each independently selected from the group of H, haloalkyl, optionally substituted alkoxy, (CH2)in'OCOCH2(CH2)m,OCH2(CH2)in,C0(CH2)m,OH, (CH2)m'OCOCH2(CH2)m'CO(CH2)m'OH, optionally substituted hydroxyl alkyl, -(CH2)in,C(=0)(CH2)in,C(=0)(OH), or optionally substituted alkyl optionally with one or more carbons replaced with an oxygen;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);
W5 is selected from the group of an optionally substituted phenyl or an optionally substituted 5-10 membered heteroaryl, Ris is selected from the group of H, halogen, CN, OH, NO2, NR14aRl4b, OR14a, CONR14aR14b, NR14aCOR14b, SO2NR14aR14b, NR14a SO2R14b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl;
each Ri6 is independently selected from the group of H, CN, halo, optionally substituted alkyl optionally having one or more carbon atoms replaced with an oxygen atom, optionally substituted haloalkyl, hydroxy, or optionally substituted haloalkoxy;
o is 0, 1, 2, 3, or 4;
Ri8 is independently selected from the group of H, halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker; and p is 0, 1, 2, 3, or 4, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM') or a chemical linker moiety coupling at least one PTM
or a ULM' or both to ULM.
15. The bifunctional compound according to any of claims 1- 11, wherein the ULM
has a chemical structure selected from the group of:
HO
HO
N
Ri4a N
0 N \x Ris OyNH
R15 ' I
HO
H R14a N
N)---...----( and ''s , wherein:

R 1 is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl;
R14a is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl, (CH2)m'OCOCH2(CH2)m,OCH2(CH2)m,CO(CH2)m,OH, (CH2)m'OCOCH2(CH2)m'CO(CH2)m'OH, or cyclopropyl;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);
Ri5 is selected from the group consisting of H, halogen, CN, OH, NO2, optionally substituted heteroaryl, optionally substituted aryl; optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl;
X is C, CH2, or C=0 R3 is a bond or an optionally substituted 5 or 6 memebered heteroaryl; and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM
(ULM') or a chemical linker moiety coupling at least one PTM or a ULM' or both to the ULM.
16. The bifunctional compound according to any one of claims 1-11, wherein the ULM comprises a group according to the chemical structure:
HO, N R14a R9>r:c......0 O 411 ¨ ¨ , wherein:
R14a is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl, (CH2)m'OCOCH2(CH2)m,OCH2(CH2)m,CO(CH2)m,OH, (CH2)m'OCOCH2(CH2)m'CO(CH2)m'OH, or cyclopropyl;
each m' is individually an integer from 1 to 4 (e.g., 1, 2, 3, or 4);

R9 is H;
Rio is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
p(R18)-4:
Ri2 p(R18)" /
.
Rii iS R13 ; optionally substituted heteroaryl, .fte , 1=PN
(R18)p 0 \
/\N I \N
1-N---(R18)p or =
p is 0, 1, 2, 3, or 4; and each Ri8 is independently halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker;
Ri2 is H, C=0 Ri3 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl, Ri5 is selected from the group consisting of H, halogen, Cl, CN, OH, NO2, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted cycloheteroalkyl, OH ; I
>

-re and the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM') or a chemical linker moiety coupling at least one PTM or a ULM' or both to the ULM.
17. The bifunctional compound according to any of claims 1-11, wherein the ULM is a cereblon E3 ligase-binding moiety (CLM) selected from the group coinsisting of a thalidomide, lenalidomide, pomalidomide, analogs thereof, isosteres thereof, or derivatives thereof.
18. The bifunctional compound according to any of claim 1-11, wherein the ULM is a CLM that has a chemical structure represented by:
x X G X X G
Q
/
) __ N/
QQ4....... _I( %..../... 4,........ ..j.K
i Q2/"........_ Rn vv/N srvI\_1) Z
11 11 N __________ Z
Q 2/. .....õ:" "=---, vv/ ) 1 Qi Rn Rn \
R'\ _________________________________________________________ N
G' (al) (b) G

X X N Z
siv:// _____________________ I\l/G
X x C)4 N'Pr I I / N ) __ Z Q3 S -, Rn Q2/QW/ A _________________ N
Rn 1 x/ \ QI21 .4 / Qi Y Z
G' Rn (c) (dl) G

N Z X X
X x Q3...õ.04,..........

Q N't'S'r ______________________________________ Z
Q2/, ....7,............ wiN / ) __ I I
II Rn Q2/01 '........"N"."........A Q1 Rn Rn Rn (e) (0, x N
X X
________________________ N/G
Q()4N
11 __________________________ Z
Rn Rn Q/Ce-------1 IN/ A Q2/
Q
Rn Rn (a2) (d2) X X X /
_____________________________________________________________ N

ClIA1/ 41-1 Rn R
Rn/ Z , or Rn n (a3) (a4) wherein:
W is selected from the group consisting of CH2, 0, CHR, C=0, S02, NH, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and N-alkyl;
W3 is selected from C or N;
each X is independently selected from the group consisting of absent, 0, S, and CH2, Y is selected from the group consisting of CH2, -C=CR', NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, 0, and S;
Z is selected from the group consisting of absent, 0, S, and CH2;
G and G' are independently selected from the group consisting of H, optionally substituted linear or branched alkyl, OH, -(CH2),-0-P(=0)(0-C1-6alkyl)(OH), -(CH2),-0-P(=0)(0-C1_6a1ky1)2,-(CH2),-0-P(=0)(OH)2, -CH2OCOO(CH2CH20)eCH3,R' OCOOR, R'OCONRR", CH2-heterocycly1 optionally substituted with R', and benzyl optionally substituted with R';
n" is an integer from 8 to 35 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17. 18.
19. 20. 21. 22. 23 24. 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35);
Ql, Q2, Q3, and Q4 each independently represent a carbon C substituted with a group independently selected from H, R, N or N-oxide;

A is independently selected from the group H, optionally substituted linear or branched alkyl, cycloalkyl, Cl and F;
R comprises halogen, -CONR'R", -OR', -NR'R", -SR', -SO2R', -SO2NR'R", -CR'R"-, -CR'NR'R"-, (-CR'0).,R", optionally substituted-aryl (e.g., an optionally substituted C5-C7 aryl), optionally substituted alkyl-aryl (e.g., an alkyl-aryl comprising at least one of an optionally substituted C1-C6 alkyl, an optionally substituted C5-C7 aryl, or combinations thereof), optionally substituted-heteroaryl (e.g., an optionally substituted heteroaryl), optionally substituted linear or branched-alkyl (e.g., a C 1-C6 linear or branched alkyl optionally substituted with one or more halogen, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted alkoxyl group (e.g., a methoxy, ethoxy, butoxy, propoxy, pentoxy, or hexoxy; wherein the alkoxyl may be substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C 6 c yclo alkyl), or aryl (e.g., C 5-C7 aryl)), optionally substituted , , z Y
(e.g., optionally substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., , ' 0 )1):
, 0 C5-C7 aryl)), optionally substituted Y
(e.g., optionally substituted with one or more halogen, alkyl, haloalky, fluoroalkyl, cycloalkyl (e.g., a C3-C6 cycloalkyl), or aryl (e.g., C5-C7 aryl)), optionally substituted-cycloalkyl (e.g., optionally substituted C3-C7 cycloalkyl), optionally substituted-heterocyclyl (e.g., optionally substituted C3-C7 heterocyclyl), -P(0)(OR')R", -P(0)R'R", -0P(0)(OR')R", -0P(0)R'R", -C1, -F, -Br, -I, -CF3, -CN, -NR'SO2NR'R", -NR'CONR'R", -CONR' COR", -NR'C(=N-CN)NR'R", -C(=N-CN)NR' R", -NR' C(=N-CN)R", -NR' C(=C-NO2)NR'R", -SO2NR'COR", -NO2, -CO2R', -C(C=N-OR')R", -CR',CR'R", -CCR', -S(C=0)(C=N-R')R", -5F5 and -0CF3, wherein at least one R is modified to be covalently joined to a PTM, a chemical linker group (L), a ULM, a CLM' (e.g., CLM' is an additional CLM that has the same or different structure as a first CLM), or a combination thereof;

each of x, y, and z are independently 0, 1, 2, 3, 4, 5, or 6;
n' and n of Formulas (a) through (f) are each indepednently an integer from 1-10 (e.g. 1-4, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10);
R' and R" are independently selected from the group consisting of a H, optionally substituted linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic, -C(=0)R, optionally substituted heterocyclyl;
:zz"---":------- represents a single bond or a double bond; and represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific.
19. The bifunctional compound according to any of claims 1-11, wherein the ULM is a CLM that has a chemical structure represented by:

______________________________________________ NH
N ___________________________________________________ 0 R, wherein:
W is independently selected from the group CH2, C=0, NH, and N-alkyl;
A is independently selected from a H, methyl, or optionally substituted alkyl (e.g., C 1-C6 alkyl (linear, branched, optionally substituted));
R of Formula (g) is independently selected from a H, 0, OH, N, NH, NH2, halogen, methyl, optionally substituted linear or branched alkyl (e.g., optionally substituted linear or branched C 1-C6 alkyl), optionally substituted C 1-C6 alkoxy, optionally substituted-cycloalkyl (e.g., optionally substituted C3-C7 cycloalkyl), optionally substituted-heterocyclyl (e.g., optionally substituted C3-C7 heterocycly1),optionally substituted-alkyl-aryl (e.g., an ¨alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), optionally substituted aryl (e.g., C5-C7 aryl), amine, amide, or carboxy);
n of Formulas (g) represent an integer from 1 to 4 (e.g., 1, 2, 3, or 4), wherein at least one R
(e.g., at least one of 0, OH, N, NH, NH2, C1-C6 alkyl, C1-C6 alkoxy, -alkyl-aryl (e.g., an ¨alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, or carboxy) is modified to be covalently joined to a PTM, a chemical linker group (L), a ULM, CLM (or CLM') or combination thereof;
and . represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific.
20. The bifunctional compound according to any of claims 1-11, wherein the ULM is a CLM that has a chemical structure represented by:

NH (..)Q4 )'''NH
13 N ¨C) V -----/ N Q-3 NH p4=Q5 - N
tO
Q2. %-- \--- Q2. )/% 6 Q \---Qi W Qi W 0 2 1 (h) (i) (i) C)4. Ql.
Q3 -Q5 0 I. 02 0 Q2=Q3 -NH
612. A A , Qi\ / N tO
Qi N._.... y JNH Q3 L
R1' 11. R1 (k) (1) (m) 0 Nt 7 0 (:)ccLIAN_tz ceziriN N\Hx_R2 " 612. %`- i \µ` 62: /---`µAi \µ` /7 W N Qi W 0 Qi ""
'R1 R1 (n) (o) (10) 0 N 0 \

R'\ 0 ,¨NH
N
I
=
HN

(r) (a) \
NH o o 0 = oN).¨)1-1 0 NH
,N 00 HN_r W
oi (s) (t) o NH

x=( ______________________________________________ NH
I. v\iNI _________________________________ N

(u) (v) _c() _,\-NH Qi, _c4r0R4 R3 \ N -o Q? 1 A I N
sx 3 : /.'"- a NH
, Q4 "

(w) (x) Q1-Q5 0 0 0, C)/ ) ________ ,/ Qc(:)4_ ________ NH
b3(:).4 ,N 0 __ N t R4 -/-NH N& Qi W \_ O
0 HN) R1 (y) (z) 1C)1,A - NH

(aa) 0 (R5) n (R2) n __________________________ \ / 0 0 0 ________________________ R6 C)1_k X =X
I Q-jK NH

_____________________________________________________________ 0 Q3 \All ______ ) .
L_ 7 R',Q2 (ab) (R3) n (ac) \ / 0\
________________________________________________________ NH
_...-N
----/ \
I I N ___ (1, ' ) __ 0 N
Q2 \/..-"----.1 ,.........--________/
Q --X
1 (R.) n \ R' _______________________ 0 R1 R2 (ae) (ad) __________________________ NH
HN-.........<
N ______________________________ 0 R'/
(ag) (af) H 0 0.,II:
0 0\
Q(:)4...............,../K
) __ NH N Z
113 N¨(CH2)--N _________ 0 Q2 \i" n \ HO

Qi (ah) HO
0 0 (ai) ____________________________________ NH
Q' : N _________ 0 (di) H

R' Q2=Qi \ ________ NH 0 0 \)'L N R31 1\1 2 l 0 QcQ4---"AN4\--- NH
-il i i Xi (R')n R5 0 Qi (R2)n (ak) (al) (am) // .
Qi sQ4 0 ?¨( 0 Q4:05 NH N4 _________ i ____________________ Q3 to , _____________ / pl ¨CD
O2-Qi R4 NH
R1 0 , wherein:
W is independently selected from CH2, 0, CHR, C=0, S02, NH, optionally substituted cycloalkyl, optionally substituted heterocyclalkyl, and N-alkyl;
Ql, Q2, Q3, Q4, Q5 each independently represent a carbon C or N substituted with a group independently selected from H, R', N or N-oxide;
R1 is selected from absent, H, OH, CN, C1-C3 alkyl, C=0;
R2 is selected from the group absent, H, OH, CN, C1-C3 alkyl, CHF2, CF3, CHO, C(=0)NH2;
R3 is selected from H, alkyl (e.g., C1-C6 or C1-C3 alkyl), substituted alkyl (e.g., substituted C 1-C6 or C 1-C3 alkyl), alkoxy (e.g., C 1-C6 or C 1-C3 alkoxyl), substituted alkoxy (e.g., substituted C1-C6 or C1-C3 alkoxyl);
R4 is selected from H, alkyl, substituted alkyl;
R5 and R6 are each independently H, halogen, C(=0)R', CN, OH, CF3;
X is C, CH, C=0, or N;
X1 is C=0, N, CH, or CH2;
R' is selected from H, OH, halogen, amine, cyano, alkyl (e.g., C1-C3 alkyl), substituted alkyl (e.g., substituted C1-C3 alkyl), alkoxy (e.g., C1-C3 alkoxyl), substituted alkoxy (e.g., substituted C1-C3 alkoxyl), NR2R3, C(=0)0R2, optionally substituted phenyl;
n is 0-4;
/ is a single or double bond; and the CLM is covalently joined to a PTM, a chemical linker group (L), a ULM, CLM
(or CLM') or combination thereof.
21. The bifunctional compound according to any of claims 1-11, wherein:
the ULM is a (MDM2) binding moiety (MLM) with a chemical moiety selected from the group consisting of a substituted imidazolines, a substituted spiro-indolinones, a substituted pyrrolidines, a substituted piperidinones, a substituted morpholinones, a substituted pyrrolopyrimidines, a substituted imidazolopyridines, a substituted thiazoloimidazoline, a substituted pyrrolopyrrolidinones, and a substituted isoquinolinones; or the ULM is a IAP E3 ubiquitin ligase binding moiety (ILM) comprising the amino acids alanine (A), valine (V), proline (P), and isoleucine (I) or their unnatural mimetics.
22. The bifunctional compound according to any of claims 1-11, wherein the ULM is a IAP E3 ubiquitin ligase binding moiety (ILM) comprising a AVPI tetrapeptide fragment or derivative thereof.
23. The bifunctional compound according to claim 1, wherein at least one of: (i) the chemical linker group (L) is selected from the linkers of compounds 307-873, (ii) the ULM is selected from the ULMs of compounds 307-873, (iii) the PTM is selected from the PTMs of compounds 307-873, (iv) the compound further comprises a prodrug chemical moiety selected from the PTMs of compounds 796-873, or (v) a combination thereof.
24. The bifunctional compound according to any of claims 1-23, wherein the linker (L) comprises a chemical structural unit represented by the formula :
-(AL)q-, wherein:
(AL)q is a group which is connected to at least one of the ULM, the PTM, or a combination thereof;
q is an integer greater than or equal to 1;
each AL is independently selected from the group consisting of, a bond, CRI-1RL2,0, S, SO, S02, NI21-3, SO2N121-3, SONR1-3, CONRI-3, NI21-3CONRIA, NI2L3S02NRIA, CO, SiRL1RI-2, P(0)R1-'1, P(0)0R1-'1, NRI-3C(=NCN)NRI-A, NRI-3C(=NCN), NR1-3C(=CNO2)NRI-A, C3-llcycloalkyl optionally substituted with 0-6 RI-'1 and/or RI-2 groups, C3-llheteocycly1 optionally substituted with 0-6 121-1 and/or RI-2 groups, aryl optionally substituted with 0-6 121-1 and/or RI-2 groups, heteroaryl optionally substituted with 0-6 121-1 and/or RI-2 groups, where 121-1 or RI-2, each independently are optionally linked to other groups to form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 0-4 RI-5 groups; and RI-J, RI-2, RI-3, RI-'4 and RI-5 are, each independently, H, halo, Cl_8alkyl, 0C1_8a1ky1, SC1_8alkyl, NHC1_8alkyl, N(C1-8alky1)2, C3-11 cycloalkyl, aryl, heteroaryl, C3-11heterocyclyl, 0C3-8cyc10a1ky1, SC3_8cycloalkyl, NHC3_8cycloalkyl, N(C3-8cycloalky1)2, N(C3_ 8cyc10a1ky1)(Cl_8a1ky1), OH, NH2, SH, 502C1-8alkyl, P(0)(0C1-8alkyl)(C1-8alkyl), P(0)(0C1-8alky1)2, CCH, CH=CH(Cl_8alkyl), C(C1_8alky1)=CH(Cl_8alkyl), C(Cl_8alky1)=C(C1_8alkyl)2, Si(OH)3, Si(C1-8alky1)3, Si(OH)(C1-8alky1)2, COC1-8alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, 5F5, SO2NHC1_8alky1, 502N(C1-8alkyl)2, SONHC1_8alkyl, SON(C1-8alky1)2, CONHC1-8alkyl, CON(C1-8alky1)2, N(C 1-8a1ky1)CONH(C 1-8a1ky1), N(C1-8alkyl)CON(C1-8alkyl)2, NHCONH(Cl_8alkyl), NHCON(C1-8alky1)2, NHCONH2, N(Cl_8alkyl)S 02NH(Cl_8alky1), N(C 1-8alky1) S
02N(C 1-8a1ky1)2, NH SO2NH(Cl_8a1ky1), NH 502N(C1-8a1ky1)2, NH 502NH2.
25.
The bifunctional compound according to any of claims 1-24, wherein the linker (L) comprises a group represented by a general structure selected from the group consisting of:
-N(R)-(CH2).-0(CH2),-0(CH2),-0(CH2)p-O(CH2)q-0(CH2),-OCH2-, -0-(CH2).-0(CH2),-0(CH2),-0(CH2)p-O(CH2)q-0(CH2),-OCH2-, -0-(CH2).-0(CH2),-0(CH2),-0(CH2)p-O(CH2)q-0(CH2),-0-;
-N(R)-(CH2).-0(CH2),-0(CH2),-0(CH2)p-O(CH2)q-0(CH2),-0-;
-(CH2).-0(CH2),-0(CH2),-0(CH2)p-O(CH2)q-0(CH2),-0-;
-(CH2).-0(CH2),-0(CH2),-0(CH2)p-O(CH2)q-0(CH2),-OCH2-;
N N (CH2)p-- =
1-(CH2)m-N N--(CH2)n-NH

)es -r(CF12)m-N N----(CF12)n-0 --:--(CH2)m0(CH2)n¨N N¨(C1-12)0-NH
, µf.
-HCH2),-,-,0(CH2)n¨N N¨(CF12)0-0 -HCH260(CF12)n¨NNN¨(C1-12)o-4µ
--IT(CH2)m0(CF12)n¨N/KN¨(CF12)0-0(µ
, (CH2)m 0 H-ND/ ) (bH2)m-:-Ni,(C1;12)rn ,(CH26 -:-( 01 ; ) >0)µ =
`1>.(CH2)rn =
, =
r -/ ______________________ N __________________________ N
N ___________________ 0 _______________________ /0 __ /
=
\
N N ¨(CH2),0 (CH2),0(CH2)õ.0(C1-12)0-s HN¨(_ j)-0(CH2),O(CH2)nO(CH2)p0(CH2)q0CH2 X =
-:-NH =
0(CH2),0(CH2)ACH2)p0(CH2)q0CH2 -:-NH =
0(CH2),,,O(CH2)nO(CH2)p0(CH2)q0CH2 -:-NH
A 0(CH2),0(CH2)ACH2)p0(CH2)q0CH2 -:-NH
0(CH2)m0(CH2)nOCH2 0(CH2)m0(CH2)nOCH2 X ; and ¨ re. H
N --2,1 mn---r.H 2 , wherein m, n, o, p, q, and r, are independently 0, 1, 2, 3, 4, 5, 6, with the proviso that when the number is zero, there is no N-0 or 0-0 bond, R is selected from the group H, methyl and ethyl, and X is selected from the group H and F;
^ N
CD)s- N 0 N

H
H ) N
,,,,,,,,, /s = 0 .

H
H N
;
ss= /\"" sX\/\/ \/\/ 'i H , , =>,,....= ,...,........õ...-7õ0.õ,..õ,././,õ/õ.õ, N ,,./,.,=
= 0 \
/ N (:)''''/` ';'/N -"-...'"-\/ =.õ;.< YN ,----..,_...2 N ,,,õ 0 () C) ( H
0()0< !/N =C)0()0<
H H
0./O.>, / N %/N
H H H
;/ N %-c,cpc)'-/
H H
o N s():\( ;,'N s 0:µ( .,/
/ N ,..õ.
H H H
!/N OC)\ r =/' ,.,,,,O.,,,...-^
/ N %/N1()Os'<
H H H

%'N
d H
H
\ -lisN .._0-.. 0 0 ¨ \ , 0(:)µ
....0",0 0¨\ , \_/ A / N
H-i 0,04. , ,Nr----, H L.,./N...,/-7'-H / N
H

--,N 0 * ,., õ
/ i'1\1(3 0 H :--_---1 H '<
H

* NO'c *
-i-NH -7-H N . N \ r''\.-1--1 I , sN 0 H
s) H
1 * 0 =,,' ;,,N I. , %' \ 1 :
r-IN¨CiN¨\ r:¨ \--- 10 1 / \ :-\_,0 41_01 I.., ________________________________________________________ N4, ___ :
1 \ ___________________________________________________ , ,.,,,,,Ø,....,...õ..v.,....,..Ø...,...7..,N;(µ
H
'117, 0 ; 0 ;
H

; ;

,..,1,,,...-0 lit,0,..---..õ.. 0 ....}........
c-rcr . .
, , \L 0 ; ;
N..

rs' . .
, , N.

cc' = 0 = \ 2 =
, , , N 00j. = \
N 0 ,s ;5' =
/ / /

cs'- =
cs' = 0 =
,zzl_0õy µ
....õ..0-y 0 = 0 =
, , , =iewo,)c ,,,.õ,0).,s õLõ,0,)-cos .

0 ,......
0 _,r / . /.
'Lll- 0 =
yr '. cr /
\,,...," ==... ,,,. 0 (:)./\..,,,/ 1-; .
/

/iy, rN (3J/ X0-00-= \
S''' =
N
I I
/

OC)J1 . 0()A/ . OC)'-)/' .
/ / /
N \

. 0'. J'/ . OC)J, .
; , , \ I /0A/1 I OC)'=)/ .
0 ; , , ' 1 0 N-N
6 a eYµ
N , 0...- ,.../11=1 = 0 ' // =
/

-=-=-= 2µ
INO. .
/ /

N, 0 kFVNO
N N ).Y, 1-61/ , \---=-- NI

(:)7. N N jci, , , N 0 Ass!
N N

0 =

N C) ____ JLF , , _N/¨\,\I j \N ¨0 5 /-; '!1'` \= N \¨
0 ,= ;

-E\O-/ 0 / \ / \ NH -, 7\0¨/ \O¨( _\)*N¨N\I-1, -I-X X
ON N
I I_ ,'CjI/
µ I H

--\--ON'µ
(:)N,,', , H , ON . ON X
I H
10' ''','= 0 ,- \-`0N1-,', x x -/, I H , r1 I H
, N-,:
, % 0 0 H , o , H
. , 0 -\ \ -- \ \
1...)-11 , -µrON'Z cy-;\,,-N'/.. 0 -,, % 0 0 0 0 H
01\1: ---\ " 121N-4 H , H , _, 0 N,,, r Nce..e.\
H
. 0 (:)N-i: , /
ON( H \
N

rµ µ'µ'' \--NI\-µ
* v 0 )-1\1/
N s 7 N¨ H H
J '1-1 = X e/x X
, rµi H I H
- N,,.,.. -'0),,, ,',..
X
- ` 0 I H H H
s,=e-\NI-,: 0 0õ......õ---.õ,õN;/, ., õ,...õ.õ 0 o N',/, , , . . .
-1-N¨Nr¨\N-1- -2_¨N¨Ni--\NI-\__/j¨N\ 71-\
1'HOS0/6IOZS9/IDd t9SISO/OZOZ OM

N---\
______________________________________________________________ N--/
C--N"--------\_...\
-:-( \N-CN- 0 \._ N ---- ../----\ N
\ ______________________________________________________________________ N\-/ --\---0 õ\--,,,::.0õ,..,..,...õ.õõõ.....,NN
H
-N 11õ1.,. _1 \ / 0 NI) / N
-\-- * 0.-0-N171 \- - = 01.-0--.N171 -10-C)-01,..9.-^IN171, '-\ / IN -: / N -:-\_cN
-' b-c )-0=INH. -\¨c ,-01,..<>-=NH / )-0.-0-0NI-1 ''S
c, N
)-0...-0-^INI4 N ji)-01.0-= 14 N
ji)-0....-0-= 14 i'-= ,...
'1-= /-=
H r\23.-.....-"=0':-0õ0 H
µ,...., --- \ 0 H
- \-01 \-=/
HN-:
: -______________________________________________ \
0/(-) ( -- __________________________________________________________________ \
HNH
' HN-- +C HN-i-\-0 i--\
/---NN ',-=
-1 / HN-:-0 \- HN-HN-:--1-/ \-N/-\ N . . j0-\ /-\
N
1 \ .
\-/ HN-:- 1 -I\/1 = _:_/ _N
1 HN-:- 1 HN-:-1'HOS0/6IOZS9/IDd t9SISO/OZOZ OM

HN,..-0-"0* Zµ
01:) "/"--....0,.%10 b j- , ...Ø%10 HN ik N
-\--X
,/N
H N'O--a = ,,_ /-rr I H I v,.
X X
,/ ieØ% 10 / 'N IO'-do HN"- .. :: .
-'/'-- - / N
H iii \ , : H fat \ , _\--0 , 0 , x H H
,,NH 4110 \ , ./Na...0 4110 \ 1 o /o 0 ' 0 0 ' 0 1 .......0õ10 . , ' HN
HN..Ø...0 fi 0r \- -H1%N- ==
.01 N
HN - N \,,, , .
HN .õ.....---.,N..--\,<
141, . a = o "0 r-z--N
N N
-1\l/MN (0\1 ,-.: ,,,, .\......-N -/
l' Hi i '< L_/
H

:
-,.
/--\-K \<
--N N N +NXN-( N-/ -;-NDCN- \ ,/
\__/ /

( _2' -:-NXN-K N- '- -;-NXN-K /N- '- +NXN-K
/
0-µ
N - <- HO HQ
1 /-\
-:-N N- / 1 /-\ 1 /-\
- \ ;;
:-N N 0- ` -:-N N 0- ` \/ N \/ \/

-- -\-- 0 1 / -- \
--\ / 1 = --:-N N- -:-N N HN
N \- 0 -:
1 /--\ /i' -:-N N-% / tiN._0-=0\____\ , --N N_/-0\
y, :
0-:- \__/
1 /-\ 7( -:-N N 0 HN
\ \--A/ / N

-i-õ/
\õ
11N-CN-(1 11N-CN-µ j-Or1 D_I
i-N N N
, -,'-NH 0 --;
OP-0-10 0-i'' tiN
i- 0---= =
N
õO
H
, -r- , F F .
26. The bifunctional compound according to any of claims 1-24, wherein the linker (L) is selected from the group consisting of:

_____________ / 4 __ N \ ) N\ iN 0)\
m \ ________________ / m \ /
n / \
ss ) N
________________ N ( \./0).(4e, , n o õ j/ )na ON ( 1n%' ¨ ¨N N
/ \ \ ¨
\ ( \/0)e0 s - ) ________________ ( /N (lin n ss/
/sss - -N/
______________________ 0)Css . s \ (/ --N __ N / \ _________ s.
N iN (1/
\ _________ / o \ ______________________ / O m , \ , /
/ ) N/ \ ___________ ON (1/ ' sss< '''' ) \ __________ ON
n ______________________________________________ / (I/ s' ¨ \
0)C ,(/0 _____________________________________ /
(/ s, ¨ ¨N/ \ N Jo ss m _____ \ ____________ /

0))szss 0 A--ko)szs-m n n % , H
==,/,,,,w,0,..,(,..õõ, yszs \
0 s (/*(Or'%/ ;IN Orkm ,11-11 \ m m , n n n , H
m/
m / n `,,,.....
\ ...õN,....,...,....2,..õ,....õ.........,0-.4,4_ .-- %
k . n2 : n2/' inX-/ n ...'t NO>,/-1 N \
NI \ .......
o m o n N
, , = ';
'l m C\N = \ )^) M 0 = = ' WO
__________________ N o __________________ 1 i ,X: N / \ 1//e N N ( m 0 \ --o-...1,r..
n ' n \ m N

1 , o N
=,/
s o' , ' N ...,.....õ...õ,N.,,e, ' \\(k ) N N ( ic m n m n N ________________________________________________ ( im -1-N \ /\ (c-, / __ \ , / ___ \ __ 1(. _______________________ 0 ----N ____________________________________ NH /
-1---N N- - 1 / \ i 1 \ __ / N ( -1-N
1 \

-ofs- /S- _ / ___________________________________________ NH \ (1--_,._< ___________ \-- _i_< __ \ __ yin, _< \ ( 4 . ' 7 - / /
/
r-N
/¨ ¨
/ \ /0 \ N N ( ) n /
( N
\ ____________________ /N ( )n \ __ /

m -_, /0 ( )ni i-, 0 , 0 N
0--,Y-17-1 N 7--/
7-\ -- H H 0 .,,/ \s/
\............../N n /',, ]) N ( \I\
n =õ/
/-'.

/ \
N \

N¨( einN\ /N n 0 in \ / n 0 ___________________________ S, /
%--=
I.S.
g*, N

,...........õ..........,),õN,..............õ,*
M
Na0\
fli . .
N_ , / N
k N'I'IZZ c: 1 e , n n ,...........õ,,,..yryiN,.........,,....
,.........,õ.õ,N,),/<
% j m Ill )1N
e n ..,,,,........,N,,/
n ,..........õ..,N,..õ,-.,......._ _.o.,' /
M M
--F F
, `..,.\,.:0õ,,H...,,, N.,õ,........... .....õThl>c, = 0 N õ,...,.....õ..õ,-'s n m % i m s m n ) i OH N \
H
s 0 N ....,.....õ.....õ. =
0 N N ..................
. ..õ.., m n ¨ m n / N isr, C F
N .
OH
1\10X, \,C) N
,,,(..,0,...t...1...or.. N .,....õ
..................
n .....
m n m n N N is( N __________________________________________________________ ,,,,,(õ 0 N ,,,,...............
s'iL07 \,, N N
2 \A) 0 _____ N ___ )11 __________________________________________ N
- ¨ 0 \ / NV----- \
/ \ ......õ N ..õ,,,.....
,. N....] \
¨ \ ___________________________________________________________ / 0 N \- N
/ \
( n \ __ / m N7'1.--- \ 1 -.. = N --.,õ,...
,,=4`.o n .........õ....õ4õ),õ N.........õõ.
:'-'1 N
M
¨ / N
N ...._<-5 NIN µ4 NI\
.........,.......... ,...../.,: sp,0õ,-0 OH
0...H..... N õ..õ....õ=,,,,- -................ N.,,.....=....=õ.=-m - -- \ 0 N
`"LC) N
N.,,õ....õ......õ, m n ....,....,..../i.<>, N,,,..,..,......õ.==-F
\ / m . ' / \ Nr---- \ \ )ri \
. s = 0 P /
n v_...../....1 \ -H
N
M
n o N
n ,='.
N N
H ' N
ci "n N n F
.. ,o, ...,/,...,= õ......õ......14õ N
............../.....õ),õ N.,............... \ / N%, =
.... '''.....0,1.õ1õ. m M
N , ' m n N--D-.
, N,' _ ¨N
.
in I s N
ND_ / _ ,,/
N / ' N
in (:) ' N 7' \ ,N
H n ..-, 0 ________ / __ N N
\ _________________________________ 02/ 0 J.
)/ ) m N N (\ n 0 __ 0 _______________________________ 0 2/ ) m NO0-0 0\i A
/ \ )n ___________ N N __ /0 ( /c \ __ / 0 m \ im "(.1NaTN
,N1,!5 ,Nlge /Y.5 H 3 r, N,>
is NI\ r1:4N1 ,NQ.NL) ,N1,e \N, NIti, \ im 0 ,Ncse NN 0 NV ,'-icr--/-- -I-, ' m N =H r/;c) N H ,, , i N
N1\1) n I\IN) % ' ri crl\ill 1 1 , =
i . = sz=-, -...-. N , .,-i N 0---,-r, .)----1 i- \,N = ,,V-)r)7N 0-N7Th , CN\ ' m .s, n rN--0-:,-rN ' Nij 1 'r NC).-NnN-';-:, 7-0 n IA-N/¨\N-:-530-0> r1\1\ -0."n \ ¨/
,N.H,.) N,> m m - .
0--\___ r----\ Nr----\ , _%_ _ = , N N¨k__ bN/
\____/ N \ __ \-----\---NON
___________________________________________ N¨ r----\N
_/--N \ \ L ...._ -C---___ 1 , 0 0 \ / N\______/ -.....\)-0 , . , m A =,,,ON
, /¨\
-:-N N¨\
'is'OrNN'µ` \_/
1 , ¨N n N
C õN
n Nadri;, r\N ' P N /----\ N --N,-N\___j -(-)1:

1 /--\ 1 - -I-N N N-:-NIL , ' \__/
N;,,' ,/0.õ,.. N m NI;se , 1 1 ic(,,r/ o(,,K=N
(,e, ,,,,O.,)0(,.< N .,),,, r m n r m n o r Tri S
n 0 P q .1cfrr000(,)N (1),c, , ;
/ m n o P
q ,cw00t.i.00H),(%
r m n o P
, , 00t1.0f.( , H
0 N }c . , r m n o r m n i H
0 0 OtIN oe\ )frr i H
/ m s n o P q , , H
OH0t1Ø1.N m)(,, / m n o P
%)(t00000' s , m n o p , m n o H , m n m H
, m m n H
% =)4Am-.00i-.
s m n o P
N
\00t10 , m n o \ % 0 Ot101.01Ø12c s m n o P q \00t1.00fr)),cµ
rn n o P
H
N
111 n o rn n H
µ0./OtIN HX%
in n rn n o H
%,t0))000N
s m n o P q H
(%0(,K=OtIONtic, 111 n o P

% ON
m n o P
. .
. . .
. -, . 0 . .., . i OK
M n m n ''' 1 i..
. , N%(s.
n Nal.r n , . \ ,, N.õ.............õ.õ, o o m m n , N ,..4.......\ õ/, " o m )o -m , N o 1..M>------) ====./
, m N
m ho -n i /
\
m \Oo ii N \ /N _____ N,.... /
/...
_ \
¨ . VAN- ¨
/ N /
-_ , n n \
¨ .
N
/
1,-N
m m / "
A
N / ¨ 11 N ,-. N- ¨
-.., s - N I/ 0 ¨ - -.1-r '' N -.=
/=,. s \
\ , n 1 ...\
m .
m n m m 0..............,,,,N
/
m m =
=
, , ' ..õ......,,,,r,(,..k ,..........,,, . 0 s n N
/ m / m N /

¨N N - \ ( 41 / \,-..=
N _____________ =,,,,,,..,,,,,0 ,....,, \ __ /
N
=
m = Nõ,,...,,,,,e N,,,,,,..õ,.õ N ,/, N,,,,,..õ,õ, %.`, =
. \ /
/.=

/ _________________________________________________ ) )\ ¨ . \ N __ N
/ \ /
0 ,N, %),õ 0 ¨ N ¨ON¨ ¨ ¨ . \ ./ __________ \,.
=
; \

0,.0 .=
. \ __ /õ.
.. .
i \ i / i.
\ ____________ / __ N N,,,,.,,,,,Ø,%.,/,,,,,õ,,,,,,ox< 0 0)C=
m i = / \
: \ __ /N __ \ __ / \ i m o0 * 0 0)(s = 01 ...110 , ----(C)\
m 0 1 N n(D'rFIL--õ
N
.--4 )m ON¨et o , o . o ' .
......., / ___ \ ___________ ON-CF1') 0, ..."
%S(c11 NH ) ¨ ¨ (('') t-i 11 %
%%%.,..= 4.0)...../.."=,.... .......y \

//) N¨ ¨ m N
% 0 =

m n ________________________ \ ra ¨ ¨N \ N¨ ¨ ¨ ¨N \ / N¨ ¨ /
/
\ õ.../ ¨ ¨0 N N
\ ________________________________________________________________ 0¨ ¨
--,/
/ \
/ _______________________________________________________________ 0 N N __ ,) m N N __ n 0 __________________________________________ / \ _____ /
0 _______________________ 0 N.
_______ / \ ______ / __ N ___________________________________________ / ' N N / \ ___ /
0 __ / \ ___ / 0 N
/ \ __________________________________________________________ /
N
is--/ \ _________________ in / ______ \ /1\1 \ s/ss / \
0 _________________ 0 =-,/ )()n \ /
/--- -õ/
N ___________________________________________________________ is=
0> A
N¨i¨

/ \ N ) _____________________________ / ) )11 \ /N p N n \ m --,/
/-'-, . _____________________________________________________ 0 i 0 ) / \
/N¨ -¨ ¨0/ 0 __ ,,,,O,...........õ... .....,,,, \/r\l/\N
õ, / \ __ W 0 01'-\/.
i 0 __ v 1 m N
\ _____________ /N n 0 __ ieri kN Q(n /N.
0¨ekn /
__________________________________________________________ N ___ NiFI's'' is' cµ= \ __ N .--.-, \µ')( '. so 1 .1 /N ______________ ii Nn -----C(N ' / ) __ 7 - -_ p r - - - - = -0 /\ __ N _________ n N
rs, iss, / \ C)( _________ NH
N/
W-NH
H =/ `.
icrl r)N n c, f'=

, k )n ¨NrX r \ ¨h \ iet 1.¨,,, N
/ \ / \N-0 N N- ¨ 0 \ _______ / \L,N,/
/"... __ N
\ __________________________________________ ( c', 0¨' , ) /
____________ , \ 1 \
/ i n N ..._(7.--N N __ , / \ /
N NrN -.(jr1 - - ¨ A _ m _____________________________ i'=
, / ) __ Of( ) n - _____ r \CD ( kn \
_____________________________ N N-/-' / __ ) 0 , , H
n n 1-=
¨N/ 1 \ __ /
-.. \ N¨ - -.¨N /

ss --, ,....õ..Ø.,...
0 0 =
===' C) =
-----i-- \
--(-----t-t ) --------,...,ZN \ =
::0)0 0 ).3C/NWOX
i --, =...õ.....a., Ns\, 0 -t...rm . 0).".".0 m m cpNWO.
n \ 0 ;s / \
0 N'.'''' N

I
n in N/
..
m/
n In 0....L
i¨.-...%...y....,..y......0 s 0 s \,...
' , 0 N--.....7.-----/--.--x ,......õ,................../ON
=

0 oo ===.1 /
Lici = 0 ' 0 N,..,/
-A--).\=.:
vON =
.='s\
' n ,.../...cr,O.,..........x.õ.....õ,õ, N ,..........x.õõ....õ0 n 0 --4N =
7'-=N
s.:
71177 1 , , 0 C) n n ...'''O/
, N
\--0 I
0 i ,....Ly `.../.., \,.
..".\
0 0 =
0 \ N
(j/ m n 7,.:
'....''ON, =
,......zy.õõ0,,E,,,..,.....,,,,....,,(..1,n 0),........õ,N
= 0 -'='.
H
m -V --\0 oFil 0 ;I

c) ,.., =
isJ
CZ
--.
CZ
\ ) ? C\

C.11 I.., C.II
z ----_. z __ ¨ \ ¨ 21 \ C') \ \ z ¨
\
4.
%
z z .

z ¨

6 ...;
---No 6 z ., .
_.\-__,,, .,, co ....õ
"
"
-k"
, 0 . ?

"
o . F(' --\ 0 = 0 z \ ) \

= \
* zµ _______________________________________________________ / \
i c'z ) i Iii , \-- \

% %
%
% % 0 ,¨i u) ksJ
.
0 cz ."

...
,:, , .., n ---0---, %,0 0 1 , .-- _._i NC
ON

0 0 \ N
-..4..
s\ 0 N
0 0 \ N \
n \ 0 N
F,C
ON.......'' im C/N
, --- --F F
n \,.-0 / ..---ON n 11,(..,0 .....,./.

s 0 1 n \ ...õ0,...õ,.0,..,, ....,./' s ON

NC
I
ON

F F
NX0C)><
..., ..,, F F

\\....:

n ON____Ø----------------:-.----C) //\017-----%

0 N CF, ek: )(..n.10 ' \
NN n F,C

m .), ......ZN .
s N
I
,''COON
,...............,N,O.,.....õ0 NI,....:
0 0,,,,...../.,,,,0,,,c 0 s, , 0 0 n F F F F
Li.,0,................Y.0,...,....,,,,...õ0 .........zio,.............õ...õ,.........v0,......Y......õ.....õ,0 o CF, 0 \ ( \ /
in n n µ 0 0 n in in .*st\N =
n % OH
m ,14,1=õ,"..,...,..)=õ
ii.
m n 0,,(,.1õ,,.....i3O 0 =
m n / =
A
-- ' VC11171\
r....
, 0 , /

x j=:(0,......
--- \ -; .....,,,,_...õ..... \
',,c) .....,.,.......,N,,,,..,,.....,N,,,,, ..,........"N
j% Ci =
v C) ,,..., N NC
/ 0 ...,,,,,..,...õ,N %s= 0 \
0 = v s<
N C) =
1 ../
/ 00. v ZN '....... \

=( 1 ,i Ci =
N
of '====,....õ....e )2:rõ0,............,,,.......

0 Ns\

,i'...o s=,..,,,,,õN
.( 0 , i===,o õ...,,,,,.......,e,,N
,,,...../...,õ N
NC
HO
)::hN =,,, OX\
\ ='' / N
o=,' \
,./
,,,...../...,õ N
)::(0,............õ,,....... =
`=
/ = Ci =
0 \
, ' 0 N.,.N
'/O s=,..,,,õ N N....., )&µ 0 )::::r ==,......./..., N
õ..,,...,..,,,,,..,,,....,,,,,,õ0,,,,,........,,,,,,,DA:

N

,.
./
õN
i/) = , I

= 0 CF3 == N
=

Y0----<)---N o...
CF3 \
)iiii = -.,.
i' )iii3 = , ;.c I %=-1 =,õ,..,,,.õ,==N /"µ
= -02\

., = -02\
I
NCN
0)( =
.....õ...,,,N,..........õ,,,N,,, I

AN %
.,,,,ON =
' n /
,--'0 f 0 N Wo%c F3C.,, ,..)( N .
N
" \
n NW=,.
0 =
,,,cv./.7N,,,,=,....õ.
¨ \ ,..
N .....WO\ ) 11 .
..,=\
N \ M
NW,.,\,= 0 0 \ 0 s==' \,,cii\,,,, ,=\

n 1 7C:r N)c /

,=\ '''\\ray 11.1.1'N
n M N

,=\
)c, 0 = 0 \! N
HO n = ' 0 ,...,,,e ,=\ \\:ill,,, n )3( =
oN
0 ' N' /'..0 0, NiVrNi r , n P
N N
r , NN =,....,,...õ,,,, ..,, 0 0 q N s ss n P
N N
r , n / ______________________________ NO\
0 _____________________________________________ /
/ ____ 0 c) o i.

r---) 0 __ , __ N N
a o ________________________ (,c ______________ 0-i 0 ( _______ NQ
) :
n , H
NN NCIN)s(%
H
m 1 0 o N
, o H
NN NN( H ' m 1 0 'Clo ,1\ N
, 0 %
H %
NCI s m 1 0 \:lio ;\ N
. 0 H

N
m 1 0 113o ,I\ N
, 0 N N , N
H
.N..

,,,,,,O........ ,,..--.
N
,,,,,,0õ,.....õ,.. ..........
N N N
H , ,eµ 0 rNOX.
-\ =\:3 %,)(..,õ..0,..,....0,õ..._,0...,...Ø..0,...< -,0-N-N.) (C)C) 0.,, N . %`OWOWN\.3 :<
e\.7.\.7C) i'0WOW0`"Cr CF3 N.' i%
s, / 0-\
/
I
\'''ON , wherein rn, n, o, p, q, r, or s are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
27. The bifunctional cornpound according to any of clairns 1-24 wherein the linker (L) is selected frorn the group consisting of:
N N N
c3ic N / \ A
N N
\/ N ,s5s:s N ,ssss, x N N ,ssss, N N
s,* N N ,sss! x N N
N NI

N/\
N
NL
,312N ,15,,NN N
NL NJ
N/ ,,== v ch,z,N ,,,=Nz, C)a0 s.s 00,C)s.s k,N k,N
H
ss c3zz N (3zzN N y5 C) H
N N
,32zN N'o<N N,s5s!
CD
/
N., ssss..---N,---,......
(NN N2/. 0 N ys 55(N N N
-......õ...0 ,õ,,....,. ..,..õ>z, -,....,...õ--0 ...,..,...õ. ,I,s ssss N

N - s1\1=
-......õ...0 ,õ,,....,. ..,..õ>z, -,....,...õ--0 ...,..,...õ. ,I,s isl\IN
0 2z2, -h0¨N/ \NA¨

\ ______________________________________________ /
\N¨H.---ON/ \N
\ ________________ / _________________ \ __ /
401--0¨N/ \N¨Irsj.\- / \ 5 N\ _______________________________________________ /N¨

N/ ) N ___ N __ N / \N __ .sK / ) / \N
\ \ / \ \ /
c, / / , N N N N KA¨
\ )/ /
\ 4v/r7 \) \
/ / ( 5 0 ) ________ N N N/ _____ / ( ) NN
\ \ C 1/''.¨ \ \ C
/ ) / ( / ( 5 N\ NN ________ /-1\1 ) _______ N/ N
____________ \ __ / \
\ _____________________________________________ /
s_ /
- N ) ______ N \N N/ ) _____ N \NA¨

\ ) / sry -tr/7 \ ) /

) \ 5 "hri /
) ____________________________________ N \N /¨N ) N NI-\ ) / 'ASP \ ) /
HO HO HO
\
/ \ / \ /
\
-rN
\ / ________ -5 N\ 7 ( __________ ( NH N ( 7H
/ 5- N\ 7 ____________________________________________________ ( 71-HO HO
/ -1, 5 / ( -hN N _______ ( \N2/1 N N ______________________________ ( \N-2A
\ __ / / \ __ / /
HO
5 / ( rN _________ \N_yj ND ______________________________ N/ N\ H N N/\ µNA-- N
\ \ __ / \ /
/ \ 5 FN N/ ) N N NI- 0 \ / \ 5 N N
\ _______________________________________ /
-µ¨NC/N--____ N-----....-N 1\l' N
N\----=õ, N, 1/4/,/ v _____________________________________________ I¨N/ \N _________________________ C 5 / \
I¨N Nw=--C 1¨N/ \N111h..
\ __ / N?sss \ ______ / \ __ / CN,_cs 1-N ,N
AN
AN AN
/ ____________________________________________________ \
= N
/
\N-0 ________________________________ N/ __ \NA-\ ___________________ / -N
e _______________ \ 5 N Ny Ny Ny _cosµ00, .cr0 11.<2711.... õ,....,-..,,_õ..,..".õ.N

N,sss! c3,(NI I

N lel-----/
N N
, \,N
N 7,5 !ZC SSS!
N
N
NI\\
,3z(N
N N N)s!

/\/ N
N ,sss! `32c (k N
N,s55!
N5 /\/N
--T;
xN N N¨F
i.iN N
,.( N illibN.sss! xN N,,,s!

NN, \ _4 ssssN
N y 4N N-/F-----\ ¨I NA NA
H \--/
;sss N%

Ny Ny '70 YNOc\ µ?<C)N\Dc\
NyNõ..._._...,õcr.\
r'ss,Nzi) CN__4. , CNq )2;.0/1'=----/ µ2220 5 \-)\00"' 0 No 'a(0N-1. AINILr is-siN µZZI' "Zt,01 Srs Oja0 a7s,N IN
OC) N N N
P'(/\N/ N/ P'N
OH OH OH
OH 1\14 OH 1\1)-C-,XC)/The\
--..,,,....,N.,..........--..õ0,..\

AN C)scs )(0 Xc) `ec) /\)2, XCDN XON
sY`NN/
(:)NI OH
1 y ,32zOoNy Nµk µ3zr,C) N(j"C
1s0 AO
N 0 'k .zto AO

Aso AO
.k2C 0 ?0 Nss50--C

,s(o0o0o0o %,(000000, =000000/' ,e00000),i, %,(00000 0 =
%`. / =
0 0 = 0 0 == -%.

-\ = -\
%,!-\

--%
\..._zN-,'-NN N --`;-.==, \__/ i /---\ 1\ fl N- - iN--_Nr---\N,__\, .
, 0---7-N\ N----(--._ =,= = p---/- ___,N--,,,.)__ -= - b (\to =
ro ' N, ,--õ....,,,,..õ
N N ,C).\.N , /...__X-NO i N=IV NI,,, ,...., , ';'0 N-1-N , /4X-- NON., .=, .=, N = ' /--N---"NN-Th ,o¨/¨N---\__ /¨ , 7p- ----/
c_.-N = '; - N N-,-\__/ ' o ..
-N.'=
N 11 %)0...,/N-"'""") N''' ' -= m ;, Nv) -w¨I
"m , Or____\
N N
rN"s ¨,i-Ni i\iN
'-----N N,' -,- , ,0--7--) , .=, -,: /----\
0 )\1 . ,0 --7¨ NJ 1 ss,0 õ7 NO, rN ' ,,,0---7-"Nc. ,o)N----NO..
-, ' am 0,..........-.,0,,,,Ø....}..," õ An C)0C)ey''1/4 a,,,, rr's H = H = H / , /
, 0 .
N N
H ; H , cos N W
H = H =
/
/

010 0õ,...õ0.0jtõ,,,, "F
H ; H =
, _ V
1\1 ee0"1-r µ

CDO----.-1(\
0 ; 0 ;

H I=
, , H

r'NCIOICIs cs' = H =
=
/
H

r<NOO)c ts(Nollt-I/ H
csss = H 0 ;
, , 0 0 0 0 4 lel (:)orsss H /=

H
N rrr . N
H =
, , , 4 N isss / / 0 ; H ; H , r< N 0 el 0"1( \
o /

---.. 4, N0,..-.:...-,...,.. , N
h 0 = H = H =
, , , rss'N.'(:)'N 0 N
H
r`i,L "swo H
0 ; =0 ; 0 ;

f 0%'rr. 010 )L
o ; H
0 = H =

r4.. ...".......,, 0 N
H 1 F N .
. ,r'' ., al i U0 rµ
.,e.l.e, 4 ,o.,-,¨,o.2K o / . ' N' H
.....0 .11 0 ; 11 H , 0 ;

41\JK N1 oe.N..--,.,.....0N,,, ,0 N 0 H I 1 \ H I ' U / =,.. ,..N..---...õ.0 ,ssr 0 ; 0 =/ k 0 ; F ;
/0 ,...N...---........õ.Ø..................., 0.,.---µ

HA..N.,,,,.......".o...,,,.Ø.õ..)1,..
re' .
/
rsc....--,,0........Ø.õ.....--,..õ.Ø..}......
= `.... ...-0 = H
/

/ A.N...--..,...õ0.......õ---Nõ,0 ).=
'ssC 3 N 0 :'3c H H
1 F F = H
/ / /

/ N
csi `& 0N Q)Ni / .
H -- lei =
H =
; H /

H E N H
F F lir' ; H
/ ;

/
,s0 H H H
H 0 = 0 ; F
/ / ;

0 "s- N, - \
0eY / õcr. 0 0 1 ----.µ lei H N
H / 0 =/ F = / H / ;

Ar,r0 0 \
/ 4 4 ,,O.M)ri ,0 so 0 F ; Ill N ...--= HN N -..... ; HN / ;
/
0 o ,,,,, 0 o /
H''o 0 ' o so / µ "s-N.Cro = H 0 , . H i F F
/ / / / ;

/ I /\ ,C, ' 5 . .--....õ...o )\-11 H I H / IF1 E /
N . F F F /.
/ / / ;
\
=

0 / (:) 0 H 1 H i F

Thl.,,fr.0 rr, 0 0,/ ,) r., N /
,---.......õ..0 0 0 N \C) 0 0 0 0 0 F rs'r ' errr = H
, =

rk N 0 0 N.
H i 4 eCr 5,,,,,, ...0,0 0 0,)c/
N N /
H H ''N
F F ; F ; H
; ;

N N
H = H and H , wherein each m and n is , independently 0, 1, 2, 3, 4, 5, or 6.
28. The bifunctional compound according to any of claims 1-24, wherein the linker (L) is selected from the group consisting of:
ON N:v% :%;0 0=.v/\/' N %( , 0 H H
0.7N0,,rN.%;
%.,:ON'..', H
H ; = =
= ...0,, a 0 o.........................õ.......N;%;
=
=v0 0N..% 0 = H =
H ;
, , = = , , -,' I. ON-\
(:) N.\ H
H . .
, , % 0 -µ', 0\10 1 N.% ---'0 1 N.%
H
i ' N
=,, ,.....,) cN 01\1 I \j=NI 0,,' i ; .
, >z.ON,Th ,"N
cN 0 N cN 0 N
i) *, Is = , /
7'N 7'N
N 01\1. cN 0 N
,..õ...;,=-.0,,,, / N 1 ' ; ;'s =
, µ 0 N ./ ,,...._ .= 'µN- .µ,01\1.
c.N 0 N
1, IX H
, . ; = = , .
, N
N
N c N c)Ø=N%: ()/()())% .
H ;
, si-N-1 c,N 0Ø=N;; =,,,1001\1µ..
H ; H = '''0 0)%
, /
/ ./ N
i*N- 1 ., ..-,õ iGN
cN - C)/C)µ'µ F F
F F
00'µ`
F F = =
, , ,=
µµ,0N
,' - N
N N cN u1\1 F F H
= F F H
=
. ' N
,I;00N-% ,µON
H
= F F H =
F F =
, N
cN
F F F F
=
= =
/ N
cN
N
0 IV`
F F
H .
= =
0 N ;/µ0N
H . H =
= =
, =
OH OH
= =

OH
H
OH
= s =
OH
=,;001 ; 0 =
=
0 H ;
=
0 ; 0 =
=

H ; =
=

ooLL =;000j-L s,-N'' N".
Hs,%=J = H
= s ' = =

=
H = 0 a = =
= =

N ' . _=,-000.,,' = H ; ' H , , =
, , =:(:)00N', +(CH2)m-f-\N----(CF12)n-4- /--\
+(CF12)m-N N¨(CH2)n-O
µh.
H ; \__/ \__/ =
, , --:-(C1-1260(cH2)n¨f-\N----(cH2)o-N1H' 4-(CH260(CH2)n¨f-\N¨(CH2)o-0(' 4-(CH260(CH2)n¨NNN¨(CF12)o-N' -r-H
sh 1 (CH260(CF12)n¨N \N¨(CH2)o-d ' 1 1 .
(CH2)m-:- -i-N 0 i \
N
i -:-NDQ ( 0 . N =
, , (b1-12)rn4,-N,(CF12)m ,(CH2)m -:-( \N-(CH2)m-h = 01 ; ¨N\.... ) i /
. ,,v(CH2)rn .
,
29. The bifunctional compound according to any of claims 1-23, wherein the linker (L) comprises the following chemical structure:
( yL1)0_2 (y1Z1 )0_2 ,410 0 al 40 '242..
or , wherein:
Wu and WI-2 are each independently absent or a 4-8 membered ring with 0-4 heteroatoms, optionally substituted with RQ, each RQ is independently a H, halo, OH, CN, CF3, optionally substituted linear or branched Cl-C6 alkyl, optionally substituted linear or branched C1-C6 alkoxy, or 2 RQ groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;

Yu- is each independently a bond, optionally substituted linear or branched C1-C6 alkyl, and optionally one or more C atoms are replaced with 0; or optionally substituted linear or branched C1-C6 alkoxy;
n is 0-10; and -1\( indicates the attachment point to the PTM or ULM moieties.
30. The bifunctional compound according to any fo claims 1-23, wherein the linker (L) comprises the following chemical structure:
(0)0-6 (yL1)0_2 4:11 QL
n (RQ )0-6 (yL1 )0_2 N.<
(RQ)0-6 of L1 )0-2 (yL1 )0_2 0 QL
, or (RQ)0-6 (yL1 )0_2 wherin:

Wu and WL2 are each independently absent, aryl, heteroaryl, cyclic, heterocyclic, C1-6 alkyl and optionally one or more C atoms are replaced with 0, C1-6 alkene and optionally one or more C atoms are replaced with 0, C1-6 alkyne and optionally one or more C
atoms are replaced with 0, bicyclic, biaryl, biheteroaryl,or biheterocyclic, each optionally substituted with RQ, each RQ is independently a H, halo, OH, CN, CF3, hydroxyl, nitro, C
CH, C2-6 alkenyl, C2-6 alkynyl, optionally substituted linear or branched C1-C6 alkyl, optionally substituted linear or branched Ci-C6 alkoxy, optionally substituted 0C1-3alkyl (e.g., optionally substituted by 1 or more ¨F), OH, NH2, NRY1RY2, CN, or 2 RQ
groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;
Yu is each independently a bond, NRYL1, 0, S, NRYL2, CRYURYL2, C=0, C=,,, SO, S02, optionally substituted linear or branched C1-C6 alkyl and optionally one or more C atoms are replaced with 0; optionally substituted linear or branched C1-C6 alkoxy;
QL is a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally bridged, optionally substituted with 0-6 RQ, each RQ is independently H, optionally substituted linear or branched Cl_6 alkyl (e.g., optionally substituted by 1 or more halo or C1_6 alkoxyl), or 2 RQ groups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;
feu, RYL2 are each independently H, OH, optionally substituted linear or branched C1-6 alkyl (e.g., optionally substituted by 1 or more halo or C1-6 alkoxyl), or R1, R2 together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;
n is 0-10; and indicates the attachment point to the PTM or ULM moieties.
31. The bifunctional compounds according to claim 29 or 30, wherein the linker (L) is selected from the group consisting of:

"1/,_OeY'Itt '111.
00.r\
0 = 0 =
OH

µ111.
0 = =

,111.01HL00,,si ,tzL000 j-,,sr = .

,,,,,00 j-Lcsss 0 = =
, , 'ILL

cs"
. .
\
\ 0 0 H
= 0 = \
N
00j=,, is' =
, , c)0.)-ii =

,Ilt.Oey'\.
cr = 0 . 0 = 0 0 0 ,111.0ey\t-µ111_ ,,,,,,0,0,\=
; ; 0 =
, r-N X--0,),1 00 0 . 0 \
. --0,),, .
, , , N N
I

/ /

/ / ;
I I N
Nr 0 0 0 I oo ji / / /

, I I
jo/ la 6 et -.. ...--..õ.0,....õ../11." .
0 `, ....--...õ-0,......)1y / ; / 0 ;
0 o N-N
= =
/ /
o o NLII
I N \ / \

. .
rN 0 (:)ONO
N N j'Lcss! 1.1-t.. ¨ N

N cos, . .

=)/N 0)=/, 1\1 N

0 , = .
, HO

e-o/-1-:sss N Js ss, _i\j/-\N j \
----(N-O\ 1-N N ___________________________________________________ r 0 ; 11,1% \=N \__/
=
, , \i.. \__/ ; \-/ ; and \- .
32.
The bifunctional compound according to any of claims 1-23, wherein the linker (L) includes an optionally substituted Ci-C100 alkyl, wherein:
each carbon is optionally substituted with CRI-1R1-2, 0, S, SO, SO2, NW-3, SO2NRI-3, SONRI-3, CONRI-3, NRI-3CONRI-A, NR1-3S02NRI-A, CO, CRI-1=CRI-2, CC, SiRL1RL2, p(c)RL1, P(0)ORL1, NRI-3C(=NCN)NRI-A, NRI-3C(=NCN), NR1-3C(=CNO2)NRI-A, C3-llcycloalkyl optionally substituted with 0-6 121-1 and/or RI-2 groups, C5-13 spirocycloalkyl optionally substituted with 0-9 121-1 and/or RI-2 groups, C3-11 heteocyclyl optionally substituted with 0-6 RI-J and/or RI-2 groups, C5-13 spiroheterocyclyl optionally substituted with 0-8 RI-J
and/or RI-2 groups, aryl optionally substituted with 0-6 RI-J and/or RI-2 groups, heteroaryl optionally substituted with 0-6 RI-J and/or RI-2 groups, where RI-J or RI-2, each independently are optionally linked to other groups to form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 0-4 RI-5 groups; and Ru, Ru, -L3, K
RI-'4 and RI-5 are, each independently, H, halo, Cl_8alkyl, 0C1_8a1ky1, SC1_8alkyl, NHC1_8alkyl, N(C 1-8 alky1)2, C3-11cycloalkyl, aryl, heteroaryl, C3-11heterocyclyl, OC 3-8cycloalkyl, 5C3-8cycloalkyl, NHC3_8cycloalkyl, N(C3-8cycloalky1)2, N(C3_ 8cyc10a1ky1)(Cl_8a1ky1), OH, NH2, SH, 502C1-8alkyl, P(0)(0C1-8alkyl)(C1-8alkyl), P(0)(0C1-8alky1)2, CC-Cl_8alkyl, CCH, CH=CH(Cl_8alkyl), C(C1_8alky1)=CH(Cl_8alkyl), C(Cl_8alky1)=C(C1_8alkyl)2, Si(OH)3, Si(C1-8alky1)3, Si(OH)(C1-8alky1)2, COC1-8alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHC1_8alky1, 502N(C1-8alkyl)2, SONHC1_8alkyl, SON(C1-8alky1)2, CONHC1-8alkyl, CON(C1-8alky1)2, N(C 1-8a1ky1)CONH(C 1-8a1ky1), N(C1-8alkyl)CON(C1-8alkyl)2, NHCONH(Cl_8alkyl), NHCON(C1-8alky1)2, NHCONH2, N(Cl_8alkyl)S 02NH(Cl_8a1ky1), N(C 1-8alky1) S
02N(C 1-8a1ky1)2, NH SO2NH(Cl_8a1ky1), NH 502N(C1-8a1ky1)2, NH 502NH2.
33. The bifunctional compound according to any of claims 1-24 and 32, wherein the linker is selected from the group consisting of:
1¨\_ / r /\ r --\ 0 \_ -- _r ' \_ /¨
/
0 0-- = ' 0 0 ` ' = 0 0 =
, , ,,,¨\_/-0\ /O¨\ / ,,¨\ /¨ /-0\ /O¨\ /¨
0 0¨/ __ \-0 = ' \-0 0¨/ ______________________________ \-0 0--, /--\ /,--\ ro,, . / _________ \ /0 _______ . \_ ,, \_,..., . ,,, \ \
, ,, . , , = 0-u ;
/¨NH /-0 HN---/¨\-0 HN--- = / '' \-00¨/ µ` = ' \-0/¨\0¨/ \¨
; , /0¨k /
\¨NH = /¨\-00¨/-0\ /0¨\ /¨
0 0¨/ __________________________________________________ \-0 HN---, ,,, ____________________________________ \ /¨ 0 0¨/ /-0\ /0¨\/¨N,1-1 i, . = =
\¨ \-0 0¨/ ' =
, , = = =
- * di . -- II 0 /--- II 0/¨\ -- I. 0/¨\---, , , 0 O¨N 0---- * 0/ \ '' ' Ai \ = Ai %
.
, =
, , 0¨\ ,/ 0 ---0-/-\-d -- . \ ' -- * \__/' __ o-, , ;
.
-- . o = -- . /--\ /
o o--= -- *

--\ _r .
o o , , , 0 0- - . 0/-\0_/-0\__/o-\\_0 ,, . or-\o-/- \__/
, . cno_/-o\_ jo-\ /--\
-- \-o o-- = o/-\o-/
, = 0/O-1-- , -- * 0/ \-151 = 0/ \-or --.
;
, = _____________ 0/ \ %)-- , = 0/- ; \
r-`0-- -- # -\- ' 0 .

= 0¨\
/

= II 00 ¨
. - -\-0 ; ; .
;
= __________________________________________________________________________ 0/ \-0/0- - -- * 0/¨\0¨/ \_.c)( _ID 0/¨\0_/ \O--, , --* 01 ____________ \_0" \_ 0, , _ it , ___________________________________ \ __ /0¨\¨\ , , , 0 \ 0 ---( _____ N¨

`/¨ µ
; _ . , .
, --< ____ \NI __ / \ __ -- 0 < \NJ \¨ //
- - \ ____ /0-< N
- - / ¨
/ N /¨µ.

- - < \N¨f \ ____________________________ / / __ \
< \N¨f \ 'O
.
/ __ \
\
\_15/ __/ __ \N ___ ,-0\ /-0\ /0__ , \ , . N
;
( = 0/ \ _______ N/¨\N--- -- * N/¨\N--4i. N/¨\N¨r_ ¨ \_/
. = 0/ \ =
, , N/
íj /¨\
. 0/ \ ________ 7 . , cr ¨ \ __ /¨NI N---. , /--\
=
N N---* 0/0¨/¨ /--\ _Jr-N/ ______________________________________________________________ )---0 0 \
. .
, , -, 0 (jON) -- III N/¨\N¨/ \O¨

. \__/ .
, , 0.7-----\
-.. =0() 0 o #
, .
, ZSCH
, , o 1-1/1\1¨/<_ / ______________________ \ \ 0 0. _ _ ---N H Q¨\
= )/ r - - ---N H 0 0 = - -0 / ,/ __ / \-0 _____________________________________________________________ \ __/

, , , = = = 0 ---N H 0 ¨ \ /0 = ---N H
= - - Hp 4 o ' \ , o o , , , = 0 = 0 = 0 Hp 0 = - 4 - Hp 4 . - -\
/ \-0 ---N H 0 , , = 0 =
\ 0 41 - ----N H \ / \ 4-0\ /0 ¨ \ /--\ /¨

H N \-0 0 ¨/ 0 0 II - -\ __/

, ---N H /0 ¨ \ /--\ /¨ 0\ /0 . - -)/ \¨ 0 0 ¨/

, , = 0 = 0 Hp ¨/<_ /¨\ _/¨ 0 0 4. - - \ /¨ 0\ /0 . - -0 0 \ __/ ¨/
, : (¨\0 0 0 0 = \
__/ \ _r ¨_ /--\
, 4-0\ /0 II H N 0 0 I-IN

, = ---N H /0 ¨ \ /--\ /¨ 0 0 \ / ¨ \ //
)/ \-0 0 ¨/

, , = /0 = 0\\
Hp _______ /,(_ 0 o \ o o Y
/--\ _/¨ \__/ ¨\// _/¨
o o ---N H 0 , : : /
, = \ 4-0\ /0 ¨ \ __,/
- - - N/ )¨ N /-N
/ > - - N
i > - -H N
\ \ / \ D / /¨N \

//1\1 _____________________________________ , : , = . , 0 00 /¨\ /¨N > - --- \N¨rN/\ __ > N N ¨' \
1W .
/ \ /
.
, , -0 .

o0, r---__/--- 0 - - _.
, 1'HOS0/6IOZS9/IDd t9SISO/OZOZ OM

-- * 0/ \-0/ ' NH __ lik Or-\0- / I
NH
= 0 =
0 =
* 0-\ 0 0 -- /0-\ N(H/
= _______________________________________________________________ \-/ -/ NI-I
0- = o' =
, , o __ = o¨\ /
\-d -i\iii-i - - li. / __________________________________ ./
0 HN--- -- __ NH
0 ; ; 0 =
, HN---, -- \ / _______________ -- * 0/--\
-1\1H \ . , __ j\-N1-1 , =
= 0 %
0 = , =

,1-,1 __ = 0,-\ /-/ __ .1 -- \ / N HN--- -- \

, ;
.
, -- * 121-\ /-1\1 * 0\ /
i HN--- -- . 0-/ HN---; ; ;

NH
. __ NH j¨N,H
__ * o/ \-0/--\05¨ \ __. 0/--\ ______ /--\0 .
.
.
, , --*
0/--\0_/ _______________ \_0/ HN---. - = / \_ / \_ /

= ______________________ \
/ -\-01 ii-1\1--- -- \N-/- \ NH
__ µ -- \N-/ \0)-CH`
/ 0 = ______ /
, , -- 0 \N-/ \- / \ HN--- -- __________ ____________________________________________________________________ N/I-1 = / = /
d =
, , , \N j¨o\_ jo¨)r , \ o\ /-0 HN----- / NH, - - __ / < /N-F
\-µ
-\ __ /
0 = 0 =
, , -- \N-/- \ ________ / \ NH -- \N-rO\¨/ \-0/ 1-t1---____ / =
, __________________________________________ / .
, r\N----- - / __ \NJ-0\ ro\_/0-\ N,1 -- = c...._, N\ HN--\ ___ / Cr = - =
, , r\N
. 0 0 , II 0/ ' _______________________________________________ N N
0 = \__/ =
, , /¨\

H N - _ -- . 0/¨\ _____ r \¨/ --N/1-1 , , = 0 =
/¨\
N N
* 0/0 -r \¨/ N/1-1 __ . Cr-O-FN/ ") -N1/1/-1 0 = 0 =
/¨\ /\) / ___ \N j-N\_11-\ /
\
- < N-rN _______ 1/ __ NH
-\ __ / 0 = / 0 =
, , -- ( /\N
\N-/ ________ / __ NH N õ.......0 - - < \N-( \N
/ / NI-I
____ / 0 . \.N HN, . 0 =
, - , , = I\1-1 ,,,¨\ r0\ H N---,.
\\
0 = I' \ / 0-\

0 / \ _ / ./

= ' 0 HN--- =
, =, , b0 0,, -N, '/¨\ /
Fi . ,,,¨\0i-r . - - = 0 /-IN--- = /¨\ 7 , , , ., 0 ., 0 N-. N-Jj __ . __ fik 0 N-0 Q---\----_,- .

, , N --Ck N-0 0 C) 0 . ,- ---- * 0 / z --=
, * = 0 N-0 -- -, NXIC--- NONA_ .
, õ 0O 0 - - . 00Q---.
, õ 0 --- - = 0"\-==-=-= _ _ , O 0NN,o N-0 _ _ * 0 N-0 - - _ = O'NA---, O 0 : * 0 XONc)--13, \..--N N-0 _ _ - - / -- O'NON
. / - -, õ 0 - -N-0 ' el N-0 I /
OC) Q"---(DO
._ 0 - - 0 w ooQ---._ 0 N-0 ' 0 ()C)- - - --., 0 .
N-0 ' 0 .;0_1 - -oc)()Q-o.",.,,O.,....,,",,o I / --,o --4I N/--\N-0 -- * /--__\____/,\N ji , N. =
\/ , .
, - _ *
r--\
N/Th 1)-111 --N - =
r-Nni -" * N-C) - - * Nix_ j"---\__O li\l--0 \---õ .
m -0 = .
r\ NI j -- = N \___ V -, . -- 440 .
, = N
\0_- N-0 r-NN
it N\__j ----\---\._0\______N-0 ,...
\....... j -- --= .
, /¨\ /¨ _r0, /¨ _ro\_ JD- - /¨\
--o o-- = --o o , = --o o = --o ____________ 0¨/ \-0 , , , /¨\ /¨o\ io¨\ /¨\ /¨\ /¨o\ io¨\ /¨\ /¨o, r --0 0-1 \-0 0- - = - -0 __ 0-/ \-0 0-/
` = - -0 , , - _____________________ / \-0 0 , = µ0-/- = --/ \ P-- /--\ _/ \
-0 = -0 0 0 = 0 /--\ ______________________________________________________________ /--\

, , , , /--\ \_ , /-0\ 0, - -0/ \-0/ \¨d = --O 0 -/ 0' = - -0 0-' /-, , /¨ _/ _________________________________ \ _r0, 0 ______________________ 0 / \ __________________________________________________________ / -\ _____ r ' ¨0/ \-01--\ ___________ r , = 0 0 0 ' = 0 .
, , __0/¨\ _____________ /--\ 0 _/- µ 0 \ - -0 0 /--\ , _/- / \ /--\ _/ \0 _/ \
` = - = 0--, 00 /--\ _/ \_ / / \ /--\ 0 -\_ / / \ /-\ 0 - -0 0 0 0-- = - -0 0 0 = -0 -\ ________________________________________________________________ /0--, , /-\ /-\ _/-0, --0/-\ _________________________________________________ /-\0-/ \O- - = --0/-\-/-\-0/0-- = - -N
, ,N---. - -N N ' ' ' , /¨\ _/ \ /\ / r 0 ¨
\/
- -N N 0-- - -N¨N-/ \ 1/ -0 - -N N
, . \ , / . \__/ .
, , /¨\
/¨ J-N N--- P¨\
- -N N N N N ' \-0 \-N
N---, , , , /--\ _r \
- -N N % - -N N ' _N-/ N N __ r \ --N/¨\N r . ; \__/ = \__/ -\
, =
, /--\ /--\
- __________________________________________________________________________ -Nr-\N \ / -\ /0-\ ,0- - -N7, \ /0- - -N, /N0- - .
___________________ ' , , ' , /¨\ /¨\
/¨\r\N'\,, - -N\ 7-\ /¨N\ ,N--- . - -0, r N\ 7¨\ ,o- . (31 ---\-----\_.N. ....j , .
\ ________________________________________ / , , LSOT
, ---NH __________ o 0 0 = -NH
=.µ 0 / \O-/ \O-/- \

, = ---NH /-0\ / / 0 µ = --NH 0-, i' __________ / \ _/- .
o i' /
o o , = ---NH /0-\ rO\ /-µ 0 =

/' µ /. /-\ __ /-\ ______ /-µ µ

, = ---NHrg = _____________________________________________________________________ ---NH
/0-\_ / \
)/' 0 F--= ---NH /O--\ /o-\ p--t---NµI-1 O-\
/-\ / 00--t. 00- -)/ 1// HNµ \ __ /

, 0--\ 0- = µ / \ 0 t 14N4 , 141,1_ __ \0/ __ \ __ /

, ,_0\_/, _______________ \ ,\__,0_ __ \ ______ < __________ ,o0\ __ /0-- =,. %
.. ,___\ .. / 00_\ .. /0_ HµN HN \ I-IN

, , /-0 /-0 0-- == p = 0 I- IN- \ ____ / \- Hp-\_ /-\ rg HN ________________ ./ 0-\ /-0 0 0 . ,/ \ __ / \ _______ /
\
, , = p = o =
1-1/N-4 rO\ T-R 1-,1p- /--\ _/--0µ 1-11\14 \--/
. 0 \ 0 , , = ---NH /0-- 0 0 = 0 >i Hp 0- /
1-lp- HN 0--0 r \___I , __ ./( / 0 -\ , \
/ = 0 t ---N)/1-1 / \ /o t N r0 0t -Hp __ =(_ / __ \ 0 7/-/H O \ /

, = 0 = 0 :

-/0- 0-- 1-1\N--/-Ck /0-\/-0\ /0-\ /
_________________________________________________ \-0 0-/ _______________ \--NH \ ____________________ / 0 , . 0µ 0-\ /--\ /-0 -A 0-- = ---N ;0-\ /--\ _/-0 I-IN __ /-\ __ / \ __ / \-0 0-/ / / \-0 0 \___/

, :
= p = o , o o-- , = µ
Hp __ ',(_ / 0 0 \ _r , c 0- HN \__/
\o--oO--/- \- ---NH 0 \__/ 0 1'II0S0/6IOZS9/IDd t9SISO/OZOZ OM

µ0¨/ HN ______________________ = \O¨/ HN--- =
; ;

/¨\ r0 HN---µµ _F \__/¨\__/-4 N N \ ,.( \\
\ b ¨/ \O¨/¨\¨/-4HN--- = 0 HN--- = \¨/ 0 =
; ; , -/¨\ _/ \ NH /--\ / __ \ __ / , NI-I0¨\
ii --N N Oi¨ \ --N/¨\N¨/ \-0/ HN--- -N N / = \/ ; \
\/ 0 __/ ; , /¨\ rO\ /O¨\ / /¨ /O\ ______ r0 HN
\ r-----N N¨/ ¨1\1/1-1 --N N¨

\--\/ 0 = \/ 0 =
, , /--\ rO\ ________ / / \ j-1\1- --N N_ µ1 __/ \_ /

N ¨/
\__/ = \__/ .
, , /
/

HN
/¨\ r0\_/0¨\_0 / ____________________________ F. .c/ N___ pN/Th õ.,./.0 )0¨\ d \ o --N N¨/
\__/
, , V......../N
\ ________________________________________________________________ / =
, /---N/f /¨\
N /¨\ r N
/ ___________________ \ /--\ ,\1-1 \ \ HN--- -0 _____________________________________________________________________ - -0 ` __ N N \ . --0/....N--../
\__/ 0 =
, , , /¨\ /
/ / ¨\ _rN N /¨\ J¨N\ ) ______ _N,i - __________ -0 0 \¨/ ¨)/ N/H - -0 0 0 = 0 =
, , /¨\
/¨\ /¨N N / /¨\ rN/\ ) ______ _N,i --N N \¨/ NH - -N N
0 = \__/ 0 =
, , /¨\ / ______ ( \_N¨\ 0 --Nr-\N¨( \N
--N N __ / e NI-I 'I\1 N
\¨/ / ¨)rN1/-1 0 , . N HN, .
- , 0 =
, N-N-0 N-0 N-o --Cl..--- = \ s(3/..-- ; --1 \/Q--- = ''Co--.- =
, , , r R
(:).,1 ;-N-C) ---.
, , --0.)!.õ1 - - ---C)j--.> - _0 ; 0 , = =

01- - - . - -0 - -0 0 0 N-C) , ; - - -----,0..,,...õ..---...õ,..õ..---,, --- 0 = --0.---....,_.õ---.......,õ0 , - - - ., 0 I / - -= 0 , -- - -, = 0 -- . - -''OWO = 'OC) , --' , 00()- -N-0 /\ N.-0 'N N-0 -- - -N N¨Us \__/ --- ., . N ---=
, , rN N-0 1--, --N\____J 7 -, , , - -N \._--/ \----, . N 0,--- . N

, , 'N N-0 rNN N-0 /
=

NN N-0 C) NN
- -N I
= - - CD'- - -, =
, and
34. The bifunctional compound according to claim 1, wherein the compound is selected from Table lA through Table 1C.
35. The bifunctional compound according to any of claims 1-34, further includes at least one polyethylene glycol chain.
36. A composition comprising an effective amount of a bifunctional compound according to any of claims 1-35, and a pharmaceutically acceptable carrier.
37. The composition according to claim 35, wherein the composition further comprises at least one of an additional bioactive agent or another bifunctional compound of any of claims 1-34.
38. The composition according to claim 36, wherein the additional bioactive agent is anti-cancer agent.
39. A composition comprising a pharmaceutically acceptable carrier and an effective amount of at least one compound according to any of claims 1-35 for treating a disease or disorder in a subject, the method comprising administering the composition to a subject in need thereof, wherein the compound is effective in treating or ameliorating at least one symptom of the disease or disorder.
40. The composition according to claim 38, wherein the disease or disorder is associated with BRaf accumulation and aggregation.
41. The composition according to claim 38 or 39, wherein the disease or disorder is cancer; cardiofaciocutaneous syndrome; neurofibromatosis type 1; Costello syndrome; Noonan Syndrome; or Lentigo, Electrocardiographic abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retarded growth, Deafness (LEOPARD) syndrome associated with RAF accumulation and aggregation.
42. The composition according to claim 39, wherein the cancer is renal cell carcinoma; pancreatic cancer, colorectal cancer; lung cancer; ovarian cancer;
thyroid cancer;
pilocytic astrocytoma; prostate cancer; gastric cancer; hepatocellular carcinoma; or melanoma.
CA3109981A 2018-09-07 2019-09-07 Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides Pending CA3109981A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728581P 2018-09-07 2018-09-07
US62/728,581 2018-09-07
PCT/US2019/050114 WO2020051564A1 (en) 2018-09-07 2019-09-07 Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides

Publications (1)

Publication Number Publication Date
CA3109981A1 true CA3109981A1 (en) 2020-03-12

Family

ID=68051923

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3109981A Pending CA3109981A1 (en) 2018-09-07 2019-09-07 Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides

Country Status (9)

Country Link
EP (1) EP3846907A1 (en)
JP (2) JP2022500368A (en)
KR (2) KR102642203B1 (en)
CN (1) CN113164775A (en)
AU (2) AU2019335516B2 (en)
CA (1) CA3109981A1 (en)
IL (1) IL281188A (en)
MX (1) MX2021002559A (en)
WO (1) WO2020051564A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
CA3162266A1 (en) * 2019-12-17 2021-06-24 Nikolai Kley Bifunctional agents for protein recruitment and/or degradation
CN115298173A (en) * 2020-03-31 2022-11-04 田边三菱制药株式会社 Hydroxypyrrolidine derivatives and medical use thereof
CN115996719A (en) 2020-06-19 2023-04-21 C4医药公司 BRAF degradation agent
WO2021255213A1 (en) * 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Heterobifunctional compounds as degraders of braf
JP2023539663A (en) * 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド Rapidly Progressive Fibrosarcoma Proteolytic Compounds and Related Methods of Use
JP2024504932A (en) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド isoindolinone compound
WO2022266206A1 (en) * 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2022270994A1 (en) 2021-06-25 2022-12-29 한국화학연구원 Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
WO2023023941A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same
CA3235512A1 (en) * 2021-10-22 2023-04-27 Xiaobao Yang Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
TW202330548A (en) * 2021-11-30 2023-08-01 英屬開曼群島商百濟神州有限公司 Compounds for the degradation of egfr kinase
CN115894450B (en) * 2021-11-30 2023-09-12 山东如至生物医药科技有限公司 Novel polycyclic compound and composition and application thereof
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN115806503A (en) * 2022-12-02 2023-03-17 中国海洋大学 Selective histone deacetylase inhibitor as well as preparation method and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206929B2 (en) 2004-01-16 2008-01-24 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
CA2558615C (en) 2004-03-23 2013-10-29 Genentech, Inc. Azabicyclo-octane inhibitors of iap
DK2253614T3 (en) 2004-04-07 2013-01-07 Novartis Ag IAP inhibitors
CN101035802A (en) 2004-07-02 2007-09-12 健泰科生物技术公司 Inhibitors of IAP
EP1836201B2 (en) 2004-12-20 2013-09-04 Genentech, Inc. Pyrrolidine inhibitors of iap
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
WO2008014236A1 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
NZ580468A (en) 2007-04-13 2012-02-24 Univ Michigan Diazo bicyclic smac mimetics and the uses thereof
US9500653B2 (en) 2010-12-07 2016-11-22 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
WO2013071039A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
CN117736134A (en) 2012-01-12 2024-03-22 耶鲁大学 Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases
US9603889B2 (en) 2012-10-02 2017-03-28 Bristol-Myers Squibb Company IAP antagonists
WO2015006524A1 (en) 2013-07-12 2015-01-15 Bristol-Myers Squibb Company Iap antagonists
KR20210132233A (en) * 2014-04-14 2021-11-03 아비나스 오퍼레이션스, 인코포레이티드 Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
BR112017019751A2 (en) * 2015-03-18 2018-05-29 Arvinas Inc bifunctional compound, pharmaceutical composition, and methods for treating or preventing a disease or disorder, and for degrading a target protein in a cell
EP3544957A4 (en) * 2016-11-22 2020-09-02 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
MX2019007649A (en) * 2016-12-23 2019-09-10 Arvinas Operations Inc Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides.

Also Published As

Publication number Publication date
EP3846907A1 (en) 2021-07-14
KR102642203B1 (en) 2024-03-04
CN113164775A (en) 2021-07-23
AU2019335516A1 (en) 2021-03-11
IL281188A (en) 2021-04-29
KR20240028539A (en) 2024-03-05
AU2022228150A1 (en) 2022-09-29
WO2020051564A1 (en) 2020-03-12
JP2022500368A (en) 2022-01-04
JP2023159166A (en) 2023-10-31
MX2021002559A (en) 2021-07-21
AU2019335516B2 (en) 2022-06-16
KR20210073519A (en) 2021-06-18

Similar Documents

Publication Publication Date Title
AU2021200099B2 (en) Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CA3109981A1 (en) Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
AU2022221407B2 (en) Modulators of estrogen receptor proteolysis and associated methods of use
CA3042968C (en) Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
CA3095912A1 (en) Cereblon ligands and bifunctional compounds comprising the same
CA3095494A1 (en) Modulators of proteolysis and associated methods of use
CA3047586A1 (en) Egfr proteolysis targeting chimeric molecules and associated methods of use
CA2988430A1 (en) Mdm2-based modulators of proteolysis and associated methods of use
CA3050309A1 (en) Cereblon ligands and bifunctional compounds comprising the same
WO2017011590A1 (en) Alanine-based modulators of proteolysis and associated methods of use
WO2019177902A1 (en) Modulators of btk proteolysis and methods of use
US11173211B2 (en) Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CA3214806A1 (en) Modulators of bcl6 proteolysis and associated methods of use
RU2782458C2 (en) Compounds and methods for targeted cleavage of rapidly accelerated fibrosarcoma polypeptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217